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Preface
The work presented in this thesis has been performed from May 2004 to December 2007 in the 
Division of somatic cell genetics of the Department of Human Genetics at the University of Wurz-
burg, Biocenter, under the direction of Professor Detlev Schindler.
My thesis deals with an inherited disease, Fanconi anemia, fi rst described in 1927 by the Swiss 
pediatrician Guido Fanconi. This rare disorder exemplifi es the close connection between genetic 
instability, physical defects, organ malfunctions and, most prominently, neoplasia. For a long time, 
Fanconi anemia was a disease only known to a small fi eld of clinicians and basic researchers. 
This has changed during recent years as molecular defects in a newly defi ned family of caretaker 
genes have been recognized as cause of the disease. Presently, research on Fanconi anemia 
is conducted by scientists coming from very different fi elds, including areas such as DNA repair, 
cancer, stem cells, and development. Model organisms like drosophila, zebrafi sh, chicken and 
mouse are increasingly used to study the connection between defective caretaker genes and de-
fective cellular function. The fi rst FA gene was discovered in 1992, and since that time the pace 
of gene discovery has been astounding. During my work as a graduate student I have witnessed 
and participated in the discovery of three FA genes, bringing the total number of these genes to 
currently 13. Nevertheless, the exact details of the socalled “FA/BRCA” network and its precise 
role in the recognition and repair of DNA-interstrand crosslinks are not fully understood. We need 
to know more about how the FA proteins work, how they interact with other caretaker proteins, 
and how they manage to maintain genomic stability which is a prerequisite for the exceptional 
longevity of our species. Conversely, elucidation of the molecular causes and consequences of 
genetic instability is an important research objective to which the study of Fanconi anemia, as 
portrayed in this thesis, is likely to make signifi cant contributions.
This thesis is divided into four main parts. First, the reader will be introduced to the subject of Fan-
coni anemia and its many clinical, cellular and molecular features. The introduction is followed by 
the main body of the thesis. This consists of a series of original papers which present the results 
of my experimental work. The third part is a brief discussion of the implications of my research, 
including the many open questions that remain to be solved in future studies. In the last part I will 
summarize the various aspects of my thesis work in both English and German. 
Since the scientifi c literature on Fanconi anemia has grown exponentially in recent years, it will be 
impossible to cover all relevant publications within the framework of this thesis. For the purpose 
of introduction to this rather complex fi eld of research, I will concentrate on a number of key pa-
pers, including the review types of publications listed below. As fi rst or co-author of this particular 
series of publications, I take the proprietary liberty to incorporate their main messages into the 
introduction section. Copies of these publications are provided as supplements to this thesis.
 1. Schindler D and Neveling K. Fanconi Anemia. In: Schwab M (ed) Ency-
     clopedia of Cancer. Springer, in press 
 2. Neveling K, Bechtold A, Hoehn H (2007). Genetic instability syndromes 
     with progeroid features. Z Gerontol Geriat 40:339-348
 3. Neveling K, Kalb R, Schindler D (2007). Cancer in Fanconi Anemia and Fan-
     coni Anemia Genes in Cancer. In: Schindler D, Hoehn H (eds) Fanconi 
     Anemia. A Paradigmatic Disease for the Understanding of Cancer and Aging.
     Monogr Hum Genet. Basel, Karger, vol 15, pp 59-78
 4. Kalb R, Neveling K, Herterich S, Schindler D (2007): Fanconi Anemia Genes: 
     Structure, Mutations, and Genotype-Phenotype Correlations. In: Schindler D,
     Hoehn H (eds) Fanconi Anemia. A Paradigmatic Disease for the Understan-
     ding of Cancer and Aging. Monogr Hum Genet. Basel, Karger, vol 15, pp 39-58
 5. Hoehn H, Kalb R, Neveling K,..., Schindler D (2007): Revertant Mosaicism in
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     Fanconi Anemia: Natural Gene Therapie at Work. In: Schindler D, Hoehn H
     (eds) Fanconi Anemia. A Paradigmatic Disease for the Understanding of Can-
     cer and Aging. Monogr Hum Genet. Basel, Karger, vol 15, pp 149-172
 6. Schindler D,..., Neveling K,..., Hoehn (2007). Applications of Cell Cycle Testing
     in Fanconi Anemia. In: Schindler D, Hoehn H (eds) Fanconi Anemia. A Para-
     digmatic Disease for the Understanding of Cancer and Aging. Monogr Hum Ge
     net. Basel, Karger, vol 15, pp 110-130
 7. Kalb R, Neveling K, Nanda I, Schindler D, Hoehn H (2006). Fanconi Anemia:
     Causes and Consequences of Genetic Instability. In: Volff (ed) Genome and Di
     sease. Genome Dynamics, Basel, Karger, vol 1, pp 218-242
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1.1 Fanconi Anemia - Defi nition
Fanconi anemia (FA; synonyms: Fanconi’s anemia, Familial (constitutional) panmyelocytopathy 
Fanconi, Familial hypoplastic anemia Fanconi) is a human disease clinically characterized by 
congenital anomalies, bone marrow failure and cancer susceptibility, and cellular features of chro-
mosomal instability and hypersensitivity to DNA-crosslinking agents. It is a mostly autosomal and 
occasionally X-chromosomal recessive disorder with an overall prevalence of about 1 in 300.000 
(Schindler and Neveling, in press).
1.2 The FA Clinical Phenotype
Fanconi anemia is a multisystem disorder with pleiotropic clinical manifestations (reviewed in Ne-
veling et al., 2007a). Approximately 70% of FA patients display variable presence of (intrauterine) 
growth retardation, hyper- and hypopigmentations of the skin, radial ray and external ear defects, 
microcephaly, microphthalmia, and malformations of the inner organs including most frequently 
kidney, gastrointestinal tract, heart and brain (Kutler et al., 2003). Up to 80% of FA patients exhibit 
disturbances of the endocrine system, including growth hormone and thyroid hormone defi ciency, 
type 2 diabetes and premature gonadal failure (Wajnrajch et al., 2001). Nearly all patients ex-
perience bone marrow failure during childhood, and at all ages there is a strongly elevated risk 
of neoplasias. A minority of FA patients are of normal stature and display few or no congenital 
malformations such that the diagnosis may be missed until they present with bone marrow failure 
or young adult-onset neoplasias. Average life expectancy of FA patients is around 20 years, and 
patients reaching the age of 50 are exceedingly rare (Kwee et al., 1997; reviewed in Kalb et al., 
2006). The classical clinical course is marked by childhood onset of bone marrow failure, which 
fi rst manifests as low platelet counts, complicated by transfusion-dependent anemia and irrever-
sible pancytopenia in the fi rst two decades of life. However, clinical course and clinical phenotype 
are highly variable both within and between families. Treatment is mostly supportive and includes 
blood product substitution and stimulation of bone marrow cell growth by androgens, hydrocor-
tisone and cytokines; the only curative therapy of bone marrow failure is hematopoetic stem cell 
transplantation, but a high proportion of successfully transplanted patients develop solid cancers 
later in life (Rosenberg et al., 2005).
1.3 The FA Cellular Phenotype
The FA cellular phenotype is characterized by increased chromosomal instability, both spontane-
ous and induced (Fig. 1A) (reviewed in Neveling et al., 2007a). FA cells are uniformly sensitive to-
wards DNA-crosslinking agents such as diepoxybutane (DEB), mitomycin C (MMC), cisplatinum 
(CDDP) or nitrogen mustard (NM). In response to these agents, FA cells show elevated rates of 
chromatid breaks and chromatid exchanges (Sasaki and Tonomura, 1973; Auerbach and Wol-
man, 1978). Challenging patient cells in vitro with any of these agents and measuring the resul-
ting chromosome breakage rate serves as diagnostic test. As a consequence of damaged and/or 
misrepaired DNA, FA cells accumulate with 4c DNA content at the S/G2 phase checkpoint of the 
cell cycle (Dutrillaux et al., 1982; Kubbies et al., 1985; Seyschab et al., 1993; Akkari et al., 2001). 
As a convenient alternative to chromosome breakage studies, the accumulations of cells with 4c 
DNA content in response to crosslinking agents can be assessed via fl owcytometry (reviewed in 
Schindler et al., 2007a). As illustrated in fi gure 1B, cell cycle analysis yields a clear distinction bet-
ween crosslink-sensitive (= FA) and crosslink-resistant (= non-FA) cells. These diagnostic tests 
are routinely performed with peripheral blood mononuclear cells, skin fi broblasts or amniocytes, 
the only prerequisite being a certain degree of proliferative activity of the tested cell types. An 
important conceptual aspect of the cell cycle test involves the unequivocal demonstration of an 
altered cell cycle distribution of FA cells as a consequence of accumulated DNA damage.
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Unlike any other genetic instability syndrome, FA cells are hypersensitive towards oxygen and 
grow poorly in conventional cell culture incubators with ambient oxygen tension (reviewed in 
Kalb et al., 2006). Under ambient-air cell culture conditions FA cells show elevated spontaneous 
chromosomal breakage rates with a predominance of chromatid-type lesions (Joenje et al., 1981). 
However, in vitro growth and cloning of FA cells can be restored to near normal under hypoxic cell 
culture conditions (Schindler and Hoehn, 1988). In contrast to ATM, FA cells are not markedly hy-
persensitive towards ionizing radiation under (physiological) low-oxygen conditions, nor do they 
show consistent hypersensitivity towards UV irradiation (Kalb et al., 2004). 
Figure 1
a) Chromatid-type chromo-
some lesions (arrows/ar-
rowheads) as cytogenetic 
hallmarks of spontaneous and 
induced chromosome fragility 
in Fanconi anemia (FA). Blood 
lymphocyte karyotype stained 
with Giemsa. b) Cell cycle alte-
rations as fl owcytometric hall-
marks of FA. The upper panels 
show bivariate fl owcytograms 
of 72-h peripheral blood mo-
nonuclear blood cell cultures 
grown in the presence of a lec-
tin mitogen (PHA) and the base 
analog bromodeoxyuridine 
(BrdU). Double staining with 
ethidium bromide (EB) (Y-axis) 
and the Hoechst 33258 dye (X-
axis) resolves the distribution 
of cells throughout the G1, S 
and G2/M phases of three con-
secutive cell cycles. In contrast 
to non-genetic aplastic anemia 
(AA), cells from patients with FA 
accumulate in the G2-phases 
of consecutive cell cycles. The 
three-dimensional representa-
tion of the bivariate cytogram 
data (bottom panels) empha-
sizes the cell cycle differences 
between the non-genetic and 
the genetic form of aplastic an-
emia (derived from Kalb et al., 
2006).
1.4 FA Genes and Proteins
There are 13 genes to date whose biallelic (or in case of the X-chromosomal group FA-B hemi-
zygous) mutations cause FA or FA-like disease: FANCA, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M 
and -N. The FA genes are scattered widely throughout the human genome (Fig. 2, Tab. 1) and 
vary considerably in both size and structure. Sequence comparisons indicate that many of the 
FA genes must have arisen fairly recently in evolution, lacking homologs beyond the vertebrate 
kingdom. However, there are also some FA genes (FANCD1, FANCD2, FANCJ, FANCL, FANCM) 
A
B
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that are more ancient and highly conserved, having orthologs in lower organisms as far back as 
drosophila, c. elegans, and yeast (Patel and Joenje, 2007). In the following paragraphs, the FA 
genes and their proteins will be discussed in alphabetical order (reviewed in Kalb et al., 2007a). 
FANCA
The FANCA gene is located on chromosome 16q24.3 and consists of 43 exons. The correspondi-
ng FANCA protein has a size of 163 kDa and contains a leucine zipper-like motif, two overlapping 
bipartite nuclear localization signals (NLS) (Lightfoot et al., 1999) and fi ve functional leucine-rich 
nuclear export sequences (NES) that contribute to CRM-dependent nuclear export (Ferrer et al., 
2005). Since the fi rst identifi cation in 1996 more than 200 different mutations of all possible types 
have been described (reviewed in Levran et al., 2005b). Especially large deletions are frequent in 
FANCA with a striking overlap of the affected exons. Even though the exact break points have not 
been determined in all cases, a number of reports indicate a direct correlation between the pre-
sence of Alu repeats and deletion breakpoints (Centra et al., 1998; Levran et al., 1998; Morgan et 
al., 1999). In addition to large deletions, small deletions and insertions/ duplications are also pre-
valent. These changes often are associated with short direct repeats, homonucleotide tracts, and 
hotspot consensus sequences like CpG dinucleotides (Levran et al., 1997). Base substitutions 
account for less than half of the mutations in FANCA and cause premature termination, amino 
acid exchanges, or are affecting translation initiation or normal exon recognition.
FANCB
FANCB is the only X-linked FA gene. It is located on chromosome Xp22.31 and comprises 10 
exons.The FANCB protein is of 95 kDa. To date, mutations in FANCB have been reported for 7 
male FA patients including a deletion affecting the promotor region and portions of the 5´ untrans-
lated regions, three recurrent microdeletions/-insertions, and a single splice site mutation (Meetei 
et al., 2004; Holden et al., 2006; Ameziane et al., 2007). The analysis of three healthy female 
FANCB carriers revealed the preferential inactivation of the X-chromosome carrying the mutated 
allele in both peripheral blood cells and fi broblasts, suggesting a proliferative advantage for cells 
with the wildtype allele early in embryogenesis (Meetei et al., 2004).
FANCC
FANCC (chromosome 9q22.3) was the fi rst known FA gene, identifi ed in 1992 (Strathdee et al., 
1992). At the genomic level, FANCC is one of the larger FA genes spanning more than 200 kb, 
but coding for a protein with a molecular weight of only 63 kDa. Two putative p53 binding sites of 
unknown functional signifi cance have been described in FANCC (Liebetrau et al., 1995). Muta-
tions in FANCC are responsible for around 10% of all FA cases, but surprisingly few private muta-
tions have been reported. The mutational spectrum is heterogenous, and changes are scattered 
widely throughout the gene with the exception of a possible cluster in the C-terminal region. So 
far, only a single large deletion has been detected in FANCC (Rischewski et al., unpublished 
data). 
FANCD1
FANCD1 (chromosome 13q12.3) is identical to the gene coding for the breast cancer associated 
protein 2 (BRCA2) (Howlett et al., 2002). Biallelic mutations in FANCD1/BRCA2 result in a se-
vere form of FA with a high and very early risk for the development of malignancy (Wagner et al., 
2004; Reid et al., 2005; Alter, 2006). At the mRNA level, FANCD1/BRCA2 is the largest of the FA 
genes with an open reading frame of 10254 nucleotides. The FANCD1/BRCA2 protein has a mo-
lecular weight of 380 kDa. There are numerous functional domains which have been extensively 
reviewed (West, 2003; Shivji and Venkitaraman, 2004). Crucial for FANCD1/BRCA2 function are 
8 BRC repeats, a helicase domain followed by 3 oligonucleotide/-saccharide binding folds (OB1, 
OB2, OB3), and a tower domain inserted in OB2. The FANCD1/BRCA2 protein shows structure 
specifi c DNA binding activity and interacts directly with several other proteins some of which have 
been implicated in DNA repair like RAD51, FANCG and FANCD2 (Hussain et al., 2003; Tarsounas 
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et al., 2003; Hussain et al., 2004). FANCD1/BRCA2 appears to function in multiple and diverse 
cellular processes including stabilization of stalled replication forks, homologous recombination 
(via interaction with the RAD51 recombinase), and regulation of cytokinesis (Daniels et al., 2004). 
Mutations in FANCD1/BRCA2 are distributed over the entire gene, but monoallelic preservation 
of a functional BRC-repeat domain has been observed for the majority of mutations in FA-D1 
patients. Compared to the prevalence of gene carriers in different populations, the frequency of 
FA-D1 patients appears low, suggesting non-viability of most biallelic types of mutations (Popp 
et al., 2003; Reid et al., 2005). 
FANCD2
FANCD2 (chromosome 3p25.3) is a highly conserved gene which is fl anked by two distinct pseu-
dogene regions, FANCD2-P1 and FANCD2-P2, showing homologies to the middle part of the 
gene. It is expressed in two alternatively spliced variants, one with a large continuous exon 43, 
and one with an additional exon 44 (Timmers et al., 2001). FANCD2 protein is recruited to chro-
matin after DNA damage-induced monoubiquitination at lysine 561 (Garcia-Higuera et al., 2001; 
Montes de Oca et al., 2005) where it colocalizes with other proteins involved in DNA repair inclu-
ding BRCA2, RAD51 and BRCA1 (Hussain et al., 2003; Hussain et al., 2004). Purifi ed FANCD2 
has DNA-binding activity with structure-specifi c affi nity to branch points and free DNA ends such 
as Holliday junctions and DNA double strand breaks, supporting its active participation in DNA 
repair pathways (Park et al., 2005). Based on the analysis of more than 30 patients and disregar-
ding recurrent mutations, there is a non-random distribution of mutations with preferential involve-
ment of the N-terminal region. In fact, more than 50% of the mutations observed in FANCD2 affect 
splicing, which is much higher than in any of the other FA genes. Residual levels of FANCD2 
protein were detected in all patient-derived cell lines, which underlines the functional importance 
of FANCD2 (Kalb et al., 2007b).
FANCE 
The complementation group FA-E was defi ned in 1995 by cell fusion studies (Joenje et al., 1995) 
and the fi rst patient was described shortly thereafter (Wegner et al., 1996). Using linkage analy-
sis and homozygosity mapping the FANCE gene was mapped in 1999 to chromosome 6p21-22 
(Waisfi sz et al., 1999b). The corresponding RNA of the FANCE gene was isolated one year later 
(de Winter et al., 2000a). FANCE  consists of 10 exons coding for a 58 kDa nuclear protein of 536 
aminoacids. Other than a bipartite nuclear localisation signal (NLS) and a newly described “FANC” 
domain, there are no other known protein motifs (de Winter et al., 2000a; Pace et al., 2002; 
Nookala et al., 2007). Owing to its NLS, FANCE has a strong tendency for nuclear localization. 
The protein is required for the nuclear accumulation of FANCC (Pace et al., 2002; Taniguchi and 
D‘Andrea, 2002; Leveille et al., 2006). As part of the FA core complex, FANCE is also essential 
for FANCD2 monoubiquitination (Taniguchi and D‘Andrea, 2002). Direct interactions with FANCC 
and FANCD2 have been described. This has led to the speculation that FANCE serves as a cri-
tical bridge molecule connecting the FA core complex to FANCD2 (Pace et al., 2002; Gordon et 
al., 2005; Leveille et al., 2006). FA-E patients are relatively rare, amounting to less than 2% of all 
FA patients. The fi rst comprehensive clinical, molecular and functional characterization of a larger 
cohort of FA-E patients is presented as part of this thesis.
FANCF 
FANCF is located on chromosome 11p15 and consists of only a single exon. The encoded protein 
(42 kDa) shares homologies to the prokaryotic RNA-binding protein (ROM), but this is without 
known signifi cance (de Winter et al., 2000b; Leveille et al., 2004). In the core complex, FANCF 
serves as a adaptor, linking the subcomplexes A/G and C/E. It has a C-terminal helical repeat 
structure similar to the Cand1 regulator of the Cul1-Rbx1-Skp1-Fbox (Skp2) ubiquitin ligase com-
plex and mutants with base substitutions in this C-terminal region fail to interact with other com-
ponents of the FA core complex (Kowal et al., 2007). To date, only 5 nonsense mutations and 
microdeletions (de Winter et al., 2000b) and one mutation resulting in a predicted splicing error 
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(Ameziane et al., 2007) have been found in FA-F patients. However, FANCF has gained special 
prominence as a gene that is frequently silenced by hypermethylation of its promotor region in 
various types of malignancies (reviewed in Neveling et al., 2007c), including bladder carcinomas 
which is reported in this thesis (Neveling et al., 2007b).
FANCG 
FANCG, which is located on chromosome 9p13, is identical to XRCC9 which was identifi ed in Chi-
nese hamster cells as a gene involved in DNA repair (Liu et al., 1997; de Winter  et al., 1998). The 
FANCG protein (68 kDa) has seven tetratricopeptide repeat motifs (TRPs) thought to function as 
a scaffold for mediating protein-protein interaction (Blom et al., 2004). The molecular function of 
FANCG is not restricted to the FA core complex, since it has been shown to interact with BRCA2 
and XRCC3 directly and independently of other FA proteins (Hussain et al., 2006). Mutations in 
FANCG are of all types, with the exception of deletions. They are scattered throughout the gene, 
with possible preference for the N- and C-terminal regions. 
FANCL 
FANCL (chromosome 2p16.1) was identifi ed by mass spectroscopy of a previously isolated 43 
kDa FA-associated polypeptide (FAAP43, Meetei et al., 2003a). Sequence analysis revealed 
identity to the WD40-repeat containing PHD fi nger protein 9 (PHF9), which is highly conserved. 
FANCL is thought to serve as the catalytic subunit of the FA core complex during monoubiquiti-
nation of FANCD2. Consistent with this important role in the FA/BRCA pathway, there is only a 
single patient published to date whose disease is caused by a homo- or hemizygous insertion 
of 177 bp into a pyrimidine-rich sequence between intron 10 and exon 11, leading to skipping of 
exon 11 (Meetei et al., 2003a). However, further FANCL patients were identifi ed recently and their 
description is part of this thesis.
FANCM
FANCM (located on chromosome 14q21.3) also belongs to the highly conserved FA genes (Mee-
tei et al., 2005). Its protein shows similarities to the archael protein Hef which displays a helica-
se- and an endonuclease- domain. However, the biological relevance of these domains for the 
current function of FANCM has yet to be established. Using specifi c antibodies, lack of FANCM 
protein was discovered in a single cell line from a patient previously excluded from most of the 
known complementation groups (Meetei et al., 2005). Genetic work up revealed compound he-
terozygous mutations, a maternal nonsense mutation in exon 13 and a paternal deletion within 
exon 15.
FANCI, FANCJ and FANCN
The FA genes FANCJ, FANCN and FANCI were identifi ed in 2005, 2006 and 2007, respectively 
(Levran et al., 2005a; Reid et al., 2007; Sims et al., 2007). The characterization of these genes 
was part of my work as a graduate student. The papers describing the identifi cation of these 
genes are included in the results part of this thesis.
Depending on the underlying gene defect, FA patients are classifi ed into different FA subtypes, 
also referred to as complementation groups. Complementation studies using somatic cell fusion 
or retroviral transduction have assigned around 66% of FA patients to complementation group A, 
and 8-10% each to groups C and G. The other complementation groups account for around 2% or 
less of the patients (FA-A: 66%, FA-B: 2%, FA-C: 10%, FA-D1: 2%, FA-D2: 2%, FA-E: 2%, FA-F: 
2%, FA-G: 9%, FA-I: 2%, FA-J: 2%, FA-L: < 0.2%, FA-M: < 0.2%, FA-N: 2% (Wang, 2007).
FA candidate genes
Although 13 FA genes are known, there still are a number of FA patients without recognizable 
defects in one of the known FA genes. This implies that additional FA genes will be discovered. 
These missing genes are tracked down in several laboratories using a plethora of different ap-
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Figure 2 Human karyotype map with locations of the 13 Fanconi anemia (FA) genes known to date. FA 
genes are denoted with the prefi x ‘FANC’ and alphabetical letters. Note that there are two types of FANCD 
genes: FANCD1 (corresponding to BRCA2) and FANCD2. FANCB is the only X-chromosomal FA gene. 
Modifi ed from Kalb et al., 2006.
Complementation 
group FA gene
Prevalence 
in FA
Chromosomal 
localisation Exons
Protein size 
(kDa)
Mono-
ubiquitination 
of D2
FA-A FANCA 66% 16q24.3 43 163 no
FA-B FANCB ~2% Xp22.31 10 95 no
FA-C FANCC 10% 9q22.3 15 63 no
FA-D1 FANCD1/BRCA2 ~2% 13q12.3 28 380 yes
FA-D2 FANCD2 ~2% 3p25.3 44 155, 162 -
FA-E FANCE ~2% 6p21-22 10 58 no
FA-F FANCF ~2% 11p15 1 42 no
FA-G FANCGXRCC9 9% 9p13 14 68 no
FA-I FANCI ~2% 15q25-26 38 140, 147 no
FA-J
FANCJ/
BRIP1/
BACH1
~2% 17q22 20 140 yes
FA-L FANCL/PHF9 <0.2% 2p16.1 14 43 no
FA-M FANCM/HEF <0.2% 14q21.3 13 250 no
FA-N FANCN/PALB2 ~2% 16p12 13 140 yes
Table 1 Characterisation of the FA complementation groups, genes and proteins
*Prevalence of FA complementation groups according to Wang, 2007
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proaches, including candidate gene analysis, expression cloning, positional cloning or physical 
isolation of interacting proteins. Each gene that might be an FA gene remains a mere “candidate” 
as long as there are no FA patients with proven mutational inactivation of the respective gene. A 
highly successful approach for fi nding new FA genes was carried out in Weidong Wangs‘ labo-
ratory at the US National Institute of Aging. Wang´s group used co-immunoprecipitation experi-
ments with an FANCA antibody to investigate whether there are proteins which would bind to the 
“bait” FANCA protein. Proteins interacting with FANCA were called “FAAP” for “FANCA-associated 
polypeptide”. They were numbered according to their respective molecular weights (Meetei et al., 
2003b). By this approach, Weidong Wangs’ group identifi ed many of the members of the FA core 
complex. For example, FAAP95 later became FANCB (Meetei et al., 2004), FAAP43 became 
FANCL (Meetei et al., 2003a) and FAAP250 is now FANCM (Meetei et al., 2005). To date, there 
still are FAAPs that interact with FA core complex members, but there are no corresponding pa-
tients such that their identifi cation as bona fi de FA genes has not been achieved. These putative 
but not proven FA genes have been named FAAP10, FAAP16, FAAP24 (Ciccia et al., 2007), and 
FAAP100 (Ling et al., 2007).
1.5 The FA-Pathway
The products of the FA genes interact with themselves and with a number of other proteins in 
a common pathway. The FA pathway for genomic maintenance, also called FA/BRCA pathway, 
is a DNA damage-activated signaling pathway, important for the recognition of DNA-interstrand 
crosslinks and the initiation of repair of these lesions by translesion synthesis and homologous 
recombination (see below “FA and DNA Repair”). According to their presumptive functions, the 
FA genes and their proteins can be divided into three major groups (reviewed in Neveling et al., 
2007a and Wang, 2007) (Fig. 3). The fi rst group comprises proteins FANCA, B, C, E, F, G, L, and 
M. These “group 1 proteins” form a multiprotein complex, labelled “FA core complex”. In response 
to DNA damage, this FA core complex is sequentially assembled into different subcomplexes. 
The fi rst subcomplex is the heterodimer FANCA/FANCG, which is usually found in the cytoplasm. 
It is thought that binding of FANCG blocks the bipartite nuclear localisation signal (NLS) of FAN-
CA, thus retaining FANCA in the cytoplasm. In response to DNA damage, FANCA is phosphory-
lated, possibly leading to a conformational change and translocation of FANCG to another region 
of FANCA, initiating its nuclear translocation (Medhurst et al., 2006). A second subcomplex lo-
cated in the cytoplasm consists of FANCB, FANCL and FAAP100 (Medhurst et al., 2006; Ling et 
al., 2007). The nuclear localization of this subcomplex depends on FANCA and FANCM (Ling et 
al., 2007). Inside the nucleus, the subcomplexes FANCA/FANCG and FANCB/FANCL/FAAP100 
assemble around FANCM, which has a predominant nuclear localization. Depending on FANCM, 
FANCA/FANCG and FANCB/FANCL/FAAP100 interact with each other and form another stable 
subcomplex. This subcomplex is independent of FANCC, FANCE and FANCF, suggesting that 
these proteins act „downstream“ with regard to core complex formation (Medhurst et al., 2006). 
FANCC and FANCE are part of yet another subcomplex, while FANCF serves as a adaptor 
between this heterodimer and the proteins around FANCM. The subcomplex FANCC/FANCE 
appears to recruit FANCD2 to the core complex, while FANCF stabilizes the entire complex by 
interactions with FANCA/FANCG and FANCC/FANCE (Medhurst et al., 2006).
FANCM binds directly to a protein called FAAP24, which is a likely candidate protein of the FA 
core complex (Ciccia et al., 2007). FANCM and FAAP24 are the only components of the core 
complex shown to have DNA interacting domains and activities (Ciccia et al., 2007; Wang, 2007). 
The primary role of FANCM might be the detection of ICLs. FANCM and FAAP24 thus might target 
the core complex to stalled replication forks, where activation through phosphorylation by ATR 
takes place. There are several components of the FA core complex that are hyperphosphorylated 
in response to DNA damage, including FANCM, FANCA, FANCE and FANCG. However, these 
proteins are not only phosphorylated by ATR, but phosphorylation also depends on the down-
stream checkpoint kinase 1 (CHK1), and possibly other kinases (Wang, 2007).
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It is suggested that the core complex has at least three important roles in the FA/BRCA network 
(Wang, 2007). One of these functions is the interaction with DNA through FANCM and FAAP24 
which anchors the core complex to sites of DNA damage. Processing DNA for subsequent repair 
might be another function. However, the main function of the group 1 proteins seems to be the 
posttranslational modifi cation of the two proteins that form “group 2”. This occurs via monoubiqui-
tination of group 2 proteins (FANCD2 and FANCI, also called “ID complex”) at their highly conser-
ved lysine residues. This posttranslational modifi cation is carried out by UBE2T as the E2 ligase 
and FANCL as the E3 catalytic subunit. Monoubiquitinated FANCD2 and FANCI are recruited to 
nuclear foci as presumptive  sites of DNA repair. Interestingly, the formation of these foci depends 
not only on the FA core complex, but also on BRCA1, ATR and the phosphorylated histone H2A 
variant yH2AX which specifi cally associates with damaged DNA (Wang, 2007).
Once activated in response to DNA damage or stalled replication forks, the active ID complex, 
supported by BRCA1, recruits downstream effector proteins. These remaining three FA proteins 
(group 3) are not involved in the posttranslational modifi cation of the ID complex itself. Group 3 
proteins include FANCD1 (= BRCA2), FANCN (= PALB2, i.e. partner and localizer of BRCA2), and 
FANCJ (= BRIP1, i.e. BRCA1 interacting protein 1, also known as BACH1). While FANCJ/BRIP1 
is thought to stabilize the replication fork and enable translesion synthesis, FANCD1/BRCA2 in 
combination with FANCN/PALB2 uploads the RAD51 recombinase. These proteins may also 
function in restarting  the replication fork after homologous recombination. All of the latter proteins 
also colocalize within repair foci.
Figure 3 Model of the FA/BRCA signaling network. An ICL stalls a replication fork. ATR is activated and 
phosphorylates FANCM, FANCD2, FANCI and FANCD1/BRCA2. The FA core complex (FANCA, -B, -C, 
-E, -F, G, -L and -M, orange to red) is assembled and loaded onto dsDNA through FANCM and the Hef-
interacting protein, HIP (FAAP24). The active FA core complex translocates along DNA and, as a E3 
ligase, monoubiquitinates FANCD2 and FANCI by means of UBE2T as the E2 ligase and FANCL as the E3 
catalytic subunit. The ID complex (FANCI and -D2, yellow) is directed to chromatin at the stalled replication 
fork via γH2AX. The active ID complex, supported by BRCA1, recruits downstream effector proteins (green). 
While FANCJ/BRIP1 is thought to stabilize the replication fork and enable translesion synthesis, FANCD1/
BRCA2 in combination with FANCN/PALB2 uploads RAD51 (violet) and is attributed a role in restart of the 
replication fork after homologous recombination. From Schindler and Neveling, in press.
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1.6 FA and DNA Repair
As already mentioned, FA cells are hypersensitive towards DNA crosslinking agents, implying a 
defect in the repair of DNA interstrand crosslinks (ICLs). ICLs inhibit essential processes such 
as DNA replication and transcription. They therefore must be repaired or bypassed for cells to 
survive (Wang, 2007). However, in eukaryotes the pathway that repairs ICLs is not well under-
stood (Dronkert and Kanaar, 2001). A current concept of ICL repair implies that DSBs (which are 
intermediates during repair of ICLs) are probably not required for the activation of the FA pathway. 
Rather, the FA pathway may instead be activated by stalled replication forks that result from ICLs. 
It is thought that FANCM and FAAP24 might target the FA core complex to stalled replication forks, 
where it is phosphorylated by ATR. ATR also phosphorylates other proteins such as the H2AX, 
which is incorporated in the chromatin surrounding the damaged DNA. The ICL is unhooked by 
two endonuclease-heterodimers MUS81-EME1 and XPF-ERCC1. Unhooking of the ICL results 
in a DNA double strand break (DSB). The activated FA core complex then monoubiquitinates both 
members of the ID complex, FANCD2 and FANCI, via its catalytic subunit FANCL. The activated 
ID complex is recruited to chromatin and retained there by yH2AX and BRCA1. The complex con-
sisting of BRCA2/PALB2/RAD51 is likewise recruited, promoting homologous recombination as 
error free repair of the DSB. The ID complex is also thought to recruit the translesion polymerases 
REV1 and REV3, possibly similar to monoubiquitinated PCNA that allows translesion bypass by 
polymerase switching. Loading of the translesion polymerases might be facilitated by the helicase 
BRIP1 (= FANCJ). Owing to their DNA-processing qualities, other proteins like TOPBP1, MLH1 
or PMS2 may participate in the complex network of DNA repair proteins (Wang, 2007). Cells with 
defective core complex genes show only modest reductions of homologous recombination repair. 
In contrast, homologous recombination is severly affected in cells defi cient for BRCA2 or PALB2 
(= FANCN).
1.7 FA and Cell Cycle
Since FA cells are defective in the removal of ICLs, persisting stalled replication forks activate 
cell cycle checkpoint controls (reviewed in Schindler et al., 2007a). These signaling cascades 
ensure that cell cycle progression occurs only after successful bypass or repair of a given lesion. 
While cells in G0/G1 have a 2c DNA content, cells in G2/M have completed semiconservative 
DNA replication. These cells therefore have a 4c DNA content. FA cells accumulate at the S/G2 
border content after exposure to DNA damaging agents. Since cells in both G2 and  M have a 4c 
DNA content, G2 and M phase cells cannot be discriminated solely on the basis of DNA content. 
However, a series of experiments using phosphohistone 3 (3HP) as a cellular marker (whose 
expression is limited to the M phase of the cell cycle) proved that the MMC-induced accumulation 
of cells occurs prior to the M-phase but after completion or near completion of DNA-replication. 
These observations localize the putative crosslink-sensitive checkpoint into the early portion of 
the G2 phase, presumably close to the S/G2 border. Early cell kinetic studies by Kubbies et al. 
(Kubbies et al., 1985) clearly showed delay and arrest during both, the S and G2 phases of the 
cell cycle. Since cell cycle studies uniformly prove the 4c DNA content of cells that accumulate 
in response to crosslinking agents, is comes down to a more or less semantic argument whether 
to call these accumulations late S or early G2. These observations leave little doubt that the G2 
phase checkpoint functions normally in FA cells, as previously demonstrated by the careful stu-
dies of Heinrich et al. (Heinrich et al., 1998) and Freie et al. (Freie et al., 2004). As pointed out by 
these authors, spontaneous or crosslink-induced accumulations of FA cells in the G2 phase of the 
cell cycle do not refl ect an abnormal cell cycle response per se, but rather represent a completely 
normal cellular response to unresolved DNA damage.
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1.8 FA and Revertant Mosaicism
Revertant mosaicism is a rather frequent phenomenon in FA (Lo Ten Foe et al., 1997; Gregory et 
al., 2001; Gross et al., 2002; reviewed in Hoehn et al., 2007). One out of four to fi ve patients with 
FA experience a reversion or attenuation of their constitutional mutations during their lifetime. If 
the reversion event takes place in a bone marrow stem cell or in an early precursor cell of hema-
topoiesis, peripheral blood cell counts may gradually recover, leading to improved quality of life. 
Depending on the mechanism of somatic reversion, the function of the affected cell lineage may 
be partly or completely restored (reviewed in Kalb et al., 2006). Complete restoration of a cellular 
phenotype to wildtype usually results from mechanisms such as intragenic recombination, back-
mutation (reverse point mutation), or gene conversion (Gregory et al., 2001; Hirschhorn, 2003). 
Partial restoration of protein function has been observed with socalled compensating or second 
site mutations (Waisfi sz et al., 1999a). All four principal mechanisms have been implicated in 
revertant mosaicism in FA (reviewed in Hoehn et al., 2007): Intragenic crossover is a conserva-
tive mechanism of mitotic recombination, leading for example to haplotype differences between 
MMC-sensitive fi broblasts and MMC-resistent lymphoblasts suggesting a mitotic recombination 
event as explanation for the phenotypic reversion to MMC-resistance (Lo Ten Foe et al., 1997) or 
leading to the simultaneous presence of different alleles in the reverted lymphoid cells, the wild-
type alleles and alleles carrying both mutations (Gross et al., 2002). Gene conversion is another 
conservative mechanism of mitotic recombination without, however, mutual strand exchange. An 
intact homologous copy of the mutated region is required in order to serve as template for the 
conversion of the mutated to wildtype sequence. Gene conversion can only function in compound 
heterozygous patients, and it does not function if the homologous gene region on the other allele 
is deleted. Back mutation is another possible mechanism underlying revertant mosaicism. In 
compound heterozygous FA patients, back mutation has been assumed as probable mechanism 
of reversion since (1) the homologous gene region opposite to the reverted mutation was deleted 
in some of these patients, and (2) the reverted allele displayed the original wildtype rather than 
any random sequence (Gross et al., 2002). Most presumptive cases of back mutation reported 
were observed in FANCA. Compensatory or second site mutations in cis appear to be the most 
frequent type of mechanism underlying revertant mosaicism in FA. Even though this type of rever-
sion may not result in complete restoration of protein function, it leads to at least partial functional 
rescue. The compensating second site mutations can lead to partial or complete mRNA rescue 
without the necessity for elimination of the constitutional mutation. Even though the resultant pro-
tein may differ from wildtype, its function often turns out to be suffi cient for phenotypic reversion 
(Waisfi sz et al., 1999a).
Evidence for each of these mechanisms has been obtained in mosaic FA patients, but their mo-
lecular details are not fully understood. Patients belonging to subtypes FA-A, FA-C, FA-D1, FA-
D2 and FA-L have developed revertant mosaicism, with subtypes FA-A and FA-D2 being most 
frequently involved. 
1.9 FA and Oxidative Stress
In addition to their increased sensitivity towards DNA-crosslinking agents, FA cells are exceedingly 
sensitive to reactive oxygen species (ROS) which is unique for any of the human caretaker gene 
syndromes (reviewed in Neveling et al., 2007a). FA cells grow poorly in conditions of ambient oxy-
gen concentration (Schindler and Hoehn, 1988) and demonstrate a clear oxygen-dependence of 
chromosomal aberrations (Joenje et al., 1981). Growth and cell cycle transit of FA fi broblasts can 
be restored to near normal by growing these cells under hypoxic cell culture conditions (5 instead 
of 21% v/v oxygen). There are speculations that oxidative stress might account for many of the 
clinical and cellular abnormalities in FA, including malformations, bone marrow failure, malignan-
cies, pigmentary changes and diabetes (Pagano et al., 2005). Experiments with murine FA bone 
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1.10 FA and Cancer
As most detrimental manifestation of genetic instability, FA patients share a high risk for the oc-
currence of characteristic malignancies at relatively young age (reviewed in Neveling et al., 2007c 
and Schindler and Neveling, in press). Approximately 23% of FA patients develop one kind of neo-
plasm or more during their lifetime. In most cases, there are sharply increased risks for acute my-
eloid leukemia (AML) during childhood and squamous cell carcinomas (SCC) becoming effective 
during young adulthood. These risks are associated with defects of any of the FA genes except 
FANCD1 and -N. FANCD1 is also known as BRCA2 and FANCN as PALB2. Biallelic mutations in 
either of these genes consistently result in a type of FA with very early onset of cancers such as 
medulloblastomas, nephroblastomas (Wilms tumor), and AML. Defects of FANCD1 and -N inclu-
de a number of cases affected by multiple tumors. FA-D1 and -N patients invariably succumb to 
their malignancies at early age. Given the high degree of genomic instability and elevated mutati-
on rates seen in FA cells, there is little doubt about a causal relationship between the FA-specifi c 
defect of genomic maintenance and the emergence of cancer in FA patients.
Figure 4 Hypothetical role of human caretaker genes in the DNA damage response. DNA damage can 
be induced in different ways, for example by chemicals or ionizing radiation or, endogenously, by reactive 
oxygen species. As long as caretaker genes are intact, DNA damage is recognized and, dependent of the 
kind of damage, checkpoints are activated, and either DNA repair or elimination via apoptosis will occur. 
In the case of defective caretaker genes, a regulated and orderly cell response is not guaranteed. DNA 
damage recognition and repair might be impaired, not occur at all, or be error-prone, resulting in genetic 
instability. As a result, mutations accumulate, ultimately leading either to cell death or to the emergence of 
malignant cell growth. From Neveling et al., 2007c.
marrow cells lead to the hypothesis that the accumulation of DNA damage resulting from ROS 
provides a plausible explanation for bone marrow failure in FA. This hypothesis assumes that (1) 
DNA damage in FA is caused by ROS and oxidative stress, and (2) mutational inactivation of any 
of the FA genes causes inability to properly recognize and/or repair ROS-induced DNA damage 
(Fig. 4). So far, there is no direct evidence for any of these assumptions.
1 Introduction
- 20 -
1.11 Thesis Aims
The fi rst question I tried to answer was whether the hypersensitivity of bladder cancers from non-
FA patients towards the chemotherapeutic agent cisplatinum might be due to disruption of the 
FA/BRCA pathway. Bladder cancers show frequent deletions of chromosomal regions including 
FANCC and FANCG such that lack or alteration of these proteins might explain sensitivity to-
wards cisplatinum as a DNA-crosslinking agent. However, the experiments showed that the only 
instance of disruption of the FA/BRCA pathway occurred via hypermethylation of FANCF, and this 
seemed to be rather by chance. Thus, epigenetic silencing of FANCF in many types of cancers is 
a likely consequence and not a cause of tumor initiation. 
The important question of genotype-phenotype correlations in FA has so far not been suffi ciently 
answered. I therefore studied two of the rarer FA genes and their resulting phenotypes in de-
tail, hoping to establish a pattern of genetic changes that would explain and predict the clinical 
manifestations of the disease. The fi rst gene I investigated was FANCE. At the beginning of this 
study, not much was known about FANCE, except that it was thought to form a bridge between 
FANCL and FANCD2 by bringing the substrate protein FANCD2 to the catalytic protein FANCL. 
FA-E belongs to the rare FA subgroups with only six patients described. I was able to collect a 
worldwide cohort of fi fteen additional FA-E patients (collaborating laboratories were in Germany, 
Spain, the Netherlands and the USA). Other than typical FA core complex genes, the pattern of 
genetic alterations in FANCE turned out to be rather unusual with mostly truncating and only a 
single, albeit recurrent, missense mutation. This unusual pattern is reminiscent of that found in 
FANCF, another rare core complex gene. By performing an extensive series of complementation 
studies employing retroviral vectors I was able to prove the innocuous nature of a large number 
of FANCE missense mutations. c.1111C>T remained as the only missense alteration that impairs 
protein function. These fi ndings suggest that genetic variability is well tolerated and can be rather 
high in genes whose products functions as mere adaptor proteins.
The second gene investigated in the context of putative genotype-phenotype correlations was 
FANCL. FANCL is thought to be the catalytic subunit of the E3 ubiquitin ligase represented by 
the FA core complex and necessary for monoubiquitination of FANCD2 and FANCI. I succeeded 
in identifying and analyzing the worldwide second, third and fourth FANCL patients. In one of 
these patients a somatic reversion event had occurred, adding FANCL to the list of FA genes 
that experience somatic reversions (“natural gene therapy”). Although based on only few patients, 
the results of my study show that FA-L patients have a similar spectrum of mutations and clinical 
phenotypes to most other FA core complex genes. Prior to the present work only a single FA-L 
patient had been published. This patient had a severe phenotype and died in early infancy. This 
single observation has led to the speculation that FA-L patients might be so rare because the ma-
jority of FANCL mutations would not be compatible with survival. The data presented in paper 3 
of my thesis are at clear variance to this theory. The study of FANCL was initiated by my graduate 
student colleague Reinhard Kalb, now Cambridge UK, who discussed one of these patients in his 
PhD thesis (“Fanconi anemia and RAD50 defi ciency: genetic and functional analysis”, Reinhard 
Kalb, 2007). Together, we also worked on the molecular analysis and functional characterization 
of FANCD2 by examining a cohort of 33 patients. We were able to show that all FA-D2 patients, 
although severly affected, carry at least one hypomorphic mutation allele which obviously as-
sures their survival. This is an important fi nding which underlines the central role of the FANCD2 
protein in the FA/BRCA network of caretaker genes. 
As ongoing effort throughout the entire time of my graduate work, I participated in the worldwide 
search for novel FA genes. In order to make progress in this highly competitive area of gene dis-
covery, I collaborated with a number of laboratories in Germany, UK, Spain, the Netherlands and 
the USA. I was very fortunate to be part of the discovery of three new FA genes: FANCJ/BRIP1, 
FANCN/PALB2 and FANCI. FANCJ/BRIP1 was found by positional cloning using consanguineous 
Inuit families. The principle investigator in this collaboration was Arleen Auerbach from the Ro-
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ckefeller University in New York. FANCN/PALB2 was identifi ed under the leadership of Nazneen 
Rahman (Sutton, Surrey, UK) by a candidate gene approach. FANCI was detected in the labora-
tory of Tony Huang (New York University, USA) by FANCD2 protein sequence- based homology 
search. My contributions to these gene discoveries were in the area of complementation and cell 
cycle studies, candidate gene evaluations, mutation analysis and protein expression studies.
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more frequently affected than females with major risk fac-
tors being advanced age and exposure to arylamines, most-
ly due to cigarette smoking (Borden et al., 2005). There are 
two major types of bladder cancer: around 80% present as 
superficial papillary tumors (pTa or pT1), only 10–15% of 
which may later invade the muscle wall during tumor pro-
gression. Non-invasive tumors can successfully be treated 
by transurethral resection (TUR), often followed by adju-
vant intravesical immunotherapy or chemotherapy using 
mitomycin C (MMC). In contrast, 20% of bladder cancers 
show muscle invasion at initial presentation (pT2–pT4). The 
prognosis of these patients is poor despite aggressive treat-
ment with radical cystectomy, radiation and chemotherapy 
 Abstract.  Bladder carcinomas frequently show extensive 
deletions of chromosomes 9p and/or 9q, potentially includ-
ing the loci of the Fanconi anemia (FA) genes  FANCC and 
 FANCG . FA is a rare recessive disease due to defects in any-
one of 13 FANC genes manifesting with genetic instability 
and increased risk of neoplasia. FA cells are hypersensitive 
towards DNA crosslinking agents such as mitomycin C and 
cisplatin that are commonly employed in the chemotherapy 
of bladder cancers. These observations suggest the possibil-
ity of disruption of the FA/BRCA DNA repair pathway in 
bladder tumors. However, mutations in  FANCC or  FANCG 
could not be detected in any of 23 bladder carcinoma cell 
lines and ten surgical tumor specimens by LOH analysis or 
by FANCD2 immunoblotting assessing proficiency of the 
pathway. Only a single cell line, BFTC909, proved defective 
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for FANCD2 monoubiquitination and was highly sensitive 
towards mitomycin C. This increased sensitivity was re-
stored specifically by transfer of the  FANCF gene. Sequenc-
ing of  FANCF in BFTC909 failed to identify mutations, but 
methylation of cytosine residues in the  FANCF promoter 
region was demonstrated by methylation-specific PCR, 
 Hpa II restriction and bisulfite DNA sequencing. Methyla-
tion-specific PCR uncovered only a single instance of 
 FANCF promoter hypermethylation in surgical specimens 
of further 41 bladder carcinomas. These low proportions 
suggest that in contrast to other types of tumors silencing 
of  FANCF  is a rare event in bladder cancer and that an intact 
FA/BRCA pathway might be advantageous for tumor pro-
gression.  Copyright © 2007 S. Karger AG, Basel 
 Bladder cancer is a disease heterogeneous in morpholo-
gy, tumor biology, natural history and prognosis (Borden et 
al., 2005; Knowles, 2006). It belongs to the ten leading types 
of diagnosed malignancies with a documented number of 
63,210 new cases in the US in 2005. Males are three times 
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with cisplatin-based regimes (Knowles, 2001; Borden et al., 
2005). A number of chromosomal changes have been asso-
ciated with bladder tumor development and tumor progres-
sion. While oncogenic mutations of  FGFR3 and loss of het-
erozygosity (LOH) at chromosome 9 are the most common 
alterations in non-invasive tumors, numerous genetic alter-
ations including  TP53 mutations and LOH at 3p, 8p, 9p/q, 
13q, 14q and 17p are detectable in invasive urothelial carci-
nomas (UC) (Knowles, 2006; Schulz, 2006). Loss of genetic 
material on chromosome 9 is the most frequent alteration 
in UC and is found in more than 50% of all bladder tumors 
(Knowles, 1999; Kimura et al., 2001; Williams et al., 2002). 
Frequently deleted regions include 9p13 ] p12, 9p21, 9q12, 
9q13 ] q31, 9q22.3, 9q32 ] 33, 9q33 ] 34 and 9q34 (Keen and 
Knowles, 1994; Knowles, 1999; Kimura et al., 2001; Florl and 
Schulz, 2003). 
 Since deletions on chromosome 9 are found throughout 
all stages and grades of bladder cancer, it is believed that 
inactivation of genes on chromosome 9 represents an early 
event in tumor progression. One established target of dele-
tions is  CDKN2A at 9p21. However, as several other regions 
on 9p and 9q are consistently affected by LOH, the involve-
ment of further, as yet unidentified tumor suppressor genes 
must be considered. 
 Two prominent human caretaker genes are located in the 
frequently deleted regions of chromosome 9. These genes, 
 FANCC (9q22.3) and  FANCG (9p13), belong to a family of 
at least 13 genes  (FANCA, -B, -C, -D1/BRCA2, -D2, -E, -F,
-G, -I, -J/BRIP1, -L, -M/HEF  and -N/PALB2) which act in the 
FA/BRCA pathway of DNA damage recognition and repair 
(Reid et al., 2007; Xia et al., 2007). The products of eight of 
these genes  (FANCA, -B, -C, -E, -F, -G, -L  and -M) form
a nuclear complex required for monoubiquitination of 
FANCD2 during S-phase and in response to replication 
fork-stalling DNA damage. Monoubiquitinated FANCD2 is 
targeted to chromatin and assembles in nuclear foci repre-
senting regions of DNA repair. FANCD2 directly interacts 
with BRCA2, and co-localizes with DNA repair proteins 
such as BRCA1 and RAD51 involved in translesion synthe-
sis and homologous recombination (Joenje and Patel, 2001; 
Kennedy and D’Andrea, 2005; Niedernhofer et al., 2005; 
Thompson et al., 2005). Three of the FA proteins, FANCD1, 
FANCJ, and FANCN, are not required for FANCD2 mono-
ubiquitination (working downstream), and these three pro-
teins are thought to be involved in tumorigenesis in hetero-
zygous state:  FANCD1 is identical to the breast cancer sus-
ceptibility gene  BRCA2 (Howlett et al., 2002), FANCJ is also 
known as BRCA1-interacting protein (BRIP1) (Levran et 
al., 2005) and FANCN is a partner and localizer of BRCA2 
(Xia et al., 2006). Cells deficient in any of the FA proteins 
show chromosomal instability, increased sensitivity to-
wards DNA damaging agents such as cisplatin, MMC or 
diepoxybutane (DEB) and hypersensitivity towards oxygen 
(Sasaki and Tonomura, 1973; Joenje et al., 1981). Biallelic, or 
hemizygous in case of  FANCB , germline mutations in any 
one of the FA genes cause the recessive hereditary disease 
FA which is associated with a greatly increased risk for neo-
plasia (Alter, 2003). 
 There are three main reasons for investigating a putative 
connection between FA genes and bladder cancer. First, the 
cellular and clinical phenotypes of FA indicate a connection 
between the FA proteins, DNA repair and tumorigenesis. 
Bladder cancer cells from invasive tumors are known to be 
genomically unstable. Second, cisplatin is a widespread 
component of all current chemotherapy regimes for inva-
sive bladder cancer, and MMC is the most commonly used 
drug for adjuvant treatment of papillary bladder cancers. FA 
cells are highly sensitive towards these two DNA crosslink-
ing agents. Third, deletions of chromosome 9 often include 
the loci of two of the FA genes  (FANCC and  FANCG) . In or-
der to establish whether disruption of FA genes might be 
involved in bladder cancer tumorigenesis or tumor progres-
sion, we investigated DNA from ten bladder cancers for 
LOH at  FANCC and  FANCG . Further 41 tumor tissues were 
investigated for methylation of the  FANCF promoter region 
and 23 bladder cancer cell lines for defects in the FA/BRCA 
pathway.
 Materials and methods 
 Cancer tissues 
 DNA from 41 bladder carcinoma tissues was used which had been 
analyzed for methylation of multiple other genes in a previous study 
(Neuhausen et al., 2006). Of the 41 carcinomas, two were staged as pTa, 
five as pT1, 13 as pT2, 16 as pT3 and five as pT4. One case was graded 
as G1, two as G2, 37 as G3, and one as G4, respectively. Use of patient 
tissues was approved by the Institutional Review Board at the faculty 
of medicine of the Heinrich Heine University Düsseldorf. 
 Cell lines and cell culture 
 The following cell lines derived from human bladder carcinomas 
were investigated in this study (see  Table 1 for references): 5637, 
BFTC905, HT1376, SD, SW1710, VMCub1 and VMCub2 were obtained 
from the DSMZ (Braunschweig, Germany), the cell lines 253J, 639V, 
647V, BFTC909, EJ, J82, RT112, RT4, T24, Umuc3 and VMCub3 were 
from Dr. J. Fogh (New York, NY). HIA was a gift of H. Hameister (Ulm, 
Germany) and MGHU4 of W. Beecken (Frankfurt, Germany). DSH1 
was established by one of the authors (M.A.K., reported in Williams et 
al., 2002). In addition, we investigated the only known cell line derived 
from a squamous cell carcinoma of the bladder (Scaber) and a novel cell 
line derived from an invasive bladder carcinoma (BC44; Seifert et al., 
unpublished). Primary urothelial strains (UP124, UP125) were used as 
controls.
 Bladder cancer cell lines were cultured in Eagle’s minimal essential 
medium (MEM) (Gibco, Karlsruhe, Germany) supplemented with 16% 
fetal bovine serum (FBS) (Sigma, Taufkirchen, Germany). All cell cul-
tures were kept in high humidity incubators equipped with CO 2 sen-
sors in an atmosphere of 5% (v/v) CO 2 by replacing ambient air with 
nitrogen. Primary urothelial cells were cultured with the specifics de-
scribed (Swiatkowski et al., 2003). 
 Cell cycle analysis  
 Approximately 5  ! 10 5 cells each were cultured for 48 h with-
out or with 5 or 10 ng/ml MMC, respectively. Cells were harvested
by trypsinization and centrifuged. The cell pellets were resuspended 
in 1 ml staining buffer/1 million cells (staining buffer: 154 mM
NaCl, 0.1 M Tris pH 7.4, 1 mM CaCl 2 , 0.5 mM MgCl 2 , 0.2% BSA, 0.1% 
NP40) and 1   g/ml DAPI. Following incubation for 30 min at 4  °  C, 
DNA histograms were recorded using an analytical f low cyto-
meter of conventional design (LSR, Becton Dickinson, Heidelberg, 
Germany).
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 Complementation 
 One of the bladder cancer cell lines was transduced with retroviral 
constructs containing full-length cDNAs of  FANCA, -C, -E, -F, -G or 
 -L and analyzed for MMC sensitivity using cell cycle analysis as de-
scribed (Hanenberg et al., 2002).
 FANCD2 immunoblotting 
 FANCD2 immunoblotting was performed as described (Garcia-
Higuera et al., 2001) with minor modifications: cells were left untreat-
ed or were treated with 1   g/ml cisplatin for 6 or 16 h. Lysis was achieved 
with 1 ! lysis buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 2 mM 
EDTA, 2 mM EGTA, 25 mM NaF, 25 mM   -glycerophosphate, 0.1 mM 
Na 3 VO 4 , 0.3% NP40, 0.2% Triton X-100, proteinase inhibitors (Roche 
Diagnostics GmbH, Mannheim, Germany)). 50   g of protein extract 
was loaded on 7% Tris-acetate gels (Invitrogen, Karlsruhe, Germany) 
and electrophoresis was performed at 120 V for 6 h. Protein transfer 
was overnight at 4  °  C and 20 V onto PVDF membranes (HybondP, Am-
ersham Biosciences, Little Chalfont, UK). Immunoblots were blocked 
with 5% non-fat dry milk (Hu et al., 2002) in 1 ! PBS, 0.05% Tween 
(PBS-T). As primary antibody, the mouse monoclonal FANCD2 anti-
body FL-17 (Santa Cruz Biotechnology Inc., Heidelberg, Germany) was 
used at a dilution of 1: 800. As secondary antibody we used the anti-
mouse IgG horseradish-peroxidase-linked F(ab  ) 2 from sheep (Amer-
sham Biosciences, Little Chalfont, UK, dilution 1: 2000). For chemilu-
minescence detection, a standard ECL reagent (Amersham Bioscienc-
es, Little Chalfont, UK) was employed.
 Fluorescence in situ hybridization (FISH) 
 FISH was performed as described elsewhere (Lichter and Cremer, 
1992). The bacterial artificial chromosome (BAC) clone RP11-139M16 
containing the entire  FANCF  gene  was obtained from the Wellcome 
Trust Sanger Institute (Cambridge, UK). 1   g of BAC DNA was nick-
translated using biotin-16-dUTP and used as a probe on chromosome 
spreads prepared from the BFTC909 cell line. 100 ng of labeled probe 
dissolved in hybridization mixture per slide was hybridized to dena-
tured metaphase chromosomes for 48 h at 37 °  C. Prior to hybridization, 
the labeled probe was annealed with a 100-fold excess of Cot-1 DNA at 
37  °  C. Post-hybridization washing, detection of the probe with fluores-
cein isothiocyanate (FITC)-conjugated avidin, biotinylated anti-avi-
din antibody and FITC-avidin and counterstaining with 4  ,6-diamid-
ino-2-phenylindole (DAPI) were accomplished according to a standard 
protocol (Lichter and Cremer, 1992). Images of FITC and DAPI fluo-
rescence were recorded separately using a Zeiss epifluorescence micro-
scope equipped with appropriate excitation filters and a CCD camera. 
Digitalized images of the FITC and DAPI signals were overlaid using 
the Easy FISH 1.0 software (Applied Spectral Imaging, Edingen-Neck-
arhausen, Germany). A minimum of 15 metaphases per hybridization 
were examined to assess the location of the probe on specific chromo-
somes.
 In addition, human chromosome 11 paint obtained from a com-
mercial source (HPW Diagnostics, Rabenau, Germany) was used to 
hybridize on metaphases of the BFTC909 cell line according to the 
manufacturer’s protocol. 
 PCR and sequencing 
 High molecular weight genomic DNA was prepared using a salting-
out technique. Amplification of  FANCC, FANCG and  FANCF exons 
was performed using Taq polymerase and, where available, published 
primer sets ( FANCC : Gibson et al., 1993;  FANCG :  Auerbach et al., 
2003). For  FANCF  primers see  Table 2 . PCR products were purified us-
ing the GFX PCR DNA and Gel Band Purification kit (Amersham Bio-
sciences, Little Chalfont, UK). DNA sequencing of PCR products was 
performed using ABI-PRISM big-dye terminator chemistry on the ABI 
310 instrument (Applied Biosystems, Darmstadt, Germany). 
 Denaturing HPLC (dHPLC) 
 Ten different DNAs from blood cells and the corresponding ten 
tumor-derived DNA preparations were analyzed. Heteroduplex for-
mation of  FANCC and  FANCG PCR products was achieved by dena-
turating for 2 min at 96  °  C and cooling down to 4  °  C at 2  °  C/s. dHPLC 
Table 1. Bladder cancer cell lines used in this study, modified from Williams et al. (2005)
Cell line Grade/stage of tumor Sex Other information Reference
5637 UC M Primary tumor, bladder Williams, 1980
253J UC, G4 T4 M Metastatic tumor, lymph node Elliott et al., 1974; Masters, 2000
639V UC, G3 M Primary tumor, ureter Elliot et al., 1976
647V UC, G2 M Primary tumor, bladder Williams, 1980
BFTC905 UC, G3 papillary F Primary tumor, bladder Tzeng et al., 1996
BFTC909 UC, Tx G3 M Primary tumor, renal pelvis Tzeng et al., 1996
DSH1 UC, T1a G2 M Recurrence, untreated, bladder Williams et al., 2002
EJ UC, G3 F Primary tumor, untreated, bladder Williams, 1980
HIA UC not recorded not recorded Bruch et al., 1999
HT1376 UC, G3 F Untreated, bladder Rasheed et al., 1977
J82 UC, poorly differentiated, papillary M Primary tumor, treated, bladder O’Toole et al., 1978
MGHU4 UC M Urothelial atypia Lin et al., 1985
RT4 UC, G1 T2 M Recurrence, treated, bladder Rigby and Franks, 1970
RT112 UC, G2 papillary F Primary tumor, untreated, bladder Masters, 2000
SD UC not recorded Primary tumor, bladder Paulie et al., 1983
SW1710 UC, G3 papillary F Bladder Kyriazis et al., 1984
T24 UC, G3 F Primary tumor, untreated, bladder Williams, 1980
Umuc3 UC M Bladder Grossmann et al., 1986
VMCub1 UC M Primary tumor, bladder Williams, 1980
VMCub2 UC M Metastatic tumor, lymph nodes Williams, 1980
VMCub3 UC M Primary tumor, bladder Williams, 1980
Scaber Squamous cell carcinoma Bladder O’Toole et al., 1976
BC44 UC, T4 G3 F Bladder Seifert et al., unpublished
UP124 Normal urothelium, control M Ureter Swiatkowski et al., 2003
UP125 Normal urothelium, control F Ureter Swiatkowski et al., 2003
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analysis was performed on a Transgenomic WAVE system using the 
DNASep TM column (Transgenomic, Flein, Germany). The melting 
characteristics and separation modus of the DNA fragments were pre-
dicted by use of the wavemaker TM software (version 4.1.44). 5   l of the 
PCR products were injected and separated. If PCR products of DNAs 
from patients’ blood cells suggested heteroduplex formation, the cor-
responding tumor-derived DNAs were also analyzed.
 DNA methylation analysis 
 The  Hpa II-restriction assay, as well as methylation-specific PCR 
(MS-PCR) were performed as described previously (Taniguchi et al., 
2003). Bisulfite modification of genomic DNA employed the Cp-
Genome TM  DNA Modification Kit (Q-Biogene, Heidelberg, Germany). 
For bisulfite sequencing, bisulfite-treated DNA was amplified as previ-
ously described (Florl et al., 2004) with primers FF345B (nt –345 to
–315; 5  -GTTTAGAAAATTTTTATTTAAGGATA-3  ) and FR27B (nt 
–6 to +24; 5  -ATCCAAATACTACAAAAAAAATTCCATAAA-3  ) for 
37 cycles at 52  °  C annealing temperature. PCR products were separated 
by agarose gel electrophoresis and cloned into the TA-vector pCR4-
TOPO (Invitrogen, Karlsruhe, Germany). Several clones from each 
sample were sequenced by standard methods. 
 Comparative genomic hybridization (CGH)  
 CGH was performed as described previously (Tönnies et al., 2003) 
with slight modifications. In brief, test and control DNA were differ-
ently labeled by nick translation using SpectrumGreen  -dUTP and 
SpectrumOrange  -dUTP (Vysis, Wiesbaden, Germany). 200 ng of la-
beled test DNA, 200 ng reference DNA, and 12.5   g Cot-1 DNA were 
co-precipitated, denatured, and hybridized to denatured normal male 
metaphase spreads. After incubation for 3 days at 37  °  C, standard post-
hybridization washes were performed. Metaphase images were evalu-
ated as with the FISH studies. Image analysis and karyotyping were 
performed using the ISIS analysis system (Metasystems, Altlussheim, 
Germany).
 Spectral karyotyping (SKY) analysis 
 SKY was performed on chromosome preparations prepared from 
the BFTC909 cell line. The human SKY-Paint DNA kit from Applied 
Spectral Imaging (Migdal Ha’Eemek, Israel) was hybridized to dena-
tured metaphase spreads. After hybridization for 2 days at 37 °  C, slides 
were washed and haptenized probe sequences were detected following 
the manufacturer’s protocol. Slides were counterstained with DAPI 
and embedded in an antifade reagent (para-phenylenediamine). The 
multicolor hybridizations were visualized with the Spectral Cube sys-
tem (SD200). Spectral analysis and classification was done with the 
SKY-View 1.6 software (Applied Spectral Imaging). 
 Results 
 Bladder carcinomas often show deletions of chromosome 
9, apparently including regions that harbor the FA genes 
 FANCC and  FANCG . High sensitivity of these tumors to 
MMC and cisplatin raised the questions whether these FA 
genes are indeed subject to allelic loss in such cases and if so, 
whether the remaining alleles contain inactivating muta-
tions. According to a previous study using microsatellite 
markers between D9S168 and D9S158 (Kimura et al., 2001), 
DNA from ten bladder carcinoma tissues showed LOH in-
volving the regions of interest of chromosome 9 in the vicin-
ity of  FANCC and  FANCG . In our initial experiments, this 
tumor DNA and DNA from corresponding peripheral blood 
mononuclear cells was investigated for LOH at  FANCC and 
 FANCG  by comparing germline and tumor DNA on direct 
sequencing (see  Table 3 ). All base substitutions observed 
within  FANCG were polymorphisms rather than bona fide 
mutations. These polymorphisms included IVS4 –18T/G, 
IVS5 +58C/T (rs17885726) and IVS12 +7A/G (rs17882272). 
Our study revealed LOH at these sites in five tumors (T1, T2, 
T5, T6 and T7), while one case showed retention of hetero-
zygosity (T10). No LOH at  FANCG was detectable in the oth-
er four tumors: two were non-informative cases (T8, T9), 
and in the two remaining cases (T3, T4), the markers could 
not be analyzed because of inadequate amounts of tumor 
DNA ( Table 3 ).  FANCG is located between the 9p STR mark-
ers D9S171 and D9S1862. All five tumors with LOH at 
 FANCG showed also LOH of D9S171. Two of them (T2, T7) 
also exhibited LOH of D9S1862; in the three remaining (T1, 
T5, T6) this marker was not determined. 
 Sequencing of  FANCC in the DNA from the ten patients 
showed one case with retention of heterozygosity (IVS11 –
25A/C in T2), while all the remaining tumors were non-in-
formative cases ( Table 3 ).  FANCC is located between mark-
ers D9S196 and D9S287 on 9q. Two tumors (T2, T7) dis-
played LOH involving both these markers, while a single 
tumor had LOH involving D9S196 but was non-informative 
for D9S287 (T4).
 Since our pilot study confirmed frequent LOH on chro-
mosome 9 in bladder cancer involving at least the  FANCG 
gene locus, as a next step functional testing of the FA/BRCA 
pathway in bladder cancer cell lines was performed via 
FANCD2 immunoblotting. Defects in any FA core complex 
gene (to which both  FANCC and  FANCG  belong) result in 
lack of FANCD2 monoubiquitination after exposure to 
MMC or cisplatin. All 23 bladder cancer cell lines tested are 
known to carry extensive chromosomal aberrations which 
in the majority of cases involve chromosome 9 (Williams et 
al., 2002, 2005; Florl and Schulz, 2003). With the exception 
Primers for Designation Sequence (5]3)
Amplification FA-F, –50 for GCG GAT GTT CCA ATC AGT ACG 
FA-F, +50 rev CAC GAA GGC ATA TAT TTG GTG AGA 
Sequencing FA-F, –50 for GCG GAT GTT CCA ATC AGT ACG
FA-F, 123 for GCG CCA CAT CCA TCG GCG
FA-F, 681 rev GTG GAT GCC GGG TTC CAA CTC 
FA-F, 944 rev CAG AGG CTT TGA AAC CTA TTG TGC
FA-F, +50 rev CAC GAA GGC ATA TAT TTG GTG AGA 
Table 2. Oligonucleotide primers used
for genomic amplification and sequencing
of FANCF
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of a single cell line (BFTC909), all cell lines tested respond-
ed normally to cisplatin treatment with the appearance of 
monoubiquitinated FANCD2 (FANCD2-L) in addition to 
the native isoform (FANCD2-S), indicating a fully func-
tional FA core complex ( Fig. 1 A). Furthermore, prolonged 
cisplatin incubation times (16 h vs. 6 h) resulted in an in-
crease of the monoubiquitinated FANCD2 isoform, sug-
gesting regular function. In these cell lines, abrogation of 
the FA/BRCA pathway by mutations in  FANCD1/BRCA2 or 
 FANCJ/BRIP1 , located downstream of  FANCD2 (and there-
fore not necessary for FANCD2 monoubiquitination), were 
excluded via immunoblotting (data not shown).  FANCN 
mutations were not excluded since the gene had not been 
reported at the time of this study. The single exceptional
cell line BFTC909 displayed only the non-ubiquitinated 
FANCD2-S isoform suggesting a defect in one of the FA core 
complex genes. 
 Since defective FA genes cause cellular sensitivity to-
wards DNA damaging agents, the FANCD2 monoubiqui-
tination-deficient cell line BFTC909 and six randomly cho-
sen proficient bladder cancer cell lines were tested for MMC 
sensitivity resulting in G2 phase arrest.  Figure 1 B shows the 
cell cycle distribution of BFTC909 in comparison to the two 
proficient cell lines BFTC905 and RT112. BFTC909 proved 
higher sensitivity towards MMC as evidenced by a dispro-
portionate elevation of the G2 phase cell cycle fraction. A 
paired t-test indicated statistical significance of this hyper-
sensitivity, when the ratios of percentages of cells in G2 
phase relative to cells in S phase were compared with and 
without MMC treatment ( P = 0.014). In contrast to BFTC909, 
all other cell lines tested showed only minor increases of the 
G2:S ratio in response to MMC ( Fig. 1 C). 
 Lack of the FANCD2-L isoform combined with increased 
sensitivity towards MMC is characteristic of a defect in one 
of the FA core complex genes. In order to determine which 
FA core complex gene might disrupt the pathway in 
BFTC909, the cell line was transduced with six known FA 
core complex genes  (FANCA, -C, -E, -F, -G and  -L) . Surpris-
ingly, transduction with the vector expressing  FANCF in 
BFTC909 rather than  FANCG or  FANCC  restored a normal 
MMC response on cell cycle analysis ( Fig. 2 A). Comple-
mentation of BFTC909 exclusively by  FANCF was con-
firmed by FANCD2 immunoblotting ( Fig. 2 B). Only the 
 FANCF -transduced cells showed both, the native and the 
monoubiquitinated isoforms of FANCD2, while transduc-
tion with all other FA genes failed to restore FANCD2 
monoubiquitination. 
 Sequencing of  FANCF in BFTC909 failed to detect any 
mutation. Since silencing of  FANCF via hypermethylation 
of the promoter region had been reported in other types of 
neoplasias (reviewed in Taniguchi and D’Andrea, 2006), we 
investigated the methylation status of  FANCF in BFTC909, 
initially using a standard  Hpa II-restriction assay ( Fig. 3 A). 
In this line,  FANCF was found to be resistant to digestion 
by  Hpa II, but sensitive to  Msp I. This suggested at least par-
tial hypermethylation of  FANCF . Methylation-specific PCR 
confirmed methylation of the BFTC909  FANCF promoter 
which turned out to be almost complete ( Fig. 3 B). With the 
same technique, two further cell lines, VMCub1 and 639V, 
and one out of 41 surgical bladder tumor specimens (TCC8), 
Table 3. LOH analysis in bladder carcinoma tissues
Marker Position T1 T2 T3 T4 T5 T6 T7 T8 T9 T10
D9S168 10.578K LOH LOH LOH LOH LOH LOH n.i. LOH MI LOH
D9S157 17.618K LOH RET LOH n.i. LOH LOH n.i. n.i. RET n.i.
D9S162 19.669K LOH LOH LOH n.i. LOH LOH RET LOH n.i. LOH
D9S942 21.980K RET n.i. RET LOH RET RET RET RET LOH RET
D9S171 24.524K LOH LOH LOH LOH LOH LOH LOH LOH LOH LOH
FANCG 35.063K LOH LOH n.d. n.d. LOH LOH LOH n.i. n.i. RET
D9S1862 68.373K n.d. LOH n.d. LOH n.d. n.d. LOH n.d. n.d. n.d.
D9S15 69.571K LOH LOH n.i. n.i. n.i. LOH n.i. LOH n.i. LOH
D9S273 69.768K LOH LOH LOH n.d. LOH LOH LOH LOH LOH LOH
D9S153 78.810K n.d. LOH n.d. LOH n.d. n.d. LOH n.d. n.d. n.d.
D9S283 89.643K LOH n.d. LOH LOH LOH LOH n.i. LOH LOH LOH
D9S196 93.553K n.d. LOH n.d. LOH n.d. n.d. LOH n.d. n.d. n.d.
FANCC 94.490K n.i. RET n.i. n.i. n.i. n.i. n.i. n.i. n.i. n.i.
D9S287 95.545K n.d. LOH n.d. n.i. n.d. n.d. LOH n.d. n.d. n.d.
D9S180 97.729K n.d. n.d. n.d. LOH n.d. n.d. LOH n.d. n.d. n.d.
D9S176 99.137K n.i. LOH LOH n.i. LOH LOH n.i. LOH n.i. n.i.
D9S53 104.641K LOH n.d. n.i. n.i. LOH n.i. LOH LOH n.i. n.i.
D9S1872 118.869K LOH LOH RET LOH LOH LOH n.i. LOH LOH LOH
D9S63 129.734K n.d. n.i. n.d. LOH n.d. n.d. LOH n.d. n.d. n.d.
D9S1847 132.466K n.d. n.d. n.d. LOH n.d. n.d. n.i. n.d. n.d. n.d.
D9S158 136.325K LOH n.i. RET n.i. LOH LOH n.i. LOH LOH LOH
 Microsatellite markers were from Kimura et al. (2001). LOH: loss of heterozygosity; n.d.: not determined; n.i.: not informative; RET: retention 
of heterozygosity; MI: microsatellite instability.
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revealed partial hypermethylation. However, there was no 
concomitant evidence for defective FANCD2 monoubiqui-
tination in the two cell lines (data not shown). The hyper-
methylated BFTC909 cell line, one of the partially methyl-
ated cell lines (639V) and a non-methylated cell line (J82) 
were chosen for bisulfite sequencing in addition to normal 
peripheral blood mononuclear cells as control. As shown in 
 Fig. 3 C, nearly all CpG sites of the promoter region of 
 FANCF in cell line BFTC909 were methylated. Partial hy-
permethylation of 639V and the unmethylated status of J82 
were confirmed.
 Fig. 2.  Retroviral complementation of BFTC909. ( A ) Flow cytomet-
ric analysis (DNA histograms). Cells were native or transduced with 
retroviral vectors separately expressing the FA genes  FANCA , - C , - E , 
- F , - G or - L . Subsequently, cells were left untreated or treated with 10 
ng/ml MMC for 16 h. Treatment of BFTC909 with MMC results in a 
prominent G2 phase arrest, indicating that this cell line is hypersensi-
tive towards MMC. Only the transfer of  FANCF was able to restore the 
G2 phase arrest to normal. ( B ) FANCD2 immunoblotting of the cell 
line BFTC909 after transduction with retroviral vectors separately ex-
pressing six FA genes of the nuclear core complex. Only  FANCF was 
able to complement the defective FANCD2 monoubiquination as evi-
denced by the appearance of the FANCD2-L band. 
Fig. 1.  Functional analysis of the FA/BRCA pathway. ( A ) FANCD2 
immunoblotting of a primary urothelial cell culture (UP124) and the 
bladder carcinoma cell lines SD, BFTC909 and HT1376. Cells were 
treated with 1   g/ml cisplatin for 6 or 16 h. The blots reveal both non-
ubiquitinated (S) and monoubiquitinated (L) FANCD2 protein in the 
control cells UP124 as well as in bladder carcinoma cell lines SD and 
HT1376, with increasing levels of FANCD2-L upon longer treatment. 
In contrast, BFTC909 displays only the FANCD2-S band. ( B ) Flow cy-
tometric analysis (DNA histograms) of three bladder cancer cell lines 
(BFTC905, BFTC909 and RT112) following incubation with 5 ng/ml 
MMC. In contrast to the cell lines BFTC905 and RT112, proficient for 
FANCD2 monoubiquitination, BFTC909 responded to MMC with a 
pronounced G2 phase arrest indicating hypersensitivity towards the 
crosslinking agent. ( C ) Bar graph showing the sensitivity of seven blad-
der cancer cell lines towards MMC, represented by the ratios of per-
centages of cells in G2 phase to cells in S phase after treatment with 
5 ng/ml MMC (48 h). 
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 Chromosome 11, where  FANCF is located, is represent-
ed in BFTC909 by one intact copy and one copy involved 
in a translocation, as demonstrated by chromosome 11 
painting ( Fig. 4 A). Spectral karyotyping of BFTC909 re-
vealed a hypo-tetraploid karyotype with a large number of 
chromosomal aberrations including a translocation be-
tween chromosomes 11 and 3 ( Fig. 4 B). CGH revealed an 
underrepresentation of 11p and of distal 11q relative to 
overall ploidy status, but retention of proximal 11q ( Fig. 4 C) . 
Although there is no obvious breakpoint in 11p15, we ad-
ditionally excluded microdeletions affecting  FANCF at 
11p15 by FISH using a  FANCF probe. As shown in  Fig. 4 D, 
two signals each were detected for  FANCF  in control cells 
as well as in BFTC909 cells, indicating disomy for  FANCF 
 in BFTC909. In the NCBI single nucleotide polymor-
phism (SNP) database, four SNPs are described for the 
1125-nt coding region of  FANCF  (rs11556562, rs11026706, 
rs7103674, rs7103293). In BFTC909, all of these are homo-
zygous, suggesting loss of one allele early in tumor progres-
sion or evolution of the cell line and subsequent reduplica-
tion of the other allele. 
 In order to investigate the prevalence of  FANCF promot-
er hypermethylation in native bladder cancer tissues, DNA 
from 41 bladder cancer tissues previously studied for a range 
of methylation alterations (Neuhausen et al., 2006) was in-
vestigated by methylation-specific PCR of  FANCF . While all 
samples yielded strong bands using primers specific for the 
unmethylated sequence, only a single case was weakly pos-
itive with primers specific for the methylated sequence 
(TCC8, see above). In this particular tumor, hypermethyl-
ation in several other genes together with pronounced glob-
al hypomethylation had been observed in the previous study 
(Neuhausen et al., 2006). 
 Discussion 
 This is the first study of the FA/BRCA pathway in blad-
der cancer cells. Crosslinking compounds such as cisplatin 
or mitomycin C are frequent components of current chemo-
therapy regimens for bladder cancer. Their use is based on 
empirical clinical data, while an understanding of the bio-
logical basis of their efficacy is lacking (Lehmann et al., 
2003). Since many bladder carcinomas display extensive de-
letions of chromosome 9 carrying the FA genes  FANCC and 
 FANCG , loss of these genes might have been responsible for 
hypersensitivity towards DNA crosslinking agents. In par-
ticular,  FANCC is located at 9q22.3 within one of the most 
frequently deleted regions in bladder cancer (Knowles, 
1999; Kimura et al., 2001). We therefore expected to detect 
genetic alterations of  FANCC or  FANCG in bladder carcino-
mas. Contrary to our expectation, neither LOH analysis and 
sequencing of the two genes in tumor tissues with LOH, nor 
FANCD2 immunoblotting in cell lines revealed consistent 
defects in  FANCC or  FANCG .
 Following treatment with DNA damaging agents,  cells 
with defects in any of the FA core complex genes, including 
 FANCC and  FANCG, typically show prominent G2 phase 
accumulation and lack of monoubiquitination of FANCD2 
(Garcia-Higuera et al., 2001; Shimamura et al., 2002). 
When tested for these FA-typical cell cycle and immuno-
blotting phenotypes, only a single cell line out of 23 bladder 
carcinoma cell lines displayed such a typical FA cellular 
feature. Again contrary to our expectation, neither  FANCC 
nor  FANCG were found to be defective in this cell line 
BFTC909. Instead, its FA-like phenotype was caused by si-
lencing of the  FANCF  gene  due to promoter hypermethyl-
 Fig. 3.  Methylation analysis. ( A )  Hpa II restriction assay of BFTC909 
DNA. The  Hpa II restriction assay shows that the fragment +280 to 
+432 of  FANCF is not restricted by  Hpa II in BFTC909, while it is re-
stricted in a control DNA. U: untreated DNA; N: negative control. ( B ) 
MS-PCR analysis of  FANCF . Bladder carcinoma cell lines and tumor 
tissues were analyzed for  FANCF hypermethylation. Among the cell 
lines, only BFTC909 appeared almost completely methylated, whereas 
VMCub1 and 639V showed partial methylation. BFTC905, T24, 
HT1376, SW1710 and J82 are unmethylated. Leukocytes (Blood) and 
normal urothelial cells (UEC) served as controls. Among the three tu-
mor tissues shown here (TCC8, 9 and 10), one (TCC8) showed weak 
methylation. Note that the figure is composed from three different gel 
runs. U: unmethylated, M: methylated, SssI: Blood DNA methylated in 
vitro with CpG-methyltransferase from  Spiroplasma species. ( C ) Bisul-
fite sequencing analysis of the CpG island in the  FANCF promoter 
(from –345 to +24; 21 CpGs). The methylation status in different blad-
der cancer cell lines was investigated. A control DNA derived from 
normal human blood showed no methylation in the  FANCF  CpG is-
land, whereas the FA-deficient cell line BFTC909 was hypermethyl-
ated. Consistent with the results of methylation-specific PCR, the blad-
der cancer cell line 639V showed partial methylation and J82 essen-
tially lacked methylated sites. Open circle: non-methylated CpG, filled 
circle: methylated CpG. 
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Fig. 4.  Cytogenetic analysis of BFTC909. ( A ) Chromosome 11 painting. Chromosome 11 painting of the cell line 
BFTC909 showed only one intact chromosome 11. A second chromosome 11 was involved in a translocation. ( B ) Spec-
tral karyotyping of BFTC909. The cell line revealed a hypo-tetraploid karyotype with a large number of chromo-
somal aberrations including a translocation between chromosomes 11 and 3. For chromosome 11, the cell line is di-
somic with no structural aberrations of 11p15, the gene locus of  FANCF . ( C ) CGH ratio profile of BFTC909. CGH 
analysis shows underrepresentation of 11p and distal 11q relative to hypo-tetraploid status of the bladder cancer cell 
line with multiple structural aberrations. ( D ) Fluorescence in situ hybridization (FISH). In situ hybridization using a 
probe containing  FANCF resulted in two specific signals on the short arms of the two chromosome 11 homologs (red 
arrows), showing that BFTC909 is disomic for  FANCF . 
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ation. Hypermethylation of  FANCF has been described for 
several kinds of tumors, including cervical cancer (Naray-
an et al., 2004), ovarian cancer (Olopade and Wei, 2003; 
Taniguchi et al., 2003; Dhillon et al., 2004; Teodoridis et 
al., 2005; Wang et al., 2006), AML (Tischkowitz et al., 
2003), head and neck squamous cell carcinoma (HNSCC) 
and non-small-cell lung cancer (NSCLC) (Marsit et al., 
2004). Even though  FANCF hypermethylation has been 
observed in a large variety of tumors, the proportion of 
cases affected by hypermethylation is relatively low in each 
of these tumors. 
 FANCF is located on chromosome 11p15 adjacent to a 
region known to represent a hot-spot for hypermethylation 
(de Bustros et al., 1988; Feinberg, 1999). Dysregulation of 
imprinted genes in this region can be found in several tu-
mors. A prominent example is the altered expression of
 CDKN1C resulting from promoter hypermethylation in the 
Beckwith-Wiedemann syndrome and in several other hu-
man cancers, including bladder cancer (Hoffmann et al., 
2005). In this context, it is interesting that the only instance 
of  FANCF hypermethylation in a bladder cancer tissue 
found in this study occurred in a tumor with multiple other 
hypermethylation events. 
 These considerations raise the question whether hyper-
methylation of  FANCF reflects a ‘bystander’ effect resulting 
from spreading of epigenetic modification of genes located 
in such hot spot regions, or whether the disruption of the 
FA/BRCA pathway via  FANCF silencing is a specific event 
during tumorigenesis. Inactivation of  FANCF causes genet-
ic instability and might therefore be an early step in can-
cerogenesis, preferentially in FA-typical cancers that occur 
in non-FA patients (Tischkowitz et al., 2003). This concept 
has received strong support by the recent observation of fre-
quent epigenetic silencing of another caretaker gene,  WRN , 
in human tumors (Agrelo et al., 2006). However, other than 
squamous cell carcinoma of the upper digestive tract or the 
genital organs, bladder cancer is not a common type of can-
cer in FA (Alter, 2003). Our results show that  FANCF hyper-
methylation is a rare event in bladder tumors since it was 
found in only one out of 23 established tumor cell lines, and 
rarely in native tumor tissues. Taniguchi et al. (2003) sug-
gested that  FANCF methylation may be found less than ex-
pected because secondary demethylation may render tumor 
cells resistant to DNA damaging agents. This hypothesis 
implies that hypermethylation accompanies tumor initia-
tion. More typically, however, partial hypermethylation ac-
companies the early stages of tumor formation and meth-
ylation increases as the tumor progresses. This is particu-
larly well documented in bladder cancer, where aberrant but 
weak hypermethylation is common in morphologically 
normal urothelial tissue of bladders carrying tumors (Dha-
wan et al., 2006; Neuhausen et al., 2006). The partial meth-
ylation of  FANCF in two bladder carcinoma cell lines
(VMCub1 and 639V) might reflect this standard situation. 
Secondary demethylation appears to be an unlikely expla-
nation for the findings in bladder cancer, since the tumor 
samples studied were typically acquired prior to the initia-
tion of chemotherapy. 
 The physical and functional preservation of  FANCC 
 and  FANCG in bladder cancer suggests that these two 
genes might be essential for survival of the tumor. This no-
tion would fit with the general observation that both con-
stitutional and somatic FA gene mutations are relatively 
rare in human neoplasia (reviewed in Lyakhovich and 
 Surralles, 2006). Only a small minority of non-FA tu-
mors were found to harbor mutations in FA genes, apart 
from  BRCA2/FANCD1 and the low-penetrance breast 
 cancer genes  BRIP1/FANCJ and  PALB2/FANCN (Seal et 
al., 2006; Rahman et al., 2007). Possible exceptions are 
AML with described mutations in  FANCA and  FANCC as 
well as pancreatic cancer where also several sequence 
changes in  FANCA,  FANCC and  FANCG have been de-
scribed (van der Heijden et al., 2003; Couch et al., 2005). 
However, other researchers found no convincing evidence 
for frequent occurrence of FA gene mutations in non-FA 
AML (reviewed in Neveling et al., 2007). In addition, it 
seems that germline  FANCA  mutations do not contribute 
to familial pancreatic cancer susceptibility and that  FANCC 
and  FANCG mutations may overall have a comparatively 
low penetrance, if any, for the pancreatic cancer pheno-
type. 
 The paucity of involvement of FA genes in human neo-
plastic disease suggests that an intact FA pathway might be 
important for tumor cell survival. Our data shows that al-
though tumors typically exhibit a high rate of mutations, in 
all but a single bladder cancer cell line the FA genes were 
found to be functional, including those FA genes that are 
located within the frequently deleted regions of chromo-
some 9. Moreover, if disruption of the FA pathway were a 
first and general step during tumor development, we would 
expect a much wider range of tumor types in FA patients as 
is actually observed. Conversely, if disruption of the FA core 
complex should favor the development of rather specific tu-
mor types, hypermethylation of  FANCF should be restrict-
ed to these particular tumors. However, hypermethylation 
of  FANCF  has been observed in a wide variety of tumors 
other than those typically seen in FA (Taniguchi and 
D’Andrea, 2006). 
 Taken together, these arguments lead to the conclusion 
that although reduction or elimination of a DNA repair sys-
tem of a given cell may facilitate the generation of mutations 
in tumor suppressor genes, disruption of the FA/BRCA 
pathway may be disadvantageous for tumor cells by render-
ing them vulnerable to the adverse effects of DNA damag-
ing agents and oxidative stress. In contrast, retention of a 
functional FA/BRCA pathway might be important for tu-
mor cells to retain a certain human cell character despite 
chromosomal rearrangements, gains and losses and the re-
sulting consequences. We suggest that silencing of the 
 FANCF  gene via  hypermethylation is a secondary and non-
causal event in tumorigenesis, resulting primarily from the 
location of  FANCF within a known hotspot region for meth-
ylation at 11p15. This would also imply that the therapeutic 
effectiveness of crosslinking agents used for bladder cancer 
chemotherapy does not result from defects in the FA DNA 
repair pathway in most of these tumors. However, if disrup-
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Abstract
FANCE is one of at least eight Fanconi anemia (FA) proteins required for monoubiquitination 
of the ID complex during S phase or in response to DNA damage. Together with FANCC and 
FANCD2, FANCE forms a ternary subcomplex that may provide a critical bridge function between 
the FA core complex proteins and the ID complex. FANCE belongs to the group of recently in 
evolution emerged FA genes with paralogs limited to the vertebrate lineage. Because of the rare 
occurrence of patients belonging to the FA-E subtype, there is only limited information on the 
pattern of genetic alterations in FANCE. We assigned 15 patients from 12 families to subtype FA-
E and determined their remarkably limited spectrum of mutations. With the exception of a single 
recurrent amino acid substitution, R371W, only alterations causing premature protein truncation 
were found. R371W was present in more than 50% of our patients. Other types of FANCE 
missense substitutions leading to amino acid changes and disruption of phosphorylation sites 
have been expressed and functionally tested, but did not correct MMC sensitivity. We conclude 
that only mutations leading to premature protein truncation or instability of protein structure are 
detrimental in FANCE, while many other types of alterations qualify as innocuous variants.
Introduction
Fanconi anemia (FA) is a rare recessive inherited disease with variable congenital malformations, 
cancer susceptibility, and progressive bone marrow failure. At the cellular level, hypersensitivity 
to bifunctional alkylating agents such as mitomycin C (MMC), diepoxybutane (DEB) or cisplatin 
(CDDP) results in increased chromosomal breakage, reduced cell survival, and cell cycle arrest 
at the S/G2 transition. These parameters are used to confi rm or rule out the clinical suspicion of 
FA (Schindler D, 2007). At present 13 genes (FANCA, B, C, D1, D2, E, F, G, I, J, L, M, N) have 
been identifi ed whose mutational inactivation cause corresponding complementation groups of 
FA (reviewed in (Wang, 2007). 
The protein products of the FA genes interact in a common pathway involved in the cellular response 
to DNA damage (Wang and D‘Andrea, 2004; Kennedy and D‘Andrea, 2005; Niedernhofer et al., 
2005; Wang, 2007). During S phase and in response to DNA damage, at least eight of the FA 
proteins assemble in a nuclear core complex. This complex is necessary to monoubiquitinate and 
thereby activate the key FA proteins FANCD2 (Garcia-Higuera et al., 2001; Medhurst et al., 2001; 
Meetei et al., 2003) and FANCI (Dorsman et al., 2007; Sims et al., 2007; Smogorzewska et al., 
2007) . Monoubiquitinated FANCD2 and FANCI colocalize in nuclear foci with proteins such as 
BRCA2 and RAD51 known to be involved in DNA repair by homologous recombination (Garcia-
Higuera et al., 2001; Taniguchi et al., 2002; Hussain et al., 2004; Wang et al., 2004; Montes 
de Oca et al., 2005). The FA pathway is important to sustain genomic stability and to prevent 
cancer.
FA-E was fi rst reported in 1995 as the fi fth FA subgroup (Joenje et al., 1995), and the corresponding 
clinical and cytogenetic data of the fi rst patient were published one year later (Wegner et al., 1996). 
In 1999, Waisfi sz and colleagues used cell fusion and complementation analysis to assign three 
families to complementation group FA-E. Using linkage analysis and homozygosity mapping, they 
subsequently assigned the FANCE gene to chromosome 6p21-22 (Waisfi sz et al., 1999). Shortly 
thereafter, the Amsterdam group succeeded in isolating a cDNA representing FANCE and identifi ed 
the fi rst mutations (de Winter et al., 2000a). FANCE contains 10 exons encoding a 58 kDa nuclear 
protein that consists of 536 amino acids. Other than a bipartite nuclear localisation signal (NLS) 
and the recently described FANC repeats, there are no known protein motifs (de Winter et al., 
2000a; Pace et al., 2002; Nookala et al., 2007). Owing to its NLS, FANCE has a strong tendency 
for nuclear localization and appears to be required for the nuclear accumulation of FANCC (Pace 
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et al., 2002; Taniguchi and D‘Andrea, 2002; Leveille et al., 2006). As one of the components of the 
FA core complex, FANCE is essential for FANCD2 monoubiquitination (Taniguchi and D‘Andrea, 
2002). Direct interactions with FANCC and FANCD2 have been described such that FANCE may 
function as a critical bridge molecule connecting the FA core complex to FANCD2 (Pace et al., 
2002; Gordon et al., 2005; Leveille et al., 2006). It is currently thought that the FA core complex 
serves as E3 ligase with FANCE mediating the close proximity of the FA core complex to its 
substrates FANCD2 and FANCI, thereby facilitating monoubiquitination of these proteins.
In addition to the three FA-E patients whose mutations were described in 2000 (de Winter et al., 
2000a), three other patients were recently reported (Ameziane et al., 2007), although the status 
of one of the latter remained arguable. We here present clinical and molecular data of 15 further 
patients from 12 families assigned to subgroup FA-E. Whereas these patients display a typical 
FA clinical phenotype, we show that the pattern of mutations in FANCE deviates from that of most 
other FA genes. By functional testing we provide a possible explanation for the rareness of this 
FA subgroup and the limited pattern of mutations observed in these patients.
Materials and Methods
Patient’s statistics
The present studies were performed with the informed consent of the patients and/or their families 
and approval of the local IRBs. A total of fi fteen FA-E patients (patients 1-15) from 12 different 
families (family 4 has two affected children, patients 4 and 5, and family 6 has three affected 
children, patients 6, 7 and 8) were assigned to complementation group FA-E and mutation 
analysis was performed in all of them. Clinical data were not available from patient 15, therefore 
this patients is not part of phenotype analysis. The only fetal case (patient 1) is included in the 
phenotype analysis, but excluded from data concerning median age of diagnosis, median age 
of death and hematological manifestations. However, results concerning the mutations and 
haplotypes of both patients are included in the text, fi gures and tables. Haplotype analysis was 
limited to FA-E families with c.1111 C>T.
Cell culture
Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) were established using 
cyclosporin A (Neitzel, 1986). They were maintained, like whole blood and primary lymphocyte 
cultures, in RPMI 1640 medium supplemented with GlutaMAX (Gibco, Karlsruhe, Germany) and 
15% fetal bovine serum (FBS; Sigma, Taufkirchen, Germany). Fibroblast strains were established 
using standard cell culture protocols. They were propagated in Eagle’s MEM with GlutaMAX 
(Gibco, Karlsruhe, Germany) supplemented with 15% FBS. All cultures were kept in high humidity 
incubators equipped with CO2 and O2 sensors, in an atmosphere of 5% (v/v) CO2. In case of 
fi broblasts, hypoxic cell culture conditions were used (5% (v/v) O2) by replacing ambient air with 
nitrogen (Schindler and Hoehn, 1988).
Diagnostic procedures
The clinical diagnosis of FA was confi rmed by the detection of cellular hypersensitivity to DNA-
crosslinking agents by chromosome breakage or cell survival studies or by cell cycle analysis. 
For chromosome breakage studies, baseline and MMC- or DEB-induced chromosomal breakage 
in phytohemagglutinin (PHA)-stimulated cultured peripheral blood lymphocytes were analyzed 
as described (Joenje H, 1997; Auerbach et al., 1989). Cell survival was determined using 
CD3/CD28/IL2-stimulated lymphocytes or lymphoblasts. The cells were exposed to various 
concentrations of MMC for 5 days. Live/dead cell ratios were determined by propidium iodide 
exclusion/uptake on fl ow cytometry (Hanenberg et al., 2002). For cell cycle analysis, PHA-
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stimulated blood lymphocytes isolated via Ficoll-Paque PLUS (Amersham Biosciences, Little 
Chalfont, UK) separation, lymphoblasts or fi broblasts were grown for 48 or 72 h and subjected to 
mono- or bivariate (BrdU-Hoechst/Ethidium bromide) cell cycle analysis (Schindler and Hoehn, 
1999). Cell cycle distributions refl ecting DNA content and cell cycle progression were quantitated 
using the MPLUS AV software package (Phoenix Flow Systems, San Diego, CA). The cellular FA 
phenotype was recognized by the detection of typical G2 phase accumulations. Cell cycle testing 
for G2 phase arrest has previously been shown to arrive at the same diagnostic conclusions as 
standard chromosome breakage analysis (Seyschab et al., 1995). 
Retroviral complementation
For complementation studies, cell lines were transduced with retroviral vectors containing full-
length cDNA of FANCE (S11FEIEG2, S11FEIN) (fi gure 1). S11FEIEG2 has been previously 
described (Huck et al., 2006), S11FEIN was cloned by restriction of S11FEIEG2 with NotI-DraIII 
and ligating the FANCE-containing fragment into S11IN cut identically. S11IN contains the 
neomycin resistance gene (NEO) instead of eGFP (Kalb et al., 2007). The empty vectors or 
those with other FANC cDNAs served as controls. S11 vectors are based on the spleen focus-
forming virus and are derived from the GR plasmid (Hildinger et al., 1999). Selection of cells 
transduced with S11FEIN, S11IN or other vectors containing the neomycin resistance gene was 
in G418 (Sigma) at a fi nal concentration of 0.8 to 1.2 mg/ml for about 10 days. Transduced cells 
were analyzed for their sensitivity to MMC using fl ow cytometry (Hanenberg et al., 2002; Chandra 
et al., 2005; Casado et al., 2007). Positive complementation was indicated by loss of G2 arrest, 
indicating correction of MMC sensitivity. The FANCE-negative cell line EUFA622 (de Winter et 
al., 2000a) and an LCL from patient 2 with biallelic nonsense mutations in FANCE were used for 
testing the effect of expressed sequence alterations using the site-mutated vector S11FEIEG2.
Figure 1  Circular maps of the vectors S11FEIEG2 and S11FEIN that were used for retroviral complementation. 
The S11FEIEG2 vector is an S11 vector based on spleen focus-forming virus. It contains a bicistronic 
construct of FANCE and eGFP cDNAs connected via an internal ribosomal entry site (IRES) (Huck et 
al, 2006). The S11FEIN vector was cloned by restriction of S11FEIEG2 with NotI-DraIII and ligating the 
FANCE-containing fragment into S11IN cut identically. It contains the neomycin resistance gene (NEO) 
instead of eGFP. Long terminal repeats (LTRs) and restriction sites used for construction of the vectors and 
site-directed mutagenesis are indicated. Bacterial resistance is AmpR.
2.2 Recurrent disruptive mutations...
- 40 -
FANCD2 immunoblotting
FANCD2 immunoblotting was performed as described (Garcia-Higuera et al., 2001) with minor 
modifi cations: cells were treated with 50 ng/ml MMC for 16 hours. Lysis was achieved with 1x 
lysis buffer (50 mM Tris-Cl, pH 7.4; 150 mM NaCl; 2 mM EDTA; 2 mM EGTA; 25 mM NaF; 25 mM 
β-glycerophosphate; 0.1 mM Na3VO4; 0.3% nonidet P-40; 0.2% tritone X, protease inhibitors 
(Roche Diagnostics GmbH, Mannheim, Germany). 50 μg of whole protein extract were loaded on 
7% tris-acetate gels (Invitrogen, Karlsruhe, Germany) and electrophoresis was performed at 120 
V for 6 hours. Protein transfer was overnight at 4°C and 20 V onto PVDF membranes (HybondP, 
Amersham Biosciences, Little Chalfont, UK). Immunoblots were blocked with 5% non-fat dry 
milk (Roth, Carl Roth GmbH + Co. KG, Karlsruhe, Germany) in PBS/0.05% tween (PBS-T). As 
primary antibody, the mouse monoclonal FANCD2 antibody FL-17 (Santa Cruz Biotechnology 
Inc., Heidelberg, Germany) was used at a dilution of 1:800. As secondary antibody, we used 
the anti-mouse IgG horseradish peroxidase linked F(ab‘)2 from sheep (Amersham Biosciences, 
Little Chalfont, UK, dilution 1:2000). For chemiluminescence detection, a standard ECL reagent 
(Amersham Biosciences, Little Chalfont, UK) was employed.
FANCE immunoblotting
Cell lysates (~400.000 cells) from lymphoblastoid cell lines were obtained as previously described 
(Leveille et al., 2004) and proteins were separated on SDS-polyacrylamide gels. Proteins were 
transferred to a PVDF membrane and immunoblotted with FANCE antibody.
PCR and sequencing
Genomic DNA (gDNA) was prepared using a modifi ed salting-out technique (Miller et al., 1988). 
Amplifi cation of FANCE exons was performed using Pfx polymerase (exons 1+2) (Invitrogen, 
Karlsruhe, Germany) and Taq polymerase (exons 3-10). Primers were obtained from TibMolBiol 
(TIB MOLBIOL Syntheselabor GmbH, Berlin, Germany). PCR products were purifi ed using the 
GFX PCR DNA and Gel Band Purifi cation Kit (GE Healthcare; Munich, Germany). DNA sequencing 
of PCR products was performed using ABI-PRISM big-dye terminator chemistry and the ABI 
310 instrument (Applied Biosystems, Darmstadt, Germany). gDNA amplifi cation and sequencing 
primers are provided in supplementary tables S1A and S1B.
For analysis of splice site mutations, RNA was purifi ed using the Micro-to-Midi Total RNA Purifi cation 
System (Invitrogen, Karlsruhe, Germany). Isolated RNA was reverse transcribed using SuperScript 
II Reverse Transcriptase and Oligo(dT)20 (both Invitrogen, Karlsruhe, Germany) according to the 
manufacturers instructions. FANCE cDNA was amplifi ed in 2 overlapping fragments. Amplifi cation 
was performed using FailSafe™ PCR System with buffers G or K (EPICENTRE® Biotechnologies, 
Madison, WI). Purifi cation of PCR products and sequencing was as described for gDNA. cDNA 
amplifi cation and sequencing primers are provided in supplementary tables S2A and S2B.
Site-directed mutagenesis
For site-directed mutagenesis, the 3’ portion of FANCE (containing the nucleotides to be mutated) 
was subcloned into a smaller vector. To this end, the vector S11FEIEG2 was cut with BstBI 
(inside FANCE) and HindIII. The resulting 1331-nt fragment was cloned into the multiple cloning 
site of pETM30 (EMBL, Heidelberg, Germany). pETM30 containing the FANCE-insert was cut 
by HindIII and XbaI. Using these sites, the fragment containing FANCE was cloned into pUC18 
(Invitrogen, Karlsruhe, Germany). Site-directed mutagenesis was performed using this pUC18-
FANCE construct with the QuikChange® Site-Directed Mutagenesis Kit and Pfu polymerase 
(both Stratagene, La Jolla, CA). Site-mutated plasmids were isolated by plasmid mini preparation 
(Qiagen, Hilden, Germany) and the substitutions introduced were checked by direct sequencing. 
After successful mutagenesis, the corresponding fragment was cut out of pUC18-FANCE by 
HindIII and BstBI and cloned back into S11FEIEG2. The following plasmids were generated 
by this technique: S11FEIEG2-T346A, S11FEIEG2-S356G, S11FEIEG2-R365K, S11FEIEG2-
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R371W, S11FEIEG2-S374A, S11FEIEG2-S486A, S11FEIEG2-S486T, and S11FEIEG2-A502T.
For construction of plasmid S11FEIEG2-P184Q, S11FEIEG2 was cut by NcoI and BstBI (both 
inside FANCE). The resulting 350-nt fragment was cloned into pETM30 (EMBL, Heidelberg, 
Germany) and cut out by HindIII and XbaI. Using these sites, the fragment was cloned into 
pUC18 (Invitrogen, Karlsruhe, Germany) (see above). Site- directed mutagenesis was performed 
as described above. After successful mutagenesis, the corresponding fragment was cut out of 
pUC18-FANCE by NcoI and BstBI and cloned back into S11FEIEG2 using BstBI-NdeI and NdeI-
NcoI fragments in a two-insert ligation. Primers for site-directed mutagenesis are provided in 
supplementary table S3.
Haplotype analysis
For haplotype studies, we used Haploview 4.0 to create a LD Plot of a 100 kb region containing 
FANCE +/- 50 kb (Barrett et al., 2005). Data from 300 normal individuals analyzed with a 550K 
Illumina-Chip were used as source of this LD Plot. SNPs in FANCE are located in block 4. Block 
4 contains 5 tagSNPs (2 inside and 3 outside of FANCE). These SNPs were used for haplotype 
analysis by direct sequencing. SNP amplifi cation and sequencing primers are provided in 
supplementary tables S4A and S4B.
Results
Assignment to subgroup FA-E
The diagnosis of FA was confi rmed either by chromosome breakage studies (not shown) or 
via cell cycle analysis after exposure of cells to DNA damaging agents (table S5 and fi gures 
2 A and B). Absence of monoubiquitinated FANCD2 isoform FANCD2-L was confi rmed by 
FANCD2 immunoblotting (data not shown). Assignment to subgroup FA-E was by retroviral 
complementation using the vectors S11FEIEG2 and/or S11FEIN (see materials and methods) or 
via direct sequencing (patients 14 and 15). Successful retroviral complementation is shown by 
reduction of G2-phase accumulations of MMC-treated FA-E lymphoblasts following transduction 
with the vector S11FEIN (fi gure 2C) or by graphic presentation of representative survival curves 
(fi gure 2D). FANCE immunoblotting showed absence of FANCE protein in patient 14 (=EUFA279) 
and two previously reported FA-E patients (Ameziane et al., 2007) (fi gure 2E). Seven FA patients 
(patients 4-11) listed in the International Fanconi Anemia Registry (IFAR) were assigned to 
complementation group FA-E. Three other FA-E patients emerged in a cohort of 372 confi rmed 
FA patients diagnosed in two German laboratories (patients 1-3). Two FA-E patients each 
were identifi ed by the Spanish FA network (patients 12+13) and the Dutch FA groups (patients 
14+15). 
Clinical data 
As shown in table S6, the clinical phenotype of our cohort of FA-E patients refl ects the entire 
spectrum of developmental defects that tend to occur in the majority of FA patients. Most patients 
had growth retardation (11) and radial ray defects (10). Six patients each had microcephaly, 
microphtalmia, cardiac malformations and café-au-laits spots. Five patients had absence or 
malformations of the kidney. Two patients had anal atresia (patients 10 and 13) and single patients 
were affected by brain malformations (patient 1), esophageal atresia (patient 2), abnormal genitalia 
(patient 9), microtia (patient 9), skeletal malformations other than radial ray defects (patient 12) 
and jaundice at birth (patient 13). Hematological manifestations including thrombocytopenia and 
anemia were recorded in eight of the patients. Two patients (patient 6 and 7) underwent bone 
marrow transplantation (see below). Another (patient 9) died prior to onset of hematological 
changes. Among our cohort, hematological manifestations occurred between 2.5 and 10.5 years 
of age. The median age of diagnosis was 2.8 years (n=13) ranging from birth to 10 years of age. 
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Figure 2 A) Increased spontaneous 
G2-phase accumulations in primary 
phytohaemagglutinin (PHA)-stimulated 
lymphocytes from two FA-E patients 
(patient 2 and patient 3). Black squares 
show the proportions of cells in the G2 
phase relative to the growth fraction of a 
72h culture without MMC (0.393 for patient 
2 and 0.502 for patient 3). The G2-phase/
growth fraction ratios are increased when 
compared to 630 controls (0.174 ± 0.035, 
dark grey circles) and fall into the range 
of 394 FA-positive cultures (0.456 ± 0.098, 
light grey squares). The non-cycling cell 
fractions are 38.7% for patient 2 and 39.1% 
for patient 3 (means ± SD are 25.19 ± 
11.72 for the controls and 32.32 ± 18.30 for 
the FA cultures). B) Cell cycle distributions 
of an LCL of FA-E patient 1. Exposure to 
MMC causes accumulation of cells in the 
G2 phase of the cell cycle. Relative number 
of cells in G2 without MMC: 11.3%, relative 
number of cells in G2 after exposure to 
MMC: 46.1%. C) Retroviral transduction 
of an FA-E patients’ fi broblasts (patient 
9) using vector S11FEIN complements 
the cellular MMC sensitivity and reduces 
the G2 phase to near nomal (from 33.8% 
to 9.5%). D) Survival curves of FA-E LCL 
(patient 4/II) transduced with the FANCE 
containing vector S11FEIN (■), eGFP (▬) 
or FANCD2 (▲). The curves show MMC 
dose-dependent cell survival, which is 
increased after transduction with the vector 
S11FEIN containing a functional FANCE 
cDNA. There is no change with any of the 
other vectors. E) FANCE immunoblotting 
shows the total absence of FANCE 
protein in three FA-E patients (EUFA279, 
EUFA410, EUFA1331). Patient EUFA279 
is part of this study (patient 14), while 
patients EUFA410 and EUFA1331 were 
published in Ameziane et al (2007). Non-
FA cell line HSC93 serves as control.
Five of the 13 fully informative patients are deceased, with age of death ranging from 8 month 
to 10 years. Median age at death was 6.1 years (n=13). There were no cancer clusters in these 
families or tumor types other than those believed to be infl uenced environmentally. The family 
of patient 1 had a history of spontaneous abortions and previous affecteds with FA: there was 
one spontaneous abortion during the 8th week of pregnancy, one previous stillborn with FA, and 
a stillborn. Two of our patients (patients 6/I and 6/II) underwent bone marrow transplantations 
(BMTs). Patient 6/I had alternative donor BMT at age 8 years. This patient died two years later. 
Patient 6/II underwent a BMT at age 2½ before the occurrence of a bone marrow failure. In this 
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Figure 3 Pedigree of FA-E family 6, a consanguineous family of Arabian origin. The parents of our proband 
(patient 6/I) are second cousins and have seven offspring. Three of the children are affected, one female 
(patient 6/I) and two male (patients 6/II and 6/III). Patient 6/II was diagnosed at age 1.3. This patient 
underwent bone marrow transplantation at age 2½ prior to the occurrence of bone marrow failure. The 
mother served as an 8/8 matched donor. HLA alleles are given next to the pedigree symbols. Allele A must 
be coupled with the mutation, since it is common to all carriers and affected individuals. Patient 6/II is a 
likely recombinant, since this patient has the opposite maternal HLA alleles but is homozygous for the 
FANCE mutation. Black asterisk indicates the recombination event.
case, the mother of the patient served as an 8/8 matched donor for her son. At the last follow-up, 
this boy survived at 5 years of age (fi gure 3).
Mutations and polymorphisms in FANCE
Table 1 lists genetic alterations and their predicted consequences at the protein level, whereas 
mutations in combination with other diagnostic data are presented in table S5. 
Two nonsense mutations, c.265 C>T (p.R89X) and c.355 C>T (p.Q119X), were homozygous, the 
latter was also reported by de Winter et al. (de Winter et al., 2000a). 
One patient (patient 13) showed the duplication c.1418dupG. At the protein level, this leads to 
a premature stop codon six amino acids downstream (p.M473NfsX6). This patient is the only 
compound heterozygote in our cohort (the corresponding second mutation being c.1111 C>T, see 
below). 
Three splice site mutations included c.248+1 G>A (IVS1+1 G>A). Sequencing of cDNA from the 
respective LCLs revealed that splice site disruption results in the activation of two cryptic splice 
sites, located at positions IVS1+30 and IVS1+204. Usage of these two cryptic splice donor sites 
instead of the authentic GT leads to read-through of the open reading frame into the following 
intron, resulting in both cases in the same premature stop codon (p.K84X). The second splice site 
mutation was c.1114-8 G>A (IVS5-8 G>A). This particular change does not disrupt a canonical 
but generates a new splice site, with G>A at position -8 causing a GG to AG change at positions 
-7 and -8. The newly created AG is used as splice acceptor which leads to the inclusion of six 
nucleotides into the open reading frame (c.1113insCTGTAG) and results in a premature stop 
(p.R371insLX). The third splice mutation was c.1510-1 G>A (IVS9-1 G>A). In this case, the 
splice acceptor of exon 10 is disrupted (AG to AA). Splicing from exon 9 to 10 was defective. 
Downstream of exon 9, there were at least three different overlaying sequences suggesting the 
usage of multiple aberrant splice acceptors. 
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Exon/
Intron no. Patient no.
Mutation
 DNA                       RNA
Consequence 
protein
IVS 1 9 c.248 +1 G>A  (IVS1 +1 G>A)
  - r.248_249ins30
  - r.248_249ins204
- p.K84X
- p.K84X
Exon 2
1 c.265 C>T r.265 C>T p.R89X
2 c.355 C>T r.355 C>T p.Q119X
Exon 5 3, 4, 5, 11-15(13 het.) c.1111 C>T r.1111 C>T p.R371W
IVS 5 6-8 c.1114 -8 G>A(IVS5 -8 G>A) r.1113_1114 ins6 p.R371_I372 insLX 
Exon 9 13 (het.) c.1418 dupG r.1418 dupG p.M473NfsX6
IVS 9 10 c.1510 -1 G>A(IVS9 -1 G>A)
multiple aberrant 
splicing
presumably 
premature 
termination
Figure 4 Schematic depiction of the FANCE gene and corresponding mutations. Alterations identifi ed in this 
study are shown above, while mutations described by de Winter et al (2000) and Ameziane et al (2007) are 
shown underneath the gene. Nonsense mutations are indicated by black circles (●), missense substitutions 
by open circles (○). Black squares (■) show splice site mutations. A black triangle (▲) indicates duplication. 
Superscript a denotes homozygous mutations (2 alleles) and superscript b denotes siblings.
Table 1. Identifi ed FANCE mutations and their effects
There was only a single type of missense substitution (c.1111 C>T (R371W)). While all other 
mutations were private, c.1111 C>T was found in eight of the 15 patients representing seven 
of the 12 families (see tables 1 and S5). With the exception of the patient 13, all c.1111C>T 
substitutions were homozygous. The only compound heterozygous patient (patient 13) carried 
the maternal mutation c.1418dupG (p.M473NfsX6) in addition to the paternal c.1111 C>T. 
Altogether, the observed spectrum of FANCE mutations appears relatively limited (fi gure 4).
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Homozygous mutations in 14 of the 15 patients suggest a high degree of consanguinity. Such 
evidence existed in nine of our families (see table S6). The two families with the nonsense 
mutations c.265 C>T (p.R89X) and c.355 C>T (p.Q119X) are consanguineous families of Turkish 
origin (patients 1 and 2). The parents of patients 6, 7 and 8 (mutation c.1114-8 G>A) are second 
cousins of Arabian ancestry. Patients 4 and 5 (siblings), 11, 12, 14 and 15 all carry the homozygous 
mutation c.1111 C>T. These patients are from consanguineous families with Mexican, Brazilian, 
Spanish, German and Dutch ancestry. Patient 10 (homozygous mutation c.1510-1 G>A) is from 
a German family with confi rmed consanguinity. Of the remaining two patients with homozygous 
mutations, the family of patient 3 (mutation c.1111 C>T) comes from Dagestan, with insuffi cient 
pedigree data. Patient 9 (c.248+1 G>A) is from Guatemala without known consanguinity.
Detected polymorphisms included rs2395626 (IVS1-770 T/G), rs4713866 (ATG–56 C/T), 
rs9470029 (IVS1+58 A/C), rs7757405 (IVS1-35 A/G), rs17859434 (c.387 A/C (P129P)), rs4713868 
(IVS2+138 A/G), and rs13214239 (IVS3+39 A/G). Not previously reported polymorphisms included 
IVS2+58 A/G, IVS5+23 insC, and c.1071 C>T (p.L357L).
Haplotype analysis
In order to test the genetic background of the single missense mutation c.1111 C>T, we performed 
haplotype analysis of all seven probands carrying this mutation, including the parents of patient 
13 (being heterozygous for this mutation). An LD Plot (see materials and methods and fi gure 5A) 
was used to analyze the tagSNPs of block 4 containing FANCE (Barrett et al., 2005), including 
rs2894401, rs4713864, rs7758978, rs2395626, and rs7757405 (fi gure 5B). We observed three 
different haplotypes (fi gure 5C). The fi rst consists of the tagSNPs G-A-G-T-G and occurs in 53.3% 
of the 300 normal individuals used for haplotype construction. This haplotype was present in 
patients 3, 4, 12, 13 and 15. The second haplotype consists of A-C-C-G-A and was present in 
24.9% of the control population. This haplotype was detected only in patient 14. The third haplotype 
consists of the tagSNPs G-A-C-G-G, occurring in 6.6% of the 300 normal individuals tested, and 
was present in our patients 3 and 11. Six of the seven patients were homozygous for one of 
the respective haplotypes, including the single patient from presumably non-consanguineous 
parents (patient 13). The parents of this patient were also homozygous for this haplotype (data 
not shown). Only a single patient (patient 3) was heterozygous for two of the prevalent haplotypes 
(G-A-G-T-G and G-A-C-G-G), suggesting lack of consanguinity in this family despite homozygous 
mutation of the patient.
Investigation of additional missense substitutions
The Fanconi Anemia Mutation Database (http://www.rockefeller.edu/fanconi/mutate/) reveals 
three missense substitutions additional to R371W, which have all been identifi ed in breast cancer 
patients. These alterations are S356G, R365K, and A502T. One further missense substitution, 
P184Q, was recently reported as a FANCE mutation (Ameziane et al., 2007). In order to test the 
potential pathogenic nature of these alterations, we expressed these and additional missense 
substitutions in the FANCE-defective FA-E cell line EUFA622 (de Winter et al., 2000a) and in 
an LCL from patient 2 of the present study with two nonsense mutations. As shown in fi gure 6, 
only the c.1111 C>T (R371W) substitution was not capable of correcting MMC sensitivity. Cells 
transduced with this site-mutated vector showed a pronounced G2 phase arrest in response to 
DNA damage (fi gure 6). 
Employing retroviral complementation, we also tested three base substitutions involving sites 
critical for potential phosphorylation events. Two of them, T346A and S374A, have been reported 
as highly conserved phosphorylation sites (Wang et al., 2007). The third, S486A, involves a residue 
that was speculated to be a good candidate for phosphorylation due to proximity to the putative 
FANCD2 binding site (Luca Pellegrini, personal communication, 2007). S486T was tested as a 
control for S486A, assuming that a serine to threonine substitution would retain whereas a change 
to alanine would abolish phosphorylation. Our transfection experiments yielded complementation 
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Figure 5 Haplotype 
analysis of all FANCE 
probands carrying the 
c.1111 C>T mutation. A) 
Using Haploview 4.0, an 
LD Plot of a 100 kb region 
containing FANCE +/- 50 
kb was generated. Data 
from 300 individuals 
analyzed with a 550K 
Illumina-Chip were used 
as the source. SNPs in 
FANCE are located in 
block 4. B) Five tagSNPs 
in block 4 are highlighted 
by black triangles (▼). 
tagSNPs are rs2894401 
(65), rs4713864 
(71), rs7758978 (78), 
rs2395626 (80), and 
rs7757405 (81). Seven 
haplotypes for block 4 
were detected in the 
cohort of 300 analyzed 
individuals, with a 
population frequency 
ranging from 1.7 to 53.3%. 
C) TagSNPs from block 4 
were used to construct 
haplotypes of  individuals 
carrying the c.1111 
C>T mutation. Three 
different haplotypes were 
connected with the c.1111 
C>T change, all of them 
previously detected in 
the cohort of 300 normal 
controls. Patient 3 was 
heterozygous, while 
all other patients were 
homozygous.
by all of these substitutions, indicating their innocuous nature with respect to MMC sensitivity in 
the FANCE defective cell line (fi gure 6). 
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Discussion
It has been estimated that worldwide less than 2% of FA patients belong to subtype FA-E. 
From a clinical point of view, the FA-E patients in the present study show a similar spectrum of 
developmental defects as other FA patients carrying biallelic mutations in any of the core complex 
genes. There were no exceptional clinical features, and there was no evidence for clusters of 
neoplasia in their families. Growth retardation was present in 79%, and radial ray defects in 71% 
of our patients. Microcephaly, microphtalmia, heart malformations and café-au-laits spots were 
detected in 43% of our patients. Malformations or absence of the kidney were noted in 36% of our 
FA-E patients. 14% had anal atresia and single patients suffered from esophageal atresia, skeletal 
malformations other than radial ray defects, abnormal genitalia, microtia, and brain malformations, 
but none of the patients displayed a complete VACTERL phenotype. Only one of the 13 patients 
with fully informative clinical data presented without any malformation. Hematological problems 
were reported in 62% of our patients with onset between 2.5 to 10.5 years. Two patients had 
undergone bone marrow transplantation (see below). The median age of diagnosis in the 14 FA-E 
patients was 2.8 years of age. Presently, fi ve of the 13 fully informative FA-E patients succumbed 
to their disease at a median age of death of six years. Statistical comparisons to patients of other 
subgroups were not signifi cant due to the still small size of our cohort.
Figure 6 Cell cycle distributions of FANCE-defective LCL of patient 2 transduced with the site-mutated 
vectors S11FEIEG2 expressing various missense substitutions. Non-transduced cells or cells transduced 
with the empty vector show accumulation of cells in G2 after exposure to MMC (10.8 vs. 49.5%). G2 phase 
accumulation after exposure to MMC is reduced to near normal by transduction with the FANCE wildtype 
vector S11FEIEG2 (14.5%). Transduction with site-mutated S11FEIEG2 vectors complemented the cellular 
defect in all but a single case. Only the base substitution c.1111 C>T failed to restore MMC resistance 
(40.1%).
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A widespread belief is that preimplantation diagnosis for fully HLA-matching sibling BM donors 
to FA-E patients is useless due to close linkage of FANCE and the HLA locus. FANCE is located 
on chromosome 6p at position 35528116 to 35542859 in close vicinity to the HLA loci which span 
about 4Mb from HLA-F (29799220-29802262) to HLA-DPB2 (33188271 to 33204868). 8/8 HLA 
match between patient 7 and his mother indicated that there must have been a recombination 
event in the ~2Mb region between the HLA loci and FANCE. Recombination events in the HLA 
locus are thought to occur with frequencies of around 0.1 to 1%. This range is due to differences 
in the recombination rates at different positions of the HLA loci. For HLA class II (which is the HLA 
class closest to FANCE) there are three regions where recombination events are frequent. One 
is between HLA-DNA and BRD2 (formerly RING3), another between DQB3 and DQB1 and a 
third one in an 8.8 kb fragment in TAP2 (Cullen et al., 1997). Recombination hotspots have been 
described involving HLA-DMB, BRD2 and HLA-DOA, HLA-DOA and HLA-DPA1, and HLA-DPB1 
and HLA-DPB2 (Miretti et al., 2005). Although recombinations between FANCE and the HLA 
locus might be rare, the present example shows that they are nevertheless existing. Thus, the 
search of healthy sibling BM donors has to be considered in FA-E patients.
c.1111 C>T (R371W) occurred in more than 50% of our FA-E patients. Haplotype analysis yielded 
three different haplotypes among seven patients and two parents. Most of the patients and the 
parents were homozygous for one of the haplotypes, and only one patient presented with two 
different haplotypes. Interestingly, the patient with the two different haplotypes was one of the 
patients for whom consanguinity was unclear. The haplotyping results would argue against 
consanguinity in the family of this patient. In another non-consanguineous family the patient 
himself but also his parents are all homozygous for the same haplotype. This might be explained 
by the fact that this family belongs to the most common haplotype among the tested SNPs, with 
53.3% prevalence in a cohort of 300 individuals. The presence of three different haplotypes with 
occurrence of one and the same mutation among diverse ethnicities suggests that the missense 
mutation c.1111 C>T is a recurrent rather than a founder mutation. A more remote assumption 
would be an ancient mutation with evolution of the local haplotype. Recurrent mutations have 
been described in other FA genes, a prominent example being the R798X change in the FANCJ 
gene. This alteration was detected in 9 of 11 patients with partially different haplotypes (Levran 
et al., 2005).
Three further missense substitutions (S356G, R365K and A502T) in the Fanconi Anemia Mutation 
Database have never been mentioned in connection with FA but represent heterozygous 
substitutions found in breast cancer patients (Seal et al., 2003). As pointed out by Nookala et 
al, two of these alterations (S356G and R365K) disrupt hydrogen bond interactions between the 
side chain of the affected amino acids and neighboring main chain atoms that are important for 
maintaining the correct conformation of the polypeptide chain. We expressed all four missense 
substitutions (S356G, R365K, R371W, A502T) and in addition one with unknown pathogenic 
status (R184Q) (Ameziane et al., 2007) and assayed them of MMC sensitivity in FANCE-defi cient 
LCLs. R371W proved the only one with pathogenic status. All other substitutions resulted in 
complementation, indicating their innocuous nature with respect to protein function. A similar 
result was obtained with four additional base substitutions, T346A, S374A, S486A and S486T. 
These alterations of FANCE are thought to represent evolutionary conserved phosphorylation 
sites, whose disruption might result in loss of FANCE functionality (Wang et al., 2007; Pellegrini, 
personal communication, 2007). However, even these base substitutions were tolerated by 
FANCE and MMC sensitivity of the FANCE-negative cell lines was corrected.
As a result of our complementation assay, c.1111 C>T stands out as the only missense change 
in FANCE, that appears to affect protein function, at least with respect to MMC-sensitive cellular 
phenotype. As described by Nookala and colleagues (Nookala et al., 2007), arg371 is located in 
one of the FANC repeats (repeat 1) in the C-terminal region of FANCE. The substitution of this 
arginine with trypthophane results in the loss of several structural hydrogen bonds. This leads 
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to destabilization of the ternary structure of the FANCE protein, thus explaining its pathogenic 
nature. Nothing was known about the nature of P184Q, since molecular modelling did not extend 
to the N-terminal region of FANCE. Or results exclude P184Q as an authentic mutation. The 
missense substitutions S356G and R365K might have been disrupting mutations, since they 
abrogate hydrogen bonds between the side chain of the affected amino acids and the neighboring 
main chain chromosomes (Nookala et al., 2007). For A502T, no such effect was postulated. We 
have seen no detrimental effect for none of these three mutations. Among the phosphorylation 
sites, T346 and S374 are phosphorylated by Chk1 (Wang et al., 2007). In their report, Wang and 
colleagues have already shown that single mutants such as T346A and S374A do not abolish 
FANCE function, whereas the double mutant T346A/S374A was not able to correct MMC sensitivity, 
although FANCD2 monoubiquitination and foci formation were intact in the double mutant (Wang 
et al., 2007). In accordance with the data by Wang et al, non-phosphorable substitutions of none of 
these single phosphorylation sites had a negative effect on FANCE function. S486 was predicted 
to be a good candidate for site-directed mutagenesis, since this residue is highly conserved and 
in close proximity to the site that is predicted to bind FANCD2. However, substitutions at this 
potentially important site to either alanine or to threonine did not re-emerge MMC sensitivity.
The 15 patients of our study have either nonsense mutations or mutations leading to frameshifts 
and premature protein truncation. The only missense mutation observed is known to destroy a 
helical motif, thereby leading to destabilization of the ternary structure of the FANCE protein. As a 
conclusion from our data, we fi nd that only disruptive mutations affect FANCE function. Vice versa, 
many missense substitutions in the FANCE gene are permissive and do not present as mutations. 
The exclusive presence of disruptive FANCE mutations may also explain induced chromosome 
breakage rates of FA-E patients above the mean of FA patients of other groups, and the absence 
of residual FANCE protein from immunoblots. Tolerance of amino acid substitutions might explain 
the low number of FA-E patients, since only functionally “strong” mutations of FANCE might lead 
to a recognizable FA phenotype. Very similar observations exist for the FANCF gene, which 
appears to lack clinically relevant missense mutations (de Winter et al., 2000b; Ameziane et 
al., 2007). Permutions of different amino acids at different sites fail to affect FANCF function (de 
Winter et al., 2000b; Kowal et al., 2007). FANCF has been described as a fl exible adaptor protein 
that interacts through its C-terminus with FANCG, while its N-terminus stabilizes the heterodimer 
FANCA/FANCG and is essential for binding of FANCC/FANCE (Leveille et al., 2004). FANCE 
has been reported to bind the substrate of the FA core complex to the ubiquitin E3 ligase via an 
interaction of its N-terminus with FANCC and its C-terminus with FANCD2 (Nookala et al., 2007). 
There are also remarkable similarities in the structures of FANCE and FANCF: both exhibit repeats 
domains similar to HEAT or ARM repeats in their C-terminal regions. These domains have been 
appropriately named “FANC” repeats in the paper by Nookala and colleagues (Kowal et al., 2007) 
(Nookala et al., 2007). As a conclusion, the structural and functional similarities between FANCE 
and FANCF suggest that FANCE may also serve as a “fl exible adaptor protein”.
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Abstract
To date, thirteen Fanconi anemia (FA) genes have been identifi ed, whose products interact in 
the recognition and signalling of DNA damage. Eight of the FA proteins assemble in a nuclear 
complex, which is necessary for the monoubiquitination of FANCD2 during S phase of the cell 
cycle and in response to DNA damage. A member of the complex, the ring fi nger protein FANCL, 
provides the presumptive E3 ligase function. Here we report three further patients, all assigned 
to subgroup FA-L via retroviral complementation. Patient 1 presented with a severe phenotype, 
whereas patients 2 and 3 had mild to moderate, yet typical manifestations of FA. The mutations 
of patient 1 included heterozygosity for a 5-bp deletion and a missense substitution. Blood cells 
and lymphoid cell lines lacked the typical hypersensitivity to MMC, were profi cient of FANCD2 
monoubiquitination, and revealed a heterozygous base substitution at c.472-2A>T (IVS6-2A>T). 
This resulted in a complex compensatory event at the transcript level, indicating somatic reversion. 
Retroviral transduction of patient’s fi broblasts with the revertant cDNA led to loss of MMC 
sensitivity, emergence of FANCD2 monoubiquitination and appearance of FANCD2 nuclear foci 
formation, proving functional restoration of FANCL function by the compensatory mutation. The 
clinical course of the patient was characterized by increasing cytopenia of all cell lineages except 
lymphocytes suggesting that the reversion event occurred in a precursor cell of the lymphoid 
cell lineage rather than in a bone marrow stem cell, thus being unable to delay or prevent bone 
marrow failure. The mutations of patient 2 and 3 included a homozygous large genomic deletion, 
a 3-bp deletion and exonization of an intron fragment. Conclusions from this study are that FA-L 
patients occur at a recognizable rate, have a typical spectrum of manifestations and hematological 
course comparable with those of other FA patients with defects in the FA nuclear core complex, 
and reveal the spectrum of mutation and reversion reported for other FA genes.
Keywords: Fanconi anemia; FANCL; retroviral complementation; somatic reversion; revertant 
mosaicism; compensatory mutation
Introduction
Fanconi anemia (FA) is a recessively inherited multisystem disease characterized by congenital 
malformations, progressive bone marrow failure and cancer susceptibility. To date, 13 
complementation groups have been defi ned (FA-A, B, C, D1, D2, E, F, G, I, J, L, M and N) and 
the corresponding genes have been identifi ed (Levitus et al. 2004; Levitus et al. 2005; Levran et 
al. 2005; Meetei et al. 2005; Dorsman et al. 2007; Sims et al. 2007; Smogorzewska et al. 2007; 
Wang, 2007). The FA gene products cooperate in a DNA caretaker protein network that maintains 
genomic stability based on the effective resolution of DNA-interstrand crosslinks (Thompson 
2005). In response to DNA damage and stalled replication forks, eight of the FA proteins (FANC-
A, B, C, E, F, G, L and M) assemble in a nuclear multi-protein complex (FA core complex), whose 
function is required for monoubiquitination of the key proteins of the pathway, FANCD2 and FANCI 
(Garcia-Higuera et al. 2001; Meetei et al. 2004; Sims et al. 2007; Smogorzewska et al. 2007, 
Wang, 2007). Monoubiquitinated FANCD2 is targeted to nuclear foci containing proteins such as 
BRCA1, the BRCA1-interacting protein 1 BRIP1/FANCJ, BRCA2/FANCD1 and RAD51, which 
participate in DNA double-strand repair via homologous recombination (Digweed et al. 2002; 
Niedzwiedz et al. 2004; Godthelp et al. 2005; Nakanishi et al. 2005; Thompson et al. 2005).
The process of monoubiquitination is tightly controlled by an enzymatic cascade involving at least 
three types of enzymes: an ubiquitin activating enzyme (E1), an ubiquitin conjugating enzyme 
(E2) and a substrate-specifi c ubiquitin ligase (E3) (Sigismund et al. 2004). The presumptive 
E3 ligase activity for monoubiquitination of FANCD2 and FANCI is provided by FANCL, which 
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appears to function as the catalytic subunit of the FA core complex (Meetei et al. 2003). Recently, 
UBE2T was found to be the corresponding E2 ligase (Machida et al. 2006). FANCL contains 
three WD40 repeats, known as sites of protein-protein interaction, and a C-terminal PHD 
(plant homeodomain) zinc fi nger motif (Meetei et al. 2003). Meetei et al. (Meetei et al. 2003) 
demonstrated that FANCL is able to ubiquitinate itself in vitro and that mutations in FANCL result 
in defective FANCD2 monoubiquitination. Both, FANCL and FANCD2 belong to the small group 
of evolutionarily conserved FA genes.
To date, only a single patient with a FANCL defect has been reported in the literature, whose 
lymphoblasts (EUFA868) have served for the characterization of FANCL as an authentic FA gene 
(Meetei et al. 2003). The laboratories participating in the present study collaborate in ongoing 
efforts to assign FA patients to their complementation groups through retroviral gene transfer and 
DNA sequencing (Hanenberg et al. 2002; Chandra et al. 2005). Among our diagnostic cohort, we 
identifi ed three additional patients belonging to complementation group FA-L. We here present a 
brief report of these patients and their mutations. They are the fi rst FA-L patients on whom clinical 
information is being made available. Their mutations allow for recognition of an initial mutational 
spectrum of FANCL and functional consequences thereof. One of these patients is of additional 
interest since she developed revertant mosaicism involving a novel type of compensatory 
mutation.
Materials and Methods
Diagnosis and cell culture
Peripheral blood and skin biopsy specimens were referred to the participating laboratories for 
diagnostic testing upon suspicion of FA. Diagnostics, genetic subtyping and mutation analysis 
were performed with informed consent according to the Declaration of Helsinki. The studies were 
approved by the IRBs of the participating centers.
The clinical impression of FA was initially confi rmed by the detection of cellular hypersensitivity 
to DNA-crosslinking agents. Chromosome breakage rates were assessed in phytohemagglutinin 
(PHA)-stimulated 72-h whole blood cultures either by mitomycin C (MMC) or diepoxybutane 
(DEB) sensitivity assays following published procedures (Auerbach 1993; Joenje, 1997). In 
the Wurzburg laboratory, peripheral blood mononuclear cells (PBL) isolated via Ficoll-Paque 
PLUS (Amersham Biosciences, Munich, Germany) were cultured for 72 h and subjected to cell 
cycle analysis using an analytical, dual-laser equipped fl ow cytometer (LSR; Becton Dickinson, 
Heidelberg, Germany). Cell cycle distributions refl ecting DNA content were quantitated using 
the MPLUS AV software package (Phoenix Flow Systems, San Diego, CA). Cell cycle testing 
for FA-typical G2 phase arrest in response to MMC has previously been shown to arrive at 
the same diagnostic conclusions as standard chromosome breakage analysis (Seyschab et al. 
1995; Heinrich et al. 1998). Lymphocytes and EBV transformed lymphoblast cell lines (LCLs) 
were maintained in RPMI 1640 medium containing GlutaMAX (Gibco, Karlsruhe, Germany), 
supplemented with 16% fetal bovine serum (FBS). Fibroblast cultures were established using 
standard cell culture procedures and grown in FBS-supplemented Eagle’s MEM medium with 
GlutaMAX (Invitrogen, Karlsruhe, Germany). All cell cultures were kept in high humidity incubators 
equipped with CO2 and O2 sensors in an atmosphere of 5% (v/v) CO2 and 5% (v/v) O2 by 
replacing ambient air with nitrogen.
For cell cycle analysis, cells of logarithmical growing cultures were harvested 48 h after treatment 
with 0 and 15 ng/ml MMC. Prior to fl ow cytometry, live cells were stained using the DNA-binding 
dye Hoechst 33342 (Molecular Probes, Eugene, OR) (10 μg/ml, 30 min, 37 °C) or alternatively, 
nuclei were stained with DAPI as described previously (Schindler and Hoehn, 1999).
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Immunoblotting
FANCD2 immunoblotting was performed as described by Garcia-Higuera et al. (Garcia-Higuera 
et al. 2001) with minor modifi cations. About 16 h prior to the harvest of cell cultures, MMC (50 
ng/ml) was added to the culture medium. Cells were lysed with 1x lysis buffer (50 mM Tris-Cl, 
pH 7.4; 150 mM NaCl; 2 mM EDTA; 2 mM EGTA; 25 mM NaF; 25 mM 2-glycerophosphate; 
0,1 mM Na3VO4; 0.3% nonidet P-40, 0.2% Triton X-100, proteinase inhibitors complete, Roche, 
Mannheim, Germany). 50 μg of whole protein extract were loaded on 7% tris-acetate gels 
(Invitrogen, Karlsruhe, Germany) to be separated at 120 V for 6 h. Protein transfer was overnight 
at 4°C and 20 V onto PVDF membranes (HybondP, Amersham Biosciences, Little Chalfont, UK). 
Immunoblots were blocked with 5% non-fat dry milk (Roth, Karlsruhe, Germany) in PBS/0.05% 
Tween (PBS-T). As primary antibody, we used the mouse monoclonal FANCD2 antibody FL-17 
(Santa Cruz Biotechnology, Heidelberg, Germany) at a dilution of 1:800. The secondary antibody 
was anti-mouse IgG horseradish peroxidase linked F(ab‘)2 from sheep (Amersham Biosciences, 
Little Chalfont, UK, dilution 1:2000). For chemiluminescence detection, we used a standard ECL 
reagent (Amersham Biosciences, Little Chalfont, UK).
Vector construction and assignment to complementation group FA-L
For construction of the FANCL-IRES(internal ribosomal entry site)-EGFP(enhanced green 
fl uorescent protein) retroviral expression vector S11FLIEG, FANCL cDNA was amplifi ed using 
primers with a 5’ NotI and a 3’ SalI restriction site. Employing these restriction sites, FANCL 
cDNA was cloned into the identically cut vector S11IEG to result in a bicistronic construct of 
FANCL and EGFP cDNAs connected by an IRES site (Huck et al. 2006) (Fig. 1A). S11 vectors 
are based on the spleen focus-forming virus and are derived from the GR plasmid (Hildinger et al. 
1999). Retroviral plasmid was transfected into ecotropic Phoenix cells and ecotropic pseudotyped 
retroviruses were used to infect PG13 cells to achieve stable retroviral packaging as described 
elsewhere (Hanenberg et al. 1996; Hanenberg et al. 2002). cDNAs of other FANC genes were 
separately cloned into the same vector S11IEG (Hanenberg et al. 2002) and served as controls, 
as did the empty vector. Retroviral transduction of cultured cells followed published protocols 
(Hanenberg et al. 1997; Hanenberg et al. 2002). Previously unassigned FA LCLs and cultured 
fi broblasts, all defi cient of FANCD2 monoubiquitination, were transduced to express wtFANCL. 
They were analyzed for their sensitivity to MMC (15 ng/ml, 48 h), with use of fl ow cytometry, in 
order to assess survival rates and cell cycle arrest (Hanenberg et al. 2002; Chandra et al. 2005, 
Casado et al. 2006).
The FANCL mutation vector S11FLIEG891 was generated by site-directed mutagenesis (see 
below). The FANCL reversion vector S11FL*IEG was constructed with cDNA from an LCL of 
patient 1.
Reference sequences
Nucleotide sequence NM_018062 (NCBI) was used as human FANCL cDNA reference. The 
genomic reference sequence was ENSG00000115392 (Ensembl).
Genetic analyses
Genomic DNA was isolated with a modifi ed salting-out technique (Miller et al. 1988). For exon 
scanning sequencing, we amplifi ed all 14 FANCL exons and adjacent intron regions using primers 
given in Supplementary table S1. PCR products were purifi ed using the GFX PCR DNA and Gel 
Band Purifi cation Kit (GE Healthcare; Munich, Germany). Sequencing of the PCR products was 
performed wih ABI-PRISM big-dye terminator chemistry and different types of ABI automated 
sequencers (Applied Biosystems, Darmstadt, Germany) using primers shown in Supplementary 
table S1; Supplementary table S2 contains customized, sequence-specifi c primers.
For a subset of cell lines, PCR products were subjected to heteroduplex analysis (Frueh and 
Noyer-Weidner 2003) using the WAVE system (Transgenomic, Glasgow, UK). DHPLC profi les 
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were run both spiked with control DNA and unspiked in order to detect homo- and heterozygous 
alterations.
Total RNA was isolated using the PureLink Micro-to-Midi Total RNA Purifi cation System (Invitrogen, 
Karlsruhe, Germany) and was reverse transcribed using SuperScript II Reverse Transcriptase and 
Oligo(dT)20 (both Invitrogen, Karlsruhe, Germany) according to the manufacturers instructions. 
FANCL cDNA was amplifi ed with Phusion polymerase (Finnzyme, Espoo, Finnland) and purifi ed 
with the GFX PCR DNA and Gel Band Purifi cation Kit (Amersham Bioscience, Munich, Germany). 
Primers used for cDNA amplifi cation and sequencing are shown in Supplementary table S3.
For site-directed mutagenesis, FANCL (containing the nucleotides to be mutated) was 
amplifi ed from the vector S11FLIEG. The PCR product was directly subcloned into the pCR2.1-
TOPO vector using the TOPO TA cloning kit (Invitrogen, Karlsruhe, Germany). Site-directed 
mutagenesis was performed in this vector with the QuikChange® Site-Directed Mutagenesis 
Kit and Pfu polymerase (both Stratagene, La Jolla, CA). Site-mutated plasmids were isolated 
by plasmid mini preparation (Qiagen, Hilden, Germany) and the substitutions introduced were 
verifi ed by direct sequencing. Using EcoRI and SalI restriction sites, the site-mutated fragment 
was ligated back into S11FLIEG. Construction of the vector S11FLIEG891 was by means of the 
mutation primers FANCLmut891C>Gfor, 5’-CCAGCTCGTGCTATGCTGGAAAAATCTG-3’, and 
FANCLmut891C>Grev, 5’-CAGATTTTTCCAGCATAGCACGAGCTGG-3’.
Inverse PCR was performed exactly as described (Ochman et al. 1988). Shortly, gDNA was 
separately digested with EcoRI, XhoI, BamHI and NotI. The restriction products were ligated 
under diluted conditions that favored monomolecular circularization. Applying each crude mix as 
template, the intramolecular ligation products were used for inverse amplifi cation with an antisense 
primer upstream of exon 6 together with a sense primer downstream of exon 7 (Supplementary 
tables S1 and S2).
Splice assay
A potential effect of the base substitution c.891C>G, aberrant splicing, was examined by cloning 
a genomic fragment extending from FANCL exon 9 to 12 into the vector SVcrev (Freund et al. 
2003). gDNAs of patient 1 and a normal control were used as templates for amplifi cation with 
the sense primer FALex9-12EcoRI, 5´-GAAGAATTCGTAATAATGTTTCCATAAATATAG-3’, and 
the antisense primer FALex9-12XhoI, 5´-GAACTCGAGCTCATATAAGCATATTTGATGG-3’. Both 
PCR products and the target vector were cut with EcoRI and XhoI (restriction sites highlighted in 
the primer sequences), followed by ligation at 14 °C o/n. Fidelity of the inserted sequence was 
verifi ed by sequencing. Transfection was done as previously described (Freund et al. 2003).
Immunofl uorescence
Cells were fi xed with 3.7% paraformaldehyde in PBS (w/v) for 15 min, followed by permeabilization 
with 0.5% Triton X-100 in PBS for 5 min. After blocking for 30 min (10% FBS, 0.1% NP-40 
in PBS), FANCD2 protein was detected using the same mouse monoclonal FANCD2 antibody 
as for immunoblotting (FL-17, Santa Cruz Biotechnology, Heidelberg, Germany) at a dilution of 
1:200. Subsequently, the cells were washed in TBS three times. As secondary antibody, we used 
Alexa Fluor 594 anti-mouse IgG(H+L) (Molecular Probes, Leiden, The Netherlands) diluted in 
TBS (1:1000). After incubation for 45 min at RT, the cells were washed three times and covered 
with DAPI-containing Vectashield mounting medium (Vector Laboratories,Burlingame, CA).
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Results
Prescreen
In a pilot study, 43 DNAs of LCLs originating from well-characterized FA patients previously 
excluded from belonging to any of the complementation groups FA-A, B, C, D1, D2, E, F and G 
were screened for sequence alterations of FANCL by DHPLC analysis and primary sequencing 
in 13 fragments. A total of 11 sequence variants were identifi ed (Table 1). These include one 
synonymous missense variant, S327S, and 10 intronic variants. They represent annotated or 
anonymous SNPs that are characterized as polymorphisms by their nature or location. They may 
be useful for DNA chip arrays or the construction of haplotype maps. None of the LCLs revealed 
a mutation. This led us to require positive complementation in a functional assay as a prerequisite 
for sequence analysis of FANCL in further FA patients.
Position Site Designation Frequency
Exon 12 c.981T>C(p.S327S) rs848291 43% (16/37)
Intron c.217-11T>C(IVS3-11T>C) – 19% (7/37)
c.273+20insT
(IVS4+20insT) – 8.1% (3/37)
c.374+35delT
(IVS5+35delT) – 8.3% (3/36)
c.540+93C>T
(IVS7+93C>T) – nd
c.541-27A>G
(IVS7-27A>G) rs12624152 8.3% (3/36)
c.691+59delTAA
(IVS8+59delTAA – 32% (12/37)
c.691+70A>G
(IVS8+70A>G) rs848288 nd
c.775+22C>T
(IVS9+22C>T) rs10445896 35% (13/37)
c.775+31A>G
(IVS9+31A>G) rs10445895 25% (9/36)
c.1021-65G>A
(IVS13-65G>A) rs3732136 32% (12/37)
Table 1. Sequence variants / polymorphisms detected in FANCL
nd: Frequency was not determined in the present study
Assignment to complementation group FA-L
Patient-derived primary fi broblast cultures were used to determine the constitutional FANCD2 
patterns. According to the type of FA/BRCA pathway disruption, patients were classifi ed as ‘FA 
core’, FA-D2 and a downstream group (Soulier et al. 2005). Cells of ‘FA core’ patients with their 
defects upstream of FANCD2 (and FANCI) were screened for complementation after retroviral 
transfer of FANCA, -B, -C, -E, -F, -G and -L cDNAs. As shown for patient 1, transfer of FANCL cDNA 
in this case led to functional correction of the MMC-sensitive cellular phenotype as evidenced by 
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restoration of the previously increased G2 phase cell cycle fractions to normal control levels (Fig. 
1B), in contrast to transduction with EGFP or other FANC cDNAs. Concomitantly, the cells became 
profi cient of FANCD2 monoubiquitination (see below). On the basis of such complementation 
results, three patients were assigned to complementation group FA-L. In case of non-mosaic 
patients, cultures of stimulated PBL or LCLs could be used as well for the complementation 
assays.
Case histories
Patient 1 was born prematurely after 35 weeks of gestation as the second child of non-
consanguineous parents of German ancestry. Physical examination after birth and prior to 
transplantation revealed short stature, pigmentation anomalies of the skin and malformations 
of the skeleton, eyes and inner organs. In addition to severe growth retardation (at the 3rd 
percentile) and growth hormone defi ciency (treated with growth hormone from her second to 
ninth year of life), the patient exhibited microcephaly, malposition of the thumbs, rudimentary 
preaxial polydactyly, cutaneous syndactyly of toes II and III, congenital hip dysplasia and Klippel-
Feil deformity. Microphtalmia was present together with blepharophimosis and Sicca syndrome. 
Malformations of inner organs included duodenal atresia with malrotation II and crossed renal 
atopia combined with vesicorenal refl ux causing stage IV chronic renal failure. In addition, she 
suffered from renal tubular acidosis type II. Statomotor development was delayed.
The clinical diagnosis of FA was considered at age 4 years following the onset of mild 
thrombocytopenia, neutropenia and megaloblastic anemia. Confi rmation at that time was by DEB 
testing and cell cycle analysis of PBL (Auerbach 1993; Seyschab et al. 1995). At age 6, the patient 
was started on androgen therapy, which was continued until 11 years of age. The combined 
treatment with androgens and erythrocyte transfusions (at Hb levels below 8 g/dl) stabilized 
her blood cell counts for nearly 3 years. At age 9, a gradual decrease of platelets was noted, 
which was followed by a decrease of neutrophil counts 2 years later, necessitating hematological 
stem cell transplantation (HSCT). HSCT from a fully HLA-matched unrelated stem cell donor 
was successfully performed using a higly reduced and modifi ed conditioning regimen based on 
fl udarabine, busulfan and antithymocyte globulin. Two years after successful engraftment and 
complete hematologic remission, the 13-year-old patient developed a squamous cell carcinoma 
of the tongue that was detected during a routine examination. The carcinoma was successfully 
removed and she is in complete remission at her present age of 16 years (Reinhard et al. 2007).
Patient 2 is the third child to second cousins of Turkish descent. He was recognized by sonography 
at 28 weeks of gestation with intrauterine growth retardation, ventriculomegaly, radial fl exion of 
both hands, aplasia of the right and hypoplasia of the left radius, and aplasia of both thumbs. 
FA was diagnosed prenatally, the parents nonetheless decided to continue the pregnancy. The 
malformations, stunted growth and anomalies of skin pigmentation were confi rmed after birth. 
Hydrocephaly required drainage by shunt installation. No hematological manifestations occurred 
until to the present age of 1 year.
Patients 3 is the offspring of European and native American parents. She was recognized at 
birth with absent thumbs and radii bilaterally, skin pigmentation anomalies and short stature. FA 
was confi rmed by abnormal chromosome breakage rates (spontaneous 0.18, DEB-induced 10.4 
breaks per cell in PBL). She also has small auditory canals and bilateral hearing loss, whose 
specifi c nature is not entirely clear. Bone marrow failure started at age 5 years and required bone 
marrow transplantation at 10 years of age. She is doing fi ne at her present age of 11.5 years.
Mutation analysis
Mutation analysis in patient 1 was performed with cDNA and gDNA from primary fi broblasts. The 
patient was found to be heterozygous for a 5-bp deletion in exon 7 (c.483delATCAC) and a base 
substitution in exon 11 (c.891C>G, I297M). The deletion causes a frameshift and premature 
termination of translation at amino acid position 185 (E161DfsX26). The effect of the missense 
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substitution was unclear initially. ESE fi nder software (rulai.cshl.edu/tools/ESE/) predicted the 
loss of a potential SC35 binding site accompanied by reinforcement of a putative SRp40 motif 
as a result of the substitution. In a mini gene-based splicing assay, we detected transcripts with 
skipping of exons 10 and 11 or 11 only. However, this observation appeared to be independent of 
the base substitution as it also occurred in normal controls (Fig. 1C) and was fi nally interpreted 
as alternative splicing of exons 10 and 11 or 11 only. Retroviral transfer of full length FANCL 
cDNA containing the base substitution c.891C>G failed to complement fi broblasts of patient 1, 
indicating the pathogenetic nature of the missense mutation (Fig.1 D). 
Figure 1.   Assignment to 
complemetation group FA-L and 
FANCL mutations in patient 1. 
A) Circular map of the retroviral 
vector S11FLIEG that was used 
in complementation assays. Long 
terminal repeats (LTRs) and 
restriction sites used for construction 
of the vector and for site-directed 
mutagenesis are indicated. SD, 
splice donor. Bacterial resistance 
is AmpR. B) MMC sensitivity of 
primary fi broblasts from patient 
1 results in prominent G2 phase 
peaks (after transduction with eGFP 
and FANCF vectors for negative 
control), but is reversed to control 
levels (CON) after transduction 
with FANCL-cDNA; DAPI stain. 
C) Polyacrylamide gel of RT-PCR 
products probing alternative 
splicing of FANCL mRNA in a mini 
gene-based splicing assay. The 
genomic region of FANCL exons 9 
to 12 was amplifi ed, cloned into the 
vector SVcrev and transfected into 
human cells. Isolated mRNA was 
reverse transcribed and amplifi ed 
with vector specifi c primers. Both, 
patient 1 and control cDNA show 
an identical pattern of alternative 
splicing with skipping of exons 
10 and 11 or 11 only. D) FANCD2 
immunoblot with fi broblasts 
from FA-L patient 1. Retroviral 
transduction of wtFANCL cDNA 
restores FANCD2-L expression, 
as does FANCL* cDNA with the 
somatic reversion, but FANCL891 
cDNA with the substitution 
c.891C>G does not, indicating that 
the former is a valid compensatory 
mutation, the latter an authentic 
mutation. Negative controls, EGFP 
and FANCA cDNA transfer.
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Chromosome breakage and cell cycle analysis of PBL at 4 years of age revealed sensitivity 
towards MMC. In contrast, at age 10 prior to bone marrow transplantation, PBL of patient 1 proved 
MMC-resistant, suggesting the emergence of a mosaic status in the hematopoietic system. Two 
independently established LCLs likewise proved MMC-resistent as evidenced by the detection of 
both, the native and the monoubiquitinated FANCD2 isoform on immunoblots (Fig. 2A) and absent 
G2 phase arrest on cell cycle analysis (Fig. 2B) refl ecting functional reversion. A de novo skipping 
of 10 bp preceding the 5-bp deletion was detected in PBL and lymphoblast cDNA and restored 
the ORF (Fig. 2C). At the genomic level, the basis of the 10-bp skipping in transcripts with the 5-
bp deletion the proved to be a heterozygous base substitution c.472-2A>T (IVS6-2A>T) present 
in PBL, bone marrow and LCLs (at patient age 10), but not in patient´s fi broblasts (Fig. 2D). This 
base substitution is predicted to abrogate the splice acceptor upstream of exon 7 by disrupting 
the canonical AG dinucleotide. In turn, a downstream AG functions as a cryptic splice acceptor 
for aberrant splicing of exon 7 (Fig. 2E). This cryptic splice site is located 10 bp downstream of 
the normal exon boundary and 1 bp upstream of the germline deletion (c.483delATCAC). The 
predicted protein resulting from the combined alteration in transcripts contains a tyrosine instead 
of threonine at position 158, followed by a deletion of 5 amino acids (p.T158Ydel5) (Fig. 2F). This 
change might infl ict the second WD40 repeat of FANCL, which is located between aa 147-202. 
Figure 2. Molecular characterization of the somatic reversion in LCLs of patient 1. A) Revertant LCLs of 
FA-L patient 1 are profi cient of FANCD2 monoubiquitination on immunoblots; negative control, FANCC-
defi cient cell line. B) Revertant LCLs of FA-L patient 1 lack G2-phase arrest on fl ow cytometric cell cycle 
analysis after exposure to MMC; (left to right) normal control cells, FA-C control and FA-L patient 1 LCLs; 
DAPI stain. C) Compared to fi broblasts, cDNA of LCLs derived from patient 1 shows the germline 5-bp 
deletion (c.483del5) and, in addition, somatic skipping of 10 bp (c.472del10). D) gDNA from PBL and 
LCLs of patient 1 shows coexistence of the germline 5-bp deletion in exon 7 and a base substition in cis, 
IVS6-2A>T, abrogating the normal splice acceptor upstream of exon 7. E) At the mRNA level, the base 
substitution IVS6-2A>T results in the usage of a cryptic splice acceptor located 10 bp downstream and 
skipping of the fi rst 10 bp (red) of exon 7. F) The lack of altogether 15 bp at mRNA level (FANCL*) restores 
the reading frame but leads to a chande of 1 aa (T158Y) and the deletion of 5 aa.
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In order to examine the function of the altered protein, we cloned the revertant FANCL* cDNA into 
the retroviral S11 vector (Fig. 3A) and transduced patient-derived fi broblasts with this construct. 
As shown in Fig. 3B, FANCL* cDNA abolished the hypersensitivity of patient’s fi broblasts towards 
MMC, indicating complementation. Comparison between the wt and revertant FANCL cDNAs 
revealed no difference regarding complementation effi ciency on cell cycle analysis. In addition, 
DNA damage-induced FANCD2 foci formation was restored by revertant FANCL* cDNA (Fig. 3C). 
No signifi cant difference in the number of foci per nuclei or the number of foci-containing nuclei 
was observed after retroviral transduction with wtFANCL or revertant FANCL* cDNAs (Fig. 3D).
In case 2, lymphoblast gDNA was used for amplifi cation and sequence analysis. Sequencing of 
PCR products from FANCL exons 6 through 14 including the adjacent intron regions revealed no 
mutations. Efforts to amplify exons 1 through 5 failed repeatedly; no PCR products were obtained. 
Figure 3. Evidence of the 
compensatory nature of the 
somatic reversion event 
in patient 1. A) Graphic 
presentation of a retroviral 
FANCL* vector construct 
containing revertant cDNA from 
LCLs of FA-L patient 1 (with 
c.472del10 and c.483del5), 
denoted S11FL*IEG. B) Wt and 
revertant FANCL reduce G2-
phase arrest of MMC-exposed 
fi broblasts from patient 1. Flow 
cytograms after transduction of 
fi broblasts from patient 1 with 
(from left to right) EGFP cDNA, 
wt FANCL cDNA and FANCL* 
cDNA (containing the revertant 
sequence); Hoechst 33342 
vital stain. C) Fibroblasts from 
patient 1 lack nuclear FANCD2 
foci after exposure to MMC 
(left), while transduction with 
FANCL* cDNA restores their 
formation (red, right). Nuclei 
were counterstained with 
DAPI (blue). D) Quantitative 
assessment of nuclear FANCD2 
foci formation (mean and 
SD of 200 nuclei each) after 
transduction of fi broblasts from 
patient 1 with EGFP, wtFANCL 
and revertant FANCL* cDNA, 
without (light bars) and after 
(dark bars) exposure toMMC. 
These experiments characterize 
IVS6-2A>T and the resulting 
10-bp skipping as an authentic 
compensatory mutation.
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A homozygous large deletion was suspected with breakpoints upstream of exon 1 and within intron 
5, upstream of the binding site of the sense primer for exon 6 amplifi cation. Using downstream 
walking with arbitrary forward primers in intron 5 in combination with the reverse primer for exon 
6 amplifi cation, the 3’ breakpoint of the putative deletion was limited to the approximate region of 
IVS5-328 to IVS5-247 (c.375-328 to c.375-247). In order to determine both breakpoints exactly, 
we used a technique addressed as ‘inverse PCR’, that permits the amplifi cation of regions 
of unknown sequence fl anking any specifi ed DNA segment (Fig. 4A) (Ochman et al., 1988). 
Restriction digests of different enzymes were ligated and thus circularized (Fig. 4B). Inverse PCR 
and two rounds of nested amplifi cations with internal primers within the known sequence revealed 
a PCR product exclusively with the NotI fraction. This was subjected to sequence analysis, which 
permitted identifi cation of the breakpoints corresponding with the transition junction of sequence 
upstream of the FANCL translation start codon into intron 5 sequence (Fig. 4C). Formal description 
specifi es the deletion EX1_5del as g.1-219_36840del37059 or c.1-219_375-248del37059. Since 
the 5’ breakpoint of the deletion is located further upstream than all cDNA sequences available in 
various databases extend, it is likely that the deletion reaches into the putative FANCL promotor 
region. Therefore it is likely that neither a FANCL protein nor even a transcript are made.
In case 3, gDNA from fi broblast was used as template for amplifi cation and exon scanning 
sequencing. A heterozygous 3-bp deletion in exon 12 was identifi ed, c.1007_1009delTAT. This 
mutation is out of the reading frame; it deletes two original amino acids and creates a new one at 
the deletion union, designated as p.I336_C337delinsS. There was no second mutation detected 
in the exons and adjacent introns. In order to analyze the transcripts, cDNA from fi broblasts 
was sequenced. At the mRNA level, the small deletion appeared homozygous suggesting 
instability of the elusive other transcript. Therefore we designed a mismatch primer with wtFANCL 
sequence at the site of the 3-bp deletion, destined to bind and amplify preferentially the unstable 
transcript without the mutation at this site. Using this as antisense in combination with FANCL -43 
(Supplementary table S3) as sense primer, we obtained two PCR products, one of which contained 
a 33-bp sequence from deep within intron 5. Genomic analysis showed a 5’-fl anking cryptic splice 
acceptor. A heterozygous base substitution 3’-fl anking the inserted intron sequence created a 
new splice donor with high complementarity for U1snRNA binding, indicated by the score of 75.10 
(Splicefi nder version Screen 3; http://www.splicefi nder.net). This event resulted in the exonization 
of IVS5-2066_IVS5-2034 to create a new exon 5a. Formal description of this mutation specifi es 
it as g.35021C>G or c.375-2066_375-2034ins33 or p.K125_L126insNYELINEKEFR.
During these studies, we recognized another site of alternative FANCL mRNA splicing. In intron 
7, there is a direct repeat of the exon-intron junction sequence. This repeat of 15 bp length 
(CCTCAGGTAAATTCT) also repeats the splice donor upstream of exon 7 (c.540+15), which 
appears to be used. We detected minor transcripts that contain a corresponding insertion (c.540_
541insGTAAATTCTCCTCAG; p.Q180_S181insVNSPQ).
The FANCL mutations identifi ed in the present study and that reported by Meetei et al. (Meetei et 
al. 2003) are depicted in Fig. 4D.
2.3 Mutations and Reversion in FANCL...
- 71 -
Figure 4. Mutation analyses in patient 2 and 3. A) Assay to characterize the breakpoints of a large 
genomic deletion of FA-L patient 2. Graphic presentation of unknown sequence containing the deletion 
breakpoints and an upstream NotI restriction site next to known sequence, a genomic fragment of FANCL 
containing exons 6 and 7, as well as a downstream NotI restriction site. B) Circular map of circularized 
NotI restriction products of A. Sequence elements are indicated. The arrows show primer binding sites for 
inverse amplifi cation and nested PCR. C) The chromatogram of sequencing across the breakpoints in B 
shows the transition from putative FANCL promotor into IVS5 sequence, defi ning the deletion breakpoints. 
D) Positions and identity of the mutations identifi ed in the present study are shown above a schematic 
presentation of FANCL, the mutation reported by Meetei et al. (Meetei et al. 2003) is below.
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Discussion
General considerations
Three of the FANC genes represented FA subgroups with single patients when they were fi rst 
reported, namely FANCH, FANCL and FANCM (Joenje et al. 1997; Meetei et al. 2003; Meetei et al. 
2005). There are even proteins that are members of the FA core complex such as FAAP100, which 
does not stand for any complementation group because there is no patient with a corresponding 
gene defect, although the function of this protein is FA-like (Ling et al. 2007). While it may be 
premature to judge the success of screens for defects in recently identifi ed genes without FA 
patients, the fate of the complementation groups with initially single patients is instructive. Group 
FA-H was withdrawn after the only patient of this group was reclassifi ed to group FA-A (Joenje et 
al. 2000). Complementation group FA-M is intermediate in that it is represented by a single family 
for more than two years. Facts that would make this group special are not obvious to date. It is 
therefore to be expected that group FA-M will follow the fate of group FA-L. With the present study, 
the number of members of this group increases from one to four not less than 4 years after the 
fi rst report of FANCL, which now renders FA-L a classical FA complementation group.
Genotype-phenotype correlations
With the original report it remained unclear howt the phenotypic presentation of FA-L patients 
is like, since there was no clinical information on the single patient who is since deceased and 
unavailable for study. Here we present the clinical and molecular data of three additional FA-L 
patients. Patient 1 clearly belongs to the more severely affected FA phenotypes with short stature, 
congenital malformations, microcephaly, microphthalmia, childhood onset of bone marrow failure 
and juvenile onset of neoplasia. At the cellular level, patient derived fi broblasts and T-lymphocytes 
(age 4) proved highly sensitive towards MMC, which is typical for all FA complementation groups. 
One of the underlying mutations causes a frameshift, and, presumably, protein truncation. The 
other allele shows loss of function caused by a missense mutation. The single FA-L patient 
mentioned above was described with skipping of exon 11 based on a homozygous or hemizygous 
insertion of 177 bp in the polypyrimidine tract of the splice acceptor site leading to little or no 
protein in whole cell extracts of lymphoid cell line (Meetei et al. 2003). Leaky mutations due to 
aberrant splicing are known to predominate in the target of FANCL, the FANCD2 gene (Kalb et al. 
2006), and only very few mutations have been found in FANCM, another evolutionarily conserved 
FA gene (Meetei et al. 2005). Patients carrying mutations, let alone biallelic null mutations, in 
any of these conserved genes occur much less frequently than patients with mutations in the 
evolutionarily recent genes FANCA, FANCC or FANCG. This underlines the functional importance 
of the highly conserved FA genes. FANCL provides the presumed E3 ligase activity for FANCD2 
monoubiquitination, and both FANCL and FANCD2 seem to play important roles in ontogenesis. 
The murine FANCL/PHF9 homologue was identifi ed as the gene underlying the mouse phenotype 
of gcd (germ cell-defi cient) denoted POG (proliferation of germ cells) (Agoulnik et al. 2002). POG 
was shown to be essential for proper primordial germ cell proliferation in the embryonic stage, but 
is not needed for spermatogonial proliferation after birth (Lu and Bishop 2003).
Somatic reversion in patient T- and B-lymphoid cells
At age 10, examination of primary T-lymphocytes and of B-cell derived LCLs of patient 1 of 
the present study revealed loss of MMC sensitivity that had not been detected in primary T-
lymphocytes obtained at age 3. Therefore, the shift to MMC-resistance of peripheral blood 
mononuclear cells must have taken place between ages 3 and 10. As other cell lineages such as 
thrombocytes, erythrocytes and neutrophils continued to decline during this time necessitating 
bone marrow transplantation, the reversion event must have taken place in a lymphoid precursor 
cell rather than in a hematopoietic stem cell. To date, revertant mosaicism has been described for 
FA patients belonging to complementation groups A, C and D2 (Lo Ten Foe et al. 1997; Waisfi sz et 
al. 1999; Gregory et al. 2001; Gross et al. 2002; Soulier et al. 2005, Kalb et al. 2006). Mechanisms 
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of reversion include intragenic crossover, gene conversion, back mutation, and compensating 
mutations in cis (Waisfi sz et al. 1999; Gross et al. 2002; Mankad et al. 2006). Only two patients, 
both belonging to complementation group FA-A, showed functional correction of a frameshift 
mutation by a somatic alteration in cis similar to what we observed in our patient 1 (Waisfi sz et 
al. 1999). One of the reported FANCA frameshift mutations, a microdeletion (c.1615delG), was 
compensated by two additional single base-pair deletions located downstream of the germline 
mutation. The other example, a microinsertion (c.3556insG), was compensated by a second site 
insertion (c.3580insCGCTG). In both cases, the open reading frame of FANCA was restored 
enabling the expression of a functional protein.  
A novel type of compensatory mutation in cis
Our patient provides an example for another so far unique type of compensatory mutation 
upstream of a 5 base pair deletion (483delATCAC, exon 7) in the FANCL gene. The mutation 
of the natural splice acceptor of exon 7 results in the usage of an alternative splice site, located 
10 base pairs downstream next to the germline deletion, leading to restoration of the open 
reading frame. The deduced amino acid sequence is predicted to contain a tyrosine instead of a 
threonine at position 158 affecting the fi rst third of second WD40 in FANCL. Loss of the WD40 
repeats results in defective FANCD2 monoubiquitination and FA core complex assembly (Gurtan 
et al. 2006). However, WD-repeats are minimally conserved domains of approximately 40–60 
amino acids containing both variable and characteristic domains, such as a tryptophan-aspartic 
acid (WD) dipeptide at the C terminus. The putative common function of these repeats is the 
assembly of multiprotein complexes by serving as a rigid platform or as a scaffold for protein-
protein interactions (Smith et al. 1999; Li and Roberts 2001). In our patient 1, the compensatory 
deletion evidently did not alter protein function, indicating that no structurally important domain 
was affected. Functionality of the reverted gene product was evidenced by transduction of 
FANCL cDNA containing the compensatory mutation into patient-derived primary fi broblasts. This 
transduction resulted in loss of MMC sensitivity and restoration of FANCD2 monoubiquitination. 
In addition, the MMC-induced recruitment of FANCD2 into nuclear foci was restored to normal 
levels refl ecting the truly compensatory nature of the somatic reversion event.
In summary, we report the clinical and mutational data of three additional FA-L patients. These 
data actually show an increasing complementation group FA-L emerging, FA-L patients present 
with a typical spectrum of manifestations and hematological course comparable with those of FA 
patients with the most common gene defects (FANCA, -C and G). Finally, FA-L patients reveal a 
spectrum of mutation and reversion similar to that reported for the commonly mutated FA genes.
- 74 -2.3 Mutations and Reversion in FANCL...
References
Agoulnik AI, Lu B, Zhu Q, Truong C, Ty MT, Arango N, 
Chada KK, Bishop CE (2002) A novel gene, Pog, 
is necessary for primordial germ cell proliferation 
in the mouse and underlies the germ cell defi cient 
mutation, gcd. Hum Mol Genet 11:3047-3053
Auerbach AD (1993) Fanconi anemia diagnosis 
and the diepoxybutane (DEB) test. Exp Hematol 
21:731-733
Casado JA, Callen E, Jacome A, Rio P, Castella M, 
Lobitz S, Ferro T, Munoz A, Sevilla J, Cantalejo 
A, Cela E, Cervera J, Sanchez-Calero J, Badell 
I, Estella J, Dasi A, Olive T, Jose Ortega J, 
Rodriguez-Villa A, Tapia M, Molines A, Madero 
L, Segovia JC, Neveling K, Kalb R, Schindler 
D, Hanenberg H, Surralles J, Bueren JA (2007) 
A comprehensive strategy for the subtyping of 
patients with Fanconi anaemia: conclusions from 
the Spanish Fanconi Anemia Research Network. 
J Med Genet 44, 241-249
Chandra S, Levran O, Jurickova I, Maas C, Kapur 
R, Schindler D, Henry R, Milton K, Batish SD, 
Cancelas JA, Hanenberg H, Auerbach AD, 
Williams DA (2005) A rapid method for retrovirus-
mediated identifi cation of complementation 
groups in Fanconi anemia patients. Mol Ther 
12:976-984
Digweed M, Rothe S, Demuth I, Scholz R, Schindler 
D, Stumm M, Grompe M, Jordan A, Sperling K 
(2002) Attenuation of the formation of DNA-repair 
foci containing RAD51 in Fanconi anaemia. 
Carcinogenesis 23:1121-1126
Dorsman JC, Levitus M, Rockx D, Rooimans MA, 
Oostra AB, Haitjema A, Bakker ST, Steltenpool J, 
Schuler D, Mohan S, Schindler D, Arwert F, Pals 
G, Mathew CG, Waisfi sz Q, de Winter JP, Joenje 
H (2007) Identifi cation of the Fanconi anemia 
complementation group I gene, FANCI. Cell 
Oncol 29:211-218
Freund M, Asang C, Kammler S, Konermann C, 
Krummheuer J, Hipp M, Meyer I, Gierling W, 
Theiss S, Preuss T, Schindler D, Kjems J, Schaal 
H (2003) A novel approach to describe a U1 
snRNA binding site. Nucleic Acids Res 31:6963-
6975
Frueh FW, Noyer-Weidner M (2003) The 
use of denaturing high-performance liquid 
chromatography (DHPLC) for the analysis of 
genetic variations: impact for dignostics and 
pharmacogenetics. Clin Chem Lab Med 41:452-
461
Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn 
MS, Timmers C, Hejna J, Grompe M, D‘Andrea 
AD (2001) Interaction of the Fanconi anemia 
proteins and BRCA1 in a common pathway. Mol 
Cell 7:249-262
Godthelp BC, Wiegant WW, Waisfi sz Q, Medhurst 
AL, Arwert F, Joenje H, Zdzienicka MZ (2006) 
Inducibility of nuclear Rad51 foci after DNA 
damage distinguishes all Fanconi anemia 
complementation groups from D1/BRCA2. Mutat 
Res 594:39-48
Gregory JJ, Jr., Wagner JE, Verlander PC, Levran 
O, Batish SD, Eide CR, Steffenhagen A, Hirsch 
B, Auerbach AD (2001) Somatic mosaicism in 
Fanconi anemia: evidence of genotypic reversion 
in lymphohematopoietic stem cells. Proc Natl 
Acad Sci U S A 98:2532-2537
Gross M, Hanenberg H, Lobitz S, Friedl R, Herterich 
S, Dietrich R, Gruhn B, Schindler D, Hoehn H 
(2002) Reverse mosaicism in Fanconi anemia: 
natural gene therapy via molecular self-correction. 
Cytogenet Genome Res 98:126-135
Gurtan AM, Stuckert P, D‘Andrea AD (2006) The 
WD40 repeats of FANCL are required for Fanconi 
anemia core complex assembly. J Biol Chem 
281:10896-10905
Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, 
Williams DA. (1996) Colocalization of retrovirus 
and target cells on specifi c fi bronectin fragments 
increases genetic transduction of mammalian 
cells. Nat Med 2:876-882
Hanenberg H, Hashino K, Konishi H, Hock RA, Kato 
I, Williams DA. (1997) Optimization of fi bronectin-
assisted retroviral gene transfer into human 
CD34+ hematopoietic cells. Hum Gene Ther 
8:2193-2206
Hanenberg H, Batish SD, Pollok KE, Vieten L, 
Verlander PC, Leurs C, Cooper RJ, Gottsche 
K, Haneline L, Clapp DW, Lobitz S, Williams 
DA, Auerbach AD (2002) Phenotypic correction 
of primary Fanconi anemia T cells with retroviral 
vectors as a diagnostic tool. Exp Hematol 30:410-
420
Heinrich MC, Hoatlin ME, Zigler AJ, Silvey KV, Bakke 
AC, Keeble WW, Zhi Y, Reifsteck CA, Grompe M, 
Brown MG, Magenis RE, Olson SB, Bagby GC 
(1998) DNA cross-linker-induced G2/M arrest in 
group C Fanconi anemia lymphoblasts refl ects 
normal checkpoint function. Blood 91:275-287
Hildinger M, Abel KL, Ostertag W, Baum C (1999) 
Design of 5‘ untranslated sequences in retroviral 
vectors developed for medical use. J Virol 
73:4083-4089
Huck K, Hanenberg H, Gudowius S, Fenk R, Kalb 
R, Neveling K, Betz B, Niederacher D, Haas R, 
Gobel U, Kobbe G, Schindler D (2006) Delayed 
diagnosis and complications of Fanconi anaemia 
at advanced age--a paradigm. Br J Haematol 
133:188-197
Joenje H, Oostra AB, Wijker M, Di Summa FM, 
van Berkel CG, Ebell W, van Weel M, Pronk JC, 
Buchwald M, Arwert F (1997) Evidence for at 
least eight Fanconi anemia genes. Am J Hum 
Genet61:940-944
Joenje H (1997) Fanconi anemia: cytogenetic 
- 75 -2.3 Mutations and Reversion in FANCL...
diagnosis. Free University of Amsterdam, 
Amsterdam
Joenje H, Levitus M, Waisfi sz Q, D‘Andrea A, Garcia-
Higuera I, Pearson T, van Berkel CGM, Rooimans 
MA, Morgan N, Mathew CG, Arwert F (2000) 
Complementation analysis in Fanconi anemia: 
assignment of the reference FA-H patient to 
group A. Am J Hum Genet 67:759-762
Levitus M, Rooimans MA, Steltenpool J, Cool NF, 
Oostra AB, Mathew CG, Hoatlin ME, Waisfi sz 
Q, Arwert F, de Winter JP, Joenje H (2004) 
Heterogeneity in Fanconi anemia: evidence for 2 
new genetic subtypes. Blood 103:2498-2503
Levitus M, Waisfi sz Q, Godthelp BC, de Vries Y, 
Hussain S, Wiegant WW, Elghalbzouri-Maghrani 
E, Steltenpool J, Rooimans MA, Pals G, Arwert F, 
Mathew CG, Zdzienicka MZ, Hiom K, De Winter 
JP, Joenje H (2005) The DNA helicase BRIP1 is 
defective in Fanconi anemia complementation 
group J. Nat Genet 37:934-935
Levran O, Attwooll C, Henry RT, Milton KL, Neveling 
K, Rio P, Batish SD, Kalb R, Velleuer E, Barral 
S, Ott J, Petrini J, Schindler D, Hanenberg H, 
Auerbach AD (2005) The BRCA1-interacting 
helicase BRIP1 is defi cient in Fanconi anemia. 
Nat Genet 37:931-933
Li D, Roberts R (2001) WD-repeat proteins: 
structure characteristics, biological function, and 
their involvement in human diseases. Cell Mol 
Life Sci 58:2085-2097
Ling C, Ishiai M, Ali AM, Medhurst AL, Neveling K, 
Kalb R, Yan Z, Xue Y, Oostra AB, Auerbach AD, 
Hoatlin ME, Schindler D, Joenje H, de Winter JP, 
Takata M, Meetei AR, Wang W (2007) FAAP100 
is essential for activation of the Fanconi anemia-
associated DNA damage response pathway. 
EMBO J 26:2104-2114
Lo Ten Foe JR, Kwee ML, Rooimans MA, Oostra 
AB, Veerman AJ, van Weel M, Pauli RM, Shahidi 
NT, Dokal I, Roberts I, Altay C, Gluckman E, 
Gibson RA, Mathew CG, Arwert F, Joenje H 
(1997) Somatic mosaicism in Fanconi anemia: 
molecular basis and clinical signifi cance. Eur J 
Hum Genet 5:137-148
Lu B, Bishop CE (2003) Late onset of spermatogenesis 
and gain of fertility in POG-defi cient mice indicate 
that POG is not necessary for the proliferation of 
spermatogonia. Biol Reprod 69:161-168
Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer 
GM, D‘Andrea AD, Dutta A (2006) UBE2T is the 
E2 in the Fanconi anemia pathway and undergoes 
negative autoregulation. Mol Cell 23:589-596
Mankad A, Taniguchi T, Cox B, Akkari Y, Rathbun RK, 
Lucas L, Bagby G, Olson S, D‘Andrea A, Grompe 
M (2006) Natural gene therapy in monozygotic 
twins with Fanconi anemia. Blood
Meetei AR, de Winter JP, Medhurst AL, Wallisch M, 
Waisfi sz Q, van de Vrugt HJ, Oostra AB, Yan Z, 
Ling C, Bishop CE, Hoatlin ME, Joenje H, Wang 
W (2003) A novel ubiquitin ligase is defi cient in 
Fanconi anemia. Nat Genet 35:165-170
Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, 
Bier P, Steltenpool J, Stone S, Dokal I, Mathew 
CG, Hoatlin M, Joenje H, de Winter JP, Wang 
W (2005) A human ortholog of archaeal DNA 
repair protein Hef is defective in Fanconi anemia 
complementation group M. Nat Genet 37:958-
963
Meetei AR, Yan Z, Wang W (2004) FANCL replaces 
BRCA1 as the likely ubiquitin ligase responsible 
for FANCD2 monoubiquitination. Cell Cycle 
3:179-181
Miller SA, Dykes DD, Polesky HF (1988) A simple 
salting out procedure for extracting DNA from 
human nucleated cells. Nucleic Acids Res 
16:1215
Nakanishi K, Yang YG, Pierce AJ, Taniguchi T, 
Digweed M, D‘Andrea AD, Wang ZQ, Jasin M 
(2005) Human Fanconi anemia monoubiquitination 
pathway promotes homologous DNA repair. Proc 
Natl Acad Sci U S A 102:1110-1115
Niedzwiedz W, Mosedale G, Johnson M, Ong 
CY, Pace P, Patel KJ (2004) The Fanconi 
anaemia gene FANCC promotes homologous 
recombination and error-prone DNA repair. Mol 
Cell 15:607-620
Ochman H, Gerber AS, Hartl DL (1988) Genetic 
application of an inverse polymerase chain 
reaction. Genetics 120:621-623
Reinhard H, Peters I, Gottschling S, Ebell W, Graf N 
(2007) Squamous cell carcinoma of the tonguein 
a 13-year-old girl with Fanconi anemia. J Pediatr 
Hematol Oncol 29:488-491
Rosenberg PS, Socie G, Alter BP, Gluckman E 
(2005) Risk of head and neck squamous cell 
cancer and death in patients with Fanconi anemia 
who did and did not receive transplants. Blood 
105:67-73
Seyschab H, Friedl R, Sun Y, Schindler D, Hoehn H, 
Hentze S, Schroeder-Kurth T (1995) Comparative 
evaluation of diepoxybutane sensitivity and 
cell cycle blockage in the diagnosis of Fanconi 
anemia. Blood 85:2233-2237
Sigismund S, Polo S, Di Fiore PP (2004) Signaling 
through monoubiquitination. Curr Top Microbiol 
Immunol 286:149-185
Sims AE, Spiteri E, Sims RJ 3rd, Arita AG, Lach 
FP, Landers T, Wurm M, Freund M, Neveling K, 
Hanenberg H, Auerbach AD, Huang TT (2007) 
FANCI is a second monoubiquitinated member 
of the Fanconi anemia pathway. Nat Struct Mol 
Biol 14:564-567
Smith TF, Gaitatzes C, Saxena K, Neer EJ (1999) 
The WD repeat: a common architecture for 
diverse functions. Trends Biochem Sci 24:181-
185
- 76 -2.3 Mutations and Reversion in FANCL...
Smogorzewska A, Matsuoka S, Vinciguerra P, 
McDonald ER 3rd, Hurov KE, Luo J, Ballif BA, 
Gygi SP, Hofmann K, D‘Andrea AD, Elledge 
SJ (2007) Identifi cation of the FANCI protein, a 
monoubiquitinated FANCD2 paralog required for 
DNA repair. Cell 129:289-301
Soulier J, Leblanc T, Larghero J, Dastot H, 
Shimamura A, Guardiola P, Esperou H, Ferry 
C, Jubert C, Feugeas JP, Henri A, Toubert 
A, Socie G, Baruchel A, Sigaux F, D‘Andrea 
AD, Gluckman E (2005) Detection of somatic 
mosaicism and classifi cation of Fanconi anemia 
patients by analysis of the FA/BRCA pathway. 
Blood 105:1329-1336
Thompson LH (2005) Unraveling the Fanconi anemia-
DNA repair connection. Nat Genet 37:921-922
Thompson LH, Hinz JM, Yamada NA, Jones NJ 
(2005) How Fanconi anemia proteins promote 
the four Rs: Replication, recombination, repair, 
and recovery. Environ Mol Mutagen 45:128-142
Waisfi sz Q, Morgan NV, Savino M, de Winter JP, van 
Berkel CG, Hoatlin ME, Ianzano L, Gibson RA, 
Arwert F, Savoia A, Mathew CG, Pronk JC, Joenje 
H (1999) Spontaneous functional correction of 
homozygous fanconi anaemia alleles reveals 
novel mechanistic basis for reverse mosaicism. 
Nat Genet 22:379-383
Wang W (2007) Emergence of a DNA-damage 
response network consisting of Fanconi anaemia 
and BRCA proteins. Nat Rev Genet 8, 735-748
- 77 -
Supplementary Tables
Designation (Exon) Sequence (5’>3’)
FANCLex1F
FANCLex1R
AGGATCTTCCCGCCAAGG
CCTAGCCCGTCACAGACTTC
FANCLex2F
FANCLex2R
GAGTTATTTTCCCTCAAATGCAA
TACTGCCTGTCCCACCAAA
FANCLex3F
FANCLex3R
TTGTCCAAATTATGTTTGTCATTC
CAACATTGTGCAAAGCAGGT
FANCLex4F
FANCLex4R
TTCACTTGGGCCTACATTTTT
AAAGAAAACATCAAATGACTGAGA
FANCLex5F
FANCLex5R
TGAAATTATGTTTTGCAATCAGG
TGACTAAAATCAGGTATAAACTGCTAA
FANCLex6F
FANCLex6R
ACCATCTCCAGTTCCCCTCT
TGAGAGCATTCACAGAGTTCATT
FANCLex7F
FANCLex7R
CCCGGCCCCTAATACATCT
CCCATGGATACTCTGGGACA
FANCLex8F
FANCLex8R
ATGTGAAGCAGGGAGAGTCG
AAGTCTGAGTCCAACTGTCATTGT
FANCLex9F
FANCLex9R
AGCCAGACCAACACCTCTTT
ATCGCGCCATTACACTACAT
FANCLex10F
FANCLex10R
CATTCTGTATCAAATGTGGCTTT
TTCTGGATCCCTGAAAGCAT
FANCLex11F
FANCLex11R
TGTGGTAGGTACCTTGGCAAT
CAGCCTCATTTTTCACTGAGAG
FANCLex12F
FANCLex12R
CCCTCCCAAATATGTACAACG
CAGGAATACTTCCTATGTTGTGTTAG
FANCLex13F
FANCLex13R
CAAAGGGAATGACATTTGGAG
ATGTTTTTGATCAGAGAATTTGAA
FANCLex14F
FANCLex14R
TTCAGAAGTGTTTTCCAAACTGT
TGAAGATGATACCAAAATTCCTTT
Supplementary Table S1. Genomic primers for FANCL amplifi cation and sequencing
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Designation Sequence (5’>3’)
FANCL ex 7 for
FANCL ex 7 rev
(Mutation screen, patient 1)
CCTCAGTGATATTAACACACAGAAGC
GTATACAGAAGAGTGTGCACAGGC
IVS6-521
IVS6-200
(Reversion, patient 1)
CCAAATCACCAAACTTGCACCTC
GGCGAGGTTTCACCGTATAG
FANCLEx 9-12 F
FANCLEx 9-12 R
FANCLIVS9 for
FANCLIVS9 rev
FANCLEx10int F
FANCLIVS10int3F
FANCLIVS11 for
FANCLIVS11int2F
FANCLIVS11 rev
(Alternative splicing)
TAGGTAGCCAGACCAACACCTC
GATCAGGAATGGTACCGTCAAG
GCTCTTGTTGCCCAGTATGTAGTG
CAGTTCAGAATGCTGAGACATTGTC
GCAGGAACATACATTTGTGGTAGG
CATTCTTCCTGATCTTACCTTGTG
AGTACAACTGTCTCTTGGAACAGGG
GAACTCCAAAGTAGCTAATGAGATG
TTTGATGCAGATCAGAAGTCTGTG
7F.for1
IVS5Frg11rev
(Inverse nested PCR, patient 2)
CCTCAGTGATATTAACACACA
GGGAACTGGAGATGGTTGAATTTG
840allel2rev
(Allele-specifi c PCR, patient 3) 
TCCTCTCAGCCACTCATATAAGCATA
840IVS5for1
840IVS5for2
840IVS5rev1
840IVS5rev2
(Exonization, patient 3)
CTCCCTCTTTATATTCATCATGGTTATG
GTACAGAAAGTAGTAGGTGGTGATG
CCATCTTTAATTGAATGGACGTGAAAG
CCAAGAATACGCAATGCTAAAAGAC
Supplementary Table S2. Customized, sequence-specifi c FANCL primers
Designation Sequence (5’>3’)
FANCL -43F CAGCAGGTCTAGAGCTTTTCTG
FANCL 293F GACAAGAGCTGTATGCACTAC
FANCL 355F GGAACTCTTGGTTGGGATAAAC
FANCL 671F CAGCACGCAGAATTGCATTAGG
FANCL 745F CCTGAGTGCTTCTTTCTTGGAG
FANCL 386R GCATACACAAGTTTATCCCAACC
FANCL 686R GCAATTCTGCGTGCTGTTG
FANCL 896R TCCAGGATAGCACGAGCTG
FANCL 1321R GACTTTGGCCTACAATTTCCCAG
Supplementary Table S3. FANCL cDNA primers
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ARTICLE
Hypomorphic Mutations in the Gene Encoding a Key Fanconi
Anemia Protein, FANCD2, Sustain a Significant Group of FA-D2
Patients with Severe Phenotype
Reinhard Kalb, Kornelia Neveling, Holger Hoehn, Hildegard Schneider, Yvonne Linka,
Sat Dev Batish, Curtis Hunt, Marianne Berwick, Elsa Calle´n, Jordi Surralle´s, Jose´ A. Casado,
Juan Bueren, A´ngeles Dası´, Jean Soulier, Eliane Gluckman, C. Michel Zwaan,
Rosalina van Spaendonk, Gerard Pals, Johan P. de Winter, Hans Joenje, Markus Grompe,
Arleen D. Auerbach, Helmut Hanenberg, and Detlev Schindler
FANCD2 is an evolutionarily conserved Fanconi anemia (FA) gene that plays a key role in DNA double-strand–type
damage responses. Using complementation assays and immunoblotting, a consortium of American and European groups
assigned 29 patients with FA from 23 families and 4 additional unrelated patients to complementation group FA-D2.
This amounts to 3%–6% of FA-affected patients registered in various data sets. Malformations are frequent in FA-D2
patients, and hematological manifestations appear earlier and progress more rapidly when compared with all other
patients combined (FA–non-D2) in the International Fanconi Anemia Registry. FANCD2 is flanked by two pseudogenes.
Mutation analysis revealed the expected total of 66 mutated alleles, 34 of which result in aberrant splicing patterns.
Many mutations are recurrent and have ethnic associations and shared allelic haplotypes. There were no biallelic null
mutations; residual FANCD2 protein of both isotypes was observed in all available patient cell lines. These analyses
suggest that, unlike the knockout mouse model, total absence of FANCD2 does not exist in FA-D2 patients, because of
constraints on viable combinations of FANCD2 mutations. Although hypomorphic mutations arie involved, clinically,
these patients have a relatively severe form of FA.
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Fanconi anemia (FA) is a rare genome-instability disorder
with the variable presence of congenital malformations,
progressive bone-marrow failure (BMF), predisposition to
malignancies, and cellular hypersensitivity to DNA-inter-
strand crosslinking agents.1 There are at least 13 comple-
mentation groups (FA-A [MIM 607139], -B [MIM 300515],
-C [MIM 227645], -D1 [MIM 600185], -D2 [MIM 227646],
-E [MIM 600901], -F [MIM 603467], -G [MIM 602956], -I
[MIM 609053], -J [MIM 609054], -L [MIM 608111], -M
[MIM 609644], and -N [MIM 610355]), each of which is
associated with biallelic or hemizygous mutations in a dis-
tinct gene.2–4 To date, 12 of the underlying genes have
been identified: FANCA, FANCB, FANCC, FANCD1/BRCA2,
FANCD2, FANCE, FANCF, FANCG/XRCC9, FANCJ/BRIP1,
FANCL/PHF9, FANCM/HEF, and FANCN/PALB2.3–7 Eight of
the FA proteins (FANCA, -B, -C, -E, -F, -G, -L, and -M) and
other components assemble in a nuclear complex, the FA
“core complex,” that is required for the monoubiquitin-
ation of FANCD2 at amino acid residue K561.8,9 Mono-
ubiquitination occurs in response to DNA damage and dur-
ing the S phase of the cell cycle.9,10 Themonoubiquitinated
FANCD2 isoform (FANCD2-L, as opposed to FANCD2-S)
is targeted to nuclear foci containing proteins such as
BRCA1 [MIM 113705], BRCA2, and RAD51 [MIM 179617]
that are involved in DNA-damage signaling and recom-
binational repair.11–14 The precise role of FANCD2 remains
unknown, but FANCD2-deficient DT40 cells show defects
in homologous recombination-mediated DNA double-
strand break (DSB) repair, translesion synthesis, and gene
conversion.11,15,16 Therefore, FANCD2 is thought to play a
central role in the maintenance of genome stability.11,16,17
The human and murine Fancd2 genes show a higher
degree of homology than do the corresponding Fanca,
Fancc, Fance, Fancf, and Fancg genes.18 Fancd2-knockout
mice suffer from perinatal lethality, microphthalmia, and
early epithelial cancers,19 but it remains controversial
whether the murine FA-D2 phenotype in general is more
severe than the corresponding murine knockouts of the
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Figure 1. Circular map of vector S11FD2IN. The retroviral-ex-
pression vector S11FD2IN contains a bicistronic construct of the
full-length FANCD2 cDNA (“FANCD2”) and the neomycin resistance
gene (NEO). Translation of the latter is ensured by an IRES. Also
shown are the long terminal repeats (LTR), the restriction sites
and their positions, and the bacterial resistance (AmpR). Used for
cloning of FANCD2 into the target vector S11IN were the 5′ EcoRI
and the 3′ SalI (insert) and BamHI (vector) sites; the latter two
were destroyed by blunting.
Table 1. FANCD2 cDNA Amplification Primers
PCR
Fragment
Forward Reverse
PCR
Product
Size
(bp)Designation
Binding
Position
Sequence
(5′r3′) Designation
Binding
Position
Sequence
(5′r3′)
1 FA-D2, Fr.1 F 47 to 27 GCGACGGCTTCTCGGAAGTAA FA-D2, Fr.1 R 998 to 976 CTGTAACCGTGATGGCAAAACAC 998
2 FA-D2, Fr.2 F 763 to 787 GACCCAAACTTCCTATTGAAGGTTC FA-D2, Fr.2 R 1996 to 1975 CTACGAAGGCATCCTGGAAATC 1,234
3 FA-D2, Fr.3 F 1757 to 1777 CGGCAGACAGAAGTGAATCAC FA-D2, Fr.3 R 2979 to 2958 GTTCTTGAGAAAGGGGACTCTC 1,223
4 FA-D2, Fr.4 F 2804 to 2829 TTCTACATTGTGGACTTGTGACGAAG FA-D2, Fr.4 R 3942 to 3922 GTCTAGGAGCGGCATACATTG 1,139
5 FA-D2, Fr.5(L) F 3761 to 3781 CAGCAGACTCGCAGCAGATTC FA-D2, Fr.5(L) R 4700 to 4679 GACTCTGTGCTTTGGCTTTCAC 940
other FA genes.19,20 Fancd2 is required for survival after
DNA damage in Caenorhabditis elegans.21 Fancd2-deficient
zebrafish embryos display severe developmental defects
due to increased apoptosis, which underscores the im-
portance of Fancd2 function during vertebrate ontogen-
esis.22 Finally, knock-down ofDrosophila Fancd2 causes pu-
pal lethality.23 In humans, it has been estimated that com-
plementation group FA-D2 accounts for between !1%24 and
3%25 of all patients with FA. The presence of FANCD2pseu-
dogenes complicates mutation analysis, which may ex-
plain why there has been just one other report of a single
human FANCD2 mutation since the original descrip-
tion.26,27 As a concerted effort among nine laboratories, we
present a comprehensive mutation profile of the FANCD2
gene (Ensembl Genome Browser [accession number
ENSG00000144554]). We show that the FA phenotype re-
sulting from FANCD2 deficiency is relatively severe. In
contrast to all other FA genes, (1) the mutation spectrum
of FANCD2 is dominated by splicing mutations, and (2)
residual FANCD2 protein exists in all tested cell lines from
FA-D2 patients, which suggests lethality of biallelic null
mutations.
Patients, Material, and Methods
Diagnostic Procedures
Anticoagulated peripheral blood and skin-biopsy samples were
referred to the participating laboratories for diagnostic testing.
Confirmation of the diagnosis of FA, subtyping, and mutation
analysis were performed with informed consent according to the
Declaration of Helsinki. The study was approved by the institu-
tional review boards of the participating centers. Clinical suspi-
cion of FA was confirmed by the detection of cellular hypersen-
sitivity to DNA-crosslinking agents following published proce-
dures.28–32 In patients with increasing and/or long-term stable
blood counts, the possibility of somatic reversion leading to mo-
saicism of hematopoietic cells was considered, and cultured fi-
broblasts were used for mitomycin-C (MMC) sensitivity testing
and for complementation studies.
Patient Statistics
A total of 29 fully informative FA-D2 patients (patients 1–29)were
included in the present genotype-phenotype study. A fetal case
(number 19) and five patients with hematopoieticmosaicism (pa-
tients 3, 14, 15, 25, and 26) were excluded from clinical follow-
up studies. Four additional FA-D2 patients (patients 30–33) with
incomplete clinical data were not part of the phenotype analysis,
but results concerning their mutations are indicated in the text,
tables, and figures.
Three end points were evaluated to determine hematologic se-
verity: time to hematological onset, defined as “cell count of at
least one lineage constantly below normal range”; period from
BMF to hematological stem-cell transplantation (HSCT); and time
to HSCT. Kaplan-Meier estimates were computed for the length
of overall survival. Birth was taken as the date of FA onset for all
these calculations. Comparisons were made with patients in the
International Fanconi Anemia Registry (IFAR), as reported else-
where,33 by means of log-rank test statistics. Multivariate and
competing-risk analyses were not possible because of the limited
number of informative patients.
Cell Culture
Epstein-Barr virus (EBV)–transformed lymphoblastoid cell lines
(LCLs) were established using cyclosporin A, as described else-
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Table 2. FANCD2 cDNA Sequencing Primers
Designation
Binding
Position
Sequence
(5′r3′)
sFA-D2, 244 F 244 to 263 ACCCTGAGGAGACACCCTTC
sFA-D2, 545 F 545 to 566 GGCTTGACAGAGTTGTGGATGG
sFA-D2, 1011 F 1011 to 1033 CAGCGGTCAGAGCTGTATTATTC
sFA-D2, 1308 F 1308 to 1327 GTCGCTGGCTCAGAGTTTGC
sFA-D2, 1574 F 1574 to 1596 CCCCTCAGCAAATACGAAAACTC
sFA-D2, 2142 F 2142 to 2162 GGTGACCTCACAGGAATCAGG
sFA-D2, 2381 F 2381 to 2404 GAGAGATTGTAAATGCCTTCTGCC
sFA-D2, 2679 F 2679 to 2699 TGACCCTACGCCATCTCATAG
sFA-D2, 3268 F 3268 to 3288 GCCCTCCATGTCCTTAGTAGC
sFA-D2, 3573 F 3573 to 3594 GCACACAGAGAGCATTCTGAAG
sFA-D2, 4049 F 4049 to 4069 ACACGAGACTCACCCAACATG
sFA-D2, 4303 F 4303 to 4323 GAGTCTGGCACTGATGGTTGC
sFA-D2, 367 R 367 to 347 CATCCTGCAGACGCTCACAAG
sFA-D2, 621 R 621 to 600 CAGGTTCTCTGGAGCAATACTG
sFA-D2, 951 R 951 to 929 CTGTAACCGTGATGGCAAAACAC
sFA-D2, 1158 R 1183 to 1158 TCTGAGTATTGGTGCTATAGATGATG
sFA-D2, 1414 R 1414 to 1396 CCTGCTGGCAGTACGTGTC
sFA-D2, 1704 R 1704 to 1684 GAATACGGTGCTAGAGAGCTG
sFA-D2, 2253 R 2253 to 2232 CTCCTCCAAGTTTCCGTTATGC
sFA-D2, 2526 R 2526 to 2505 GTTTCCAAGAGGAGGGACATAG
sFA-D2, 3346 R 3346 to 3328 GGACGCTCTGGCTGAGTAG
sFA-D2, 3674 R 3674 to 3653 GTAGGGAATGTGGAGGAAGATG
sFA-D2, 4159 R 4159 to 4139 CCAGCCAGAAAGCCTCTCTAC
sFA-D2, 4409 R 4409 to 4387 GGGAATGGAAATGGGCATAGAAG
Table 3. FANCD2 Superamplicon Primers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
where.34 All blood-derived cell cultures were maintained in RPMI
1640 medium with GlutaMAX (Gibco) supplemented with 15%
fetal bovine serum (FBS) (Sigma). Fibroblast strains were estab-
lished using standard cell-culture procedures and were propa-
gated in Earle’s minimal essential medium with GlutaMAX
(Gibco) and 15% FBS. All cultures were kept in high-humidity
incubators in an atmosphere of 5% (v/v) CO2 and, in the case of
fibroblasts, 5% (v/v) O2 by replacing ambient air with nitrogen.
35
MMC treatment was for 48 h at 12 ng/ml (fibroblasts) or 15 ng/
ml (LCLs) to cause cell-cycle arrest, or for 12 h at 100 ng/ml to
induce monoubiquitination of the protein, FANCD2-L. In some
cases, RNA stabilization was achieved by the addition of cyclo-
heximide (CHX) to cell cultures at a final concentration of 250
mg/ml 4.5 h before RNA isolation.
Retroviral Complementation
For construction of the D2-IRES (internal ribosomal entry site)–
neo retroviral expression vector S11FD2IN, the D2-IRES-puro
plasmid pMMP-FANCD226 was cut using SalI. The ends were
blunted, and the fragment containing the FANCD2 ORF was cut
out with EcoRI and was ligated into S11IN, which was cut with
BamHI, was blunted, and was cut again with EcoRI (fig. 1). S11
vectors are based on the spleen focus–forming virus and are de-
rived from the GR plasmid.36 Sequencing of the retroviral plasmid
S11FD2IN revealed three reported polymorphisms in the FANCD2
ORF—c.1122ArG, c.1509CrT, and c.2141CrT26—and another si-
lent base substitution, c.3978CrT. Stable retroviral packaging
cells were generated by infection of PG13 cells and selection in
G418 (Sigma), as described elsewhere.37 In addition, the cDNAs
encoding enhanced green fluorescent protein (GFP) and FANCA
cDNAs were separately cloned into the vector S11IN for trans-
duction of the cells under study, with GFP serving to monitor
complete selection and FANCA serving as negative complemen-
tation control.
Retroviral transduction of cultured cells followed published
protocols.38,39 Selection of transduced cells was in G418 (Sigma)
at a final concentration of 0.8–1.2 mg/ml for ∼10 d. Transduced
cells were analyzed for their sensitivity to MMC, with use of flow
cytometry, to assess survival rates and cell-cycle arrest.39,40
Immunoblotting
FANCD2 immunoblottingwas performed as described elsewhere,9
with minor modifications. Detection was by the chemilumines-
cence technique with use of standard enhanced chemolumines-
cence reagent (Amersham) or SuperSignalWestFemto (Pierce).
Mutation and Haplotype Characterization
Primers used for cDNA amplification are shown in table 1, and
those additionally used for cDNA sequencing are shown in table
2 (GenBank accession numbers NM_033084 and AF340183).
A total of seven large amplicons (superamplicons) were gen-
erated with primers that are unique to certain regions of the
functional FANCD2 gene. These primers and the sizes of the su-
peramplicons I–VII are shown in table 3. The superamplicons
served as templates in place of genomic DNA. They were used to
amplify the genomic sequence before sequencing; an exception
to this was superamplicon V, which was used for direct sequenc-
ing. Genomic primers for the amplification of all FANCD2 exons
and adjacent intron regions and their sizes are displayed in table
4. Additional genomic mutation-specific primers are shown in
table 5.
For haplotyping, four microsatellite markers flanking FANCD2
on chromosome 3 were studied: D3S1597, a dinucleotide re-
peat at 9.340 Mb; D3S1038, a dinucleotide repeat at 10.488
Mb; D3S3611, another dinucleotide repeat at 10.529 Mb; and
D3S1675, a tetranucleotide repeat at 10.643 Mb. Primers used for
microsatellite amplifications are specified in table 6. Two of the
forward primers were 5′-Cy5-; the other two 5′-Cy5.5- primers
were labeled for multiplex fragment analysis with DNA Sizing
standards on a CEQ 8000Genetic Analysis System (bothBeckman
Coulter).
Results
Assignment to and Frequency of Group FA-D2
Figure 2 demonstrates our strategy for the assignment of
cultured FA cells to group FA-D2. MMC sensitivity was
demonstrated by cell-cycle analysis that showedG2-phase
arrest of the tested LCLs (fig. 2B, lane 2).30–32 The apparent
absence of FANCD2 bands on standard-exposure immu-
noblots suggested their belonging to complementation
group FA-D2 (fig. 2A, lane 2).41 Transduction of putative
FA-D2 LCLs with FANCD2 cDNA with use of the retroviral
vector S11FD2IN restored FANCD2 expression and func-
tion, as reflected by the emergence of both FANCD2 iso-
forms (FANCD2-S and -L) (fig. 2A, lane 3); simultaneously,
the MMC sensitivity of transduced cells returned to nor-
mal control-cell levels, as evidenced by the reduction of
G2 phase cell–cycle fractions (fig. 2A, lane 1, and fig. 2B,
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Table 4. FANCD2 Exon Primers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 2. Delineation of FA-D2. A, Assignment to group FA-D2
on the basis of the absence of either FANCD2 band on immunoblots
after exposure of the patients’ cells to MMC, here shown for an
LCL from patient 6 (lane 2). Transduction with FANCD2 cDNA with
use of S11FD2IN restores both isoforms of FANCD2—S and L (lane
3)—similar to a nontransduced normal control (lane 1). Trans-
duction with FANCA cDNA in the same vector fails to show such
restoration (lane 4). B, Assignment to group FA-D2 on the basis
of cell-cycle analysis. After exposure to MMC, the LCL of the same
patient shows pronounced G2-phase arrest (56.6%) (lane 2;
Hoechst 33342 staining). Transduction with FANCD2 cDNA by use
of S11FD2IN reduces the G2 phase to normal (14.9%) (lane 3,
arrow), similar to the nontransduced normal control (16.6%) (lane
1). Transduction with FANCA cDNA in the same vector fails to
reverse the G2-phase arrest (53.1%) (lane 4). Panels C and D are
analogous to panels A and B and show complementation with
cultured fibroblasts from patient 10; staining in panel D was with
4’,6-diamidino-2-phenylindole (DAPI). G2-phase proportions in
panel D are 20.3% (lane 1, control), 61.3% (lane 2, nontransduced
FA), 19.9% (lane 3, FANCD2-transduced FA), and 58.5% (lane 4,
FANCA-transduced FA). RAD50 [MIM 604040] was used as the load-
ing control in panels A and C. WTpwild type.
Table 5. FANCD2 Mutation-Specific Primers
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
lanes 1 and 3). Transduction of D2 LCLs with GFP or
FANCA resulted in neither the restoration of either FANCD2
isoform nor a normalization of G2 phase arrest, as ex-
emplified for FANCA with use of S11FAIN, as shown in
figure 2A and 2B, lanes 4. In cases with suspected hema-
topoietic mosaicism, cultured fibroblasts were assayed us-
ing a corresponding strategy (fig. 2C and 2D). As shown
in table 7, only a minority of patients were assigned to
group FA-D2 by primary mutation analysis. This group
includes four affected siblings of four different index pa-
tients and an unrelated deceased patient with only DNA
available.
In the North American IFAR collection, of 630 classified
patients with FA, 7 (patients 19–25) were fully informative
clinically and were included in the present cohort; an-
other (patient 32) is among the four additional patients.
Results of immunoblotting data alone suggested that 10
more IFAR patients belonged to the FA-D2 group, for a
maximum estimate of 18 FA-D2 subjects in the IFAR group
of 630. Among the patients referred to the two German
laboratories, 15 of 243 patients with FA were assigned to
complementation group FA-D2. The latter figures suggest
that the proportion of patients who meet criteria for
complementation group D2 may be higher than reported
elsewhere.2,24,25
Clinical Data for FA-D2 Patients
Including, where appropriate, information fromaprenatal
case (number 19), phenotypic details in the present cohort
of 29 FA-D2 patients with adequate clinical information
are shown in tables 8 and 9. With the exception of two
families (those of patients 19 and 22), there was no general
tendency for increased rates of spontaneous abortions in
this study. Among the 28 fully informative FA-D2patients,
there was only a single malignancy observed (acute mye-
logenous leukemia [AML] in patient 1), and there was no
apparent overrepresentation of malignancies in the par-
ents or grandparents of the FA-D2 patients in our cohort.
The median age at diagnosis of these FA-D2 patients was
4 years and 5 mo ( ). When the fetal case (numbernp 29
19) and five mosaic patients (patients 3, 14, 15, 25, and
26) were excluded, the median age at transfusion depen-
dency was 10 years and 10mo ( ). Figure 3 comparesnp 23
the progressive hematological course and the outcome of
our group of FA-D2 patients with that reported elsewhere
for 754 North American IFAR patients.42 BMF in our D2
group ( ) occurred at an earlier age (median for FA-np 23 D2 patients was 2.4 years vs. 6 years and 7 mo for IFAR;
) (fig. 3A), and the period from BMF to HSCT wasPp .001
shorter (median age at HSCT for FA-D2 patients [ ]np 9
was 5 years and 6 mo vs. 11 years and 4 mo for IFAR
[ ]; ) (fig. 3B). Age at HSCT for our FA-D2np 218 P ! .08
patients was earlier than in the IFAR patients of combined
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Table 6. Microsatellite Primers
STR
Genomic
Position
(Mb)
Primer Sequence
(5′r3′)
Sense Antisense
D3S1597 9.34 AGTACAAATACACACAAATGTCTC CAATTCGCAAATCGTTCATTGCT
D3S1038 10.49 AAAGGGGTTCAGGAAACCTG CCCTCCAGTAAGAGGCTTCCTAG
D3S3611 10.53 GCTACCTCTGCTGAGCATATTC CACATAGCAAGACTGTTGGGGGC
D3S1675 10.64 GGATAGATGGATGAATGGATGGC CCTCTCTAACTACCAATTCATCCA
Table 7. Laboratory Diagnostic Data for
the Cohort of 29 FA-D2 Patients
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
groups (median age for FA-D2 patients was 10 years and
11 mo vs. 27 years and 11 mo for IFAR; ) (fig. 3C).P ! .01
Of 23 FA-D2 patients, 9 patients of our cohort received
HSCT. Kaplan-Meier estimates (fig. 3D) suggest that our
FA-D2 patients ( ) may have a shorter life span thannp 23
the IFAR patients overall, since their survival curve falls
below that of the IFAR patients after age 9 years; however,
the difference of median survival (11 years and 4 mo for
FA-D2 patients vs. 24 years and 3 mo for IFAR) was not
significant, because the number of nonmosaic FA-D2 pa-
tients (two) of our cohort who reached adulthood was too
low for statistical support.
FANCD2 and the FANCD2 Pseudogenes
BLAT searches (Human BLAT Search) identified two pseu-
dogene regions: FANCD2-P1 spanning 16 kb, located ∼24
kb upstream of FANCD2, and FANCD2-P2 spanning 31.9
kb, located ∼1.76 Mb downstream of FANCD2 (fig. 4A).
P1 and P2 are in the same orientation as the functional
gene. They are characterized by high sequence homology
with certain FANCD2 exons and have retained ordered
succession of their exon/intron equivalents, compared
with the functional gene. On the other hand, the exon
replicas of FANCD2-P1 and FANCD2-P2 have acquired nu-
merous deletions and insertions. Striking sequence simi-
larity of the D2 pseudogenes extends into some FANCD2
introns, particularly in the regions of IVS21-IVS26. Thus,
P1 and P2 reveal recognizable patterns of conserved gene
structure (fig. 4B). FANCD2-P1 is roughly a copy of the
front portion of FANCD2, including, with intermittent
gaps, the region of exons 1–18 (homology with FANCD2
exons 1 and 12–16 and the 3′ portion of exon 18). The
region upstream of FANCD2-P1 shares homology with the
putative FANCD2 promoter predicted within theCpG-rich
region of ∼800 bp upstream of the start codon of the func-
tional gene.60 The corresponding region upstream of P1 is
interrupted by an AluY element (RepeatMasker). FANCD2-
P2 is an approximate match of the middle portion of
FANCD2. Including gaps, it spans the region of exons 12–
28 (homology with FANCD2 exons 12–14 and 17–28).
Mutations in FANCD2
Unique amplification of the functional FANCD2 gene
was achieved using primers that exclude pseudogene se-
quences. In FANCD2 regions sharing extensive homology
with FANCD2-P1 and -P2, seven superamplicons (fig. 4C)
were used for genomic mutation screens. Studies at the
RNA level were implemented to guide the genomic anal-
yses. All identified mutations and their predicted conse-
quences at the protein level are compiled in table 10. The
distribution of the mutations among the individual pa-
tients is shown in table 7.
Mutations Affecting Pre-mRNA Splicing
In peripheral-blood lymphocytes (PBLs), LCLs, and cul-
tured fibroblasts from unaffected controls, two species of
FANCD2 cDNAs were consistently detected by sequence
analysis of the regions corresponding to exon 22 (fig. 5A
and 5B) and exons 15–17 (data not shown). This obser-
vation suggests low-level skipping of these exons, consis-
tent with FANCD2 RNA being subject to alternative splic-
ing. mRNA stabilization via CHX treatments of cultured
cells resulted in a relative increase of the alternatively
splicedmRNA species (fig. 5A and 5C), implying instability
of the alternatively spliced FANCD2 mRNAs. On genomic
sequencing, alternative splicing of exon 22 was not as-
sociated with any mutation or variant in exon 22 or the
adjacent intronic regions in 25 controls.
Without CHX treatments, cell lines from patients 2, 8,
9, 10, 14, 15, and 20 in our cohort displayed almost equal
levels of exon 22 skipping and retention (fig. 5A and 5D).
Patients 9 and 10, with balanced levels of exon 22 skipping
and retention, were compound heterozygous carriers of
the mutation c.1948-16TrG. A different base substitution
preceding exon 22, c.1948-6CrA, was present on one al-
lele of the compound-heterozygous patients 2, 8, 14, 15,
and 20, likewise resulting in similar levels of exon 22 skip-
ping and retention. Both mutations—c.1948-16TrG and
1948-6CrA—are predicted to disrupt the splice-acceptor
recognition in intron 21 suggested by impaired scores of
the 3′ splice site relative to the wild type (see, e.g., table
11). Both result in skipping of exon 22.
Three apparently unrelated patients (patients 6, 12, and
30) showed balanced levels of skipping and retention of
exon 5 due to heterozygous insertional mutagenesis by an
Alu element between positions c.274–57 and c.274–56
into an AT-rich target sequence in IVS4. Integration site,
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Table 8. Clinical Phenotype of the Cohort of FA-D2 Patients
Malformation
No. of
Affected/
Totala
Frequency
(%)
Symptom:
Microcephaly 25/28 89
(Intrauterine) growth retardation 25/29 86
Anomalies of skin pigmentation 21/28 75
Radial-ray defects 21/29 72
Microphthalmia 17/28 61
Renal anomalies 10/28 36
Malformations of the external ear 9/28 32
Brain anomalies 9/29 31
Including hydrocephalus 5/29 17
Psychomotor retardationb 8/28 29
Hypogonadism/genital anomalies 7/28 25
Hip dysplasia/dislocation 6/28 21
Heart anomalies 4/28 14
Malformations of the gastrointestinal tract 4/28 14
Distinct syndromic association:
Michelin-tire baby syndrome (MIM 156610) 2/28 7
VACTERL-like association (MIM 192350) 1/28 4
Holoprosencephaly (MIM 236100) 1/28 4
Kartagener syndrome (MIM 244400) 1/28 4
a A prenatal case (number 19) was partially informative. Pertinent information
was used where applicable.
b Including attention-deficit/hyperactivity disorder.
Table 9. Clinical Diagnostic Data for the
Cohort of 29 FA-D2 Patients
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
type, length, and orientation of the Alu and the duplicated
FANCD2 intron sequence were identical in all three pa-
tients. We did not detect any such Alu insertions in 300
unaffected control alleles.
Aberrant splicing of exons 4, 5, 10, 13, 15–17, 28, and
37 was observed in other patients also (analysis of the
regulatory splec sequences by ESEfinder and Rescue-ESE).
Patients 28 and 29 showed skipping of exon 4 caused by
a base substitution in the preceding canonical splice-ac-
ceptor site (c.206-2ArT). Patients 26 and 27 had a base
substitution in exon 5 (c.376ArG) abrogating the down-
stream splice donor. This change led to the inclusion of
13 bp of IVS5 into the transcript by activating a cryptic
5′ splice site in intron 5 (r.377_378ins13) also reported
elsewhere.26 Patient 18 showed skipping of exon 10 due
a base substitution in the upstream splice acceptor (c.696-
2ArT). Exon 10 skipping was observed in patient 31, who
had a substitution of the second-to-the-last base of exon
10 (c.782ArT). In patient 8, we detected a splice-acceptor
mutation upstream of exon 13 (c.990-1GrA). This change
results in the activation of a cryptic splice acceptor 8 bp
downstream and the exclusion of the corresponding se-
quence from the mature mRNA. A 2-bp deletion in exon
16 (c.1321_1322delAG) in patient 18 causes skipping of
exons 15–17. In that case, aberrant splicing occurs in the
same position as low-grade alternative splicing in normal
controls, but at heterozygous levels. Patients 10 and 22
showed inclusion of a 27-bp sequence of intron 28 into
mRNA because of a splice-donor mutation (c.27151GrA)
and the use of a cryptic splice-donor downstream. Patient
11 had a base substitution in exon 37 (c.3707GrA), re-
ported elsewhere,26 that abrogates the normal splice ac-
ceptor 25 bp upstream and activates a cryptic site 19 bp
downstream of the mutation, resulting in skipping of 44
bp. Interestingly, an adjacent base substitution(c.3706CrA)
in patient 32 generates a new splice acceptor that is used
instead of the normal one 23 bp upstream, leading to
skipping of the 24 nt in between. With the exception of
those of patient 1, all of these splicing aberrations were
due to heterozygous mutations. Patient 1 showed homo-
zygous exonization of an IVS9 fragment because of a mu-
tation in intron 9 (c.696-121CrG), which activates cryptic
splice sites. Predicted scores and consequences of some of
these splice mutations are computed in tables 11 and 12.
Apart from 1321_1322delAG, which causes skipping of
exons 15–17, all mutations affecting splicing in the pa-
tients in this study result in frameshifts and subsequent
premature termination of translation. More than half—
that is, 30 of 58 mutated alleles of the 29 clinically in-
formative FA-D2 patients, or 34 of all 66 alleles—were
splicing mutations, which makes that the most prevalent
type of mutation.
Other Mutations
There were five different heterozygous nonsense muta-
tions in nine patients from six families (c.757CrT in sib-
lings 23 and 24, c.1092GrA in patient 7, c.2404CrT in
patient 21, c.2775_2776CCrTT in siblings 14 and 15, and
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Table 10. Identified FANCD2 Mutations and Their Effects
Location and Patient No(s).
Mutationa Consequencea
Genomic DNA RNA Protein
Exon 2:
32 c.2TrC r.2TrC Failure of normal translation
initiation
Intron 3:
28 and 29 c.206-2ArT (IVS3-2 ArT) r.206_273del68 (exon 4 skipping) p.A69DfsX7
Intron 4:
6, 12, and 30 c.274-57_-56insinvAluYb8nt36_319 dup c.274-69_57b r.274_377del104 (exon 5 skipping) p.I92YfsX7
Exon 5:
26 and 27 c.376ArG r.376ArGr.377_378ins13 (aberrant splicing) p.S126RfsX12
Exon 9:
19 c.692TrG r.692TrG p.L231R
Intron 9:
1 c.696-121CrG (IVS9-12 1CrG) r.6951619_696-126ins34 (exonization) p.S232insQNNFX
18 c.696-2ArT (IVS9-2 ArT) r.696_783del88 (exon 10 skipping) p.S232RfsX6
Exon 10:
23 and 24 c.757CrT r.757CrT p.R253X
31 and 33 c.782ArT r.696_783del88 (exon 10 skipping) p.S232RfsX6
Exon 11:
9 c.810_812delGTC r.810_812delGTC p.S271del
Exon 12:
7 c.904CrT r.904CrT p.R302W
Intron 12:
8 c.990-1GrA (IVS12-1 GrA) r.990del8 (aberrant splicing) p.S330RfsX16
Exon 13:
7 c.1092GrA r.1092GrA p.W364X
Intron 14:
33 g.13377_17458dup4082 (duplication, including exons 11–14) r.784_1134dup (duplication of 351 nt in-frame) p.262_378dup (duplication of 117 aa)
Exon 16:
18 c.1321_1322delAG r.1135_1545del411 (exon 15–17 skipping) p.V379_K515del
23 and 24 c.1367TrG r.1367TrG p.L456R
31 c.1370TrC r.1370TrC p.L457P
Exon 17:
28, 29 g.22875_23333del459 (c.1414-71_c.1545256del459) r.1414_1545del132 p.E472_K515del
Intron 21:
3, 4, 5, 9, 10, 13, and 25 c.1948-16TrG (IVS21-16 TrG) r.1948_2021del74 (exon 22 skipping) p.E650X
2, 8, 14, 15, and 20 c.1948-6CrA (IVS21-6 CrA) r.1948_2021del74 (exon 22 skipping) p.E650X
Exon 26:
21 c.2404CrT r.2404CrT p.Q802X
16, 17, 19, 21, 22, and 30 c.2444GrA r.2444GrA p.R815Q
Exon 28:
20 c.2660delA r.2660delA p.E888RfsX16
Intron 28:
10 and 22 c.27151GrA (IVS281GrA) r.2715_2716ins27 (aberrant splicing) p.E906LfsX4
Exon 29:
14 and 15 c. 2775_2776CCrTT r. 2775_2776CCrTT p.R926X
11 c.2835dupC r.2835dupC p.D947RfsX3
Exon 34:
12 c.3453_3456delCAAA r.3453_3456delCAAA p.N1151KfsX46
Exon 36:
2 c.3599delT r.3599delT p.I1200KfsX12
Exon 37:
32 c.3706CrA r.3684_3707del24 (aberrant splicing) p.R1228S_F1235del
11 c.3707GrA r.3684_3727del44 (aberrant splicing) p.H1229EfsX7
Exon 38:
6, 26, and 27 c.3803GrA r.3803GrA p.W1268X
a Nomenclature is according to the Human Genome Variation Society.
b This Alu was identical to the evolutionary young subfamily Yb8.43,44 It was lacking its annotated nucleotides 1–35, had integrated in reverse orientation (with its poly-A tail toward the 5′
end of FANCD2), and had duplicated the 13-nt sequence c.274–69 to c.274–57 of FANCD2 IVS4, such that this duplicated sequence flanked the Alu repeat on both sides. Altogether, the insertion
length was 298 bp.
c.3803GrA in patient 6 and siblings 26 and 27) (tables 7
and 10). In addition, we detected five different missense
mutations in 11 patients from nine families (c.692TrG in
patient 19; c.904CrT in patient 7, identical to a mutation
reported elsewhere26; c.1367TrG in siblings 23 and 24;
c.1370TrC in patient 31; and c.2444GrA in siblings 16
and 17 and patients 19, 21, 22, and 30). These amino acid
substitutions were classified as missense mutations be-
cause of their absence from unaffected controls, their ab-
sence from FA-D2 patients of our cohort with other bial-
lelic mutations, and their occurrence at evolutionarily
conserved residues (ClustalW; ExPASy). Missense muta-
tions were either compound heterozygous in combination
with other types of FANCD2 mutations or were homo-
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Figure 3. Clinical course of 23 fully informative, nonmosaic FA-D2 patients in this study. A, The cumulative incidence of BMF of the
FA-D2 patients in the present study (FA-D2) precedes that of all patients with FA in the IFAR42 ( ). B, The period from BMF toPp .001
HSCT, which was shorter in the patients of the present study than in those of the IFAR42 (trending, ). C, Cumulative incidenceP ! .08
of HSCT of the FA-D2 patients in our study, which likewise antedates that of all patients in the IFAR42 ( ). D, Kaplan-Meier curvesP ! .01
of survival, which suggest higher death rates of the FA-D2 patients than of all patients in the IFAR aged 110 years.
zygous in consanguineous families. Three unrelated pa-
tients had small deletions (c.2660delA in patient 20,
c.3453_3456delCAAA in patient 12, and c.3599delT in
patient 2) resulting in frameshifts. Another small dele-
tion was in frame and affected a single codon (c.810_
812delGTC in patient 9). There was only a single small
frameshift duplication (c.2835dupC in patient 11). A large
genomic deletion (g.22875_23333del459) spanning the
entire exon 17 (similar to a mutation reported elsewhere
without defined breakpoints26) and the adjacent 71 bp of
intron 16 and 256 bp of intron 17 was found in sibling
pair 28 and 29. This deletion resulted in a net loss of 41
aa. A large genomic duplication in patient 33 included
exons 11–14 and resulted in the insertion of 132 aa. Both
gross gene rearrangements retained the reading frame. In
all of our patients, nonsense mutations, deletions, and
insertions affected exclusively single alleles in combina-
tion with splice or missense mutations. A unique case was
a compound heterozygous start codon mutation (c.2TrC)
in patient 32.
Figure 6 illustrates the distribution of FANCD2 muta-
tions that were identified in this study, including those of
four FA-D2 patients who were reported elsewhere.26,27
Ethnic Associations and Shared Alleles
Relatively severe birth defects and early hematological on-
set were observed in three patients (4, 5, and 13) whowere
homozygous for the splice mutation c.1948-16TrG with
exon 22 skipping. These three patients and two other ho-
mozygotes with reverse mosaicism in the hematopoietic
system (patients 3 and 25) were all from four consan-
guineous Turkish families. Of two other FA-D2 patients
who were compound heterozygotes for this mutation, one
was also of Turkish origin; the other came from the eastern
Czech Republic. The splice mutation c.1948-6CrA, like-
wise leading to exon 22 skipping, was detected in five
patients (2, 8, 14, 15, and 20), including two sisters (pa-
tients 14 and 15). These patients came from three families
in northern Germany and an American family of German
ancestry (patient 20). They presented with intermediate
phenotypic and hematological severity. Relatively mild
birth defects and a protracted hematological course into
adulthood was observed in two siblings, from a consan-
guineous Spanish family (patients 16 and 17), with the
homozygous missense substitution c.2444GrA. Of four
compound heterozygotes for this mutation with mild dis-
ease manifestations, one hadmixed ethnicity (patient 19),
one was Hispanic American (patient 21), one had Sicilian
ancestry (patient 22), and another had Spanish and Por-
tuguese ancestry (patient 30). An allele with the insertion
of an AluYb8 element was found in compound heterozy-
gous patients of German (patient 6), Danish (patient 12),
and Spanish/Portuguese (patient 30) descent. No othermu-
tations occurred in more than two families.
On haplotype analysis using markers flanking FANCD2,
all patients homozygous for the intron 21 mutation de-
tected in the Turkish population were homozygous for
markers D3S1597, D3S1938, D3S3611, and D3S1675. The
resulting haplotype was shared, in a heterozygous state,
with the nonconsanguineous compound heterozygous
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Figure 4. Topography of FANCD2, its pseudogenes, and the superamplicons. A, The two pseudogenes—FANCD2-P1 and FANCD2-P2—
located upstream and downstream, respectively, of the functional FANCD2 gene. All three have the same orientation. The scale denotes
Mb on chromosome 3. B, FANCD2 exons and their pseudogene equivalents, connected by dashed lines, indicating percentages of nucleotide
identity. Homology also extends into many introns nearby, as indicated by the boxes beyond and below the active gene. C, Graphic
presentation of the positions and sizes of 7 superamplicons relative to the active gene shown in panel B. These amplicons represent
FANCD2 exon-exon or exon-intron regions. Unique primer-binding sites ensure specific amplification.
Turkish patient (patient 10). The Czech patient (patient
9) with the samemutation had a different haplotype. Lack
of homozygotes for the intron 21 mutation prevalent in
the German population (c.1948-6CrA; patients 2, 8, 14,
15, and 20) and unavailability of patients’ parents pre-
cluded construction of a mutation-associated haplotype.
However, all patients with this mutation had one or two
identical marker(s) on at least one side of their mutated
FANCD2 gene. This finding suggests that c.1948-6CrA is
an old mutation, with erosion of an ancient haplotype.
The consanguineous siblings (patients 16 and 17) homo-
zygous for the mutation prevalent in Spanish or southern
European populations (c.2444GrA) were also homozy-
gous for the set of markers used. Of their common hap-
lotype, the microsatellite markers adjacent to FANCD2
were shared with a Hispanic patient (patient 21), a patient
with Sicilian ancestry (patient 22), and a patient of Span-
ish/Portuguese descent (patient 30), all compound het-
erozygotes for this mutation. Additional support for a con-
served haplotype came from linkage disequilibrium. All
of the patients homo- or heterozygous for the mutation
c.2444GrA were also homo- or heterozygous for the poly-
morphism c.2702GrT (p.G901V). Sequence analysis of
the parents indicated that both substitutions were on the
same allele. A single patient (patient 19)with themutation
c.2444GrA shared neither the haplotype nor the poly-
morphism c.2702GrT. Apart from c.2702GrT, which was
also observed without association with the mutation
c.2444GrA, the only new FANCD2 polymorphisms de-
tected in our study were c.3978CrT (synonymous base
substitution, exon 41) and c.4478ArG (3′ UTR, according
to GenBank accession number NM_033084, or intron 43,
according to accession number AF340183). All others have
been reported elsewhere.26 Despite clear ethnic association
of the patients with the insertion of an AluYb8 element
in intron 4, two of these patients (6 and 12) shared all of
the four markers studied. Patient 30, with the same mu-
tation, had retained a single identical marker adjacent to
FANCD2. A base substitution in the Alu sequence, 260GrA,
present in all three cases but in !10% of complete AluYb8
elements in the human genome (Human BLAT Search)
further suggests that the Alu insertion goes back to a single
event and is an ancient rather than a recurrent mutation.
Reverse Mosaicism
Among the 28 fully informative FA-D2 patients in this
study (excluding fetal case number 19), five (patients 3,
14, 15, 25, and 26) developed reverse mosaicism in the
hematopoietic system.Mosaic patients were recognizedby
the fact that they had levels of both FANCD2-S and -L in
protein from LCLs that were comparable to those of un-
affected controls (fig. 7A). They also had low chromosome
breakage rates in blood and blood-derived LCLs (table 7),
and they had lost the typical G2-phase arrest of their lym-
phocytes after exposure to MMC (fig. 7C). Nonetheless,
these patients displayed the characteristic clinical FA phe-
notype. Their cultured fibroblasts failed to show either
FANCD2 isoform on standard immunoblots (fig. 7B). They
were sensitive to MMC, as indicated by elevated chromo-
some breakage and G2-phase arrest (fig. 7C). Molecular
studies confirmed these findings. Two patients with het-
erozygous base substitutions in the coding sequence, re-
sulting in a nonsense (patient 14) and a splice (patient 26)
mutation, showed reversion to the respective wild-type
bases in primary blood cells and LCLs. The mechanism of
these reversions is not clear and could involve back mu-
tation, recombination with loss of heterozygosity, or re-
combination with gene conversion. Intragenic mitotic
crossover is the likely but not proven mechanism of mo-
saicism in the sibling of patient 14 (patient 15) who had
retained her dinucleotide substitution in her peripheral-
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Figure 5. Exon 22 splicing. A, Schematic depiction of the splicing
patterns resulting from exon 22 retention or skipping. B, cDNA
sequencing in an LCL from a normal control (CON), showing pre-
dominance of exon 22 sequence following that of exon 21 but also
low levels of underlying sequence readable as exon 23. C, Treatment
of the same LCL from a normal control with CHX for 4 h before
cDNA synthesis, which increases the relative level of sequence with
exon 22 skipping. D, cDNA sequencing in an LCL from a compound
heterozygote (HET) for splice-acceptor mutation in intron 21,
c.1948-16TrG (patient 9), which shows comparable levels of in-
clusion and exclusion of exon 22 sequence following that of exon
21. Expexon; WTpwild type.
Table 11. FANCD2 3′ Splice-Acceptor Calculations
Exon/Intron and
Designation Sequence
MaxEntScan
Scorea
4:
Consensus ctcttcttttttctgcatagCTG 9.12
c.206-2ArT ctcttcttttttctgcattgCTG .76
10:
Consensus tctttttctaccattcacagTGA 7.39
c.696-2ArT tctttttctaccattcactgTGA .97
13:
Consensus ttcctctctgctacttgtagTTC 6.19
c.990-1GrA ttcctctctgctacttgtatTTC 2.56
22:
Consensus tgtttgtttgcttcctgaagGAA 6.43
c.1948-16TrG tgttggtttgcttcctgaagGAA 5.58
c.1948-6CrA tgtttgtttgcttcatgaagGAA 4.51
37:
Consensus ACTTTTGTTGTTTTCTTCCGTGT 2.10
c.3706CrA ACTTTTGTTGTTTTCTTCAGTGT 10.14
a MaxEntScan::score3ss for human splice sites.
blood cells. Two patients (3 and 25) with the c.1948-
16TrG splice mutation had different second-site muta-
tions nearby. The compensatorymutation of patient 3was
c.1954GrA (p.V652I), detected in blood, bone marrow,
and an LCL. The compensatory mutation of patient 25
was c.1953GrT (p.W651C), detected in blood. c.1954GrA
restored exon 22 retention correctly. c.1953GrT cDNA
was not available. Clinically, three of five mosaic patients
(3, 14, and 15) in the present cohort experienced a mild
or protracted hematological course. The other two of five
patients (patients 25 and 26) had no apparent benefit from
their mosaicism; one of them required relatively early
HSCT, and the other died of intracranial hemorrhage (ta-
ble 9). The rate of 17% mosaic FA-D2 patients in our study
is within the 15%46 to 20%47 or 25%48 range reported for
other complementation groups. With a rate comparable
to FANCA, FANCD2 appears to be another FA gene partic-
ularly prone to reverse mosaicism.
Residual FANCD2 Protein
cDNA sequencing of LCLs of patients 3, 4, 5, and 13
showed nearly complete exon 22 skipping. However, we
consistently observed a small amount of correctly spliced
mRNA retaining exon 22 (fig. 8A; compare with fig. 5A).
Genomic sequencing identified homozygosity of these pa-
tients for the common underlyingmutation, the base sub-
stitution c.1948-16TrG in IVS21. Homozygosity for this
mutation was also observed in the deceased patient 25
with no cDNA available. All of these patients were prod-
ucts of consanguineous matings. In all LCLs that were
homozygous for the above splicingmutation,wewere able
to demonstrate minute amounts of FANCD2 protein. A
more surprising finding, however, was the presence of re-
sidual FANCD2 protein in PBLs and LCLs of every tested
FA-D2 patient. Detection of residual protein required over-
exposure of FANCD2 immunoblots (fig. 8B). Unlike stan-
dard exposures that revealed no FANCD2 bands in most
of the FA-D2 cell lines (see, e.g., fig. 2), both FANCD2-S
and FANCD2-L bands were detected when films were ex-
posed overnight. As the study progressed, it became evi-
dent that the cell lines initially detected with residual pro-
tein were those with the highest levels. When we system-
atically re-examined all of our FA-D2 lines, all 21 LCLs
available from our 29 fully informative FA-D2patients had
minute but unequivocal amounts of residual protein (table
7). This was also true for CD3/CD28/IL-2–stimulated PBL
cultures from patient 13. Patients 4, 17, and 19 with no
available LCLs remained untested. In contrast, our mosaic
patients displayed levels of FANCD2 protein in the control
range. They had normal chromosome-breakage rates and
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Table 12. FANCD2 Splice-Donor Calculations
Exon/Intron and
Designation Sequence
Score
(Splicefinder) Difference Result
5:
Consensus CAGgtgtggag LC4 12FF3F2F
c.376ArG CGGgtgtggag LC2 2F8FF3F2 Large Malfunction
Cryptic splice donor GAGgcatggaaa HC1 F12F3F2F Gain of function
9:
Consensus acggtaactta LC4 FF12F2FF
c.696-121CrG ACGgtaagtta HC3 FF17FF Large Gain of function
10:
Consensus AAGgtagaaaa LC4 F12FFF2F
c.782ArT ATGgtagaaaa LC3 FF10FFF2F Small Malfunction
28:
Consensus AAGgtattgga LC4 F12FFFFF
c.27151GrA AAGatattgga No score Large Malfunction
Cryptic splice donor AAGgtttgtgaa LC4 F10FF5FF Gain of function
a Mutation-activated cryptic splice donor; calculation available only for the consensus dinucle-
otide gt.
Figure 6. Positions and identity of mutations detected in FANCD2. Mutations identified in the present study are shown above, mutations
reported elsewhere24,45 are indicated below the schematic display of FANCD2 cDNA. Blackened squares () represent mutations resulting
in aberrant splicing patterns, blackened circles (•) represent nonsense mutations, unblackened circles () represent missense mutations,
blackened triangles (H17009) represent frameshift deletions or duplications, and unblackened triangles (D) represent in-frame deletions or
duplications. Missense mutations are depicted above or below the other mutations and are underlined. Superscript a at the right upper
corner of a symbol denotes homozygous occurrence (2 alleles); superscript b denotes an affected sibling (relationship bias). Mutation
3707GrA was originally reported as a missense mutation,26 whereas we characterized it as a splicing mutation.
lacked G2-phase arrest, whereas the nonmosaic patients
had high chromosome breakage and G2 arrest. We there-
fore consider it unlikely that undetected mosaicism ac-
counts for the presence of residual protein in the remain-
der of our patients. In support of this conclusion, we were
able to detect residual protein, including both -S and -L
bands, in fibroblasts from patients 3, 14, and 26 when the
blot of figure 7B was overexposed (data not shown). Den-
sitometry suggested reductions of residual FANCD2 pro-
tein on the order of 1 of 100 to 1 of 1,000 relative to wild
type, with the degree of expression differing greatly among
individual LCLs (fig. 8B). FA-D2 LCLs with the highest
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Figure 7. Reverse mosaicism. Blood-derived cells from FA-D2 pa-
tients with reverse mosaicism of the hematopoietic system (pa-
tients 3 and 26, LCLs; patient 14, stimulated PBL; panel A, lanes
2, 3, and 4) reveal both FANCD2 bands at levels similar to a random
normal control (lane 1) after exposure to MMC. In contrast, neither
FANCD2 band was present in fibroblasts from the same patients,
but only in the control (B). RAD50 was used as loading control in
panels A and B. The LCLs and PBL used in panel A fail to show
G2-phase arrest on flow cytometric cell cycle distributions in re-
sponse to MMC (panel C) (black histograms indicate DAPI stain;
control (CON), 8.0% G2; patient 3, 8.8% G2; patient 14, 8.8% G2;
patient 26, 10.4% G2), whereas the corresponding cultured FA-D2
fibroblasts retain high G2-phase accumulations, which is again in
contrast to the non-FA control (superimposed gray histograms; CON,
22.6% G2; patient 3, 53.2% G2; patient 14, 56.0% G2; patient
26, 54.8% G2). PBLs in panel A were stimulated with anti-CD3,
anti-CD28, and Il-2 and, in panel B, with PHA.
levels of residual FANCD2 were used to examine its char-
acteristics on overexposed blots. The intensity of the
FANCD2-L band increased as a function of the concen-
tration of the DNA crosslinking agent (fig. 8C) and the
period of treatment (not shown). This time and concen-
tration dependency suggests genuine biochemical activity
of the residual FANCD2 protein, implying that most, if
not all, cases of FA-D2 result from functionally hypo-
morphic mutations.
Discussion
Our results suggest that FA-D2 is a more frequent FA com-
plementation group than previously reported, apparently
influenced by the high proportion of patients from spe-
cific ethnic groups in the present study. 2,24,25 The relatively
large proportion of FA-D2 patients with Turkish ancestry
in the present study appears to be due to a founder effect
for the FANCD2 mutation c.1948-16TrG among individ-
uals of Turkish origin. This is similar to the disparity in
the frequency of FA-C patients in the IFAR database com-
pared with the European FA population. The proportion
of FA-C patients in the IFAR is 15%,49 compared with only
10% in the European data set.2 This is due to the relatively
high frequency of Ashkenazi Jewish patients with FA in
the IFAR who have the prevalent FANCCmutation c.456
4ArG (formerly referred to as “IVS44ArG”),33 compris-
ing 7.5% of all IFAR patients and 50% of these FA-C pa-
tients. On the basis of our present data, we estimate that
∼6% of patients with FA belong to complementation
group D2. This estimate is supported by recent studies
with figures of 4 of 53 (∼7.5%),46 3 of 73 (∼4.1%),50 and
5%.49
The FA-D2 patients in our cohort displayed anomalies
and malformations typical of FA such that there were no
exceptional clinical features that had not been observed
elsewhere.51 However, it is remarkable that not a single
FA-D2 patient lacked phenotypicalmanifestations,whereas
the proportion of patients with FA without anomalies and
malformations is generally estimated to be as high as
30%.24 Growth retardation was present in 86% of the pre-
sent cohort, substantially higher than the 58%52 and
63%24 reported. Microcephaly was present in 89% of the
FA-D2 cases; in contrast, Faivre et al.52 found anomalies
of the head in only 56%. Anomalies of skin pigmentation
were present in 75% of our FA-D2 cohort, compared with
71% and 64% reported elsewhere.24,52 Of our FA-D2 pa-
tients, 72% had radial-ray defects, in contrast to only
47%52 or 49.1%51 of all patients with FA. Of the patients
in the present study, 61% had microphthalmia, whereas
38% has been the reported percentage in other patients
with FA.24 As with these rather common phenotypic al-
terations, FA-D2 patients also showed higher rates of rare
FA features, such as psychomotor retardation and hyper-
activity/attention-deficit disorder. Psychomotor retarda-
tion was present in 29% of our FA-D2 cohort versus 12%
or 10% such individuals in other studies.24,52 A third of
our FA-D2 patients had anomalies of the brain, whereas
other studies report such alterations on the order of
4.5%,52 7.7%,51 and 8%24 of their patients with FA. Of
our FA-D2 patients with brain anomalies, 17% had hy-
drocephalus, in contrast to 4.6% reported elsewhere.51
Since several laboratories contributed to the present study
and since all of our FA-D2 patients came from groups of
patients with previously unassigned FA, it is unlikely that
our rates reflect major biases. However, a more severe D2
phenotype has also been observed in Drosophila, compar-
ing Fancd2 and Fancl knock-down.23 Given the high fre-
quency of phenotypic alterations, it is not surprising that,
in 30% of our FA-D2 patients, the diagnosis of FA was
made by the time the patients were aged 2 years. The
median age at diagnosis in our cohort was 4.5 years, which
is considerably younger than for other patients with FA,
for whom the diagnosis is made in only 30% of patients
before onset of hematological manifestations at the me-
dian age of 7.6 years.53 In addition to an earlier median
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Figure 8. Residual FANCD2 protein. A, Exon 23 sequence following that of exon 21 (exon 22 exclusion, aberrant splicing), which
prevails in cDNA from homozygotes for the splice-acceptor mutation in intron 21, c.1948-16TrG, but, at low level, underlying sequence
is readable as exon 22 (exon inclusion). Depicted are results from patient 5. B, Blood-derived cells from nonmosaic FA-D2 patients
(exemplified 13, 5, 1, 21, 2, 6, 11, and 28) show faint but conspicuous FANCD2 bands of both species in response to MMC exposure
exclusively on overexposed immunoblots, as indicated by the very intense FANCD2 signals of the normal controls (CON) (patient 13,
stimulated PBL; patients 5, 1, 21, 2, 6, 11, and 28, LCLs; loading control RAD50). The individual abundance of residual protein varies
considerably at low levels. C, LCLs were subjected to the indicated concentrations of hydroxyurea (HU) for 16 h. On an overexposed
blot, the FANCD2-L band of the residual protein in the LCL from patient 21 increases with the HU concentration in a dose-dependent
response. Normal control LCLs are distinctive by their prominent FANCD2 signals.
age of hematological onset (i.e., BMF) in our patients with
FA, there was a shorter median period between BMF and
HSCT, earlier HSCT, and a tendency toward shorter me-
dian survival than of all FA-affected patients listed in the
IFAR.42 Because of relatively small numbers and the rel-
ative deficit of older patients in our cohort, statistical
significance was not reached for all of these end points.
HSCT appears to be a rather frequent therapeutic option
in FA-D2 patients. In theory, however, deficient ATM
[MIM 607585]/ATR [MIM 601215]–dependent phospho-
rylation of FANCD245,54,55 could involve additional toxicity
of conditioning regimens. Collectively, our data suggest
that FA-D2 patients represent a group with frequent but
typical congenital anomalies andmalformations andwith
relatively early hematological manifestations, compared
with most other FA complementation groups.
Among the FA proteins, FANCD2 is unique, since the
presence of residual protein and the demonstration of its
activation can be accomplished in a single assay. In our
cohort, LCLs and PBLs from 21 fully informative, non-
mosaic study FA-D2 patients showed traces of residual
FANCD2 protein. Importantly, the residual protein always
consisted of both FANCD2 isoforms, and the typical time-
and dose-dependent induction of FANCD2-L was main-
tained, suggesting a preserved function. Differences in ex-
pression levels of residual FANCD2 between individual
LCLs might result from variations of conserved splice-site
recognition, in mRNA and protein stability, and, very
clearly, from differences in cell growth. FANCD2 is highly
expressed and monoubiquitinated in the S phase of the
cell cycle.10,56 The proportion of S-phase cells is a function
of cell growth, such that differences in cell proliferation
between individual cell lines account for the wide varia-
tion of FANCD2 protein levels. These differences render
any quantitative mutation-specific comparisons of resid-
ual FANCD2 protein levels close to impossible. The exis-
tence of residual protein has been described elsewhere for
other FA-D2 patients,9,26,27,46 but our study confirms resid-
ual protein as a consistent and, in all likelihood, essential
feature of cells of FA-D2 patients. Somatic reversion as a
cause of residual protein levels could be excluded inmany
of the patients in this study, because the diagnosis of FA
in these patients was based on hypersensitivity to cross-
linking agents of their cells in vitro. It could be argued
that these LCLs might include very small, undetected
amounts of reverted cells and thus might actually repre-
sent low-proportion mosaics. However, reverse mosaicism
has been widely observed only at certain rates (!25%)
and not at the frequency at which we detected residual
FANCD2 protein. Moreover, reverted cells, once present,
tend to outgrow nonreverted FA cells rather rapidly, at
least in LCLs, which never occurred in our long-term
studies. Finally, detection of residual protein with both
FANCD2-S and -L bands in some of our FA-D2 fibroblast
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lines without the possibility of mosaicism strongly argues
in favor of residual protein and against somatic reversion.
Of note, the vast majority of our FA-D2 patients are ho-
mozygous or compound heterozygous for at least a mis-
sensemutation or a nucleotide substitution affecting splic-
ing without altering the canonical AG and GT dinucleo-
tides of splice sites. Missense mutations might lead only
to a partial degradation of FANCD2, whereas the other
type of mutations causing exon skipping or aberrant splic-
ing might compete against but not abrogate the original
splice site, guaranteeing a residual amount of FANCD2.
FANCD2 is targeted to chromatin after DNA damage-
dependent monoubiquitination. In this process, FANCE
binds to FANCD2, providing the critical bridge linking
FANCD2 to FANCC and the rest of the FA core complex.57
The binding site of FANCD2 for FANCE has not been de-
termined. Our data suggest that this binding site, in ad-
dition to K561 and apart from an intact FA nuclear core
complex, must be retained by mutated residual FANCD2
protein to become monoubiquitinated.
Despite a rather severe phenotype in most of the FA-
D2 patients, the vast majority of our FA-D2 patients were
found to carry leaky mutations, affecting merely splicing,
and displayed residual FANCD2 protein of both isotypes
in their cell lines. Splicing mutations have become an in-
creasingly successful target for experimental therapeutic
approaches. Modified and antisense oligonucleotideshave
been used to inhibit cryptic exons or to activate regular
exons weakened by mutations via targeting of the oligo-
nucleotides to the desired transcript. This approach could
eventually lead to effective therapies for the correction of
erroneous splicing (reviewed in the work of Garcia-Blanco
et al.58). The tight regulation of FANCD2 expression and
activation and the presence of low-abundant wild-type
gene products associated with FANCD2 mutations should
render FANCD2 an ideal candidate for RNA-reprogram-
ming strategies such as spliceosome-mediated RNA trans-
splicing (SMaRT) (reviewed in the work of Mansfield et
al.59).
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
ClustalW, ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX (for the poly-
peptide sequences compared using theWindows interfaceClus-
talX [v. 1.81, for the multiple sequence-alignment program])
CpG Island Explorer, http://bioinfo.hku.hk/cpgieintro.html (for
promoter analyses [v. 1.9, at the settings GC 60%, CpG O/E
ratio 0.7, and minimum length 500 nt)
Ensembl Genome Browser, http://www.ensembl.org/ (for FANCD2
genomic sequences [accession number ENSG00000144554]and
Fancd2 sequence information for other species)
ESEfinder, http://rulai.cshl.edu/tools/ESE/ (for analysis of regu-
latory splice sequences)
ExPASy, http://www.expasy.org/sprot/ (for the Swiss-Prot Fancd2
protein sequences of different species, including Homo sapiens)
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for FA-D2 [ac-
cession number NM_033084, 43 exons]) and FANCD2 [accession
number AF340183, 44 exons], used as the human FANCD2 cDNA
reference)
Human BLAT Search, http://genome.ucsc.edu/cgi-bin/hgBlat (for
genomic FANCD2 sequences)
Human Genome Variation Society, http://hgvs.org/ (for the mu-
tation nomenclature)
MaxEntScan, http://genes.mit.edu/burgelab/maxent/
Xmaxentscan_scoreseq_acc.html (for estimation of deduced
splice-acceptor function, with use of a maximum entropy
model)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I,
-J, -L, -M, -N, BRCA1, RAD51, RAD50, ATM/ATR, RAD50,Mich-
elin-tire baby syndrome, VACTERL-like association, holopro-
sencephaly, and Kartagener syndrome)
RepeatMasker, http://www.repeatmasker.org/ (for analysis of re-
petitive elements)
Rescue-ESE (http://genes.mit.edu/burgelab/rescue-ese (for analy-
sis of regulatory splice sequences)
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Splicefinder, http://www.uni-duesseldorf.de/rna/ (for predicted
splice-donor performance)
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Table 4. CITED IN TEXT  |   |
FANCD2 Exon Primers
Exon
Forward Reverse PCR
Product
Size
(bp)Designation
Sequence
(5 3 ) Designation
Sequence
(5 3 )
1 hFANCD2_exon1_F TATGCCCGGCTAGCACAGAA hFANCD2_exon1_R TCCCATCTCAGGGCAGATGA 324
2 hFANCD2_exon2_F CCCCTCTGATTTTGGATAGAG hFANCD2_exon2_R TCTCTCACATGCCTCACACAT 258
3 hFANCD2_exon3_F GACACATCAGTTTTCCTCTCAT hFANCD2_exon3_R AAGATGGATGGCCCTCTGATT 354
4 hFANCD2_exon4_F TGGTTTCATCAGGCAAGAAACT hFANCD2_exon4_R AATCATTCTAGCCCACTCAACT 253
4/5 FA-D2, exon 4 II F GAGAAGGAAAACTATGGTAGGAAAC FA-D2, exon 5 II R GTGTAAGCTCTGTTTTCCTCAGAG 509
5 hFANCD2_exon5_F GCTTGTGCCAGCATAACTCTA hFANCD2_exon5_R AGCCCCATGAAGTTGGCAAAA 298
6 hFANCD2_exon6_F GAGCCATCTGCTCATTTCTGT hFANCD2_exon6_R GCTGTGCTAAAGCTGCTACAA 341
7 hFANCD2_exon7_F AATCTCGGCTCACTGCAATCT hFANCD2_exon7_R CAGAGAAACCAATAGTTTTCAG 280
8 hFANCD2_exon8_F TAGTGCAGTGCCGAATGCATA hFANCD2_exon8_R AGCTAATGGATGGATGGAAAAG 333
9 hFANCD2_exon9_F TTCACACGTAGGTAGTCTTTCT hFANCD2_exon9_R TACTCATGAAGGGGGGTATCA 323
10 hFANCD2_exon10_F GCCCAGCTCTGTTCAAACCA hFANCD2_exon10_R CATTACTCCCAAGGCAATGAC 229
FA-D2, exon10, F GTCTGCCCAGCTCTGTTCAAAC FA-D2, exon10, R ATTACTCCCAAGGCAATGACTGACTG 232
11 hFANCD2_exon11_F GTGGGAAGATGGAGTAAGAGA hFANCD2_exon11_R AGCTCCATTCTCTCCTCTGAA 341
FA-D2, exon11, F CAGTTCAGTACAAAGTTGAGGTAGTG FA-D2, exon11, R CCGGATTAGTCAGTATTCTCAGTTAG 267
12 hFANCD2_exon12_F TGCCTACCCACTATGAATGAG hFANCD2_exon12_R TCTGACAGTGGGATGTCAGAA 211
13 hFANCD2_exon13_F CAGGAACTCCGATCTTGTAAG hFANCD2_exon13_R ATGTGTCCATCTGGCAACCAT 321
FA-D2, exon 13 F 
P1+2
CCGATCTTGTAAGTTCTTTTCTGGTACG FA-D2, exon 13 R 
P1+2
TGGCAACCATCAGCTATCATTTCCAC 302
14 hFANCD2_exon14_F CGTGTTTCGCTGATGTGTCAT hFANCD2_exon14_R TGGAGGGGGGAGAAAGAAAG 186
15 hFANCD2_exon15a_F GTGTTTGACCTGGTGATGCTT hFANCD2_exon15a_R GGAAGGCCAGTTTGTCAAAGT 325
hFANCD2_exon15b_F GTGGAACAAATGAGCATTATCC hFANCD2_exon15b_R CTTATTTCTTAGCACCCTGTCAA 204
FA-D2, exon 15 F uniq GGAACAAATGAGCATTATCCATTCTGTG FA-D2, exon 15 R/ P1 CTCAATGGGTTTGAACAATGGACTG 363
16 hFANCD2_exon16_F AGGGAGGAGAAGTCTGACATT hFANCD2_exon16_R TTCCCCTTCAGTGAGTTCCAA 332
FA-D2, exon 16 F P1 GTCTGACATTCCAAAAGGATAAGCAAC FA-D2, exon 16 R CTTGAGACCCAGGTCAGAGTTC 344
17 hFANCD2_exon17_F GATGGGTTTGGGTTGATTGTG hFANCD2_exon17_R GATTAGCCTGTAGGTTAGGTAT 422
FA-D2, exon 17 F 
P1+2
CTGGCATATTCCTAAATCTCCTGAAG FA-D2, exon 17 R GCCTGTAGGTTAGGTATAAAGAAGTG 472
18 hFANCD2_exon18_F GGCTATCTATGTGTGTCTCTTT hFANCD2_exon18_R CCAGTCTAGGAGACAGAGCT 282
19 hFANCD2_exon19_F CGATATCCATACCTTCTTTTGC hFANCD2_exon19_R ACGATTAGAAGGGAACATGGAA 328
20 hFANCD2_exon20_F CACACCAACATGGCACATGTA hFANCD2_exon20_R TGACAGAGCGAGACTCTCTAA 239
21 hFANCD2_exon21_F AAAGGGGCGAGTGGAGTTTG hFANCD2_exon21_R GAGACAGGGTAGGGCAGAAA 339
22 hFANCD2_exon22_F ATGCACTCTCTCTTTTCTACTT hFANCD2_exon22_R GTAACTTCACCAGTGCAACCAA 279
23 hFANCD2_exon23_F TTCCCTGTAGCCTTGCGTATT hFANCD2_exon23_R ACAAGGAATCTGCCCCATTCT 356
24 hFANCD2_exon24_F CTCCCTATGTACGTGGAGTAA hFANCD2_exon24_R CCCCACATACACCATGTATTG 258
25 hFANCD2_exon25_F AGGGGAAAGTAAATAGCAAGGA hFANCD2_exon25_R GTGGGACATAACAGCTAGAGA 350
26 hFANCD2_exon26_F GACATCTCTCAGCTCTGGATA hFANCD2_exon26_R TCAGGGATATTGGCCTGAGAT 324
27 hFANCD2_exon27_F GCATTCAGCCATGCTTGGTAA hFANCD2_exon27_R CCAATTACTGATGCCATGATAC 324
28 hFANCD2_exon28_F TCTACCTCTAGGCAGTTTCCA hFANCD2_exon28_R GATTACTCCAACGCCTAAGAG 354
FA-D2, exon 28 F TCTACCTCTAGGCAGTTTCCA FA-D2, exon 28 R GATTACTCCAACGCCTAAGAG 354
29 hFANCD2_exon29_F CTTGGGCTAGAGGAAGTTGTT hFANCD2_exon29_R TCTCCTCAGTGTCACAGTGTT 384
30 hFANCD2_exon30_F GAGTTCAAGGCTGGAATAGCT hFANCD2_exon30_R TACCCAGTGACCCAAACACAA 348
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FA-D2, exon 30 F CATGAAATGACTAGGACATTCCTG FA-D2, exon 30 F GCAAGATGAATATTGTCTGGCAATACG 319
31 hFANCD2_exon31_F CCATTGCGAACCCTTAGTTTC hFANCD2_exon31_R ACCGTGATTCTCAGCAGCTAA 341
32 hFANCD2_exon32_F CCACCTGGAGAACATTCACAA hFANCD2_exon32_R AGTGCCTTGGTGACTGTCAAA 336
33 hFANCD2_exon33_F CACGCCCGACCTCTCAATTC hFANCD2_exon33_R TACTGAAAGACACCCAGGTTAT 340
34 hFANCD2_exon34_F TTGGGCACGTCATGTGGATTT hFANCD2_exon34_R TATAGCAAGAGGGCCTATCCA 349
FA-D2, exon 34 II F GGCAATCTTCTTGGGCTTATTACTGAG FA-D2, exon 34 II R CAACTTCCAAGTAATCCAAAGTCCACTTC 327
35 hFANCD2_exon35_F TTAGACCGGGAACGTCTTAGT hFANCD2_exon35_R GTCCAGTCTCTGACAAACAAC 300
36 hFANCD2_exon36_F CCTCTGGTTCTGTTTTATACTG hFANCD2_exon36_R GGCCAAGTGGGTCTCAAAAC 398
37 hFANCD2_exon37_F CTTCCCAGGTAGTTCTAAGCA hFANCD2_exon37_R TCTGGGCAACAGAACAAGCAA 277
FA-D2, exon 37 II F CATCCTCTTACTAAGGACCCTAGTGAAAG FA-D2, exon 37 II R CAGCAACTTCCAAGTAATCCAAAGTCCAC 288
38 hFANCD2_exon38_F GCACTGGTTGCTACATCTAAG hFANCD2_exon38_R AAGCCAGGACACTTGGTTTCT 274
39 hFANCD2_exon39_F TGCTCAAAGGAGCAGATCTCA hFANCD2_exon39_R GCATCCATTGCCTTCCCTAAA 236
40 hFANCD2_exon40_F CCTTGGGCTGGATGAGACTA hFANCD2_exon40_R CAGTCCAATTTGGGGATCTCT 309
41 hFANCD2_exon41_F GATTGCAAGGGTATCTTGAATC hFANCD2_exon41_R CCCCAATAGCAACTGCAGATT 214
42 hFANCD2_exon42_F AACATACCGTTGGCCCATACT hFANCD2_exon42_R GCTTAGGTGACCTTCCTTACA 356
43 hFANCD2_exon43a_F GTGGCTCATGCTTGTAATCCT hFANCD2_exon43a_R AGCATGATCTCGGCTCACCA 366
hFANCD2_exon43b_F CTGCCACCTTAGAGAACTGAA hFANCD2_exon43b_R TCAGTAGAGATGGGGTTTCAC 358
hFANCD2_exon43c_F TAGAATCACTCCTGAGTATCTC hFANCD2_exon43c_R CTCAAGCAATCCTCCTACCTT 405
hFANCD2_exon43d_F AGTTGGTGGAGCAGAACTTTG hFANCD2_exon43d_R CAGCTTCTGACTCTGTGCTTT 367
hFANCD2_exon43e_F TCAACCTTCTCCCCTATTACC hFANCD2_exon43e_R CTCGAGATACTCAGGAGTGAT 381
hFANCD2_exon43f_F GGTATCCATGTTTGCTGTGTTT hFANCD2_exon43f_R AGTTCTGCTCCACCAACTTAG 306
44 hFANCD2_exon44_F CACCCAGAGCAGTAACCTAAA hFANCD2_exon44_R GAAAGGCAAACAGCGGATTTC 213
FA-D2, exon 44 II F CTAGGAGCTGTATTCCAGAGGTCAC FA-D2, exon 44 II R GGATCCTACCAGTAAGAAAGGCAAAC 250
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Table 5. CITED IN TEXT  |   |
FANCD2 Mutation-Specific Primers
Designation
Sequence
(5 3 ) PCR/Sequencing
FA-D2, exon4-6 F GAAGGAAAACTATGGTAGGAAACTGGTG PCR/Sequencing
FA-D2, exon 6 R CAGATGTATTAGGCTAATAAGCACAG PCR/Sequencing
FA-D2, exon4-i6 R CCAGAAGCAGTTTGATGAGACTCTTAG PCR/Sequencing
FA-D2, exon i4F GCTTTCCAAAAGAAGCTCTTTCAGAC PCR/Sequencing
FA-D2, exon4-IVS F GGAGACACCCTTCCTATCCCAAAG PCR/Sequencing
FA-D2, exon 5F GAGTGGGCTAGAATGATTTTTAACAGC PCR/Sequencing
FA-D2, exon 5 R CTCTGAGGAAAACAGAGCTTACAC PCR/Sequencing
D2_AluYb9 F GCAATCTCGGCTCACTGCAAGCTC PCR/Sequencing
D2_IVS4/AluYb9, R GCTGTTAAAAATCATTCTACTTTGGGAGG PCR/Sequencing
FA-D2, ex 10 F GACTTGACCCAAACTTCCTATTGAA* PCR/Sequencing
FA-D2, ex 14 F TCGTGTTTCGCTGATGTGT PCR/Sequencing
FA-D2, ex 11 R CCGGATTAGTCAGTATTCTCAGTTAG PCR/Sequencing
IVS14+2411 R CGAGACCATCCTGACTAACACG PCR/Sequencing
IVS14+2512 R GATACCCCTTAAGAATACAGAGC PCR/Sequencing
FANCD2_16S AGAGCTAGGGAGGAGAAGTCTGA PCR
FANCD2_18A GAGCTGAGATCGTGCCAACT PCR
FANCD2_17S TGGTCAAGTTACACTGGCATATT Sequencing
FANCD2_17A CCATCCTTCAGCAATCACTC Sequencing
D2_P2_21_23 F GTTTTCTGATACTTGGAAACTACTGGCTTG PCR/Sequencing
D2_P1_21_23 R GACACAGAGGTAGCAAAGGATGTTC PCR/Sequencing
FA-D2, ex21_23, int1 CTATGATGAATTTGCCAACCTGATCC Sequencing
FA-D2, ex21_23, int2 GAGGGCTCCTTCACTTAATAACAATC Sequencing
FA-D2, ex21_23, int3 GTATTGTTTACCTGCTGGCTGGTTG Sequencing
FA-D2_sup_exon26 II F uniq TAGGGTCACAAGCCTAATCTCCTTT PCR
FA-D2_sup_exon26 II R uniq GGCCATGATGAATAATCTTTCTTTTGTTTG PCR
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n)
c.
24
44
G
A
pa
tp
.R
81
5Q
c.
27
15
+1
G
A
m
at
 (a
be
rr
an
t 
sp
lic
in
g)
p.
E9
06
Lf
sX
4
N
on
e 
(r
es
id
ua
l 
pr
ot
ei
n)
23
20
/I
Ly
m
ph
oc
yt
e
N
D
N
D
.0
8
7.
4 
(D
EB
)
IB
 o
f L
C
L
c.
75
7C
T
p.
R2
53
X
c.
13
67
T
G
p.
L4
56
R
N
on
e 
(r
es
id
ua
l 
pr
ot
ei
n)
24
20
/II
Ly
m
ph
oc
yt
e
N
D
N
D
.2
0
8.
9 
(D
EB
)
IB
 o
f L
C
L
c.
75
7C
T
p.
R2
53
X
c.
13
67
T
G
p.
L4
56
R
N
on
e 
(r
es
id
ua
l 
pr
ot
ei
n)
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25
21
Ly
m
ph
oc
yt
e
N
D
N
D
D
at
a 
m
is
si
ng
D
at
a
m
is
si
ng
M
ut
at
io
n 
an
al
ys
is
c.
19
48
–1
6T
G
 (e
xo
n 
22
 sk
ip
pi
ng
) 
p.
E6
50
X
c.
19
48
–1
6T
G
 (e
xo
n 
22
 
sk
ip
pi
ng
)p
.E
65
0X
19
53
G
T
(W
65
1C
)
(b
lo
od
, L
C
L)
26
22
/I
Fi
br
ob
la
st
22
.2
 
(f
ib
ro
bl
as
t)
54
(f
ib
ro
bl
as
t,
30
0 
nM
 
10
0 
ng
/m
l 
M
M
C
)
.0
4
.1
6 
(3
00
 
nM
 1
00
 
ng
/m
l
M
M
C
)
M
ut
at
io
n 
an
al
ys
is
 
in
 fi
br
ob
la
st
s (
by
 
si
bl
in
g)
c.
37
6A
G
 (a
be
rr
an
t s
pl
ic
in
g)
 
p.
S1
26
Rf
sX
12
c.
38
03
G
A
p.
W
12
68
X
37
6A
 (b
lo
od
)
27
22
/II
Ly
m
ph
oc
yt
e
N
D
N
D
.1
2
>1
0 
(M
M
C
)
IB
 a
nd
 IP
 o
f L
C
L
c.
37
6A
G
 (a
be
rr
an
t s
pl
ic
in
g)
 
p.
S1
26
Rf
sX
12
c.
38
03
G
A
p.
W
12
68
X
N
on
e 
(r
es
id
ua
l 
pr
ot
ei
n)
28
23
/I
Ly
m
ph
oc
yt
e
N
D
N
D
.1
0
6.
0 
(M
M
C
)
IB
, I
P 
an
d 
R
C
 o
f 
LC
L
c.
20
6–
2A
T 
(e
xo
n 
4 
sk
ip
pi
ng
) 
p.
A6
9D
fs
X7
g.
22
87
5_
23
33
3d
el
45
9
(c
.1
41
4–
71
_c
.1
54
5+
25
6d
el
45
9)
p.
E4
72
_K
51
5d
el
N
on
e 
(r
es
id
ua
l 
pr
ot
ei
n)
29
23
/II
Ly
m
ph
oc
yt
e
N
D
N
D
.1
2
8.
1 
(M
M
C
)
M
ut
at
io
n 
an
al
ys
is
 
(b
y 
si
bl
in
g)
c.
20
6-
2A
T 
(e
xo
n 
4 
sk
ip
pi
ng
) 
p.
A6
9D
fs
X7
g.
22
87
5_
23
33
3d
el
45
9
(c
.1
41
4–
71
_c
.1
54
5+
25
6d
el
45
9)
p.
E4
72
_K
51
5d
el
N
on
e 
(r
es
id
ua
l 
pr
ot
ei
n)
   
  N
O
TE
.—
D
EB
=d
ie
po
xy
bu
ta
ne
; R
C
=r
et
ro
vi
ra
l c
om
pl
em
en
ta
tio
n;
IB
=i
m
m
un
ob
lo
tti
ng
; I
P=
im
m
un
op
re
ci
pi
ta
tio
n;
 N
D
=n
ot
 d
et
er
m
in
ed
;G
2=
G
2 
ph
as
e 
fr
ac
tio
n 
of
th
e 
ce
ll 
cy
cl
e;
 G
F=
gr
ow
th
fr
ac
tio
n;
G
2/
G
F=
ra
tio
 G
2 
ph
as
e
fr
ac
tio
n 
ov
er
 G
F.
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Ta
bl
e 
9.
   
  
C
IT
E
D
 IN
 T
E
X
T 
 | 
  |
C
lin
ic
al
 D
ia
gn
os
tic
 D
at
a 
fo
r t
he
 C
oh
or
t o
f 2
9 
FA
-D
2 
Pa
tie
nt
s
Pa
tie
nt
N
um
be
r
K
in
dr
ed
/S
ib
lin
g
C
on
sa
ng
ui
ni
ty
Se
x
Et
hn
ic
ity
/N
at
io
na
lit
y
A
ge
 a
t 
D
ia
gn
os
is
C
lin
ic
al
 P
re
se
nt
at
io
n
H
em
at
ol
og
ic
M
an
ife
st
at
io
n(
s)
Su
rv
iv
al
 a
t L
as
t 
Fo
llo
w
-U
p
Fa
m
ily
H
is
to
ry
1
1/
I
U
nk
no
w
n
F
A
si
an
 In
di
an
6 
m
o
IU
G
R
, p
at
en
t d
uc
tu
s
ar
te
rio
su
s, 
pi
gm
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
lo
w
-s
et
 e
ar
s, 
hy
po
pl
as
tic
th
um
b 
w
ith
 d
up
lic
at
e 
na
il 
(R
), 
ra
di
al
-r
ay
 a
pl
as
ia
 w
ith
cu
ta
ne
ou
s t
hu
m
b 
(L
), 
pe
lv
ic
 
ki
dn
ey
 (R
), 
co
ng
en
ita
l h
ip
 
di
sl
oc
at
io
n 
(L
), 
an
d 
ap
la
si
a
of
 th
e 
co
rp
us
 c
al
lo
su
m
B
M
F 
as
 o
f a
ge
 
2 
ye
ar
s a
nd
 4
 
m
o,
 tr
an
sf
us
io
ns
 
fr
om
 a
ge
 3
 
ye
ar
s a
nd
 2
 m
o,
 
A
M
L 
at
 a
ge
 7
.0
 
ye
ar
s
D
ec
ea
se
d 
at
 a
ge
 
7 
ye
ar
s a
nd
 6
 
m
o 
(A
M
L,
 
pn
eu
m
on
ia
)
N
o 
SA
B
s;
 n
o 
kn
ow
n 
ca
nc
er
2
2/
I
A
bs
en
t
F
W
hi
le
 G
er
m
an
5 
Y
ea
rs
 
an
d 
7 
m
o
G
R
, p
ig
m
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
m
ic
ro
ph
ta
lm
ia
, l
ow
-s
et
 
th
um
bs
, d
up
lic
at
e 
ki
dn
ey
 (R
), 
dy
sp
la
st
ic
 h
ip
s
B
M
F 
as
 o
f a
ge
5 
ye
ar
s a
nd
 7
 
m
o,
 c
or
tis
ol
 
fr
om
 a
ge
 8
 
ye
ar
s,
tra
ns
fu
si
on
s
fr
om
 a
ge
 8
 
ye
ar
s a
nd
 4
 m
o,
 
an
dr
og
en
 fr
om
 
ag
e 
9 
ye
ar
s a
nd
 
2 
m
o
D
ec
ea
se
d 
at
 a
ge
 
11
 y
ea
rs
 a
nd
 4
 
m
o
(s
ub
ar
ac
hn
oi
di
c
he
m
or
rh
ag
e)
1 
SA
B
; 
M
G
M
:
ce
rv
ic
al
ca
nc
er
 a
t a
ge
 
40
 y
ea
rs
3
3/
I
C
ou
si
ns
 o
f
1s
t°
M
W
hi
te
 T
ur
k
1 
Y
ea
rs
 
an
d 
11
 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
hy
po
pl
as
tic
 th
um
bs
 (L
>R
),
sy
nd
ac
ty
ly
 II
/II
I t
oe
s, 
hy
po
ge
ni
ta
lis
m
, a
nd
 
gl
om
er
ul
os
cl
er
os
is
St
ab
le
 p
ar
tia
l
m
os
ai
ci
sm
,
B
M
F 
as
 o
f a
ge
 
11
 y
ea
rs
, 
co
rti
so
l a
nd
 
an
dr
og
en
 fr
om
ag
e 
12
 y
ea
rs
, 
tra
ns
fu
si
on
s
fr
om
 a
ge
 1
8 
ye
ar
s a
nd
 9
 m
o,
 
D
ec
ea
se
d 
at
 a
ge
 
20
 y
ea
rs
 a
nd
 7
 
m
o 
(v
ira
l 
en
ce
ph
al
iti
s
af
te
r B
M
T)
N
o 
SA
B
s, 
no
 
kn
ow
n 
ca
nc
er
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an
d 
B
M
T 
at
 a
ge
19
 y
ea
rs
 a
nd
 7
 
m
o
4
4/
I
C
ou
si
ns
 o
f
2n
d°
F
W
hi
te
 T
ur
k
5 
ye
ar
s 
an
d 
10
 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
m
ic
ro
ph
ta
lm
ia
, h
yp
op
la
st
ic
 
th
um
b 
(R
), 
hy
do
ce
ph
al
us
in
te
rn
us
, h
yp
op
la
st
ic
 c
or
pu
s 
ca
llo
su
m
, m
en
ta
l r
et
ar
da
tio
n,
an
d
hy
pe
ra
ct
iv
ity
/a
tte
nt
io
n-
de
fic
it
di
so
rd
er
B
M
F 
as
 o
f a
ge
 
2 
ye
ar
s a
nd
 6
 
m
o,
 tr
an
sf
us
io
ns
 
fr
om
 a
ge
 2
 
ye
ar
s a
nd
 6
 m
o,
 
su
bd
ur
al
he
m
or
rh
ag
e 
at
 
ag
e 
6 
ye
ar
s, 
an
d 
B
M
T 
at
 7
 y
ea
rs
8 
ye
ar
s a
nd
 3
 
m
o
N
o 
SA
B
s;
 n
o 
kn
ow
n 
ca
nc
er
5
4/
II
C
ou
si
ns
 o
f
2n
d°
M
W
hi
te
 T
ur
k
4 
Y
ea
rs
 
an
d 
5 
m
o
IU
G
R
, m
ic
ro
ce
ph
al
y,
 
m
ic
ro
ph
ta
lm
ia
, s
tra
bi
sm
us
, 
m
en
ta
l r
et
ar
da
tio
n,
 a
nd
 
hy
pe
ra
ct
iv
ity
/a
tte
nt
io
n-
de
fic
it
di
so
rd
er
B
M
F 
as
 o
f a
ge
 
3 
ye
ar
s a
nd
 3
 
m
o,
 tr
an
sf
us
io
ns
 
fr
om
 a
ge
 3
 
ye
ar
s a
nd
 3
 m
o,
 
an
d
ox
ym
et
ho
lo
n
fr
om
 a
ge
 5
 
ye
ar
s a
nd
 9
 m
o
6 
Y
ea
rs
 a
nd
 1
1 
m
o
N
o 
SA
B
s;
 n
o 
kn
ow
n 
ca
nc
er
6
5/
I
A
bs
en
t
M
W
hi
te
 G
er
m
an
2 
Y
ea
rs
 
an
d 
6 
m
o
G
R
, m
ic
ro
ce
ph
al
y,
m
ic
ro
ph
ta
lm
ia
, a
bs
en
t 
an
tih
el
ix
 (R
), 
ra
di
al
-r
ay
hy
po
pl
as
ia
, p
re
ax
ia
l 
he
xa
da
ct
yl
y 
(R
), 
du
pl
ic
at
e 
pe
lv
ic
 k
id
ne
y 
(R
),
m
al
de
sc
en
su
s o
f t
he
 te
st
es
, 
m
ic
ro
pe
ni
s, 
dy
sp
la
st
ic
 h
ip
s, 
hy
po
pl
as
tic
 c
or
pu
s c
al
lo
su
m
,
m
is
sh
ap
ed
 b
ra
in
 v
en
tri
cl
es
, 
an
d 
ps
yc
ho
m
ot
or
 re
ta
rd
at
io
n
B
M
F 
as
 o
f a
ge
 
2 
ye
ar
s a
nd
 9
 
m
o,
 a
nd
 B
M
T 
at
 
ag
e 
3 
ye
ar
s a
nd
 
3 
m
o.
4 
Y
ea
rs
 a
nd
 4
 
m
o
N
o 
SA
B
s;
 
PG
M
 c
an
ce
r 
at
 a
ge
 7
0 
ye
ar
s;
ot
he
rw
is
e,
 n
o 
ca
nc
er
 h
is
to
ry
7
6/
I
A
bs
en
t
F
W
hi
te
 It
al
ia
n
2 
Y
ea
rs
IU
G
R
, p
ig
m
en
ta
tio
n
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
m
ic
ro
ph
ta
lm
ia
, a
bs
en
t 
th
um
bs
, s
ho
rt 
ra
di
i, 
ab
se
nt
an
tih
el
ix
 (R
), 
an
d 
cl
os
ed
 
B
M
F 
as
 o
f a
ge
 
4.
5 
Y
ea
rs
12
 Y
ea
rs
N
o 
SA
B
s;
 n
o 
ca
nc
er
 h
is
to
ry
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au
di
to
ry
 c
an
al
s
8
7/
I
A
bs
en
t
M
W
hi
te
 G
er
m
an
3 
Y
ea
rs
 
an
d 
9 
m
o
Pi
gm
en
ta
tio
n 
an
om
al
ie
s,
m
ic
ro
ce
ph
al
y,
 "
fla
t"
 
au
ric
le
s-
ab
se
nt
 a
nt
ih
el
ix
?,
 
pt
os
is
, s
ho
rt 
th
um
bs
, a
nd
hy
pe
ra
ct
iv
ity
/a
tte
nt
io
n-
de
fic
it
di
so
rd
er
B
M
F 
as
 o
f a
ge
 
4 
ye
ar
s
4 
Y
ea
rs
 a
nd
 4
 
m
o
N
o 
SA
B
s;
 n
o 
ca
nc
er
 h
is
to
ry
9
8/
I
A
bs
en
t
F
W
hi
te
 C
ze
ch
2 
Y
ea
rs
 
an
d 
11
 
m
o
IU
G
R
, m
ic
ro
ce
ph
al
y,
 b
ra
in
at
ro
ph
y,
 p
at
en
t d
uc
tu
s 
ar
te
rio
su
s, 
es
op
ha
gu
s a
tre
si
a,
tra
ch
eo
es
op
ha
ge
al
 fi
st
ul
a 
(I
II
b)
, h
yp
op
la
st
ic
 k
id
ne
ys
,
po
ly
cy
st
ic
 o
va
ry
 (L
), 
tri
ph
an
ge
al
 d
ig
ita
liz
ed
 
th
um
bs
, p
ed
es
 e
qu
in
ov
ar
i,
an
d 
rib
 a
no
m
al
y 
(V
A
C
TE
R
L-
lik
e 
as
so
ci
at
io
n)
B
M
F 
as
 o
f a
ge
 
2 
ye
ar
s a
nd
 1
0 
m
o 
an
d 
tra
ns
fu
si
on
s
fr
om
 a
ge
 2
 
ye
ar
s a
nd
 1
1 
m
o
D
ec
ea
se
d 
at
 a
ge
 
5 
ye
ar
s a
nd
 1
0 
m
o
(h
em
or
rh
ag
e)
1 
SA
B
 (f
irs
t 
tri
m
es
te
r)
; n
o 
ca
nc
er
 in
 th
e 
fa
m
ily
10
9/
I
A
bs
en
t
F
W
hi
te
 T
ur
k
7 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
hy
dr
oc
ep
ha
lu
s i
nt
er
nu
s, 
ab
se
nt
 c
or
pu
s c
al
lo
su
m
,
m
ic
ro
ph
ta
lm
ia
, s
m
al
l m
ou
th
, 
lo
w
-s
et
 e
ar
s, 
hy
po
pl
as
tic
th
um
bs
, u
ni
la
te
ra
l 
tri
ph
al
an
ge
al
 (R
), 
pe
lv
ic
 
ki
dn
ey
 (L
), 
hi
p 
lu
xa
tio
n,
 a
nd
ps
yc
ho
m
ot
or
 re
ta
rd
at
io
n
B
M
F 
as
 o
f a
ge
 
2 
ye
ar
s
2 
ye
ar
s a
nd
 3
 
m
o
1 
SA
B
 (f
irs
t 
tri
m
es
te
r)
; 1
 
pr
eg
na
nc
y
te
rm
in
at
ed
be
ca
us
e 
of
 
hy
dr
oc
ep
ha
lu
s
an
d 
re
na
l 
ag
en
es
is
; P
G
F 
br
on
ch
us
ca
nc
er
11
10
/I
A
bs
en
t
F
W
hi
te
 A
us
tri
an
10
 Y
ea
rs
 
an
d 
10
 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
hy
po
pl
as
tic
 th
um
bs
, a
nd
 
ec
to
pi
c 
ki
dn
ey
 (R
)
B
M
F 
as
 o
f a
ge
10
 y
ea
rs
 a
nd
 1
0 
m
o,
 tr
an
sf
us
io
ns
 
fr
om
 a
ge
 1
0 
ye
ar
s a
nd
 1
0 
m
o,
 M
D
S
(R
A
EB
-t)
 w
ith
 
de
l(7
)(
q3
2)
 a
t 
ag
e 
10
 y
ea
rs
 
an
d 
10
 m
o,
 
11
 Y
ea
rs
 a
nd
 
11
 m
o
N
o 
SA
B
s;
 n
o 
ca
nc
er
 h
is
to
ry
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B
M
T 
at
 a
ge
 1
1
ye
ar
s a
nd
 1
 m
o
12
11
/I
A
bs
en
t
M
W
hi
te
 D
an
e
3 
M
o
IU
G
R
, a
tre
si
a 
of
 th
e
du
od
en
um
, m
ic
ro
ce
ph
al
y,
 
di
la
te
d 
la
te
ra
l v
en
tri
cl
es
 a
nd
st
en
os
is
 o
f t
he
 a
qu
ae
du
ct
 
(h
yd
ro
ce
ph
al
us
), 
hy
po
pl
as
ia
 
of
 th
e 
co
rp
us
 c
al
lo
su
m
,
m
ic
ro
ph
ta
lm
ia
, c
lo
se
d 
au
di
to
ry
 c
ha
nn
el
s, 
hy
po
pl
as
tic
 th
um
bs
, a
nd
m
ic
ro
pe
ni
s
B
M
F 
as
 o
f a
ge
 
2 
w
k
5 
M
o
N
o 
SA
B
s;
 
PG
M
 a
nd
 
M
PG
M
 b
re
as
t 
ca
nc
er
,
M
G
G
F
pr
os
ta
te
ca
nc
er
13
12
/I
C
ou
si
ns
 o
f
1s
t°
M
W
hi
te
 T
ur
k
5 
Y
ea
rs
 
an
d 
5 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
m
ic
ro
ph
al
m
ia
, p
sy
ch
om
ot
or
 
re
ta
rd
at
io
n,
 a
nd
 M
ic
he
lin
-ti
re
 
ba
by
 sy
nd
ro
m
e
B
M
F 
as
 o
f a
ge
 
1 
ye
ar
s a
nd
 5
 
m
o
5 
Y
ea
rs
 a
nd
 8
 
m
o
N
o 
SA
B
s;
 n
o 
ca
nc
er
 h
is
to
ry
14
13
/I
A
bs
en
t
F
W
hi
te
 G
er
m
an
34
 Y
ea
rs
 
an
d 
2 
m
o
IU
G
R
, m
ic
ro
ce
ph
al
y,
 a
nd
 
m
ild
 ra
di
al
-r
ay
 h
yp
op
la
si
a
N
on
e
34
 Y
ea
rs
N
o 
SA
B
s;
 n
o 
ca
nc
er
 h
is
to
ry
15
13
/II
A
bs
en
t
F
W
hi
te
 G
er
m
an
21
 Y
ea
rs
 
an
d 
11
 
m
o
IU
G
R
, m
ic
ro
ce
ph
al
y,
 ra
di
al
-r
ay
 h
yp
op
la
si
a,
 d
ys
pl
as
ia
 o
f 
m
an
di
bu
la
, a
no
m
al
ie
s o
f t
he
te
et
h,
 d
ys
pl
as
ia
 o
f h
ip
 (R
), 
an
d 
m
en
ta
l r
et
ar
da
tio
n
Tr
an
sf
us
io
ns
fr
om
 a
ge
 1
7 
ye
ar
s a
nd
 6
 m
o,
 
M
D
S
(R
A
R
S-
R
A
EB
)
at
 a
ge
 1
7 
ye
ar
s 
an
d 
6 
m
o
D
ec
ea
se
d 
at
 a
ge
 
23
 y
ea
rs
 a
nd
 5
 
m
o
(p
ne
um
on
ia
,
in
va
si
ve
as
pe
rg
ill
os
is
,
an
d
he
m
or
rh
ag
e)
N
o 
SA
B
s;
 n
o 
ca
nc
er
 h
is
to
ry
16
14
/I
C
ou
si
ns
 o
f 3
°
M
W
hi
te
 S
pa
ni
sh
6 
Y
ea
rs
Pa
te
nt
 d
uc
tu
s a
rte
rio
su
s, 
pi
gm
en
ta
tio
n 
an
om
al
ie
s, 
bi
fid
 
th
um
b 
(R
), 
an
d 
hy
po
go
na
di
sm
B
M
F 
as
 o
f a
ge
 
7 
ye
ar
s (
ve
ry
 
m
ild
 h
yp
op
la
si
a 
of
 th
e 
m
ye
lo
id
 
se
rie
s)
25
 Y
ea
rs
N
o 
SA
B
s;
 
M
G
F 
lu
ng
, 
an
d 
PG
F 
st
om
ac
h
ca
nc
er
17
14
/II
C
ou
si
ns
 o
f 3
°
M
W
hi
te
 S
pa
ni
sh
8 
M
o
Pi
gm
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ph
ta
lm
ia
, h
yp
op
la
st
ic
 
th
um
b 
(R
), 
ab
se
nt
 o
s 
B
lo
od
 c
el
l 
co
un
ts
 a
t 
lo
w
-r
an
ge
20
 Y
ea
rs
N
o 
SA
B
s;
 
M
G
F 
lu
ng
, 
an
d 
PG
F 
2.4 Hypomorphic Mutations in...
- 107 -
m
et
ac
ar
pa
le
 I 
(L
), 
an
d 
gl
an
du
la
r h
yp
os
pa
di
a
no
rm
al
 le
ve
ls
st
om
ac
h 
ca
nc
er
18
15
/I
A
bs
en
t
F
W
hi
te
 S
pa
ni
sh
5 
Y
ea
rs
 
an
d 
3 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
m
ic
ro
ph
ta
lm
ia
, h
yp
ot
el
or
is
m
, 
an
d 
an
nu
la
r p
an
cr
ea
s
B
M
F 
as
 o
f a
ge
 
5 
ye
ar
s a
nd
 3
 
m
o,
 a
nd
ro
ge
n,
 
G
-S
C
F,
 E
PO
 
an
d 
tra
ns
fu
si
on
s 
fr
om
 a
ge
 5
 
ye
ar
s a
nd
 3
 m
o,
 
B
M
T 
at
 a
ge
 1
0 
ye
ar
s a
nd
 1
1 
m
o
D
ec
ea
se
d 
at
 a
ge
 
11
 y
ea
rs
 a
nd
 1
 
m
o 
(g
ra
ft 
fa
ilu
re
/d
id
 n
ot
 
ta
ke
)
N
o 
SA
B
s;
 
M
M
G
M
 c
ol
on
 
ca
nc
er
19
16
/I
A
bs
en
t
M
C
au
ca
si
an
, m
at
er
na
l 
Ir
is
h 
an
d 
En
gl
is
h,
 
pa
te
rn
al
 Ir
is
h 
an
d 
Ita
lia
n
22
 W
k 
of
 
ge
st
at
io
n
IU
G
R
, a
bs
en
t t
hu
m
b 
an
d 
ra
di
al
 a
pl
as
ia
 (R
), 
an
d 
la
te
ra
l 
ce
re
br
al
 v
en
tri
cu
la
r d
ila
tio
n 
(h
yd
ro
ce
ph
al
us
)
N
A
N
A
, t
er
m
in
at
ed
 
w
ith
 d
ia
gn
os
is
 
of
 F
A
3 Fi
rs
t-t
rim
es
te
r
SA
B
s, 
4t
h 
fe
tu
s w
ith
 
IU
G
R
, r
ad
ia
l 
ap
la
si
a,
 c
ys
tic
hy
gr
om
as
,
en
ce
ph
al
oc
el
e,
pr
ob
ab
ly
 h
ea
rt 
de
fe
ct
s,
te
rm
in
at
ed
;
M
G
M
pa
nc
re
as
,
M
M
G
M
br
ea
st
, M
G
F 
m
el
an
om
a 
an
d 
ba
sa
l c
el
l 
ca
nc
er
20
17
/I
A
bs
en
t
M
W
hi
te
 m
at
er
na
l 
G
er
m
an
, p
at
er
na
l 
D
ut
ch
4 
Y
ea
rs
 
an
d 
5 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 a
nd
 
m
ic
ro
ph
ta
lm
ia
B
M
F 
as
 o
f a
ge
 
2 
ye
ar
s, 
B
M
T 
at
 
ag
e 
5 
ye
ar
s
9 
Y
ea
rs
 (4
 
ye
ar
s p
os
t 
B
M
T)
1 
SA
B
, M
 3
×
ba
sa
l c
el
l, 
M
M
M
G
M
m
el
an
om
a,
M
M
G
F 
br
ea
st
, 
PG
M
 b
ow
el
 
ca
nc
er
21
18
/I
A
bs
en
t
M
W
hi
te
 H
is
pa
ni
c 
7 
M
o
IU
G
R
, c
af
é-
au
-la
it 
sp
ot
s,
N
on
e 
ye
t
10
 Y
ea
rs
 a
nd
 3
 
N
o 
SA
B
; o
ne
 
2.4 Hypomorphic Mutations in...
- 108 -
(M
ex
ic
an
)
m
ic
ro
ce
ph
al
y,
 m
ic
ro
ph
ta
lm
ia
, 
he
ar
in
g 
lo
ss
 (a
ud
ito
ry
 c
an
al
s?
se
ns
or
y 
he
ar
in
g 
im
pa
irm
en
t?
), 
ab
se
nt
 th
um
bs
 
an
d 
ra
di
i, 
in
te
st
in
al
 a
tre
si
a,
re
na
l d
ef
ec
ts
, g
en
ita
l 
ab
no
rm
al
iti
es
 (u
nd
es
ce
nd
ed
te
st
es
), 
an
d 
le
ar
ni
ng
 
di
sa
bi
lit
ie
s
m
o
ca
nc
er
22
19
/I
A
bs
en
t
M
W
hi
te
 m
at
er
na
l I
ris
h,
 
D
ut
ch
 Y
ug
os
la
vi
an
 
Fr
en
ch
 a
nd
 N
at
iv
e 
A
m
er
ic
an
, p
at
er
na
l 
Ir
is
h 
an
d 
Si
ci
lia
n
N
ew
bo
rn
Pa
te
nt
 d
uc
tu
s a
rte
rio
su
s,
pi
gm
en
ta
tio
n 
an
om
al
ie
s, 
lo
w
-s
et
 e
ar
s, 
m
al
fo
rm
ed
au
ric
le
 (R
), 
co
ns
tri
ct
io
n 
ba
nd
s o
f m
id
 fo
re
ar
m
s 
(M
ic
he
lin
-ti
re
 b
ab
y
sy
nd
ro
m
e?
), 
pr
ea
xi
al
 
he
xa
da
ct
yl
y 
(R
), 
an
d 
hy
po
pl
as
tic
 th
um
b 
w
ith
 
po
nc
e 
flo
tta
nt
 (L
)
B
M
F 
as
 o
f a
ge
 
1 
ye
ar
 a
nd
 4
 m
o
2 
Y
ea
rs
 a
nd
 6
 
m
o
5 
M
is
ca
rr
ia
ge
s 
w
ith
 o
ne
 
po
si
tiv
e 
fo
r 
FA
; P
G
M
 
br
ea
st
, M
PG
M
 
ce
rv
ix
 a
nd
 
lu
ng
 c
an
ce
r, 
M
M
G
M
 b
ra
in
 
tu
m
or
23
20
/I
A
bs
en
t
M
M
at
er
na
l A
fr
ic
an
 
A
m
er
ic
an
/C
au
ca
si
an
,
pa
te
rn
al
 A
fr
ic
an
 
A
m
er
ic
an
(1
 M
o)
IU
G
R
, m
ic
ro
ce
ph
al
y,
 
m
ic
ro
ph
ta
lm
ia
, h
yp
op
la
st
ic
 
th
um
b 
(L
), 
hy
po
pl
as
tic
 
m
et
ac
ar
pa
l I
 (R
), 
an
d 
ho
rs
es
ho
e 
ki
dn
ey
N
on
e
1 
Y
ea
rs
 a
nd
 4
 
m
o
G
M
: 2
 
m
is
ca
rr
ia
ge
s;
ca
nc
er
 o
nl
y 
in
 
gr
ea
t-G
P
ge
ne
ra
tio
n
24
20
/II
A
bs
en
t
F
M
at
er
na
l A
fr
ic
an
 
A
m
er
ic
an
/C
au
ca
si
an
,
pa
te
rn
al
 A
fr
ic
an
 
A
m
er
ic
an
4 
Y
ea
rs
 
an
d 
6 
m
o
IU
G
R
, c
af
é-
au
-la
it 
sp
ot
s,
m
ic
ro
ce
ph
al
y,
 a
nd
 
m
ic
ro
ph
ta
lm
ia
B
M
F 
st
ar
tin
g 
fr
om
 a
ge
 4
 
ye
ar
s a
nd
 6
 m
o
5 
Y
ea
rs
 a
nd
 9
 
m
o
G
M
: 2
 
m
is
ca
rr
ia
ge
s;
ca
nc
er
 o
nl
y 
in
 
gr
ea
t-G
P
ge
ne
ra
tio
n
25
21
/I
C
ou
si
ns
 o
f
1s
t°
M
W
hi
te
 T
ur
k
5 
Y
ea
rs
 
an
d 
5 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
m
ic
ro
ph
ta
lm
ia
, a
nd
 p
el
vi
c 
ki
dn
ey
B
M
F 
st
ar
tin
g 
fr
om
 a
ge
 4
 
ye
ar
s a
nd
 
ox
ym
et
ho
lo
ne
an
d 
pr
ed
ni
so
ne
 
fr
om
 a
ge
 5
 
ye
ar
s a
nd
 5
 m
o
D
ec
ea
se
d 
at
 a
ge
 
9 
ye
ar
s 
(in
tra
cr
an
ia
l
he
m
or
rh
ag
e)
N
o 
SA
B
; n
o 
ca
nc
er
 h
is
to
ry
2.4 Hypomorphic Mutations in...
- 109 -
26
22
/I
A
bs
en
t
F
W
hi
te
 D
ut
ch
5 
Y
ea
rs
IU
G
R
 (a
sy
m
m
et
ric
al
);
pi
gm
en
ta
tio
n 
an
om
al
ie
s;
 
m
ic
ro
ce
ph
al
y;
ve
nt
ric
ul
om
eg
al
y
(h
yd
ro
ce
ph
al
us
) a
nd
 m
ul
tip
le
 
de
ve
lo
pm
en
ta
l a
no
m
al
ie
s o
f 
th
e 
br
ai
n,
 p
os
si
bl
y
ho
lo
pr
os
en
ce
ph
al
y;
hy
po
te
lo
ris
m
; m
ic
ro
ph
ta
lm
ia
; 
na
rr
ow
 a
ud
ito
ry
 c
an
al
s;
hy
po
pl
as
tic
 o
s m
et
ac
ar
pa
le
 I;
 
re
na
l a
pl
as
ia
 (R
); 
dy
sp
la
si
a 
of
th
e 
hi
p 
(L
); 
an
d 
gr
ow
th
-h
or
m
on
e 
de
fic
ie
nc
y
B
M
F 
as
 o
f a
ge
 
5 
ye
ar
s, 
tra
ns
fu
si
on
s
fr
om
 a
ge
 6
 
ye
ar
s a
nd
 9
 m
o,
 
an
d 
G
C
SF
 a
nd
 
B
M
T 
at
 a
ge
 7
 
ye
ar
s a
nd
 1
0 
m
o
9 
Y
ea
rs
N
o 
SA
B
; n
o 
ca
nc
er
 h
is
to
ry
27
22
/II
A
bs
en
t
M
W
hi
te
 D
ut
ch
3 
Y
ea
rs
IU
G
R
, p
ig
m
en
ta
tio
n
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
hy
po
pl
as
tic
 c
or
pu
s c
al
lo
su
m
;
hy
pe
rte
lo
ris
m
,
bl
ep
ha
ro
ph
im
os
is
, a
nd
 
pr
ea
xi
al
 h
ex
ad
ac
ty
ly
 (L
)
B
M
F 
as
 o
f a
ge
 
2 
ye
ar
s a
nd
 1
 
m
o,
 tr
an
sf
us
io
ns
 
fr
om
 a
ge
 5
 
ye
ar
s a
nd
 8
 m
o;
 
B
M
T 
at
 a
ge
 7
 
ye
ar
s a
nd
 7
 m
o
7 
Y
ea
rs
 a
nd
 9
 
m
o
N
o 
SA
B
; n
o 
ca
nc
er
 h
is
to
ry
28
23
/I
A
bs
en
t
M
W
hi
te
 D
ut
ch
8 
Y
ea
rs
 
an
d 
6 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 
K
ar
ta
ge
ne
r s
yn
dr
om
e 
w
ith
 
si
tu
s i
nv
er
su
s, 
an
d 
m
ild
 
m
en
ta
l r
et
ar
da
tio
n
B
M
F 
as
 o
f a
ge
 
8 
ye
ar
s a
nd
 5
 
m
o,
 n
o 
tra
ns
fu
si
on
s,
B
M
T 
at
 a
ge
 9
 
ye
ar
s a
nd
 5
 m
o
D
ec
ea
se
d 
at
 a
ge
 
10
 y
ea
rs
 a
nd
 1
 
m
o
(g
as
tro
in
te
st
in
al
he
m
or
rh
ag
e
du
e 
to
 
ne
cr
ot
iz
in
g
en
te
ro
co
lit
is
po
st
 B
M
T)
1 
SA
B
; n
o 
ca
nc
er
 h
is
to
ry
29
23
/II
A
bs
en
t
M
W
hi
te
 D
ut
ch
5 
Y
ea
rs
 
an
d 
8 
m
o
IU
G
R
, p
ig
m
en
ta
tio
n 
an
om
al
ie
s, 
m
ic
ro
ce
ph
al
y,
 a
nd
 
m
ic
ro
ph
ta
lm
ia
B
M
F 
as
 o
f a
ge
 
5 
ye
ar
s a
nd
 8
 
m
o 
an
d 
B
M
T 
at
 
ag
e 
6 
ye
ar
s a
nd
 
7 
m
o
7 
Y
ea
rs
 a
nd
 1
0 
m
o
1 
SA
B
; n
o 
ca
nc
er
 h
is
to
ry
   
  N
O
TE
.—
L=
le
ft;
 R
=r
ig
ht
; G
R
=g
ro
w
th
re
ta
rd
at
io
n;
 IU
G
R
=i
nt
ra
ut
er
in
e 
gr
ow
th
 re
ta
rd
at
io
n;
B
M
T=
bo
ne
-m
ar
ro
w
 tr
an
sp
la
nt
at
io
n;
 M
D
S=
m
ye
lo
dy
sp
la
st
ic
 sy
nd
ro
m
e;
2.4 Hypomorphic Mutations in...
- 110 -2.4 Hypomorphic Mutations in...
SA
B
=s
po
nt
an
eo
us
 a
bo
rti
on
; M
G
M
=m
at
er
na
l g
ra
nd
m
ot
he
r;
PG
F=
pa
te
rn
al
 g
ra
nd
fa
th
er
; M
PG
M
=m
at
er
na
l a
nd
pa
te
rn
al
 g
ra
nd
m
ot
he
r; 
M
G
G
F=
m
at
er
na
l g
re
at
gr
an
df
at
he
r;
M
G
F=
m
at
er
na
l g
ra
nd
fa
th
er
; M
M
G
M
=m
ot
he
r o
f t
he
 m
at
er
na
l g
ra
nd
m
ot
he
r; 
M
M
G
F=
m
ot
he
ro
f t
he
 m
at
er
na
l g
ra
nd
fa
th
er
;M
M
M
G
M
=m
ot
he
r o
f t
he
 m
at
er
na
lg
re
at
gr
an
dm
ot
he
r;
G
P=
gr
an
dp
ar
en
t.
- 111 -
196 The American Journal of Human Genetics Volume 81 July 2007 www.ajhg.org
In the May 2007 issue of the Journal, in the article entitled
“Hypomorphic Mutations in the Gene Encoding a Key
Fanconi Anemia Protein, FANCD2, Sustain a Significant
Group of FA-D2 Patients with Severe Phenotype” by Kalb
et al. (80:895–910), there were errors in the text and in
table 3.
On page 897, in the “Retroviral Complementation” sec-
tion, the text should read “In addition, cDNAs of the en-
hanced green fluorescent protein (GFP) and FANCA genes
were separately cloned into the vector S11IN….” On page
900, in the “Mutations Affecting Pre-mRNA Splicing” sec-
tion, “splec” should be “splice.” On page 905, in the “Re-
sidual FANCD2 Protein” section, “(data not shown)” should
be “(fig. 8B, right panel).” Therefore, in figure 8, the de-
scription of panel B should be “B, Blood-derived cells from
nonmosaic FA-D2 patients (exemplified 13, 5, 1, 21, 2, 6,
11, and 28) and fibroblasts from mosaic FA-D2 patients
(exemplified 3, 14, and 26) show faint but conspicuous
FANCD2 bands of both species in response to MMC ex-
posure exclusively on overexposed immunoblots, as in-
dicated by the very intense FANCD2 signals of the normal
control LCLs (CON) (patient 13, stimulated PBL; patients
5, 1, 21, 2, 6, 11, and 28, LCLs; patients 3, 14, 26, cultured
fibroblasts; loading control, RAD50).” In the figure 6 leg-
end, two reference numbers were incorrect. The sentence
should be “Mutations identified in the present study are
shown above, mutations reported elsewhere26,27 are indi-
cated below the schematic display of FANCD2 cDNA.”
The revised table 3 contains seven superamplicons that
were actually used in the study. Their numbering corre-
sponds to their order shown in figure 4C. The table has
been modified accordingly.
The authors and the Journal regret these errors.
Table 3. FANCD2 Superamplicon Primers
Superamplicon Containing Exons
Forward Reverse PCR
Product
Size
(bp)Designation
Sequence
(5′r3′) Designation
Sequence
(5′r3′)
I 1 and 2 hFANCD2_exon1_F TATGCCCGGCTAGCACAGAA hFANCD2_super_7_15_R GGCCCACAGTTTCCGTTTCT 4,346
II 10, 11, 12, 13, 14, and 15 hFANCD2_exon10_F GCCCAGCTCTGTTCAAACCA hFANCD2_super_7_15_R TTAAGACCCAGCGAGGTATTC 5,635
III 13, 14, 15, 16, and 17 hFANCD2_super_13_17_F CATGGCAGGAACTCCGATCTTG hFANCD2_super_13_17_R CTCCCTTAAAAGCTCAAAGCTCAAGTTC 8,858
IV 19 and 20 hFANCD2_super_19_22_F ACGTAATCACCCCTGTAATCC hFANCD2_exon20_R TGACAGAGCGAGACTCTCTAA 2,749
V 21, 22, and 23 hFANCD2_21_23_F GCTTCTAGTCACTGTCAGTTCACCAG hFANCD2_21_23_R ACGTTGGCCAGAAAGTAATCTCAG 2,518
VI 22, 23, 24, 25, and 26 hFANCD2_super_22_29_F GGCCTTGTGCTAAGTGCTTTT hFANCD2_exon26_R TCAGGGATATTGGCCTGAGAT 3,252
VII 27, 28, and 29 hFANCD2_exon27_F GCATTCAGCCATGCTTGGTAA hFANCD2_super_22_29_R CACTGCAAACTGCTCACTCAA 3,371
ERRATA
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The BRCA1-interacting
helicase BRIP1 is deficient in
Fanconi anemia
Orna Levran1, Claire Attwooll2, Rashida T Henry1,
Kelly L Milton1, Kornelia Neveling3, Paula Rio4,6, Sat Dev Batish1,
Reinhard Kalb3, Eunike Velleuer4, Sandra Barral5, Jurg Ott5,
John Petrini2, Detlev Schindler3,7, Helmut Hanenberg4,7 &
Arleen D Auerbach1,7
Seven Fanconi anemia–associated proteins (FANCA, FANCB,
FANCC, FANCE, FANCF, FANCG and FANCL) form a
nuclear Fanconi anemia core complex that activates the
monoubiquitination of FANCD2, targeting FANCD2 to BRCA1-
containing nuclear foci. Cells from individuals with Fanconi
anemia of complementation groups D1 and J (FA-D1 and FA-J)
have normal FANCD2 ubiquitination. Using genetic mapping,
mutation identification and western-blot data, we identify the
defective protein in FA-J cells as BRIP1 (also called BACH1),
a DNA helicase that is a binding partner of the breast cancer
tumor suppressor BRCA1.
Fanconi anemia is a genetic disorder associated with developmental
abnormalities, bone marrow failure, predisposition to cancer and
genomic instability1. Fanconi anemia has extensive genetic hetero-
geneity; eleven complementation groups have been defined2 and nine
associated genes have been identified (FANCA, FANCB, FANCC,
BRCA2 (also called FANCD1), FANCD2, FANCE, FANCF, FANCG
and FANCL)3–5. FANCD2 monoubiquitination is intact in two
complementation groups (FA-D1 and FA-J). Whereas biallelic muta-
tions in BRCA2 have been found in individuals with FA-D1 (ref. 6),
the gene mutated in FA-J has not yet been identified. The goal of this
study was to identify new downstream gene(s) in the Fanconi anemia
pathway. Cell lines and genomic DNA samples were derived from
individuals with Fanconi anemia and their family members registered
in the International Fanconi Anemia Registry (IFAR) after obtaining
informed written consent. The studies were approved by the Institu-
tional Review Board of The Rockefeller University.
We selected five individuals from four families in the IFAR1 for a
genome-wide scan using 50K SNP arrays on the basis of the following
criteria: (i) unassigned complementation group using retroviral
complementation studies or linkage; (ii) normal expression of the
two isoforms of FANCD2 (FANCD2-S and FANCD2-L)3; and (iii)
suspected homozygosity by descent originating from consanguinity
or a founder effect. A previous genome-wide scan of 460 microsatellite
markers in DNA from consanguineous families in the IFAR7
identified the position of FANCA, the gene most commonly
mutated in Fanconi anemia, but did not detect additional Fanconi
anemia–associated genes in the individuals studied, including indivi-
dual IFAR346/1, whom we also studied here. We also carried out
genome scans of three Inuit individuals (IFAR983/1, IFAR983/2 and
IFAR1001/1) using microsatellite markers (O.L., unpublished data) but
identified no region of shared homozygosity. We suspected that the
region of homozygosity was smaller than the 10-cM average distance
between the microsatellite markers used in these studies, and so we
screened DNA from the five individuals using 50K SNP arrays
(Supplementary Methods online). We identified a statistically signifi-
cant region of homozygosity of 6 Mb on chromosome 17q23, flanked
by SNPs rs10515150 and rs2665850 (positions 53,267,127 and
59,307,844, respectively; Fig. 1a). This region contains 48 SNPs for
which Inuit siblings IFAR983/1 and IFAR983/2 share the same haplo-
type; the haplotype of the other Inuit individual IFAR1001/1 differs by
only one SNP (rs1037364), leaving a 4.5-Mb region of shared haplo-
type among the Inuit individuals (position 54,792,947–59,307,844).
Each of the Hispanic individuals IFAR943/1 and IFAR346/1 has a
unique haplotype. The extent of the homozygous region was different
in each individual (Fig. 1a). Microsatellite marker data from the
previous scan7 for individual IFAR346/1 showed that two markers
(D17S808 and D17S794) lie in the candidate region (positions
58,025,847 and 58,170,985, respectively). This individual was homo-
zygous with respect to marker D17S808 but heterozygous with respect
to marker D17S794, reducing the shared homozygous region among
the five individuals to 5 Mb (positions 53,267,127–58,170,985; Fig. 1a).
The initial 6-Mb interval contains 68 known genes and hypothetical
proteins, from which we chose two candidate genes on the basis of
their biological functions: RAD51C8 and BRIP1 (also called BACH1)9.
We found no mutations in the coding regions or the adjacent intron
portions of RAD51C. Immunoblotting with an antiserum to RAD51C
detected a normal protein in all individuals (data not shown).
Sequencing of the coding regions and the adjacent intron portions of
BRIP1 identified a 2533C-T nonsense mutation in exon 17, resulting-
in a premature stop codon (R798X; Supplementary Fig. 1 online). All
five individuals were homozygous with respect to this mutation.
Screening of family members for this mutation confirmed the auto-
somal recessive inheritance (Fig. 1b). Sequence analysis for 13 SNPs in
BRIP1, including the 3 intronic variants observed on the SNP arrays
(IVS6+9547A-G, IVS9+536C-T and IVS16–10886G-A), showed
variability for eight variants among the five individuals (Fig. 1b,c).
Haplotype analysis indicated that the Inuit individuals (IFAR983/1,
IFAR983/2 and IFAR1001/1) shared the same intragenic haplotype
Published online 21 August 2005; doi:10.1038/ng1624
1Laboratory for Human Genetics & Hematology, The Rockefeller University, New York, New York, USA. 2Memorial Sloan-Kettering Cancer Center, New York, New York,
USA. 3Institute of Human Genetics, University of Wuerzburg, Germany. 4Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, Heinrich
Heine University, Duesseldorf, Germany. 5Laboratory of Statistical Genetics, The Rockefeller University, New York, New York, USA. 6Present address: CIEMAT/Marcelino
Botin Foundation, Madrid, Spain. 7These authors contributed equally to this work. Correspondence should be addressed to A.D.A. (auerbac@rockefeller.edu).
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(Hap1), indicative of a founder effect in this small isolated population.
Intragenic haplotypes for individuals IFAR346/1 (Hap2) and IFAR943/1
(Hap3) were unique. All variants except IVS10+142T-C and
4043G-T were previously described10. The appearance of the same
mutation on at least three different haplotypes from diverse popula-
tions is notable, especially for a rare disorder such as Fanconi anemia.
We screened an additional 18 individuals from the IFAR with
Fanconi anemia of an unassigned complementation group for muta-
tions in BRIP1. Three additional individuals (Table 1) were homo-
zygous with respect to the 2533C-T (R798X) mutation, and three
were heterozygous, including individual IFAR764/1 of European
ancestry who was previously assigned to the complementation
group FA-J2. The second mutation in two of the heterozygous
individuals was identified by genomic DNA sequencing and was
confirmed in family members. Individual IFAR995/1 carries a second
nonsense mutation (2541C-G; Y800X) in exon 17, and individual
IFAR781/1 carries a missense mutation (1186G-C; A349P) in exon 8
(Table 1). The second mutation in individual 764/1 is 80037A-T in
intron 11. The base substitution generates a new GT splice donor site
that activates a cryptic AG splice acceptor at positions 79071–79072.
cDNA from this individual shows an insertion of 963 bp between
exon 11 and 12 sequence (1628_1629ins963bp).
Because we identified mutations in BRIP1, we analyzed the BRIP1
protein by immunoblotting (Supplementary Methods online). Two
different BRIP1 antisera recognized a single species of B150 kDa in
wild-type cells. This protein was not evident in lymphoblastoid cell
lines established from individuals who were homozygous (IFAR346/1,
IFAR824/1, IFAR943/1, IFAR983/2 and IFAR1010/1) or heterozygous
(IFAR764/1 and IFAR995/1) with respect to 2533C-T (R798X;
Fig. 1d). We interpret these data to indicate that these individuals
are BRIP1-deficient, but the presence of a truncated protein cannot be
excluded by these analyses, as the antibodies both bind in the
C terminus. Such a protein would not retain BRCA1 binding capacity,
as the BRCA1-BRIP1 interaction domain lies in residues 888–1,063
(ref. 9), a region lost from the mutant gene product (Fig. 1c).
Previous analyses point to a functional interaction between mono-
ubiquitinated FANCD2 and BRCA1 at presumptive sites of DNA
damage3. As FANCD2 monoubiquitination is intact in the BRIP1-
deficient cells, our findings suggest that the Fanconi pathway con-
verges on BRCA1 and the BRIP1 helicase as mediators of chromosome
maintenance downstream of FANCD2. Further, given the implication
of both BRCA1 and BRIP1 in recombinational DNA repair11–13, we
suggest that DNA double-strand breaks are the lesions that underlie
the pathology of Fanconi anemia.
Note: Supplementary information is available on the Nature Genetics website.
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Table 1 Characteristics of individuals with Fanconi anemia and mutations in BRIP1
Individual
Maternal
allele
Paternal
allele
DEB-treated
breaks/cell (%)a
Baseline
breaks/cell Ethnicity
Phenotypic and
hematologic abnormalities
346/1 2533C-T, R798X 2533C-T, R798X 4.6 (80) 0.1 Hispanic Growth retardation; cafe´-au-lait spots; bilateral hypoplastic thumbs;
microphthalmia; BMF at 6 y
764/1 2533C-T, R798X 80037A-T 2.0 (32) 0.1 Eur-Amer Severe growth retardation; cafe´-au-lait spots; microphthalmia;
urogenital abnormalities; hearing loss; developmental delay;
no BMF at 6.5 y
781/1 1186G-C, A349P 2533C-T, R798X 0.35b 0.08 Eur-Amer IUGR; radial and ulna aplasia; bilateral club feet; cleft palate;
abnormal facies; severe GI, urogenital, cardiovascular, respiratory
and CNS abnormalities; stillborn fetus, gestational age 22 wk
824/1 2533C-T, R798X 2533C-T, R798X 5.7 (95) 0.24 Eur-Amer Severe growth retardation; cafe´-au-lait spots; microphthalmia; radial
ray, urogenital and heart abnormalities; conductive hearing loss; no
BMF at 5 y
894/1 2533C-T, R798X 2533C-T, R798X 8.80 (100) 0.28 Irish traveler Severe growth retardation; cafe´-au-lait spots; microphthalmia;
hydrocephalus; radial ray defect; BMF at 2 y
943/1 2533C-T, R798X 2533C-T, R798X 9.6 (95) 0.16 Hispanic Growth retardation; cafe´-au-lait spots; thumb and kidney
abnormalities; developmental delay; BMF at 3.5 y; CMMol at
13.5 y; died at 14 y
983/1 2533C-T, R798X 2533C-T, R798X 13.3 (100) 0.5 Inuit IUGR; radial ray and genital abnormalities; died at 6 wk
983/2 2533C-T, R798X 2533C-T, R798X 23.3 (100) 0.48 Inuit Severe growth retardation; cafe´-au-lait spots; abnormal thumbs;
developmental delay; BMF at 5.5 y
995/1 2533C-T, R798X 2541C-G, Y800X 10.1 (100) 0.2 Mixedc IUGR; microphthalmia; radial ray, vertebral, urogenital, heart, CNS
and ear abnormalities; died at 4 d
1001/1 2533C-T, R798X 2533C-T, R798X 14.3 (100) 3.7 Inuit Growth retardation; cafe´-au-lait spots; hypoplastic thumbs; kidney
and anal abnormalities; other skeletal (Klippel-Feil and Sprengel)
malformations; hearing loss; BMF at 5.5 y
1010/1 2533C-T, R798X 2533C-T, R798X 18.1 (100) 1.5 Eur-Amer Growth retardation; cafe´-au-lait spots; radial ray and cardiac
abnormalities; hearing loss; developmental delay; BMF at 5.5 y
aPercentage of aberrant cells is indicated in parentheses. bFetal fibroblasts treated with 0.01 mg ml1 diepoxybutane (DEB). cPaternal ancestry is African American and European American;
maternal ancestry is European American and Hispanic. BMF, bone marrow failure; CMMol, chronic myelomonocytic leukemia; CNS, central nervous system; Eur-Amer, Americans of European
descent; GI, gastrointestinal system; IUGR, intrauterine growth retardation.
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Wild type
Heterozygote (764/1)
Homozygote (938/2)
Wild type CTALeu
AAA
Lys
CGA
Arg
CAA
Gln[
Mutant STOP
CTA
Leu
AAA
Lys
TGA CAA[
Supplementary Figure 1. Chromatograms displaying the wild type and
mutation c.2533C>T in exon 17 of BRIP1, and illustration of the creation of a
premature stop codon R798X. The protein sequence is shown below the
genomic sequence. Patients IFAR764/1 (FA-J) and IFAR983/2 are
heterozygous and homozygous, respectively, for the c.2533C>T mutation.
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1
The BRCA1 interacting helicase BACH1/BRIP1 is deficient in Fanconi anemia
Levran et al.
Nature Genetics
Supplementary Methods
Subjects and cell lines. Cell lines and genomic DNA samples were derived by
standard methods from FA patients and family members registered in the IFAR after
obtaining informed written consent. The studies were approved by the Institutional
Review Board of The Rockefeller University. The diagnosis of FA was confirmed in
patients with phenotypic manifestations of FA by study of baseline and DEB-induced
chromosomal breakage in phytohemagglutinin (PHA)-stimulated cultured peripheral
blood lymphocytes as described1 (see Table 1). Complementation studies with
retroviral vectors containing normal FANCA, FANCC, FANCD2, FANCE, FANCF,
FANCG and FANCL cDNAs were as described2. BRCA2 was sequenced by Myriad
Genetic Laboratories, Salt Lake City, UT. Immunoblotting for detection of
monoubiquitinated FANCD2 was performed as described
3
.
50K SNP array. A genome wide screen of DNA from five FA patients that had normal
FANCD2 monoubiquitination was performed at The Rockefeller University Genotyping
Resource Center, using the GeneChip® Human Mapping 50K Array 240 Xba
(Affymetrix Inc. Santa Clara, CA) according to the manufacturer’s guidelines.
GeneChip® DNA Analysis Software (GDAS) provided the score and SNPs were
annotated using data from the NetAffxTM Analysis Center (Affymetrix, Inc. Santa Clara,
CA). SNPs with ambiguous positions were excluded.
- 118 -2.5 The BRCA1-interacting helicase BRIP1 is defi cient in Fanconi anemia
2
Statistical Analysis. To localize a genomic region harboring a potential FA gene, we
searched for runs of consecutive SNPs for which all five individuals are homozygous (a
form of linkage analysis). These runs were ranked by their lengths. To determine
whether the longest runs can be considered statistically significant, a graphical analysis
was employed where the run length (y-axis) was plotted against rank (x-axis).
PCR primers and conditions. Rad51C primers flanking exons 1-9 were designed
using the Primer3 software (Whitehead Institute; http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). PCR conditions were as described4. BRIP1 primers
flanking exons 1-20 are described elsewhere5,
(http://lpg.nci.nih.gov/struewing/pubs/analysis/). Exon 19 was divided into 19a and 19b
and exon 20 was divided into 20a, 20b and 20c. All 25 fragments were amplified using a
single Touchdown PCR program that was a modification of the one described
elsewhere (http://lpg.nci.nih.gov/struewing/pubs/analysis/). BRIP1 cDNA primer
sequences are available upon request.
Sequencing. PCR products were cleaned using ExoSAP-IT (USB, Cleveland, OH)
according to manufacturer’s protocol. Sequencing was performed by Genewiz Inc.
(North Brunswick, NJ) with Big Dye Terminator v3.1 Cycle Sequencing Ready Reaction
kits (Applied Biosystems, Forester City, CA) on a 3730xl DNA analyzer. Sequence data
were generated by means of Sequencing Analysis v.5.1 (Applied Biosystems, Forest
City, CA) and analyzed with Sequencher v.4.5 (Gene Codes Corporation, Ann Arbor,
MI).
Immunoblotting. Immunoblotting was carried out as previously described6. Cells were
lysed in RIPA buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.5% Sodium
Deoxycholate, 0.1% SDS). Primary antibodies used were mouse BACH1 monopool (a
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3
gift from Sharon Cantor), mouse BACH1 1:500 (Novus Biologicals, NB-100-189), and
mouse monoclonal actin 1:2500 (Sigma). Secondary antibodies used were
ImmunoPure Protein A/G- or mouse IgG- HRP conjugated (Pierce). Detection was by
ECL (Amersham Biosciences).
References for Supplementary Methods
1. Auerbach, A.D., Rogatko, A., & Schroeder-Kurth, T.M. Blood. 73, 391-396
(1989).
2. Hanenberg, H. et al. Exp Hematol. 30, 410-420 (2002).
3. Garcia-Higuera, I. et al. Mol. Cell 7, 249-262 (2001).
4. Levran, O. et al. Hum. Mutat. 25,142-149 (2005).
5. Rutter, J. L. et al. Hum. Mutat. 22,121-128 (2003).
6. Carney, J.P. et al. Cell 93, 477–486 (1998).
- 120 -
2  
Results
2.1 Disruption of the FA/BRCA pathway in bladder cancer
2.2 Recurrent disruptive mutations and forebearable substitutions inhe- 
re in the substrate binding protein of the Fanconi anemia core com- 
plex, FANCE
2.3 Mutation and Reversion in FANCL, the Gene Encoding the E3 Ligase 
Catalytic Subunit of the Fanconi Anemia Nuclear Core Complex
2.4  Hypomorphic Mutations in the Gene Enkoding a Key Fanconi Anemia  
Protein, FANCD2, Sustain a Signifi cant Group of FA-D2 Patients with  
Severe Phenotype
2.5 The BRCA1-interacting helicase BRIP1 is defi cient in Fanconi ane-
mia
2.6 Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N  
and predispose to childhood cancer
2.7 FANCI is a second monoubiquitinated member of the Fanconi ane- 
mia pathway
2.6 Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N
- 121 -2.6 Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N
Biallelic mutations in PALB2
cause Fanconi anemia subtype
FA-N and predispose to
childhood cancer
Sarah Reid1, Detlev Schindler2, Helmut Hanenberg3,4,
Karen Barker1, Sandra Hanks1, Reinhard Kalb2,
Kornelia Neveling2, Patrick Kelly1, Sheila Seal1, Marcel Freund3,
Melanie Wurm3, Sat Dev Batish5,6, Francis P Lach5, Sevgi Yetgin7,
Heidemarie Neitzel8, Hany Ariffin9, Marc Tischkowitz10,11,
Christopher G Mathew12, Arleen D Auerbach5 &
Nazneen Rahman1
PALB2 was recently identified as a nuclear binding partner
of BRCA2. Biallelic BRCA2 mutations cause Fanconi anemia
subtype FA-D1 and predispose to childhood malignancies.
We identified pathogenic mutations in PALB2 (also known as
FANCN) in seven families affected with Fanconi anemia and
cancer in early childhood, demonstrating that biallelic PALB2
mutations cause a new subtype of Fanconi anemia, FA-N, and,
similar to biallelic BRCA2 mutations, confer a high risk of
childhood cancer.
Fanconi anemia is a rare, recessive, chromosomal instability disorder
characterized by growth retardation, congenital malformations, pro-
gressive bone marrow failure, cancer predisposition and cellular
hypersensitivity to DNA cross-linking agents1. The syndrome is
genetically heterogeneous with 12 complementation groups currently
recognized, 11 of which have been attributed to distinct genes: FANCA
(FA-A), FANCB (FA-B), FANCC (FA-C), BRCA2 (FA-D1), FANCD2
(FA-D2), FANCE (FA-E), FANCF (FA-F), FANCG (FA-G), BRIP1
(FA-J), FANCL (FA-L) and FANCM (FA-M)2,3.
BRCA2 is a DNA repair protein with a key role in the repair of DNA
double-strand breaks by homologous recombination4. BRCA2 was
originally identified through positional cloning of a familial breast
cancer predisposition gene, and monoallelic (heterozygous) mutations
are associated with high risks of breast and ovarian cancer5. Subse-
quently, biallelic BRCA2mutations were found to cause a rare subtype
of Fanconi anemia, FA-D1 (ref. 6). The phenotype of biallelic BRCA2
mutations differs from other Fanconi anemia subtypes, most notably
with respect to the high risks of childhood solid tumors, particularly
Wilms tumor and medulloblastoma, which occur very rarely in other
Fanconi anemia subtypes6–10.
Although Fanconi anemia and childhood embryonal tumors are
attributable to BRCA2 in many individuals, we identified individuals
with this phenotype who lacked BRCA2 mutations. This raised the
possibility that deficiency of other proteins might give rise to this
combination of features, and we considered proteins functionally
related to BRCA2 the most credible candidates.
PALB2 (for ‘partner and localizer of BRCA2’) was recently identified
as a nuclear partner of BRCA2 (ref. 11). PALB2 colocalizes with
BRCA2, promoting its localization and stability in key nuclear struc-
tures, which in turn facilitates BRCA2 functions in DNA repair.
Furthermore, knockdown of PALB2 sensitizes cells to MMC treatment,
which results in interstrand cross-links and double-strand breaks11.
Sensitivity to MMC is a hallmark of Fanconi anemia, and these data
therefore recommended PALB2 as a candidate Fanconi anemia gene.
We sequenced the 13 exons and intron-exon boundaries of PALB2
in 82 individuals with Fanconi anemia not due to known genes
(Supplementary Methods and Supplementary Table 1 online). We
identified pathogenic mutations in seven families (Fig. 1a and
Table 1). In four affected individuals (GESH, IFAR-847, LNEY and
IFAR-849), we identified biallelic mutations that resulted in premature
protein truncation. Analysis of parental DNA demonstrated that all
the mutations had been inherited from different parents, consistent
with autosomal recessive inheritance. No sample was available
from the affected individuals LOAO, IFAR-007 and ICR-60, but
their parents all carried truncating PALB2 mutations. We also
sequenced PALB2 in 352 control chromosomes (176 normal indivi-
duals) and did not identify any truncating mutations, providing
further evidence that such mutations are pathogenic in the individuals
with Fanconi anemia.
We saw one mutation, 3549C-G (leading to amino acid change
Y1183X), in two separate families. We also identified a different
mutation in a third family at the same nucleotide, 3549C-A,
which also results in Y1183X. 3549C is in the last exon of PALB2,
and there are only three amino acids after codon 1183 before the
protein terminates. Truncating mutations close to the end of a protein
are generally expected to escape nonsense-mediated RNA decay12.
However, there was no detectable PALB2 protein in lymphoblastoid
cells from individuals IFAR-847 and IFAR-849, who both carry
Received 14 August; accepted 27 November; published online 31 December 2006; doi:10.1038/ng1947
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Rockefeller University, 1230 York Ave., New York, New York 10021, USA. 6Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell
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Y1183X, indicating that the mutation results in a null allele and
confirming its pathogenicity (Fig. 1b).
We performed protein blot analysis on lymphoblastoid cells or
fibroblasts from four individuals with biallelic PALB2 mutations.
Using an antibody that recognizes the N terminus of PALB2, we
found absence of PALB2 protein in each case (Fig. 1b). Transduction
of cells from IFAR-849 with an expression construct carrying wild-
type PALB2 restored PALB2 expression and reversed MMC-induced
G2 phase arrest (Fig. 1c and Supplementary Methods). The com-
bined genetic, protein and complementation data provide strong
evidence that PALB2 mutations underlie a new Fanconi anemia
complementation group that we have designated subtype FA-N.
Eight of the known Fanconi anemia proteins (A, B, C, E, F, G, L and
M) form a nuclear core complex that mediates monoubiquitination of
FANCD2. Activated FANCD2 (FANCD2-L) is translocated to DNA
repair foci, where it colocalizes with various proteins involved in the
DNA damage response, including BRCA2
(refs. 2,3). Given the close functional relation-
ship between BRCA2 and PALB2, one would
predict that PALB2 acts downstream of
FANCD2. We confirmed this in different cell
types from individuals IFAR-847, IFAR-849,
LNEYand GESH, which show normal mono-
ubiquitination of FANCD2 (Fig. 1d).
The phenotype of FA-N is in many ways
typical of Fanconi anemia and includes
growth retardation and variable congenital
malformations (Table 1). The cellular phe-
notype of PALB2 deficiency is similar to
BRCA2 deficiency and more severe than
other Fanconi anemia subtypes, with elevated
spontaneous chromosome breakage rates,
markedly reduced lymphocyte survival and
increased chromosome breakage on exposure
to MMC (Supplementary Fig. 1 online).
There was also no formation of nuclear
RAD51 foci in PALB2-deficient fibroblasts
after ionizing irradiation. Again, this is simi-
lar to cells with biallelic BRCA2 mutations
and differs from other Fanconi anemia sub-
types13 (Supplementary Fig. 1).
All seven individuals with FA-N developed
cancers in early childhood, including three
Wilms tumors, five medulloblastomas, two
cases of AML and one neuroblastoma
(Table 1). One individual developed three
malignancies within the first year of life, and
three individuals had two cancers. Cancer
treatment was unsuccessful in six patients, all
of whom died before four years of age. LNEY
is currently alive at 4.5 years but is in the early
stages of treatment for medulloblastoma. The
cancer spectrum and early mortality associ-
ated with biallelic PALB2 mutations is thus
very similar to that associated with biallelic
BRCA2 mutations10. The reasons for the asso-
ciation between childhood solid tumors and
deficiency of BRCA2 or PALB2 are unclear but
are probably related to functions not shared
by other Fanconi anemia proteins.
Monoallelic (heterozygous) BRCA2 muta-
tions are associated with high risks of breast and ovarian cancer and
lesser risks of other cancers such as prostate and pancreatic cancer5.
Given the intimate functional links between PALB2 and BRCA2 and
the similar phenotypes associated with biallelic mutations in the genes
that encode them, it is plausible that monoallelic PALB2 mutations
confer susceptibility to adult cancer. Of note in this regard are the
cancer histories in the seven FA-N families we have identified. The
mother of IFAR-007 had early-onset bilateral breast cancer and has a
strong family history of breast cancer affecting her sister, mother and
other more distant relatives. BRCA1 and BRCA2 mutations have been
excluded in this family. No other first-degree relatives of FA-N
individuals are known to have developed cancer, although most are
still under 50 years of age. However, the maternal grandmother of ICR-
60 and a maternal great-grandmother of GESH developed breast
cancer at 52 years and 20 years of age, respectively. Mutational analyses
of PALB2 in individuals with adult-onset cancer, particularly familial
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Figure 1 Evidence that PALB2 deficiency causes FA-N. (a) Mutation analysis. Schematic representation
of PALB2 showing the position of mutations identified in FA-N cases. Further details of the mutations
and the individuals in which they were identified are given in Table 1. The 3549C-G mutation
(leading to amino acid change Y1183X) was identified in two separate families. We obtained informed
consent from all families and the research was approved by the London Multicentre Research Ethics
Committee (05/MRE02/17). (b) PALB2 and BRCA2 immunoblotting. PALB2 protein is absent in cells
from FA-N cases IFAR-847 (lymphoblastoid cell line (LCL)), IFAR-849 (LCL), LNEY (fibroblast) and
GESH (fibroblast) and is present in control cells (left). BRCA2 is present in FA-N and control cells and
is absent in FA-D1 cells (right). RAD50 was used as a loading control. (c) Complementation of the
cellular phenotype. Transduction of cells from IFAR-849 with the vector pOZC-PALB2 restores PALB2
expression to a similar level as in a normal control, whereas the mock vector pS11EG (expressing GFP)
does not (left). Overlay of two cell cycle distributions represented by histograms acquired with flow
cytometry after exposure of an LCL from IFAR-849 to 15 ng/ml MMC for 48 h (right). The light gray
histogram shows noncomplementation when cells were transduced with a mock vector expressing GFP
(pS11EG) (G1 phase, 42%; S, 15%; G2, 43%; G2 phase arrest is typical of FA). The darker histogram
demonstrates complementation after transduction of isogenic cells with the PALB2-expressing vector
pOZC-PALB2 (G1 phase, 57%; S, 17%; G2, 26%; G2 phase is restored). This effect has been reported
in complemented FA cell lines from other subtypes15. (d) FANCD2 monoubiquitination. There is normal
FANCD2 monoubiquitination in FA-N cells, similar to control cells.
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breast cancer, will clarify the role of monoallelic PALB2 mutations in
cancer susceptibility.
Mutations in BRCA2 and PALB2 together account for almost all the
individuals we studied having both Fanconi anemia and childhood
solid tumors. However, there are rare individuals with Fanconi anemia
not due to known genes whose cells show normal monoubiquitination
of FANCD2. Thus, it is possible that other genes encoding proteins
that physically and/or functionally interact with BRCA2 cause cur-
rently unrecognized subtypes of Fanconi anemia.
Note: Supplementary information is available on the Nature Genetics website.
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Table 1 PALB2 mutations and clinical features of FA-N
Mutation 1 Mutation 2 Clinical features
ID Origin
Nucleotide
change Effect
Nucleotide
change Effect
Cancer
(age at diagnosis) Other features
LOAOa Albanianb,
Moroccanc
395delT V132fs 3113+5G-C r.2835_
3113del279/
A946fs
Medulloblastoma
(3.5 yrs)
Growth retardation,
radial ray hypoplasia,
absent right kidney
GESH German 757_758delCT L253fs 3294_3298
delGACGA
K1098fs Wilms tumor
(0.9 yr),
AML (0.9 yr),
medulloblastoma
(1 yr)
Severe growth retardation,
hypoplastic thumbs, left pelvic kidney,
anal atresia, microcephaly, congenital
cataract,
microphthalmia
IFAR-847 Hispanicb,
North
Americanc
2257C-T R753X 3549C-A Y1183X Wilms tumor
(1 yr)
Severe IUGR, postnatal growth retardation,
microcephaly, microphthalmia,
skin hyperpigmentation
LNEY German 2393_2394insCT T799fs 3350+4A-G r.3350insGCAG/
F1118fs
Medulloblastoma
(4 yrs)
Growth retardation, microcephaly,
microphthalmia, bifurcated anus
IFAR-007a,d North
Americanb,
African
ancestryc
2521delA T841fs 3323delA Y1108fs Wilms tumor
(1.5 yrs),
medulloblastoma
(1.5 yrs)
Growth retardation, microcephaly,
skin hyper- and hypopigmentation, horseshoe
kidney, gonadal dysgenesis
ICR-60a British 2962C-T Q988X 3549C-G Y1183X Medulloblastoma
(2.3 yrs)
Growth retardation, microcephaly,
hypoplastic thumb
IFAR-849 North
American
3116delA N1039fs 3549C-G Y1183X Neuroblastoma
(0.7 yrs),
AML (2 yrs)
Growth retardation, microcephaly,
VSD, ASD, thumb and radial anomalies,
skin hyperpigmention
AML, acute myelogenous leukemia; IUGR, intrauterine growth retardation; ASD, atrial septal defect, VSD, ventricular septal defect. North American individuals are of
European ancestry.
aNo samples were available from the affected individuals; therefore, the mutations were identified in parental samples. bOrigin relates to mutation 1. cOrigin relates to mutation 2. dThis
individual’s clinical details have been published previously14.
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a) b)
c) d)CONTROLGESH
Supplementary Figure 1. Cellular phenotype of PALB2 deficiency. a) Severe chromosomal
damage in a metaphase from a fibroblast culture of GESH, treated with 50ng/ml MMC for 24
hours (left panel). Breakage rates (breaks per cell) were: GESH, spontaneous 1.58, with 10ng/ml
MMC 5.75, with 50ng/ml MMC >10 (23/25 multiaberrant metaphases); FA means, spontaneous
0.26, 10ng/ml 0.72, 50ng/mls 1.92; normal control means, spontaneous 0.02, 10ng/ml 0.06,
50ng/ml 0.18. The right panel shows 14 chromatid and chromosome breaks, indicated by arrows,
in a lymphocyte metaphase from a blood culture from the same patient, after exposure to
100ng/ml MMC for 24 hours. b) Dose-response curves demonstrate diminished survival of
primary T cells from patient LOAO as opposed to his unaffected sibling (cells are not available
from LOAO to perform this experiment in a complemented cell line). c) No cells with >5 RAD51
nuclear foci were detectable in fibroblasts from GESH after induction by irradiation with 8 Gy,
whereas a control showed a proportion of cells with >5 RAD51 signals (red) per nucleus (blue). d)
The proportion of nuclei with >5 RAD51 foci (black columns) was ~0% in fibroblasts from GESH
and LNEY compared to 16% in control cells and 24% in FA-C cells (grey columns, proportion of
nuclei with <5 foci).
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Supplementary Table 1 
Primers and PCR conditions for PALB2 coding exons 
Exon Primer Sequence 5’-3’ Size(bp) PCR
Forward Reverse 
1 GGATTTAATTGGCCGGAGTT GACACAAAGCCAGGCCTAAA 309 68-50 
2-3 ACCTTTCCACTTGCCCAGTA GGGAAAAAGAACAATAGCCAAA 400 68-50 
4A GCCTGAATGAAATGTCACTGATT GGTGATCTAGCAGGATTTTTGC 495 68-50 
4B CCCTAGTGGTGAGCAAAAGC TTCAAGGTGCTGACTACTACCG 388 68-50 
4C ACCAACTGCCCAACCAGA TGGTTTTCATTTGCTGGTAAG 357 68-50
4D AAGTAAAAGTGGCCAACTGC TTTTTCTTGACATCCAAATGACTC 387 68-50
4E GCAGAAAAACATTCTTGCACA AAGGAAGTGCCAGGCAAATA 600 68-50 
5A GATTGTCTGTTTTGTTGGGTTT GGTCCTCTTCTAAGTCCTCCATT 395 68-50
5B AAAGAGGGAAGCTGTATTTTTCC CTGCCTGAACTGTCGAATTG 398 68-50
5C CACCTGCTTTCCCCATCTTA GGCATTTCATTCCTTCAGAGA 389 68-50
6 AGTGGGTAATGCAGGCAGAC TGACTGAATTCTTTTCAGTTCATT 213 68-50
7 TGCTTTGCATAAAACAGCACT TGGTAAGCTGCCCATCTACA 293 68-50 
8 TGGAAAATCTGGATTAAACAAAAA TGCACTTAAAACCAGCTGACA 221 68-50 
9 ATTAAAAGGTTACTCCTCACATCAC CCCAACTTTCTCTGAAACCTGT 287 68-50 
10 CCTAGAGACTGCTTTAGTGCAAA TTCACAACAACCCTGTAAAATTAG 250 68-50 
11 TTTTCTGAATACTGGTTTGTTGGA CGGGGAAGGTTTGTTCATTA 244 68-50
12 TGCCAGATCTTTATTTTTCCTGA TGTGTTTGCACAGTGCCTTT 281 68-50
13 TGGTTTTGGGAACATGGTTT TTAAGTGTCATTCAGATATTCTCCTTT 400 68-50
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SUPPLEMENTARY METHODS 
Samples and cell lines 
Genomic DNA was obtained from 82 individuals with Fanconi anemia and / or their 
parents with informed consent. These individuals came from several different
clinicians and repositories. All had a clinical diagnosis of Fanconi anemia. This 
diagnosis was confirmed by study of baseline and DEB- or mitomycin C-induced 
chromosomal breakage or cell cycle arrest in PHA-stimulated cultured peripheral
blood lymphocytes as previously described1,2, except in cases that died before suitable
samples could be obtained. In some cases, diagnosis of Fanconi anemia was based on 
fibroblast analysis. None of the cases included in this study were known to be due to 
an existing Fanconi anemia gene. However, the extent to which known genes were 
formally excluded varied, depending on the available samples. Methods used for 
exclusion were sequencing, retroviral complementation group analysis3, and western 
blot analysis for FANCD1 (ref. 4), FANCD2 (ref. 5) and FANCJ6. BRCA2 mutations
had been excluded in all cases by sequencing of all exons and intron/exon boundaries 
in genomic DNA from either the case and/or parents. The 176 samples from normal
individuals were from the 1958 Birth Cohort Collection (see 
http://www.cls.ioe.ac.uk/Cohort/Ncds/mainncds.htm). This research was approved by 
the London Multicentre Research Ethics Committee (05/MRE02/17).
PALB2 sequencing 
Primers were designed to amplify the 13 exons and intron-exon boundaries of PALB2
(Supplementary Table 1). We used a touchdown 68-50qC protocol to amplify all 
products which were sequenced using the BigDyeTerminator Cycle sequencing kit 
and a 3730 automated sequencer (ABI Perkin Elmer). Sequencing traces were 
analysed using Mutation Surveyor software (www.softgenetics.com) and by visual 
inspection.
Analysis of splice site mutations 
To isolate RNA we used the PureLink Micro-to-Midi Total RNA Purification System
(Invitrogen) from which cDNA was prepared using oligo(dT)20 primers and
1
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SuperScriptII (Invitrogen). cDNA was amplified with primers
GAAATCAGAGAGATCAGGAATTTAforward/TAGGGTTAATCACAATGAGCT
GAAACreverse to show exon skipping of 9 and 10 in LOV (father of LOAO) and 
CAGTCTGTCACAAAGCCTATTCTGforward/GAGTCATCCCTGTGCCAAAGrev
erse to show the insertion of 4bps in LNEY. Amplified DNA was sequenced as 
detailed above.
Immunoblotting
PALB2 immunoblots were performed with samples containing 50 μg total protein 
each on 7% NuPage Tris-Acetate polyacrylamide gels (Invitrogen). Membranes were 
probed with polyclonal rabbit anti-PALB2 antiserum raised against the first 120 
amino acids of PALB2 at a concentration of 1:1000 (gift of B Xia). Secondary 
antibody was ECL donkey anti-rabbit IgG horseradish peroxidase-linked whole
antibody (GE Healthcare) at 1:2000. Detection was by the chemiluminescence
technique using the ECL system (Amersham). BRCA2 immunoblots were performed
with samples containing 80 μg total protein each on 3-8% NuPage Tris-Acetate
polyacrylamide gels (Invitrogen). Membranes were probed with polyclonal rabbit
anti-BRCA2 antiserum (Ab-2, Calbiochem), raised against amino acids 3245-3418 of
BRCA2, at a concentration of 1:200. Secondary antibody (1:5000) and detection were
the same as for the PALB2 immunoblots. Immunoblotting for detection of 
monoubiquitinated FANCD2 was performed using previously described methods5.
Transduction and complementation 
For complementation studies, the γ-retroviral vectors pOZC-PALB2 (ref 7) and
pS11EG (expressing GFP) were packaged in PG 13 cells and used for transduction of 
patient and control cell lines. Gene transfer was monitored by CD25 (pOZC-PALB2) 
or GFP (pS11EG) expression. Transduced cells were grown for 48 h in the presence 
of MMC at concentrations of 12 ng/ml (fibroblasts) or 15 ng/ml (LCL). The cells 
were vitally stained with Hoechst 33342 fluorescent dye (Molecular Probes) at 16 
μg/ml. DNA histograms were recorded by flow cytometry.
Lymphocyte survival assay 
Lymphocyte survival was determined using CD3/CD28/IL2-stimulated lymphocytes
(Supplementary Fig 1b). Transduction was with FANC cDNAs and GFP cDNA as a
2
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control, separately cloned into a S11-type γ-retroviral vector as described3. The cells
were exposed to various concentrations of MMC for 5 days. Live/dead cell ratios 
were determined by propidium iodide exclusion/uptake on flow cytometry.
Immunofluoresence
To examine RAD51 foci formation, nuclear foci were induced by ionizing irradiation 
with 8 Gy of fibroblast cultures grown on glass slides. Cells were fixed 8 h later using 
4% paraformaldehyde in PBS (pH 6.8) and permeabilized with 0.1% Triton X-100.
Primary antibody was mouse monoclonal anti-RAD51 (GeneTex) at a dilution of 
1:100. Secondary antibody was Alexa594-conjugated goat anti-mouse IgG (Molecular
Probes) at 1:200. DAPI was used as DNA counterstain. Nuclear foci were counted on
a fluorescence microscope. All slides were evaluated independently by several
investigators.
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FANCI is a second 
monoubiquitinated member 
of the Fanconi anemia pathway
Ashley E Sims1,6, Elizabeth Spiteri2,6, Robert J Sims III1,
Adriana G Arita1, Francis P Lach2, Thomas Landers2,
Melanie Wurm3, Marcel Freund3, Kornelia Neveling4,
Helmut Hanenberg3,5, Arleen D Auerbach2 & Tony T Huang1
Activation of the Fanconi anemia (FA) DNA damage–response 
pathway results in the monoubiquitination of FANCD2, which 
is regulated by the nuclear FA core ubiquitin ligase complex. 
A FANCD2 protein sequence–based homology search facilitated 
the discovery of FANCI, a second monoubiquitinated component 
of the FA pathway. Biallelic mutations in the gene coding for this 
protein were found in cells from four FA patients, including 
an FA-I reference cell line.
FA is a rare chromosome-instability syndrome associated with 
 developmental abnormalities, bone-marrow failure, predisposition to 
cancer and cellular hypersensitivity to DNA cross-linking agents1,2. The 
disorder is genetically heterogeneous, with 13  complementation groups 
currently defined, 12 of which are associated to distinct genes. Eight FA 
proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL 
and FANCM) form a core complex with catalytic ubiquitin E3 ligase 
 activity required for the activation of FANCD2 by  monoubiquitination2–4.
Monoubiquitinated FANCD2 is targeted to BRCA1-containing DNA 
damage and repair sites in chromatin (nuclear foci) to assist in DNA repair, 
along with three other downstream FA members, FANCJ (also called 
BRIP1)5, FANCD1 (BRCA2)6, and FANCN (PALB2)7,8. It is assumed that 
FANCD2  monoubiquitination is the key trigger activating the FA pathway. 
Negative regulation of the FA pathway can be achieved, in part, through 
FANCD2  deubiquitination by USP1 (refs. 9,10). It is unknown whether 
the FA core complex  controls the  monoubiquitination of other protein 
substrates to aid in DNA cross-link repair and genomic maintenance11.
Experiments in chicken DT40 cells have hinted at a FANCD2- independent 
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Figure 1   FANCI monoubiquitination is 
site-specific and DNA damage dependent. 
(a) CLUSTALW (http://align.genome.jp/) 
alignment of the conserved region of FANCD2 
and KIAA1794 (FANCI) identified by the LVI/LRK 
motif (boxed). Black and gray boxes, identical 
and similar amino acids, respectively; asterisk, 
conserved monoubiquitination site; hs, Homo
sapiens; mm, Mus musculus; gg, Gallus gallus;
sp, Strongylocentrotus purpuratus. Amino acid 
positions are indicated. (b) Time course of FANCD2 
and FANCI monoubiquitination (Ub) induced by 
hydroxyurea (HU), UV-C or MMC and analyzed by 
western blotting. (c) HeLa cells were transiently 
transfected with an HA vector or HA-ubiquitin 
construct and treated as indicated. Cell extracts 
were immunoprecipitated with anti-FANCI and 
probed with anti-HA (upper gel) or anti-FANCI 
(lower gel). (d) HeLa cells were transfected with 
HA-tagged wild-type (WT) FANCI or K523R 
mutant and treated as indicated. Cell extracts 
were immunoprecipitated using anti-FANCI and 
probed with anti-HA. (e) FANCI localization to DNA 
damage nuclear foci was examined by indirect 
immunofluorescence using antibodies against 
either FANCI or HA and DAPI counter-staining. 
Representative image of HU-treated HeLa cells 
stained for endogenous FANCI, HA-FANCI WT or 
K523R mutant is shown. (f) Cells were transfected 
with indicated constructs and analyzed as in e.
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 function of the FA core  complex12. The only FA complementation group 
that has not been assigned to a gene is FA-I or FANCI. Cells of FA-I patients 
 presumably have an intact FA core  complex but are known to be  defective 
in FANCD2  monoubiquitination13.
To identify novel substrates of the FA core complex, we began with a 
protein BLAST search (which detects short, nearly exact matches) for gene 
products that have sequence homology to the highly  conserved human 
FANCD2 monoubiquitination site, LVIRK. Although this search method 
originally yielded a large number of putative targets, we reduced this list to 
several dozen human proteins on the basis of  protein domain architecture 
and putative function (Supplementary Fig. 1 online),  placing emphasis on 
chromatin- associated factors and  proteins implicated in ubiquitin-related 
 activities. We used a ‘back search’ to determine whether any of the  proteins 
have  additional  homology to FANCD2 extending beyond the LVIRK 
motif. Notably, only one  protein, KIAA1794, has  substantial homology 
to FANCD2. KIAA1794 is a  previously  uncharacterized  protein of 1,328 
amino acid residues with a predicted molecular weight of ~140 kDa. 
Comparison between the two proteins in the region  surrounding the 
FANCD2  monoubiquitination site shows approximately 40% sequence 
 similarity (Fig. 1a), but the  remainder of the primary amino acid sequences 
show little  similarity (Supplementary Fig. 2 online). In this study, we 
 identified biallelic  mutations in the KIAA1794 gene in an FA-I  reference 
cell line (see below). Thus, we will refer to KIAA1794 as FANCI.
To test whether FANCI is a DNA damage–responsive protein that 
functions similarly to FANCD2, we measured FANCI protein levels in 
cells after treatment with various DNA-damaging agents. A more slowly 
migrating species of FANCI appeared in a time-dependent  manner, 
 mimicking the DNA damage–inducible  monoubiquitination of FANCD2 
(Fig. 1b). To determine whether the more slowly  migrating band is a 
monoubiquitinated form of FANCI, we  transfected  hemagglutinin 
(HA)-tagged ubiquitin into HeLa cells. After FANCI  immunoprecipitation, 
we observed that the upper FANCI band reacted with anti-HA, indicating 
that it is indeed monoubiquitinated (Fig. 1c). To determine whether the 
conserved Lys523 of FANCI (Fig. 1a) is crucial for its  monoubiquitination, 
HA-tagged wild-type FANCI or a K523R mutant was transiently expressed 
in HeLa cells and exposed to DNA damage. HA-FANCI was modified 
in wild-type but not K523R mutant– expressing cells, suggesting that 
the ubiquitin modification of FANCI occurs on a specific lysine residue 
(Fig. 1d). Monoubiquitination of FANCD2 is required for its localization 
to DNA damage and repair nuclear foci. Upon DNA damage, FANCI 
also formed nuclear foci and resided with FANCD2 and phosphorylated 
histone H2A.X (Fig. 1e and data not shown). The  monoubiquitination 
of FANCI was crucial for its recruitment to nuclear foci (Fig. 1f). Thus, 
our data suggests that, like FANCD2, FANCI is  activated by site- specific 
monoubiquitination upon DNA damage, which then enables it to localize 
to DNA damage nuclear foci.
To determine whether FANCI monoubiquitination is also 
 regulated by the FA core complex, we examined patient-derived cell 
lines that were  deficient in FA core complex components for FANCI 
 monoubiquitination14. We found that in FANCA- and FANCG- deficient 
cell lines, FANCI monoubiquitination was  completely  abrogated, 
whereas FANCI ubiquitination was restored in  complemented cells 
containing an intact FA core  complex (Fig. 2a). This suggests that the 
FA core complex is the  ubiquitin ligase that  activates FANCI upon DNA 
 damage. Notably, the  monoubiquitination of FANCI also depends on the 
 presence of the FANCD2 protein and its ability to be  monoubiquitinated 
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Figure 2  Activation of FANCI is regulated by both the FA core complex 
and FANCD2 monoubiquitination. (a) FANCA- or FANCG-deficient (FA-A and 
FA-G, respectively) and functionally complemented human fibroblasts were 
analyzed for damage-induced monoubiquitination of either FANCD2 (lower 
gels) or FANCI (upper gels). Cells were treated with HU (2 mM, 24 h). 
(b) FANCD2-deficient (FA-D2) human fibroblast cell line (PD20) stably 
expressing vector control, wild-type FANCD2 or the FANCD2 K561R mutant14 was examined for monoubiquitination of FANCI (as in a). (c) HeLa cells were 
transfected with siRNAs targeting the indicated genes, treated with HU (2 mM, 24 h) and probed for FANCI (upper gel) or FANCD2 (lower gel). (d) HeLa 
cells were transfected with indicated siRNAs and treated with HU (2 mM, 18 h). Monoubiquitination of both FANCI and FANCD2 was analyzed by western 
blotting. (e) HeLa cells were fractionated into cytoplasm (S100), nuclear extract (NE) and nuclear pellet (NP). NP was further biochemically fractionated, 
immunoprecipitated using anti-FANCI or control IgG, and western blotted with anti-FANCI (lower gel) or anti-FANCD2 (upper gel). (f) HeLa cells were treated with 
siRNA against FANCI or Ctrl sequence and stimulated with HU (18 h) before paraformaldehyde fixation. FANCD2 and BRCA1 proteins were detected by indirect
immunofluorescence using antibodies against FANCD2 and BRCA1. Nuclear foci were quantified (error bars show s.d. from three independent experiments).
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(Fig. 2b). As expected, restoring wild-type FANCD2 to the FANCD2-
deficient cells rescued FANCI  monoubiquitination. This effect was 
also reproduced in HeLa cells subjected to small interfering RNA 
(siRNA)-mediated FANCD2 knockdown (Fig. 2c). FANCI protein  levels 
were screened in patient lymphoblastoid cell lines (LCLs)  harboring 
diverse FANCD2  hypomorphic mutations, from the International Fanconi 
Anemia Registry15. In agreement with the cell-line data above,  various 
FANCD2-mutant patient cells  containing low  levels of FANCD2 were also 
devoid of FANCI  monoubiquitination (Supplementary Fig. 3 online). 
Therefore, cells expressing FANCD2 at low levels are probably linked to 
a  secondary defect in FANCI  activation. We also found that inhibition 
of USP1 by siRNA increased FANCI  monoubiquitination in the absence 
of the DNA  damage  treatment (Fig. 2d). These results provide evidence 
that DNA  damage–induced activation of FANCI can be regulated, in 
part, through the actions of the FA core ubiquitin ligase complex and the 
 deubiquitinating enzyme USP1.
The knockdown of FANCI by siRNAs targeting various sequences 
(siFANCI-1 through siFANCI-4; see Supplementary Methods online) 
inhibited DNA damage–induced monoubiquitination of FANCD2 and 
also reduced its protein level (Fig. 2c,d). The reduction of FANCD2 
 protein stability via FANCI knockdown could be a consequence of the 
association of these two factors in a stable protein complex. We found that 
the majority of monoubiquitinated FANCI is located in the  chromatin-
enriched nuclear-pellet fraction of asynchronous growing cells (Fig. 2e). 
We partially purified FANCD2 and FANCI from HeLa cell nuclear  pellets 
(Fig. 2e). Coeluting fractions containing FANCD2 and FANCI were tested 
for physical association by coimmunoprecipitation. These experiments 
identified a weak, but specific, interaction between FANCD2 and FANCI 
(Fig. 2e). A comparable interaction between FANCD2 and FANCI was 
observed using HeLa nuclear extracts (data not shown). It remains unclear 
whether the effect of FANCI  knockdown on FANCD2 protein stability is 
due to the loss of FANCI interaction with FANCD2. We are also  currently 
exploring the possibilities of  transcriptional or post- transcriptional 
 regulation of FANCD2  stability by FANCI.
Notably, the DNA damage–induced  formation of FANCD2 nuclear foci 
was also greatly reduced upon FANCI siRNA treatment,  suggesting a direct 
role of FANCI in  promoting efficient monoubiquitination of FANCD2 
or stabilization and recruitment of FANCD2 to proper DNA repair sites 
(Fig. 2f). Inhibition of FANCI by siRNA did not have a  general effect 
on nuclear foci formation of other DNA-repair proteins, as BRCA1 
 localization to dot  structures was unaffected (Fig. 2f).
It was recently demonstrated that FANCD2 functions in DNA repair 
by promoting homologous recombination (HR)16. To assess the role of 
FANCI in HR and double-strand break repair, we used an  engineered 
U20S cell line carrying a single, stably  integrated copy of a DR–green 
fluorescent protein (GFP) HR reporter16,17. These cells were  transfected 
with siRNAs against FANCD2, KIAA1794 or BRCA1, and their  ability to 
 perform HR repair (gene conversion) was tested. The  percentage of GFP-
positive cells was reduced in BRCA1-, FANCD2- and FANCI- knockdown 
cells compared with the  control-siRNA  samples, suggesting that FANCI 
may have a role in DNA repair (Fig. 3a). We next tested whether FANCI 
siRNA–treated cells were sensitive to the DNA cross-linking agent mito-
mycin C (MMC). Like FANCD2-knockdown cells, cells depleted of FANCI 
were sensitized to MMC at various doses (Fig. 3b). Together, these results 
suggest that FANCI behaves as a functional homolog of FANCD2 in the 
 coordination and repair of DNA cross-links.
We sequenced all of the exons and intron-exon boundaries of FANCI
and its  corresponding complementary DNAs from individuals with FA 
that were not defective for any of the known FA genes and narrowed 
the mutation search to patients whose cells have defective FANCD2 
 monoubiquitination (see Supplementary Tables 1 and 2 online). From 
this set, we identified four FA patients with biallelic mutations in the 
FANCI gene (Fig. 3c,d). We also sequenced FANCI in 100 control alleles 
(50  normal individuals) and did not find these  particular missense or 
nonsense mutations,  providing further evidence that such  mutations 
are probably  pathogenic in the individuals with FA. One of the 
 individuals (EUFA592) belonged to the  previously  uncharacterized 
FA-I  complementation group13. This enabled us to directly link the gene 
 product of KIAA1794 to the elusive FANCI protein. Our data are in 
 agreement with recently published work on FANCI18.
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Figure 3  Biallelic mutations in KIAA1794 found in FA-I reference line and 
other unknown FA cells. (a) DR-U2OS cells were treated with the indicated 
siRNAs for 48 h and then transfected with an I-SceI expression plasmid 
(pCBASce) to induce double-strand breaks, as described16. GFP-expressing 
cells were analyzed by flow cytometry as described in Supplementary
Methods. Error bars show s.d. from three independent experiments. 
(b) HeLa cells were exposed to the indicated siRNAs for 48 h and treated 
with MMC at indicated doses for 96 h. Cytotoxicity levels are plotted as 
averages from three independent experiments; error bars show s.d. 
(c) FANCI mutations in both alleles of individuals with FA. fsX# denotes 
a frameshift mutation, were X# indicates at which codon position the 
new reading frame ends in a stop (X). Clinical features of FA-I patients 
are described in Supplementary Fig. 4. (d) Schematic representation 
of the FANCI protein, highlighting positions of mutations in different 
alleles. (e) Whole-cell extracts were prepared from exponentially growing 
lymphoblastoid cell lines from normal and FA-I individuals and analyzed for 
FANCI (upper gels) and FANCD2 (lower gels) protein levels as in Figure 1b.
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The FANCI reference line EUFA592 was found to contain a T→C
 transition in FANCI that alters the first methionine codon of the FANCI 
coding sequence. The predicted outcome of this mutation is a new 
start codon at Met94. Sequencing also confirmed the presence of this 
 mutation in both alleles (Supplementary Fig. 4 online). Homozygosity 
at the  disease locus probably comes from a consanguineous family. 
We detected a  truncated FANCI protein in LCLs from this individual, 
which roughly corresponds to a loss of the N-terminal 93 amino acid 
 residues of FANCI owing to the new start site (Fig. 3e). We also  identified 
 truncating mutations in FANCI from a second individual (F010191), 
who  previously had been found not to have mutations in any known FA 
gene. In this  heterozygous patient, we saw an amino acid change of R614X 
(where X denotes a stop codon) in one allele and R1299X in the other 
(Supplementary Fig. 4). The R1299X mutation predicts a shorter form 
of the FANCI protein, which was detected in the F010191 LCLs (Fig. 3e). 
However, we were unable to detect any protein product from the other 
mutant allele. This may be due to nonsense-mediated RNA decay or to 
the instability of the truncated protein product.
Of note, the last 30 residues of FANCI constitutes a putative EDGE 
motif19, which would be deleted in FANCI encoded by the R1299X 
mutant allele (Supplementary Fig. 2). The EDGE motif is defined by the 
EDGE sequence, originally characterized in a splice variant of FANCD2 
containing exon 44 (FANCD2-44)19. FANCD2-deficient cells  expressing 
FANCD2-44 are capable of restoring FANCD2  monoubiquitination 
and correcting the MMC sensitivity. Another splice variant containing 
exon 43 (FANCD2-43) differs only in the C-terminal 24 residues and 
does not contain the EDGE motif. FANCD2-43 is still capable of rescuing 
 monoubiquitination but cannot correct for the MMC sensitivity19. This 
implies that the EDGE motif may be crucial in DNA damage sensing or 
DNA repair for both FANCD2 and FANCI. Notably, the F010191 cells were 
defective for both FANCD2 and FANCI  monoubiquitination,  suggesting 
that the extreme C-terminal region of FANCI may be  especially important 
for activation of the FA pathway. However, it is unlikely that the EDGE 
motif of FANCI is required for FANCD2  protein stability, as the level of 
FANCD2 in F010191 cells was comparable to that in the normal LCL 
control (Fig. 3e). It is also likely that FANCI has a monoubiquitination-
independent role in DNA repair, such as in the regulation of FANCD2 
protein stability. In agreement with this, we have yet to observe complete 
loss-of-function mutations in FANCI from any FA-I individual. All of the 
patients identified as mutated in FANCI express some FANCI protein, as 
detected with our antibodies (Fig. 3e). We predict that null mutations of 
FANCI may be lethal in humans. Key questions regarding how DNA  cross-
links are directly sensed and relayed to the downstream components of the 
FA pathway will undoubtedly be facilitated by the identification of FANCI 
and its potential role as a functional counterpart to FANCD2.
Accesssion codes. GenBank: FANCI, EF567077.
Note: Supplementary information is available on the Nature Structural & Molecular 
Biology website.
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Supplementary Fig. 2
Protein sequence alignment of human FANCI and FANCD2.  Exact and similar sequences are
highlighted with dark or light colors, respectively.   Asterisks denote semiconserved EDGE motif
in both FANCI and FANCD2.
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Supplementary Fig. 3
Determining the monoubiquitination status of FANCI in FA patients with low FANCD2 protein levels.
Individuals from IFAR harboring known FANCD2 mutations were analyzed for FANCD2 protein 
expression (lower panel) and FANCI monoubiquitination (upper panel).  Whole-cell extracts from 
exponentially growing lymphoblastoid cell lines (LCLs) from patients were used in this study.
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Mutation detection in genomic and cDNA sequences and Clinical features of  FA-I patient-derived cells
Supplementary Fig. 4
Sequence traces for patients F010191 and EUFA592.  Genomic DNA and transcripts represented in cDNA
 isolated from F010191 (A and B) and EUFA592 (C) were amplified by PCR and sequenced.  
The heterozygous mutations c.1840C>T and c.3895C>T identified in F010191 and the
 homozygous mutation c.2T>C identified in EUFA592 are indicated by arrows and found in both 
genomic and expressed transcripts. The location of an SNP in F010191 exon 37 is indicated by and asterisk.
Clinical features of FA-I patients are :  (F01019 )Growth retardation and microophthalmia, thumb and radial
aplasia, hearing loss, anemia at 1 year of age, transfusion dependent, alive at 31 years of age .  (F010095) 
Growth retardation and microophthalmia, multiple congenital malformations including thumb, kidney,
 hearing loss, BM failure at age 6 years, died at age 21 during HCT.  (IFAR663)  Growth retardation and 
microophthalmia, multiple congenital malformations including thumb, kidney, heart, brain, hearing loss, 
HCT at age 6 years, currently alive at age 10 years. 
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FANCI Genomic primers 5'> 3'
FANCI ex1-F CTCCCTCAACAGGACAGGAG 
FANCI ex1-R TCCACGCCAGAGAAAATACC 
FANCI ex2-F TTCCAGGGAATTTTCAGGATT 
FANCI ex2-R GGTCACAAATGCCCTCAAGT 
FANCI ex3-F GGTGTTTGTAATACTTGGCGTCT 
FANCI ex3-R CAGCAACGCAATCTCAGGTA 
FANCI ex4-F TCAAAGCCCTTAACCATTGC 
FANCI ex4-R ATGTTGCAGAGGGTGGTCTC 
FANCIex5-F CATCAGGGAACCGATACAGG 
FANCI ex5-R TTTTCCGCCACTTGTATTCC 
FANCI ex6-F CACCATTTTCCAGGACCATT 
FANCI ex6-R TTTTCCGCCACTTGTATTCC 
FANCI ex7-F TTTGCGAGTCGGGTAGGTTA 
FANCI ex7-R AAGGAGGCAGGAGTGAGGA 
FANCI ex8-F TTCTCTGCTCCCAAGTTTCA 
FANCI ex8-R TGCATGTTTTCCTTGGATGA 
FANCI ex9-F TGCGGAGGTAAAAGGGATAA 
FANCI ex9-R TTCCTGGAAAGGTGAAAATG 
FANCI ex10-F ACCACATCGGGCTGATTTT 
FANCI ex10-R GGCTTGCTTAAGGATGTGGT
FANCI ex11-F GTTGAGCCTGGGAAATCAAG 
FANCI ex11-R TCCATCAATCCCCAGAGAAC
FANCI ex12-F TGTGAATGGCAGCTCATAGG 
FANCI ex12-R AGGGCCTGAGATTCAAGGAT 
FANCI ex13-F GAGACCACTTGCCTGCTGTT 
FANCI ex13-R CGTAAGTAAGTATTCCATCAAACTGG 
FANCI ex14-F AAGCACAGAACAAGGGGAAA 
FANCI ex14-R TTGACAACTGACAATCCCAGA 
FANCI ex15-F TCGGTTTCTTCCTTTCTTTTAGG 
FANCI ex15-R TGCTCTTGCCCTTTTAATGC 
FANCI ex16-F GAGGCATTTGCAACCAGTTT 
FANCI ex16-R CTCTGCGGGGCTAGGAAT 
FANCI ex17-F TTTGTTTTGCTCTACGCTTCA 
FANCI ex17-R CACTGAGGACAGTGGCTACC 
FANCI ex18-F TGTCAAGGAAACCTTAAGGAATATG 
FANCI ex18-R TGCCCTGCCTTAAACAACTT 
FANCI ex19-F GACATTTTGGGTGGGAAAAA 
FANCI ex19-R ACCCACAGCATGTTCACAAA 
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FANCI ex20-F TTGGCTGCATTGTTCTTTGA 
FANCI ex20-R GGAAGTGATGGAAGCCTTGA 
FANCI ex21-F GGGGGAAGCATTAGAAAAGG 
FANCI ex21-R CCCATCACAAGAAAAGCACA 
FANCI ex22-F TACAGCAGGGAGAGGAGGAA 
FANCI ex22-R TCAGGGTCTGGGAAATTCTG 
FANCI ex23-F GATTGCTGTGACCTGGGAGT 
FANCI ex23-R CCTGCTGGAATTCATCCCTA 
FANCI ex24-F GAGAGTCTGCCAGTCGGAAC 
FANCI ex24-R CTGCCACCTGGCTAATGTTT 
FANCI ex25-F CTTGGAAATGGGAGGAGAGA 
FANCI ex25-R CAGCCACTCTTTGTGGTTGA 
FANCI ex26-F AGAGTGGCTGGAAAATGGAA 
FANCI ex26-R TGTTGCCTGTATGACCCAGA 
FANCI ex27-F GGTTGGAACGGAAAGAGTCA 
FANCI ex27-R CCCTGTATGGCTGCATGTAA 
FANCI ex28-F CCCTAAAACTTTTGGACCTCA 
FANCI ex28-R ACCCCCAGTGAATGAAAGGT 
FANCI ex29-F TGGTGAGGCTGGTCTTGAAT 
FANCI ex29-R TATTCCCCATGGCTCAGGTA
FANCI ex30-F CATTCTGCTGCGTGACTTGT 
FANCI ex30-R AGAACCTTCTCGGCCTGACT 
FANCI ex31-F TCCTATAGCGGCTTGTGTCC 
FANCI ex31-R TCAGGGGCTCCATTTTTATG 
FANCI ex32-F CATAAAAATGGAGCCCCTGA 
FANCI ex32-R AAACCATGACCTGCCAAGAT 
FANCI ex33+34-F GGGAAGCTTAGGAGCTTTGG 
FANCI ex33+34-R CTTGGCTTGGTCTCTGATGG 
FANCI ex35-F GGTTACAGTGGGTCGACATC 
FANCI ex35-R CAACCCACCTAGCTCTACGC 
FANCI ex36-F TACTGGCATTTGGGTCCTTC 
FANCI ex36-R AGGCCAGAGGATCACTTGAA 
FANCI ex37-F CACACTCAGCCTCTTTGCTG 
FANCI ex37-R TGCCTGATCACCTTTTAGCC 
FANCI ex38 a-F GAAAGTGGGGAAAGCATGAC 
FANCI ex38a-R CAGGTGAAGCGCTGGATATT 
FANCI ex38b-F AAGGAATCTTCTTGGCAGGTC 
FANCI ex38b-F GCCCCAGAGAATCCACTCTT 
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KIAA1794 cDNA primers 5'> 3'
cDNA
-1F GGCTTTTTGGAAGTTTGTGG 
cDNA-1R ATGGTCCTGGAAAATGGTGA 
cDNA-2F TCATAGGATTACTGATGCTGGAG 
cDNA-2R GAGGAGAGAACCAGAAGCTGA 
cDNA-3F TCTTCAAGAAATACCACCTTTGG 
cDNA-3R AAAGCTCTTTACAACCGAAGTCT 
cDNA-4F CAGGACCAGGTGCTTGATCT 
cDNA-4R TGGGAGAAGATGCTCTGGTAA 
cDNA-5F TGGAGCAGGTCCTCAACAG 
cDNA-5R GGCTGTGAACATCCACATGA 
cDNA-6F GGTTTTTGCTGCTCCTGAAG 
cDNA-6R TTCGTAGAATGCCTCTTCCTC 
cDNA-7F AACCACTGGATTATCTGCTGTG 
cDNA-7R GAAAAGAGCAGTGAGAAGACTGG 
cDNA-8F GATAGTCTTTTGTCCATGAAATTTGT 
cDNA-8R CTTGGACAAACTGGTAAGAACC 
cDNA-9F GGCAATTTCAGAGGTCCTTGT 
cDNA-9R TGGTAGGGTTGCCTGAGAAG 
cDNA-10F AGGGACAAGTGAGCCAAGAA 
cDNA-10R TGGCAAAGATGAGGTTAGGG 
cDNA-11F GCCAGAGTTCTTCGGGAAAC 
cDNA-11R GCCAGCCATTTTTCAGTAGC 
cDNA-12F TACCCAACAAGCAACAATGC 
cDNA-12R TTGCACTCTATAGGTGACAGAAAA 
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Supplementary Methods
Cell culture and transfection. HeLa, U20S (ATCC), and Fanconi anemia patient-
derived lines PD20, PD316, and GM6914 cells (Coriell Cell Repository) were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 15% fetal bovine
serum (FBS), glutamine, and antibiotics. All lymphoblastoid cell lines (LCLs) derived
from the affected patients were established according to standard procedures (1). LCLs
were maintained in RPMI 1640 medium supplemented with 20% FBS, glutamine, and
antibiotics. All cells were grown at 37°C in a humidified incubator containing 5% CO2.
SiRNA transfections were done using HiPerfect (Qiagen) and plasmid transfections were
done using Fugene6 (Roche) according to the manufacturer’s protocol.
Antibodies, Western Blotting and Immunofluorescence Staining. Anti-KIAA1794
antibodies were purchased from Abcam (ab15344 and ab15346). Anti-FANCD2, -
BRCA1 and PCNA antibodies were purchased from Santa Cruz Biotech (sc-56, sc-6954
and sc-20022, respectively). Monoclonal anti-HA (HA.11) was purchased from
Covance. Anti-tubulin was purchased from Sigma. Anti-GFP antibody (JL-8) was
obtained from BD Biosciences.. Immunostaining was performed as described (2), using
paraformaldehyde fixation. When necessary, cells were pre-extracted with PBS
containing 0.5% Triton X-100 for 5 min at room temperature. Briefly, untransfected or
transfected cells were split into 4-well chamber slides for foci analysis.
Immunoprecipitations were performed in RIPA buffer with specific antibodies and
protein G beads and incubated at 4°C overnight with gentle rotation. Western blots were
performed with whole-cell extracts and separated on Nupage 3-12% Tris-Acetate or 4-
12% Bis-Tris gradient gels (Invitrogen). Solubilization and partial fractionation of HeLa
nuclear pellets were performed as described in (3).
Plasmids and siRNAs. Full-length human KIAA1794 (FANCI) cDNA was purchased
from Origene and verified by sequencing (SeqWright). GenBank accession number for
FANCI is EF567077. KIAA1794 cDNA was subcloned into the pIRESpuro3 vector
(Clontech) that was modified to contain a 5’ sequence coding for 2X HA-epitope tag.
The point mutation K523R was generated by two-step PCR mutagenesis from the
original KIAA1794 template and verified by DNA sequencing (SeqWright). The siRNAs
were synthesized by Qiagen: KIAA1794 (FANCI)-1
(CTGGCTAATCACCAAGCTTAA), KIAA1794-2
(TTGAATTTACTTAGCAGTCAA), KIAA1794-3
(CACGGGCATCTGGGAGATATA), KIAA1794-4
(TACGAAGACCTAGATGATATA), AllStars Neg. Control siRNA, FANCA
(AAGGGTCAAGAGGGAAAAATA), FANCD2 (AACAGCCATGGATACACTTGA),
and USP1 (TCGGCAATACTTGCTATCTTA)
Homologous Recombination Assay. To test the effect of siRNA knockdown in gene
conversion-type DNA repair, DR-U2OS reporter cells (4) were first transfected with
indicated siRNAs in 6-well plates at low density. 48 hours later, cells were again
transfected with I-SceI expression plasmid (pCBASce, 1 microgram per well). 48 hours
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after the second transfection, cells were trypsinized and single cell suspensions were
analyzed by flow cytometry in a Becton Dickinson FACScan.
Mitomycin C (MMC) sensitivity assay. HeLa cells were seeded at 1000 cells per well
in 96-well plates. Eight hours later, cells were treated with MMC (Sigma) at the desired
final concentrations. Cell were incubated with the drug for 96 hours and their survival
rates were measured using a CellTiter Glo kit (Promega) following the manufacturer’s
instructions.
Subjects and cell lines. Cell lines and genomic DNA samples were derived by standard
methods from FA patients registered in the IFAR after obtaining informed written
consent. The studies were approved by the Institutional Review Board of The
Rockefeller University. MMC sensitivity was performed by cell cycle analysis of
phytohemagglutinin (PHA)-stimulated peripheral blood T cells or of skin derived
fibroblast cells according to (5).The diagnosis of FA was made by study of DEB-induced
chromosomal breakage in PHA-stimulated cultured peripheral blood lymphocytes (PBLs)
as described (6). Complementation studies with retroviral vectors containing normal
FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG and FANCL cDNAs
were as described (7). Immunoblotting for detection of monoubiquitinated FANCD2 was
also performed as described (8). FA-M (9) and FAAP100 (10) were ruled out by
immunoblotting for those proteins. Laboratory diagnosis of F010095 and F010191 were
also done by spontaneous and MMC-induced G2-phase cell cycle arrest in PBLs.
Isolation of cDNA. RNA was extracted from cells using the RNAqueous Midi kit
(Ambion, Austin Texas) following manufacturers directions. RNA was transcribed to
cDNA using the Cells-to-cDNA II kit (Ambion) following manufacturers directions.
PCR primers and conditions. KIAA1794 exons were amplified from genomic DNA
with the conditions: 94 degrees for 5 minutes, 34 cycles of 94 degrees for 30 seconds, 58
degrees for 30 seconds, and 72 degrees for 30 seconds, followed by one cycle of 72
degrees for five minutes. cDNA was amplified with the same conditions for 40 cycles.
Primer sequences are listed in Supplementary table 1 (genomic) and 2 (cDNA).
Sequencing. Direct genomic and cDNA sequencing was performed for
FANCA/B/C/D2/E/F/G/J according to standard protocols. PCR products were cleaned
using ExoSAP-IT (USB, Cleveland, OH) according to manufacturer’s protocol. Most of
the sequencing was performed by Genewiz Inc. (North Brunswick, NJ) with Big Dye
Terminator v3.1 Cycle Sequencing Ready Reaction kits (Applied Biosystems, Forester
City, CA) on a 3730xl DNA analyzer. Sequence data was generated by means of
Sequencing Analysis v.5.1 (Applied Biosystems, Forest City, CA) and analyzed with
Lasergene (DNASTAR inc., Madison, Wisconsin).
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Fanconi anemia is a disease which is very heterogeneous regarding the clinical and cellular 
phenotypes of the patients but also with respect to the different genes and proteins of the FA/
BRCA pathway. The only common ground is that all these FA/BRCA genes belong to a group 
of so called “caretaker” genes. Unlike gatekeeper genes, caretakers do not regulate directly cell 
proliferation but have the task to defend the integrity of the genome (Levitt and Hickson, 2002). 
The integrity of the genome is threatened by various kinds of DNA damage from endogenous 
and exogenous sources. DNA-damaging agents include chemicals, ionizing radiation, collapsed 
replication forks or reactive oxygen species. The resulting DNA-lesions involve loss of purines and 
pyrimidines, single strand breaks, double strand breaks, or crosslinks. Under the conditions of body 
temperature of 37 degrees and unavoidable ROS generation due to oxidative phosphorylation, 
these different types of DNA alterations can amount to several thousand lesions per cell per day. 
Therefore, an intact DNA repair machinery which includes a variety of caretaker genes, is one 
of the most important defense- and longevity assurance systems. Mutations in caretaker genes 
can have devastating effects. In the case of DNA damage, a decision must be taken whether to 
repair the damage or to channel the damaged cell into apoptosis. Mutational inactivation of DNA 
caretaker genes automatically leads to severe impairment of this complicated defense system. 
Loss of the ability to repair DNA damage can result in genomic instability and in the accumulation 
of mutations, which in turn often results in cancer development. This chain of events implies a 
close connection between DNA damage, DNA repair, genetic instability and tumorigenesis.
3.1 The FA/BRCA pathway and DNA repair
One recently described group of important caretaker genes consists of genes belonging to the 
FA/BRCA pathway. This pathway is activated in response to DNA damage and regulates in 
particular the repair of DNA interstrand crosslinks (ICLs). In bacteria, ICL repair is mediated 
by a combination of nucleotide excision repair (NER) and homologous recombination (HR) 
(Dronkert and Kanaar, 2001). Eukaryotes use at least the three different repair mechanisms: 
NER, translesion synthesis (TLS) and homologous recombination (HR). The current notion is 
that an ICL which is produced for example by one of the crosslinking agents MMC, DEB, or 
cisplatin, might be recognized by the inability of the replication fork to progress beyond the DNA 
lesion. Stalled replication forks are thought to activate the ataxia-telangiectasia and Rad3-related 
protein (ATR) and its downstream target CHK1. In turn, these “sensor” proteins phosphorylate, 
and thereby activate the FA core complex and the ID complex. The FA core complex consists 
of at least four subcomplexes. The fi rst subcomplex, established in the cytoplasm, comprises 
FANCB, FAAP100 and the catalytic E3 ligase subunit FANCL. The second subcomplex is also 
located in the cytoplasm and consists of heterodimeric FANCA and FANCG proteins. Nuclear 
transport of these two subcomplexes probably is independent, but nuclear accumulation appears 
to be mediated by FANCA. In the nucleus, both subcomplexes form a complex around FANCM 
and are joined by another subcomplex consisting of FANCC and FANCE. FANCF serves as 
an adaptor protein, presumably linking and stabilizing the respective subcomplexes. After 
complete assembly, the FA core complex is recruited to the site of DNA damage by FANCM 
and its interacting partner FAAP24, where it subsequently monoubiquitinates the phosphorylated 
proteins FANCI and FANCD2 which form the ID complex (Medhurst et al., 2006; Wang, 2007). 
E1 and E2 ligase function of the ubiquitin ligase are provided by an ubiquitin-activating enzyme 
(E1) and a conjugating enzyme (E2). The latter was recently identifi ed as UBE2T (Machida et al., 
2006). Other substrates phosphorylated by ATR are H2AX, BRCA1 and BRCA2, which are also 
recruited to the ICL. At the site of DNA damage, one of the fi rst steps of DNA repair is the incision 
of the DNA on both sides of the crosslink. This fi rst step is regulated by proteins belonging to the 
NER machinery. In the case of a TMP crosslink, for example, incisions are made at the fourth 
phosphodiester bond 3’ to the adducted thymine and at the sixth phosphodiester bond 5’ to the 
modifi ed nucleotide. Both incisions are made by the Xeroderma pigmentosum endonuclease 
XPF whose activity might be modulated by its heterodimer-partner ERCC1 (Kumaresan et al., 
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2007). The enzymatic cleavage of DNA at both sides of the ICL is followed by “unhooking” of 
the crosslink and translesion synthesis (TLS). TLS is an error-prone DNA repair mechanism 
that permits to bypass the gap in damaged DNA. In analogy to monoubiquitinated PCNA, 
monoubiquitinated ID complex might recruit translesion polymerases to the site of DNA damage. 
Thereby the monoubiquitinated ID complex would release the replicative polymerase POLδ and 
load the translesion polymerases REV1 and REV3 (Wang, 2007). Both, monoubiquitinated PCNA 
and the monoubiquitinated ID complex are de-ubiquitinated by the ubiquitin specifi c protease 
USP1 (Nijman et al., 2005). A second set of incisions is thought to be necessary for removing 
the unhooked ICL, and this step might also include XPF. As a consequence of DNA incisions and 
unhooking, a DNA double strand break (DSB) is produced. Repair of this DSB is mediated by 
homologous recombination (HR). Phosphorylation of H2AX, BRCA1 and BRCA2 by ATR might 
trigger the recruitment of these and other DNA repair proteins like RAD51 to the site of the DSB. 
BRCA2 and its partner PALB2 can promote homologous recombination and the 5’-3’ helicase 
BRIP1/FANCJ might promote translesion bypass (Niedernhofer et al., 2005;  Wang, 2007) to 
enable restart of the blocked replication fork. The exact role of the individual FA proteins in this 
complex series of events leading to DNA repair has long been elusive, but recent data suggest 
that FA defi cient cells have a defect in unhooking the ICL via XPF (Kumaresan et al., 2007). It 
is conceivable that the FA core complex is involved in this early step of ICL repair, and that the 
other FA proteins act in the recruitment of translesion polymerases and other DNA repair proteins 
(ID complex). They may also be directly (BRCA2, PALB2) or indirectly (FANCJ) involved in the 
execution of DNA repair. This notion would fi t with the observation of differences between the 
upstream and the downstream FA proteins, and also explain in part phenotypes of FA patients 
belonging to different FA subgroups. 
The FA/BRCA network of proteins is not only involved in the resolution of ICLs via NER, TLS and 
HR repair, but is also linked closely to proteins responsible for other diseases that are similar 
to FA, sharing with FA the features of genomic instability and cancer. For example, the FA core 
complex was initially identifi ed as part of a larger subcomplex called BRAFT complex (Meetei et 
al., 2003b). The BRAFT complex is composed from at least 17 different proteins, including all FA 
core complex proteins, FAAP100, FAAP24, BLM, Topoisomerase IIIα, BLAP75, RPA70, RPA34, 
RPA14 and BLAP250 (Wang, 2007). The presence of the BLM helicase and BLM associated 
proteins (BLAPs) suggests a close connection between FA and Bloom syndrome. Indeed, these 
syndromes show some clinical overlap, although they have strikingly different cellular phenotypes. 
For example, SCE (sister chromatid exchange) levels are high in Bloom Syndrome but low in 
FA. Conversely, MMC sensitivity is high in FA but low in Bloom Syndrome. There is, however, 
a closely related function in DNA repair, since the BLM complex stabilizes stalled replication 
fork and facilitates a HR dependent processs to restart stalled replication forks. Other proteins 
closely related to the FA/BRCA pathway are proteins like ATR, CHK1, RPA, ATRIP, NBS1, MRE11, 
RAD50, or HCLK2. These proteins are involved in the activation of the FA core complex or the 
ID complex via phosphorylation events. The downstream FA proteins such as FANCD1, FANCN 
and FANCJ work also in close contact to other DNA repair proteins. This is very obvious by the 
direct interaction of BRCA2 and the recombinase RAD51, one of the key players in homologous 
recombination. Most recently, an interaction between FANCJ and proteins of the mismatch repair 
pathways was described (Peng et al., 2007). FANCJ appears to interact directly with MLH1 through 
its helicase domain. This interaction is BRCA1 independent, but appears to be necessary for ICL 
induced cellular response to DNA repair. These recent observations link the FA/BRCA network 
of proteins to mismatch repair (MMR). This is a very important observation, since it shows that 
DNA repair is not an isolated process, but that different kinds of DNA repair mechanisms must 
interact and work together to preserve genomic integrity. DNA repair thus is not a fi xed process 
depending on the respective type of DNA damage, but is a fl exible process that involves multiple 
strategies that are buffered against failure by a certain degree of redundancy. 
3 General Discussion
- 148 -
3.2 Categories of FA Genes
Although it seems clear that all FA genes belong to the group of caretaker genes, there is a 
conspicuous difference between FA genes belonging to the FA core complex and the genes whose 
products are located downstream of FANCD2. So far, there are eight upstream proteins known 
and necessary for FANCD2 and FANCI monoubiquitination. Only FANCM and FANCL are highly 
conserved in evolution and can be found in vertebrates, insects and slime mould (FANCL) or 
vertebrates, invertebrates, yeast and archeae (FANCM). All other core complex genes have only 
vertebrate orthologs (Titus et al., 2006; Wang, 2007). FA genes that are more highly conserved in 
evolution code for proteins having enzymatic domains and functions. One of the conserved genes 
is FANCL, the gene coding for the catalytic subunit of the FA core complex. Mutations in FANCL 
were thought to be mostly lethal, since for a long time only a single FA-L patient was known. This 
patient was severely affected and died at young age (Meetei et al., 2003a). Within the framework 
of this thesis I was able to analyze three further FA-L patients. The clinical phenotype of these three 
patients turned out to be highly variable, probably as a consequence of the underlying different 
types of mutations. This leads to the conclusion that the clinical phenotype of FA-L patients is not 
likely to be fundamentally different from the phenotypes from other FA patients with mutations in 
the core complex genes. The rareness of FA-L patients must thus be due to other factors. Indeed, 
the clinical phenotypes were comparable to patients belonging to subgroup FA-E. Patients 
belonging to this likewise rare complementation group exhibit a variable spectrum of clinical 
phenotypes that are typical for most of the FA complementation groups. Relative to most other 
FA genes, FANCE stands out because all patients have either truncating mutations or a mutation 
leading to the disruption of the protein structure. FANCE therefore seems to function as an adaptor 
protein, connection the FA core complex via FANCC with its substrate FANCD2. This is similar for 
FANCF, the protein that connects the subcomplexes FANCA/FANCG and FANCC/FANCE. These 
observations would suggest that FANCL and FANCE share similar consequences of disruption. 
The two proteins of the ID complex, FANCD2 and FANCI, are also conserved in evolution. They 
have been referred to as “fraternal twins” and can be found in vertebrates, worms, insects and 
slime moulds (Grompe and van de Vrugt, 2007; reviewed in Wang, 2007). For FANCD2 we could 
show that all patients exhibit hypomorphic mutations leading to detectable residual protein, while 
biallelic null mutations were not found in any of our patients. Together with the relative severity of 
the FA-D2 clinical phenotype this observation suggests that patients without traces of functional 
FANCD2 protein are not viable. Although data concerning the recently identifi ed FANCI are not 
that clear and patients are too rare to make a defi nitive statement, the situation appears to be very 
similar in that all FA-I patients so far examined show residual protein resulting from hypomorphic 
mutations. The situation in the third group of FA proteins, the proteins downstream of FANCD2 
and FANCI, is again different. This downstream group must be divided into two subgroups. One 
is represented by FANCJ, a helicase found in vertebrates, invertebrates and yeast. Although 
not necessary for FANCD2 and FANCI monoubiquitination, FANCJ resembles the core complex 
members rather than the other two downstream FA proteins FANCD1/BRCA2 and FANCN/PALB2. 
Accordingly, the clinical phenotype of FA-J patients corresponds to the “average” FA patient, while 
FA-D1 and FA-N patients are much more very severely affected. The discovery of additional 
“missing link” FA-genes might explain the phenotypic discrepancy between these two subgroups 
of genes that appear to operate downstream of the ID complex. 
3.3 FA and Cancer
A high susceptibility for malignant cell growth is one of the main threads faced by FA patients.  Most 
FA patients are at high risk for MDS, AML and squamous cell carcinomas. Regarding tumor types, 
there is a surprising difference between patients belonging to the upstream and the downstream 
FA subgroups. All three known genes whose proteins act downstream of FANCD2 and FANCI 
were shown to be are breast cancer susceptibility genes. The most important of these is the 
breast cancer susceptibility protein BRCA2. Patients with heterozygous mutations in BRCA2 have 
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a tenfold higher risk to develop breast or ovarian cancer than the average population (Rahman 
et al., 2007). Patients with biallelic mutations in BRCA2 develop a very severe form of FA, with 
early childhood cancers like Wilms tumor and medulloblastoma. These tumors frequently lead to 
the patients‘ death prior to the occurrence of bone marrow failure (Offi t et al., 2003; Wagner et 
al., 2004; Reid et al., 2005; Alter et al., 2007). In contrast to BRCA2, FANCJ and FANCN are low 
penetrance breast cancer susceptibility genes (Seal et al., 2006; Rahman et al., 2007). FA patients 
with biallelic mutations in FANCN are as severely affected as BRCA2 patients, but individuals 
with heterozygous mutations have only a 2.3 fold higher risk for getting breast and ovarian cancer 
(Rahman et al., 2007). FA patients with biallelic mutations in FANCJ are not that severely affected, 
but rather resemble patients with mutations in the FA core complex (Levitus et al., 2005; Levran et 
al., 2005). Individuals with monoallelic mutations in FANCJ have a 2 fold elevated risk to develop 
breast and ovarian cancer (Seal et al., 2006). Differences between clinical phenotypes as a 
function of the particular affected gene illustrate major functional differences between upstream 
and downstream FA genes. These differences might be explained in part by the fact that BRCA2 
and PALB2 are proteins that are directly involved in homologous recombination repair (reviewed 
in Wang, 2007) while FANCJ, like the upstream members, seems to be only indirectly involved.
An important question is whether carriers of heterozygous FA core complex gene mutations 
have a higher risk for the development of cancers than non-carriers. However, there seem to 
be no obvious increased cancer risk for heterozygous carriers, although there are some data 
suggesting that FANCC mutations might be associated with an increased risk for breast cancer 
(Berwick et al., 2007). If FA genes were to function as classical tumor suppressor genes, one 
would expect frequent mutations in FA genes in tumors of non-FA patients. One of the studies 
investigating this point is part of this thesis. The aim of said study was to investigate whether there 
are mutations in FANCC or FANCG in bladder tumors of non-FA patients. The results showed 
that the only example of disruption of the FA/BRCA pathway involved silencing of the FANCF 
gene via hypermethylation, a mechanism that has been observed in several kinds of non-FA 
tumors (reviewed in Neveling K, 2007c). In such non-FA tumors, FANCF promoter methylation 
never affects all tumor specimens. Most notably, localization of FANCF near a hot spot region 
of chromosome 11p15 suggests that inactivation of FANCF via hypermethylation may not be a 
causal event leading to genetic instability and tumor development, but rather a consequence of 
tumor progression. Another important conclusion of this study was that the FA/BRCA pathway 
seems to be rather intact in most tumors investigated. The integrity of the FA/BRCA pathway is 
therefore maintained in most tumor types as if even such genetically compromised cells need to 
maintain a certain degree of DNA-damage recognition and repair.  
3.4 Identifi cation of New FA Genes
As of today, there still are patients with FA that are not assigned to any of the known complementation 
groups. To the best of our knowledge, all remaining patients are typical FA patients, meaning that 
they are not as severely affected like FA-D1 or FA-N patients. The remaining patients can be 
separated at least in two different groups, according to whether monoubiquitination of FANCD2 
is intact or defective. One of the obvious candidates for a missing FA protein was the tumor 
suppressor protein BRCA1. BRCA1 is connected to the FA/BRCA pathway by the interaction 
with the 5’-3’ helicase FANCJ, which is also referred to as BRIP1 (BRCA1 interacting protein). 
BRCA1 also interacts with BRCA2. Although intensely investigated and discussed, BRCA1 itself 
is probably not a bona fi de FA protein, since there are no FA patients with mutations in BRCA1 and 
BRCA1-/- mice are not viable. Another point is that monoallelic BRCA1 mutations are relatively 
frequent in familial breast cancer patients, but none of these patients is known have children with 
FA and biallelic mutations in BRCA1. This suggests that biallelic mutations in BRCA1 are not viable. 
Another recent candidate protein was the histone H2 variant protein H2AX. Like the members of 
the FA core complex, H2AX is a subtrate the kinase ATR, resulting in the phosphorylated form 
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γH2AX. It was shown that γH2AX is functionally connected to the FA/BRCA pathway by resolving 
stalled replication forks and preventing chromosomal instability (Bogliolo et al., 2007). It has 
been demonstrated that phosphorylated H2AX is required for recruiting FANCD2 to chromatin at 
stalled replication forks. This indicates that γH2AX and FANCD2 function in the same pathway 
in response to DNA damage. γH2AX is required for FANCD2 relocation to damaged sites but 
not for FANCD2 activation. Binding of FANCD2 to γH2AX is BRCA1 dependent. Furthermore, 
cells defi cient in γH2AX show an FA like phenotype with chromosomal aberrations and MMC 
hypersensitivity. Despite this highly suggestive evidence, FA patients with mutations in H2AX 
have not been identifi ed to date. We conclude that H2AX interacts with the FA pathway to prevent 
MMC induced damage, but H2AX itself is unlikely to be a genuine FA gene (Bogliolo et al., 2007). 
So far, FAAP100 is one of the best candidate proteins identifi ed by co-immunoprecipitation with an 
antibody against FANCA protein. It is identical to LOC80233, a predicted hypothetical protein with 
unknown function (Ling et al., 2007). FAAP100 was shown to be an integral component of the FA 
core complex and is essential for the stability of this complex. Together with FANCB and FANCL, 
FAAP100 forms a stable subcomplex which is coregulated by FANCA and FANCM during nuclear 
localization. FAAP100 is conserved in vertebrates and contains a putative coilded coil domain 
required for the interaction with FANCB and FANCL. FAAP100 defi cient cells show hallmark 
features of FA with defective FANCD2 monoubiquitination, hypersensitivity to DNA crosslinking 
agents, and genomic instability (Ling et al., 2007). Depite intensive efforts, we have so far failed 
to identify individuals with FAAP100 mutations, but FAAP100 is still one of the most convincing 
candidates for one of the missing FA genes. Several other candidate genes have been tested 
during the time of this PhD thesis, but most of them turned out to be negative. Candidate gene 
approaches are still pursued and unassigned FA patients are permanently tested for any of the 
plausible candidates, including for example the group of FAAP10, FAAP16 and FAAP24. Novel 
candidate genes include RAP80, Abraxas and hCLK2. The human homologue of the C.elegans 
biological clock protein hCLK2 is a protein that interacts with the S-phase checkpoint components 
ATR, ATRIP, Claspin and CHK1 (Collis et al., 2007). hCLK2 prevents spontaneous DNA damage 
and is required for intra S phase arrest after DNA damage. hCLK2 promotes activation of the S 
phase checkpoint and downstream repair processes by preventing unscheduled Chk1 degradation 
by the proteasome. The connection to the FA/BRCA pathway is suggested by the observation 
that hCLK2 defi cient cells are defective in damage-induced monoubiquitination of FANCD2, and 
fail to recruit RAD51 and FANCD2 to sites of DNA damage. hCLK2 depleted cells share many 
phenotypes abnormalities with cells derived from FA and Seckel syndrome patients. This raises 
the possibility that hCLK2 may be inactivated in human disease (Collis et al., 2007). However, 
so far we have failed to detect any mutations in the hCLK2 gene in our unassigned FA patients. 
Additional candidate genes that have recently emerged are Abraxas and RAP80. Abraxas codes 
for a protein that was described as interaction partner of BRCA1 (Wang et al., 2007). It binds 
BRCA1 to the exclusion of the FA protein BRIP1/FANCJ and another protein called CtIP. Abraxas 
also recruites the ubiquitin interacting motif (UIM)-containing protein RAP80 (receptor associated 
protein 80) to BRCA1. Both Abraxas and RAP80 are phosphorylation substrates of ATR or ATM. 
They are both required for DNA damage resistance, G2-M checkpoint control and DNA repair 
(Kim et al., 2007; Sobhian et al., 2007). These facts in combination with the ubiquitin interacting 
motif of RAP80 might imply that defects in one of these genes might result in FA. Therefore 
both RAP80 and Abraxas are currently tested for defects in unassigned FA patients, with special 
emphasis on RAP80 because this might be the long searched protein which interacts with the 
monoubiquitinated ID complex. In summary, it is quite clear that there must be at least two further 
FA genes, and FAAP100 and RAP80 seem to be the most promising candidates. Other candidates 
that one must keep in mind are hCLK2, Abraxas and the group of FAAPs, including FAAP10, 
FAAP16 and FAAP24. In contrast, the genes BRCA1 and H2AX are less likely to function as 
genuine FA genes.
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The only curative therapy regarding bone marrow failure is hematopoetic stem cell transplantation 
(HSCT). Despite considerable progress in recent years, HSCT still is a high risk procedure if 
no matching sibling donors are available. Although gene therapy has not been successful in 
FA, knowledge about the affected genes and mutations will be required for further effort in 
this direction. As an alternative strategy, there are exciting experiments using an agent called 
PTC124, a chemical that induces ribosomal readthrough of premature but not of terminal stop 
codons (Welch et al., 2007). Stop codon read-through has been applied in mammalian cells and 
mouse models for Duchenne muscular dystrophy, and cystic fi brosis. Unlike aminoglycosides 
such as gentamicin, treatment with PTC124 has no severe side effects such as renal and otic 
toxicities and need for intravenous or intramuscular administration. The drug is orally bioavailable 
when prepared in aqueous suspension. However, PTC124 can only be used for patients with 
mutations resulting in premature truncating codons. This requires a priori knowledge about the 
underlying mutation. Other strategies for gene therapy involve the rescue of a dystrophic muscle 
by U7 snRNA-mediated exon skipping, the usage of single-stranded short fragment homologous 
replacement (ssSFHR) and oligonucleotid-directed mismatch repair, and adeno-associated virus-
mediated gene transfer (Goyenvalle et al., 2004; Wells, 2006; Kügler et al., 2007).
Improved understanding of the FA/BRCA pathway will not only be helpful for patients and their 
relatives. The special function of the FA/BRCA pathway in the repair of ICLs by combining different 
kinds of DNA repair mechanisms is a model for basic research on DNA repair in mammalian 
cells. Understanding the FA/BRCA pathway and more detailed examination of the FA-cancer 
connection will improve our understanding of DNA repair and is likely to reveal basic principles of 
tumorigenesis. 
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Summary
In the context of this thesis, I investigated the molecular causes and functional consequences of 
genetic instability using a human inherited disease, Fanconi anemia. This rare disorder uniquely 
exemplifi es the close connection between genetic instability, organ malformation or malfunction, 
and neoplastic cell growth. FA patients display a highly variable clinical phenotype, including 
congenital abnormalities, progressive bone marrow failure and a high cancer risk. The FA cellular 
phenotype is characterized by spontaneous and inducible chromosomal instability, and a typical 
S/G2 phase arrest after exposure to DNA-damaging agents. FA is a heterogeneous disease. So 
far, 13 genes have been identifi ed, whose biallelic (or, in the case of X-linked FANCB, hemizygous) 
mutations cause this multisystem disorder. The FA proteins interact in a multiprotein network, 
instrumental and essential in the cellular response to DNA damage. With each newly discovered 
gene, there is improved understanding of the many and intertwined functions of the FA/BRCA 
caretaker gene network. Since there are FA patients without any defects in any of the known 
FA genes, it is likely that not all FA genes have been identifi ed to date. A more comprehensive 
summary of Fanconi anemia and its myriad clinical, cellular and molecular manifestations is 
provided in the introduction section of this thesis.
The results of my experimental work are presented as published papers and manuscripts ready 
to be submitted. In the fi rst publication, I investigated the connection between FA genes and 
bladder tumors. Bladder cancers frequently show deletions of regions on chromosomes 9p and/
or 9q, potentially including the FA genes FANCC and FANCG. Chemotherapy for bladder cancers 
includes the DNA-crosslinker cisplatinum, to which FA cells are highly sensitive. The question I 
tried to answer was whether a disruption of the FA/BRCA pathway may be a frequent and possibly 
causal event in bladder cancer, explaining the hypersensitivity of these cells to DNA-crosslinking 
agents. There were no defects in FANCC or FANCG in 23 bladder cancer cell lines and ten primary 
bladder cancers. However, a single bladder cancer cell line, BFTC909, displayed a disruption of 
the FA/BRCA pathway which was shown to be due to hypermethylation of the FANCF promotor 
region. The FANCF methylation status was investigated in additional 41 primary bladder cancers, 
but in these native materials there was no evidence for promoter hypermethylation as a frequent 
cause of FANCF silencing. Inactivation of FANCF via hypermethylation has been reported in a 
number of different tumors. Some authors postulate that disruption of the FA/BRCA pathway by 
FANCF hypermethylation might result in genomic instability and thereby promote tumor initiation 
and progression. However, the results of my own studies of bladder tumors suggest that silencing 
of FANCF via hypermethylation is a rather rare event in bladder cancers. If it occurs at all, it 
emerges rather late during tumor progression and might occur only by chance due to the location 
of FANCF near a known hot spot region for hypermethylation on human chromosome 11p15. 
On the basis of my experimental data and by reviewing the literature I arrived at the conclusion 
that disruption of the FA/BRCA pathway might be detrimental rather than advantageous for the 
majority tumor types by rendering them vulnerable towards DNA damaging agents and oxidative 
stress. In order to survive under unfavorable conditions, tumor cells may require functional FA 
genes just like normal cells.
The second publication deals with the gene coding for the core complex protein FANCE and 
tries to answer the question why FANCE is so rarely affected among FA-patients. Within the 
FA/BRCA network of proteins, FANCE has the important task to mediate the necessary physical 
proximity between the catalytic subunit FANCL of the E3 ubiquitin ligase and its substrate FANCD2. 
The paper represented in this thesis is the fi rst one that investigates a relatively large cohort of 
these individually rare FANCE patients. In contrast to most other FA-genes, genetic alterations in 
FANCE result in most cases in premature protein truncation. A remarkable exception was a single 
missense mutation (c.1111 C>T) which was detected in more than 50% of the patients. Using 
complementation studies with retroviral vectors, I was able to confi rm that this particular mutation 
severely affects FANCE function. A number of other types of missense mutations were tested in 
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a similar way. All were shown to restore MMC sensitivity in FANCE-defective cells, thus proving 
their innocuous nature. The conclusion from these studies is that like FANCF, FANCE functions 
as a probable adaptor protein with a high tolerance towards amino acid substitutions which would 
explain the relative rareness of FA-E patients.
In addition to the FA core complex members FANCF and FANCE, I have also investigated the 
FANCL gene whose product functions as the catalytic subunit of the E3 ligase. Since the only FA-L 
patient reported so far in the literature is deceased, there is virtually no information concerning the 
cellular and phenotypic consequences of biallelic loss of FANCL function. The third publication 
addresses this issue by providing the fi rst comprehensive description of genetic alterations and 
phenotypic manifestations in a series of three FA-L patients. There were variable mutations, 
including a large deletion of more than 37.000 nucleotides at the 5’ portion of the gene, one short 
in-frame deletion of three nucleotides, one small but out-of-frame deletion (fi ve nucleotides), one 
splice mutation leading to exonisation of an intronic sequence, and one base substitution affecting 
splicing and resulting in skipping of two exons. Additionally, one of the patients developed a 
somatic reversion, adding FANCL to the list of genes in which natural gene therapy occurs. The 
clinical phenotypes of our FA-L patients were as variable as their pattern of genetic alterations, 
ranging from mildly to severely affected. Given the key role of FANCL in the activation of the ID 
protein complex, one might have expected lethality of biallelic FANCL null mutations. However, 
the results of my study show that (a) genetic alterations of FANCL are compatible with survival, 
(b) these alterations may include large deletions such as so far common only in the FANCA gene, 
(c) FA-L phenotypes can be mild to severe, and (d) FANCL belongs to the group of FA genes that 
may undergo somatic reversion.
The central protein of the FA/BRCA network, FANCD2, is the subject of the fourth publication 
presented in this thesis. Together with my colleague Reinhard Kalb, I assigned a cohort of 33 
FA patients to complementation group FA-D2 by complementation assays and immunoblotting. 
We have shown that the majority of mutations detected in FA-D2 patients result in aberrant 
splicing. We uncovered a number of ethnic associations by investigating haplotype structures. 
Most importantly, we were able to show that there are no biallelic null mutations in FANCD2. 
Correspondingly, residual protein of both FANCD2-isotypes (FANCD2-S and FANCD2-L) was 
present in all available patient cell lines. This suggests that complete abrogation of the FANCD2 
protein cannot be tolerated and causes early embryonic lethality. Compared to other FA subgroups 
(with the exception of FA-D1 and FA-N, see below), FANCD2 patients are more severely affected. 
Malformations are frequent and hematological manifestations appear earlier and progress more 
rapidly when compared to other FA subgroups. We have further shown that FANCD2 is fl anked 
by two pseudogenes. FANCD2-P1 is spanning 16 kb and is located ~24 kb upstream of FANCD2, 
and FANCD2-P2 is spanning 31.9 kb and is located 1.76 Mb downstream of FANCD2. Both 
pseudogenes are in the same orientation as the functional gene. They display a high degree of 
sequence homology, and they reveal recognizable patterns of the conserved gene structure.
Defects in any of the FA core complex genes, including the above described genes FANCF, 
FANCE and FANCL, lead to defective FANCD2 monoubiquitination. However, there are at least 
three FA proteins that are not required for the posttranslational modifi cation of FANCD2. One of 
these proteins is the 5’-3’ helicase BRIP1 (BRCA1-interacting protein 1), a protein that interacts 
directly with the breast cancer susceptibility protein BRCA1. I participated in the identifi cation 
of BRIP1 as the FA protein FANCJ. This discovery is described in the fi fth publication of this 
thesis. BRIP1 was identifi ed as a FA-causing gene by homozygosity mapping of fi ve individuals 
from four consanguineous families. The pathogenetic nature of genetic alterations of FANCJ was 
confi rmed by mutation analysis and western blot data in these and 7 additional patients. Since 
all these patients had biallelic truncation mutations in the BRIP1 gene, and one of them had 
been assigned previously to complementation group FA-J by somatic cell fusion, BRIP1 was 
designated FANCJ. Monoubiquitinated FANCD2 and BRCA1 interact at presumptive sites of DNA 
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damage, and the newly discovered protein BRIP1/FANCJ seems to act as one of the mediators 
of genomic maintenance downstream of FANCD2.
Another protein identifi ed downstream of FANCD2 is PALB2. PALB2 was originally discovered 
as “partner and localizer of BRCA2”. FA patients with biallelic mutations in the breast cancer 
susceptibility gene BRCA2 (also known as FANCD1) represent the rare FA subgroup FA-D1. FA-
D1 patients are much more severely affected than patients from other FA subgroups. These very 
young patients suffer from early childhood cancers like Wilms tumor and medulloblastoma. PALB2 
was described as a nuclear binding partner of BRCA2, to promote its stabilization, its localisation 
and its function in DNA repair via homologous recombination. Furthermore, knockdown of PALB2 
by siRNA resulted in MMC sensitivity, leading to DNA-interstrand crosslinks and DNA double 
strand breaks. In a candidate gene approach we tested patients with early childhood cancers 
but without mutations in BRCA2 for mutations in PALB2 (publication 6). We discovered biallelic 
mutations in seven patients, all resulting in premature protein truncation. The PALB2-defi cient 
cells had no detectable PALB2 protein, very high chromosomal breakage rates, and lack of 
MMC-inducible RAD51 foci formation. Using retroviral transduction of PALB2-defi cient cells with 
wildtype PALB2 cDNA we were able to complement the defective cellular phenotype. Therefore, 
PALB2 was identifi ed as a novel FA gene and designated FANCN. Like FA-D1 patients, FA-N 
patients are very severely affected: in the seven patients, we observed fi ve medulloblastomas, 
three Wilms tumors, one neuroblastoma, and two cases of AML. Only one of the patients was still 
alive at the time of this gene discovery. All others had succumbed to their disease prior to four 
years of age.
The last publication included in my thesis describes the identifi cation of the FA gene FANCI as 
the second monoubiquitinated member of the FA/BRCA pathway (publication 7). In order to test 
whether proteins other than FANCD2 might also be substrates of the FA core complex, a BLAST 
search was performed to fi nd gene products with sequence homology to the highly conserved 
human FANCD2 monoubiquitination site, LVIRK. The large number of putative targets was reduced 
on the basis of protein domain architecture and putative function. A back search for homology to 
FANCD2 extending beyond the LVIRK motif fi nally resulted in the identifi cation of only a single 
protein, KIAA1794. KIAA1794 was a previously uncharacterized protein with 1328 amino acids 
and a molecular weight of 140 kDa. Monoubiquitination was shown to occur at Lys523, and 
required function of the FA core complex and simultaneous modifi cation of FANCD2. KIAA1794 
also forms nuclear foci in response to DNA damage, together with FANCD2 and phosphorylated 
H2AX. Like FANCD2, deubiquitination of KIAA1794 is regulated by USP1. KIAA1794 and 
FANCD2 show a weak but specifi c interaction. It thus became clear that KIAA1794 behaves as 
a functional homolog of FANCD2 and is likely to function in the coordination and repair of DNA-
interstrand crosslinks. We identifi ed biallelic mutations in KIAA1794 in four FA patients, thus 
proving the genuine FA-nature of this candidate sequence. One of the tested patients belonged 
to the previously uncharacterized FA-I complementation group, the only FA subgroup that had not 
been assigned to a specifi c gene. In analogy to what we observed with genetic alterations in the 
FANCD2 gene, all FA-I patients could be shown to express residual FANCI protein. This suggests 
that null mutations in FANCI might be likewise lethal in our species.
The general discussion provides a synopsis of the results and conclusions of my work with 
the state of art of FA research. Point by point, important issues in the area of FA (the FA/BRCA 
pathway and DNA repair, categories of FA genes, FA and cancer, identifi cation of new FA genes) 
are discussed.
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Zusammenfassung
Im Rahmen der vorliegenden Dissertation wurden molekulare Ursachen und funktionale 
Konsequenzen genetischer Instabilität am Beispiel der menschlichen Erbkrankheit Fanconi 
Anämie (FA) untersucht. Diese seltene Krankheit zeigt auf eine einzigartige Weise den engen 
Zusammenhang zwischen genetischer Instabilität, organischen Fehlbildungen oder Fehlfunktionen 
und entartetem Zellwachstum. FA Patienten zeigen einen sehr variablen klinischen Phänotyp, der 
in der Regel angeborene Fehlbildungen, progressives Knochenmarkversagen und ein hohes 
Risiko für Tumorerkrankungen beinhaltet. Der zelluläre Phänotyp der FA ist durch eine spontane 
und induzierbare chromosomale Instabilität und einen typischen S/G2-Phasen-Arrest nach 
Exposition mit DNA-schädigenden Agentien charakterisiert. FA ist eine heterogene Erkrankung. 
Biallelische oder -im Fall des X-chromosomalen FANCB- hemizygote Mutationen, die zu 
dieser Erkrankung führen, wurden in bislang 13 Genen identifi ziert. Die FA Proteine arbeiten in 
einem gemeinsamen Netzwerk und sind essentiell beteiligt an der zellulären Antwort auf DNA 
Schädigung. Mit jedem neu entdeckten Gen verbessert sich das Verständnis für die vielen und 
vernetzten Funktionen des FA/BRCA „caretaker“ Netzwerks. Da es immer noch Patienten ohne 
nachgewiesene Defekte in einem der bekannten FA Gene gibt, ist es wahrscheinlich, dass noch 
nicht alle FA Gene identifi ziert wurden. Eine umfassendere Übersicht über Fanconi Anämie und 
ihre vielfältigen klinischen, zellulären und molekularen Erscheinungsformen ist in der Einleitung 
dieser Dissertation gegeben.
Die Ergebnisse meiner experimentellen Arbeiten sind in Form von publizierten Fachartikeln 
und fertigen Manuskripten dargestellt. In der ersten Publikation habe ich den Zusammenhang 
von FA Genen und Harnblasentumoren untersucht. Harnblasentumore zeigen oft Deletionen in 
Regionen des Chromosoms 9p und/oder 9q, in denen sich die FA Gene FANCC und FANCG 
befi nden. Die Chemotherapie für die Behandlung von Harnblasentumoren beinhaltet meist das 
DNA-quervernetzende Agens Cisplatin, auf das FA Zellen hoch-sensitive reagieren. Die Frage, 
die ich zu beantworten versucht habe, war, ob ein Defekt im FA/BRCA Weg eine mögliche 
Ursache für die Entstehung von Blasentumoren sein könnte, was die Hypersensitivität dieser 
Zellen gegenüber Cisplatin erklären würde. Ich habe in Zelllinien von 23 Harnblasentumoren und 
in DNA aus 10 primären Tumoren keine Defekte in FANCC oder FANCG fi nden können. Allerdings 
zeigte eine Zelllinie, BFTC909, einen Defekt im FA/BRCA Weg, der auf einer Hypermethylierung 
der Promotor-Region von FANCF beruhte. Eine mögliche FANCF-Methylierung wurde daraufhin 
noch in Material aus 41 weiteren primären Harnblasentumoren untersucht, aber auch in diesem 
Material gab es keinen Hinweis darauf, dass eine Promotor-Methylierung eine häufi ge Ursache 
für die Inaktivierung von FANCF könnte. Die Inaktivierung von FANCF durch Methylierung des 
Promotors wurde schon für eine Reihe von verschiedenen Tumoren gezeigt. Einige Autoren 
haben postuliert, dass eine FANCF Hypermethylierung in genomischer Instabilität resultieren und 
somit Tumorentstehung und –progression begünstigen könnte. Allerdings haben die Ergebnisse 
meiner Arbeit gezeigt, dass die Hypermethylierung von FANCF in Harnblasentumoren ein eher 
seltenes Ereignis ist, das –wenn es überhaupt vorkommt- eher spät in der Tumorprogression 
auftritt und vermutlich durch die Nähe zu einer Region auf Chromosom 11p15 begünstigt wird, 
die als „Hot-Spot“ für Hypermethylierung bekannt ist. Aufgrund meiner experimentellen Daten 
und ausgiebigen Literaturrecherchen bin ich zu dem Schluss gekommen, dass ein Defekt im 
FA/BRCA Weg für einen Tumor vermutlich eher schädlich als vorteilhaft ist, da so ein Defekt den 
Tumor gegenüber DNA-schädigenden Agentien und oxidativem Stress anfällig machen würde. 
Um unter ungünstigen Bedingungen überleben zu können, scheinen Tumorzellen den FA/BRCA 
Weg genauso wie andere Zellen zu benötigen.
Meine zweite Publikation befasst sich mit dem Kern-Komplex Protein FANCE und versucht die 
Frage zu beantworten, warum das FANCE Gen in so wenigen FA Patienten betroffen ist. Innerhalb 
des FA/BRCA Netzwerks hat FANCE die wichtige Funktion, die notwendige räumliche Nähe 
zwischen der katalytischen Untereinheit der E3-Ligase, FANCL, und dessen Substrat, FANCD2, 
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herzustellen. Mein Artikel über FANCE beschreibt die Untersuchung einer relativ großen Gruppe 
dieser vergleichsweise seltenen FA-E Patienten und zeigt, dass -im Gegensatz zu anderen FA 
Genen- Mutationen in FANCE fast immer zu vorzeitigen Stop-Codons führen. Eine Ausnahme 
bildet die Missense-Mutation c.1111C>T, die in mehr als 50% der Patienten detektiert wurde. 
Mit Hilfe von retroviralen Komplementationsstudien war ich in der Lage zu zeigen, dass diese 
Mutation die Funktion von FANCE erheblich beeinfl usst. Eine Vielzahl von FANCE-Vektoren 
mit anderen putativen Missense-Mutationen wurde auf die gleiche Weise untersucht und alle 
waren in der Lage, die MMC-Sensitivität einer FANCE-defi zienten Zelllinie zu korrigieren, was 
auf einen harmlosen Charakter dieser Basensubstitutionen schließen ließ. Die Schlussfolgerung 
dieser Arbeit war, dass FANCE vermutlich genauso wie FANCF im Kern-Komplex die Rolle eines 
Adaptor-Proteins mit einer hohen Toleranz gegenüber Aminosäure-Austauschen innehat, was 
die relative Seltenheit von Patienten dieser Untergruppe erklären könnte.
Zusätzlich zu den FA Kern-Komplex Mitgliedern FANCF und FANCE habe ich auch das FANCL 
Gen untersucht, dessen Produkt als katalytische Untereinheit der E3-Ligase fungiert. Da der 
bisher einzige publizierte FA-L Patient früh verstorben ist, gab es nahezu keine Informationen 
bezüglich zellulären und klinischen Konsequenzen von biallelischen FANCL Mutationen. Die 
dritte Publikation in dieser Dissertation befasst sich mit diesem Thema und enthält eine 
umfassende Beschreibung von genetischen Veränderungen und phänotypischen Auswirkungen 
in einer Gruppe von 3 FA-L Patienten. Die detektierten Mutationen waren sehr variabel und 
beinhalteten eine große Deletion von mehr als 37.000 Nukleotiden am 5’ Ende des Gens, eine 
kurze Leseraster-haltende Deletion von drei Nukleotiden, eine kleine Leseraster-verschiebende 
Deletion (5 Nukleotide), eine Spleiß-Mutation, die zur Exonisierung einer intronischen Sequenz 
führt und einer Basen-Substitution, die im Skipping von 2 Exons resultiert. Zusätzlich hat einer 
der Patienten eine somatische Reversion entwickelt, wodurch FANCL nun zu den Genen gehört, 
in denen eine „natürliche Gentherapie“ detektiert wurde. Die klinischen Phänotypen der FA-L 
Patienten waren genauso variable wie ihre Mutationen und reichte von mild betroffen bis schwer 
betroffen. Wenn man die Schlüsselrolle von FANCL in der Aktivierung des ID (FANCD2/FANCI) 
Komplexes bedenkt, könnte man glauben, dass biallelische Nullmutationen in FANCL lethal 
sein müssten. Die Ergebnisse meiner Arbeit haben allerdings gezeigt, dass (a) genetische 
Veränderungen in FANCL mit dem Leben vereinbar sind, (b) dass diese Veränderungen sehr 
große Deletionen beinhalten können, was bisher nur für FANCA gezeigt werden konnte, (c) dass 
FA-L Phänotypen von mild bis schwer betroffen reichen können und d) dass FANCL zu den 
Genen gehört, in denen somatische Reversionen stattfi nden.
Das Schlüsselprotein des FA/BRCA Netzwerks, FANCD2, ist das Thema der vierten Publikation 
in dieser Dissertation. Gemeinsam mit meinem Kollegen Reinhard Kalb habe ich 33 FA Patienten 
mittels Komplementationsstudien und Immunoblotting zur Untergruppe FA-D2 zugeordnet. Wir 
haben gezeigt, dass eine Vielzahl der detektierten Mutationen in aberrantem Spleißen resultiert 
und haben durch Haplotyp-Untersuchungen ethnische Assoziationen erkannt. Insbesondere 
konnten wir zeigen, dass es keine biallelischen Nullmutationen in FANCD2 zu geben scheint. 
Dementsprechend war Restprotein von beiden FANCD2-Isoformen, FANCD2-L und FANCD2-S, 
in allen verfügbaren Patienten-Zelllinien nachweisbar. Dies ließ vermuten, dass ein komplettes 
Fehlen des FANCD2 Proteins nicht tolerierbar ist und frühe embryonale Letalität verursacht. 
Verglichen mit anderen FA Untergruppen (mit der Ausnahme von FA-D1 und FA-N, siehe unten) 
scheinen FA-D2 Patienten schwerer betroffen zu sein. Fehlbildungen kommen häufi g vor und 
hämatologische Probleme treten früh auf und verlaufen schwerer als in anderen FA Untergruppen. 
Wir haben außerdem gezeigt, dass FANCD2 von zwei Pseudogenen fl ankiert wird. FANCD2-P1 
umfasst 16 kb und ist ~24 kb 5’ von FANCD2 lokalisiert, während FANCD2-P2 31.9 kb groß ist 
und sich 1.76 Mb 3’ von FANCD2 befi ndet. Beide Pseudogene haben die gleiche Orientierung 
wie FANCD2 und zeigen ein hohes Maß an Sequenzhomologie und erkennbare Muster der 
konservierten Genstruktur.
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Defekte in jedem der FA Kern-Komplex Gene, einschließlich der oben beschriebenen Gene FANCF, 
FANCE und FANCL, führen zu einem Defekt in der FANCD2-Monoubiquitinierung. Allerdings gibt 
es mindestens drei Proteine, die nicht für diese posttranslationale Modifi kation benötigt werden. 
Eines dieser Proteine ist die 5’-3’ Helikase BRIP1 (BRCA1-interagierendes Protein 1), ein Protein, 
das direkt mit dem Brustkrebs-assoziierten Protein BRCA1 interagiert. Ich war an der Identifi zierung 
von BRIP1 als FA Protein (FANCJ) beteiligt. Diese Entdeckung ist in der fünften Publikation 
meiner Dissertation beschrieben. BRIP1 wurde durch Homozygotie-Studien an fünf Personen 
aus blutsverwandten Familien identifi ziert. Der pathogene Charakter genetischer Veränderungen 
in FANCJ wurde durch Mutationsanalysen und Immunoblot-Daten in diesen und sieben weiteren 
Patienten bestätigt. Da in allen Patienten biallelische Mutationen in FANCJ gefunden wurden 
und einer dieser Patienten zuvor mittels somatischer Zellfusion der Komplementationsgruppe 
FA-J zugeordnet worden war, wurde BRIP1 „FANCJ“ genannt. Monoubiquitiniertes FANCD2 
und BRCA1 interagieren an mutmaßlichen Orten von DNA Schäden, und das neu entdeckte 
Protein BRIP1/FANCJ, das direkt mit BRCA1 interagiert, scheint als einer der Mediatoren zur 
Aufrechterhaltung genomischer Stabilität downstream von FANCD2 zu wirken.
Ein weiteres Protein downstream von FANCD2 ist PALB2. PALB2 wurde ursprünglich als „Partner 
und Lokalisierer von BRCA2“ entdeckt. FA Patienten mit biallelischen Mutationen im Brustkrebs-
Gen BRCA2 (auch als FANCD1 bekannt) bilden die Untergruppe FA-D1. FA-D1 Patienten sind 
viel schwerer betroffen als Patienten aus anderen FA Untergruppen. Diese in der Regel sehr 
jungen Patienten leiden an frühkindlichen Tumoren wie Wilms Tumor und Medulloblastom. 
PALB2 wurde beschrieben als ein nukleärer Bindungspartner von BRCA2, der die Stabilisation, 
die Lokalisation und die Funktion von BRCA2 in der Homologen Rekombination fördert. 
Außerdem wurde gezeigt, dass eine Inaktivierung von PALB2 durch siRNA in MMC Sensitivität 
resultiert, was sich in DNA-Quervernetzungen und DNA Doppelstrangbrüchen äußerte. In einer 
Kandidatengen-Studie haben wir Patienten mit frühkindlichen Tumoren, aber ohne Mutationen 
in BRCA2, auf Mutationen in PALB2 untersucht (Publikation 6). Wir haben in sieben Patienten 
biallelische Mutationen gefunden, die alle in einem vorzeitigem Abbruch des Transkriptes 
resultieren. PALB2-defi ziente Zellen besaßen kein nachweisbares PALB2 Protein, wiesen sehr 
hohe chromosomale Bruchraten auf und zeigten keine MMC-induzierbaren RAD51 Foci. Mittels 
retroviraler Komplementation PALB2-defi zienter Zellen mit wildtypischer PALB2 cDNA konnte der 
zelluläre Phänotyp komplementiert werden. Aufgrund dieser Ergebnisse haben wir PALB2 als ein 
neues FA Gen identifi ziert und haben es FANCN genannt. Genauso wie FA-D1 Patienten sind 
FA-N Patienten sehr schwer betroffen: In den sieben Patienten gab es fünf Medulloblastome, drei 
Wilms Tumore, ein Neuroblastom und zwei Fälle von AML. Zur Zeit der Gen-Entdeckung war nur 
noch einer der sieben Patienten am Leben. Alle anderen waren vor dem vierten Lebensjahr an 
ihrer Erkrankung verstorben.
Die letzte Publikation meiner Dissertation beschreibt die Identifi kation des FA Genes FANCI, 
dessen Produkt das zweite monoubiquitinierte Mitglied des FA/BRCA Weges darstellt (Publikation 
7). Um zu testen, ob es zusätzlich zu FANCD2 noch andere Substrate des FA Kern-Komplexes 
gibt, wurde eine BLAST Suche durchgeführt, die Proteine mit Sequenz-Homologie zu der hoch 
konservierten FANCD2-Monoubiquitinierungsstelle, LVIRK, identifi zieren sollte. Die große Anzahl 
möglicher Produkte wurde aufgrund von Protein-Domänen-Architektur und möglicher Funktion 
eingeschränkt. Eine Rückwärtssuche nach Homologie zu FANCD2, die über LVIRK hinausgeht, 
resultierte schließlich in der Identifi kation eines einzelnen Proteins, KIAA1794. KIAA1794 war ein 
zuvor nicht charakterisiertes Protein mit 1328 Aminosäuren und einem Molekulargewicht von 140 
kDa. Es konnte gezeigt werden, dass die Monoubiquitinierung am Lys523 stattfi ndet und vom FA 
Kern-Komplex und einer gleichzeitigen Ubiquitinierung von FANCD2 abhängt. KIAA1794 bildet, 
gemeinsam mit FANCD2 und phosphoryliertem H2AX, nukleäre Foci in Abhängigkeit von DNA 
Schäden. Genauso wie bei FANCD2 wird die Deubiquitinierung durch USP1 reguliert. Außerdem 
zeigen KIAA1794 und FANCD2 eine schwache, aber spezifi sche Interaktion. Daraus resultierte 
die Schlussfolgerung, dass KIAA1794 ein funktionales Homolog zu FANCD2 darstellt und 
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vermutlich genauso in der Koordination und Reparatur von DNA Doppelstrangbrüchen beteiligt 
ist. Wir haben in vier Patienten biallelische Mutationen in KIAA1794 gefunden, und so zeigen 
können, dass KIAA1794 wirklich ein FA Gen ist. Einer der untersuchten Patienten war zuvor 
zu der uncharakterisierten FA Untergruppe FA-I zugeordnet worden, der einzigen Untergruppe, 
in der das zugrunde liegende Gen nicht bekannt war. Daher ist KIAA1794 gleich „FANCI“. In 
Analogie zu Beobachtungen bei FANCD2 zeigen alle FA-I Patienten Restprotein, was vermuten 
lässt, dass Nullmutationen in FANCI ebenfalls letal sind.
Die generelle Diskussion birgt eine Synopsis der Ergebnisse und Schlussfolgerungen meiner 
Forschung mit dem aktuellen Wissensstand über FA. Punktweise werden wichtige Themen aus 
dem Gebiet der FA (der FA/BRCA Weg und DNA Reparatur, Kategorien von FA Genen, FA und 
Tumore, Identifi kation neuer FA Gene) diskuttiert.
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